## **BEST AVAILABLE COPY**

JUN 1 3 2006

US-5,830,759

US-4,859,581

US-4,882,318

US-5,129,877

US-5,206,223

US-5,332,812

US-5,362,641

40

43

44

03-3-1998

08-22-1989

11-21-1989 07-14-1992 04-27-1993

07-26-1994

08-8-1994

PTO/SB/08a (08-03)

Under the P	perwark	Recharation Specific		to respond to a c	Approved for U.S.Patent and Trademark Offic collection of information unless it contains a	e: U.S.	rough 07/31/2006. OMB 0651- DEPARTMENT OF COMME MB control number.
		Substitute for form 1449A			Comple		
			<del>-</del>		Application Number		54,805
		RMATION DISC FEMENT BY AP			Filing Date	Octo	aber 17, 2001
1	SIA.	I ENLENI DI API	PLICA	MI	First Named Inventor	Oro	n JACOBY-ZEEVI
	(1	use as many sheets as ne	cessary)		Art Unit	1636	5
				Examiner Name	unkr	nown	
Sheet		1	of	19	Attorney Docket Number	2971	14
			U.S	PATENT	DOCUMENTS		
Examiner Initials*	Cite No. 1	Document Number	Public	ation Date DD-YYYY	Name of Patentee or Applicant of Cited Document		Piges, Columns, Lines, Where Relevant Passages or Relevant
	<u> </u>	Number-Kind Code <sup>2 (Flame)</sup>	<u>l</u>		l		Figures Appear
<u> </u>	1	US-6,177,545	01-13-2	001	Pecker et al.	_	
	2	US-6,348,344	02-19-2		Ayal-Hershkovitz et al.	/	
	3	US-4,946,778	08-8-19		Ladner et al.	<b></b>	
	4	US-5,997,863	07-7-19	99	Zimmermann et av.		
	1	US-6,242,238	05-5-20	01	Freeman et al		
]	6	US-5,688,679	11-18-1	997	Powell		
	7	NS-6,387,643	05-14-2	002	Heinrikson et al.		
	8	US 6,423,312	07-23-2	002	Yacoby-Zeevi		
	9	US-6,331,129	03-11-2	003	Pecker et al.		
	10	US-4,453,296	06-19-1	984	Hansen et al.		
	11	US-5,571,586	05-5-19	96	Regan et al.		
	12	US-5,917,830	06-29-1	999	Chen et al.		
	13	US-5,859,660	01-12-1	999	Perkins et al.	-	
	14	US-5,600,366	04-4-19	97	Schulman		
	15	US-6,020,931	01-1-20	00	Bilbrey et al.		
	16	US-5,968,822	10-19-1	999	Pecker et al.		
	17	US-6,153,187	11-28-2	000	Yacoby-Zeevi		· · · · · · · · · · · · · · · · · · ·
	18	US-6,664,105	12-16-2		Pecker et al.		
	19	US-5,145,679	08-8-19	92	Hinson		
	20	US-5,736,137	07-7-19	98/	Anderson et al.		
	21	US-5,194,596	03-16-1	993	Tischer et al.		
	22	US-5,350,836	09-27/1	994	Kopchick et al.		
	23	US-6,562,950	05-/3-2	003	Peretz et al.		
	24	US-6,699,672	02-2-20	04	Pecker et al.		
	25	US-5,580.862	03-3-19		Rosen et al.		
	26	US-5,474,983	12-12-1	995	Kuna et al.		· · · · · · · · · · · · · · · · · · ·
	27	US-2002/0102560	01-1-20		Packer et al.		
	28	US-6,790,658	09-14-2		Pecker et al.		
	29	US-6,798,658	09-28-2	004	Takedomi et al.		
	30	US-5,618,709	08-8-19	97	Gewirtz et al.		
	31	US-5,656,595	08-12-1		Schweighoffer et al.		
	32	US-4,682,195	07-28-1	987	Mullis et al.		
	33	US-5,602,095	02-11-1	997	Pastan et al.		
	34	US-2004/0142427	07-22-2	004	Pecker et al.	1	
	35	U9-4,117,841	03-3-19	78	Perrotta et al.	-	
	36	S-2003/0161823	08-28-20	003	Ifan et al.	$\neg \neg$	
	37	US-5,962,321	05-5-19		Gough et al.	$\neg$	
	39	119 5 920 750	02 2 100		<u> </u>		

Chang et al.

Nicholson et al.

Vlodavsky et al.

Gallo et al.

Vlodavsky et al

Nicolson et al.

Fuks et al.

	45	US-5,399,351	03-21-1995	<u> </u>	Γ	Leshchine	r et al		
	46	US-5,550,116	08-27-1996		<b></b>	Lormeau			
	47	US-5,667,501	09-16-1997		<b>-</b>	Fowler e			
	48	US-5,739,115	04-14-1998			Fugedi e			
									$\dashv$
					<u> </u>				
			FOREIGN	PATE	NT DOC	UMENTS		<del></del>	
Examiner Initials*	Cite No. 1	Foreign Patent Docum	nents	Public	ttion Dune	Nam	e of Patentee or	Pages, Columns, Lines, Where Refevent Passages	Ţ
<u> </u>	404	Country Code Number Kind C	ode <sup>s</sup> (If known)					or Relevant Figures Appear	$\mathbf{I}^{\bullet}$
	49*	PCT WO 99/57244	<u> </u>	11-11-		Ben-Artz			$\Box$
	50*	PCT WO 99/57153		11-11-		Pecker et			П
<u> </u>	51*	PCT WO 99/11798		03-11-		Pecker e			$\top$
ļ	52*	PCT WO 88/01280		02-25-		Nicolson			$\Box$
L	53*	PCT WO 95/04158		09-9-1		Hoogewe	erfet al.		П
	54*	PCT WO 99/21975		Q6-6-1		Freeman			П
<b></b>	55*	PCT WO 91/19197		12 12-		Nicolson	et al.		П
	56*	PCT WO 95/04518		02-16		Midha et	,		П
<u> </u>	57*	PCT WO 03/006645 A2	2	01-25-		Bohlen e			$\Box$
ļ	58*	PCT WO 97/11684		<i>8</i> 3-3-1		Bennett e	t al.		$\Box$
	59*	PCT WO 91/02977		07-7-1		Fuks et a			П
	60*	PCT WO 97/27327		07-31-	1997	Van Ness	s et al.		$\sqcap$
	61*	PCT WO 00/52149		08-8-2		Yacob Z	zeevi		П
	62*	PCT WO 00/52178		08-8-2		Pecker et	×		П
	63*	PCT WO 00/52178		08-8-2		Pecker et	al.		$\Box$
-	64*	PCT WO 99/40207		08-12-		Nakjima	et al.		П
	65*	PCT WO 98/46258		10-22-		Bhaskar e	et al.		П
	66*	EP 0254067		01-27-	1988	Cohen et	al.		П
	67*	PCT WO 98/03638		01-29-		Freeman	et al.		П
	68*	PET WO 01/00643		04-4-2	001	Pecker et	ai.		П
	69*	DE 2819129		11-15-	1979	Köhler et	al.		$\sqcap$
	75.	PCT WO 99/48478		09-30-	1999	Yacoby-Z	Zeevi		П
	نہ`								П
Examiner Signature							Date Considered		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinda Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is an object to add before the patient by 37 OFD 4 CV and 4 CP. The Information of the patient by the supportant in the patient by 37 OFD 4 CV and 4 CP. The Information is an object to the patient by the patient by the patient by 37 OFD 4 CV and 4 CP. The Information is a patient by 37 OFD 4 CV and 4 CP. The Information is a patient by the patient by a patient by the pa

Transitation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number.

	•	Act of 1995, no persons are required to respond to a collection for form 1449A/PTO	ection of information un	Complete		n
	Suc	Suite for form 144 WAP 10		Application Number	11/15	4,805
. \	INFO	DRMATION DISCLOSURE		Filing Date		er 17, 2001
\	STA	TEMENT BY APPLICANT		First Named Inventor		JACOBY-
				Group Art Unit	2EEV	<u>'</u>
		use as many sheets as necessary)	_	Examiner Name	unkno	wn
Sheet	3	Of	19	Attorney Docket Number	29714	
		OTHER PRIOR ART – NON I	PATENT LITER	ATURE DOCUMENTS		
Examiner	Che	include name of the author (in CAPITAL LE	TTERS), title of the a	rticle (when appropriate), title	of the	
Initials	No.	item (book, magazine, journal, serial sympos publisher, city an	rum, cararog, etc.) dai d/or country where pu	te, page(s), volume-issue numb ublished	pr(s),	T²
	71	Wight et al. "The Role of Proteoglyca	ns in Cell Adhesi	on, Migration and		
		roliferation", Curr. Opin. Cell. Biolo	gy, 4: 793-801, 1	992.		
	72	Jackson et al. "Glycosaminoglycans: l			and	
	72	Role in Physiological Processes", Phy	siological Reviev	v, 71(2): 481-529, 1991.		
	73	Schoepe et al. "Neutralization of Hem Perfringers Alpha-Toxin Need Simul	olytic and Mouse	Lethal Activities of C.		
		Monoclonal Antibodies", Microbiol. I	Sathogenesis 33.	1-10 1067		
	74	Chiba et al. Generation of Neutralizing	no Antihodu to th	e Reserve Transcrintage	of	
	1	Human Immunodeficiency Virus Typ	e I by Immunizin	g of Mice With An Infec	tions	
	ì	Vaccinia Virus Recombinant", J. Imm	unological Metho	ods, 207:53-60, 1997.		
	75	Wong "Monoclonal Antibodies: There	peutic Application	ns Grow in Promise and		
		Number, Genetic Engineering News,	P.23-49, 1999.			
	76	Sherman-Gold "Monoch nal Antibodi	es: The Evolution	n From '80s Magic Bullet	s to	
		Mature, Mainstream Applications as (	Clinical Therapeu	tics", Genetic Engineerin	g	
		News, P.4, 35, 1997.				
	77	Danheiser "Rituxin Leads Line of Ho	peful Mab Therap	pies, Yet FDA Still Has B	ulk	
	70	Manufacture Concerns", Genetic Eng	neuring News, P.	1, 6, 33, 38, 1997.		
	78	Rader et al. "A Phage Display Apphoa Designed Combinatorial V Gene Lib	on for Rapid Ant	ibody Humanization:	••	
		8915, 1998.	ries", Proc. Nati.	. Acad. Sci. USA, 93: 89	10-	
	79	Mateo et al. "Humanization of Mou	se Monoclonal A	ntibody That Blocks the		
	."	Epidermal Growth Factor Receptor: R				
		Immunotechnology, 3: 71-91, 1997.		, ,		
	80	Nakajima et al. "Heparapases and Tur	nor Metasasis", J	Journal of Cellular		
		Biochemistry, 36(2): 127-167, 1988.				
	81	Ngo et al. "Computational Complexity	y, Protein Structur	re Prediction, and the		
		Levinthal Paradox, The Protein Fold	ing Problem and	Tertiary Structure Predict	ion,	
	+	Birkhauser, Boston, P.433, 492-495, 1	994.	1		
	82	Colman "Effects of Amino Acid Sequ	ence Changes on	Artibody-Antigen	i	
	83	Interactions, Research in Immunolog Abaza et al. "Effects of Amino Acid S	y, 143(1): 33-36.	1994		
•	<sub>63</sub>	Protein Binding to Monoclonal Antibe	vice of Producer	nice An Anugenic Site on	ad bas	
		Peptide Immunization: Demonstration	With Region 94	-100 (Antionic Site 3) o	f o	
		Myoglobin", Journal of Protein Chem	istry, 11(5): 433-	444 1992	•	
<del></del>	84	Jederman et al. "A Single Amino Aci	d Substitution in	A Common African Alle	le of	
		the CD4 Molecule Ablates Binding of	the Monoclonal	Antibody, OKT4 Mole	cular	
		Immunology, 28: 1171-1181, 1991.				
	85	Li et al. "β-Endorphin Omission Anal			m	
		Other Biological Activities", PNAS, 7				
	86	Marchetti et al. "Neurotrophin Stimul	ation of Human N	Aelanoma Cell Invasion:	1	
	<b>"</b>	Selected Bnhancement of Heparanase	Activity and Hep	paranase Degradation of	\	
		Specific Heparan Sulfate Subpopulati			96. 🔪	
		Also in: Advances in Enzyme Regular				<b>\</b>
	07		na Colle Produce	PYTESCELINISE HERSESHSE		
$-\!\!\!\!/-$	87	Kosir et al. "Human Prostate Carcinor		Extracellular Treputablis	•	
$\neq$	87	Journal of Surgical Research, 67: 98-1 Köhler et al. "Continuous Cultures of	05, 1997.	•	_	

193   Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. Biolog. Chemistry, 274(3): 2413-2416(6), 1999.  191   Kussie et al. "Cloning and Functional Expression of A Human Heparanase Gene", Biochemical and Biophysical Research Communication, 261(1): 183-187, 1999.  202   Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutrotrophin Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.  31   Freenan et al. "Evidence That Pitestle and Tumour Heparanases Are Similar Enzymes", Biochem J., 342: 361-368, 1999.  32   Emst et al. "The Expression of Glycosaminoglycams", Crit. Rev. in Nicohemistry and Molecular Biology, 30(3): 387-444, 1995.  33   John Hard Character		89	Living and RClaring of Manual in The Control of the	
90 Toyoshima et al. "Human Heparanas: Purification, Characterization, Cloning, and Expression", J. Biolog, Chemistry, 274(3): 2413-24160, 1999. 91 Kussie et al. "Cloning and Functional Expression of A Human Heparanase Gene", Biochemical and Blophysical Research Communication, 261(1): 183-187, 1999. 92 Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutotrophin Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cella", Int. J. Cancer, 82: 112-120, 1999. 93 Freman et al. "Evidence That Platelet and Tumour Heparanases Are Similar Enzymes", Biochem J., 142: 361-368, 1999. 94 Enst et al. "Enzymeit Degradation of Glycosaminoglycans", Crit. Rev. in Riochemistry and Molecular Biology, 30(5): 387-444, 1995. 95 Zhu et al. "A 182 Bp Fragment of the Mouse Prort (11) Collagen Gene If Sufficient to Diecet Chondrocyte Expression in Transgenic Mices", J. Cell Science, 08: 3677-3684, 595. 96 Hormuzik et al. "A Gene-Targeting Appreach Identifies A Punction for the First Intro in Expression of the al (I) Collagen Gene.", Mol Cell Biol 18(6): 3368-3375, 1998. Abstract. 97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Blements for Transgene Expression in Lung Airways", Proc. Nutl. Acad. &cl. USA, 94: 14695-14700, 1997. 98 Ye et al. "Targeted Quae Correction: A New Strategy for Molecular Medicine", Molecular Medicine Tology, 24:31-437, 1998. 99 Lal et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract. 100 Yanside al. "This Survey and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochmica et Riophyleta Agh, 1172: 37-42, 1993. 101 Le Fur et al. "Selective Incress to Specific Micranite Splice Variants of Tyrosinaso in Murine Medanomas: A Projectoh-Basis for Immunotherapy", Proc. Netl. Acad. &ci. USA, 94: 5325-5337, 1997. 102 Gewitz et al. "ToNA Vaccination With HuD habits Growth of A Neuroblastoma in Mice," Clinical Encor y Expression of the Human Heparanase Procursor o		67	Hulett et al. "Cloning of Mammalian Heparanase, An Important Enzyme in Tumor	
Expression", J. Biolog. Chemistry, 274(34): 24153-24160, 1999.  9 Kustie et al. "Cloning and Functional Expression of A Human Hoparnanse Gene", Biochemical and Biophysical Research Communication, 26(1): 183-187, 1999.  92 Walch et al. "Correlation of Overtexpression of the Low-Affinity p75 Neutrotrophin Receptor With Augmented Invasion and Heparnanse Production in Human Malignant Melanoma Cella", 11. Cancer, 82: 112-120, 1999.  93 Freeman et al. "Evidence That Platelet and Tumour Heparnanses Are Similar Enzymes", Biochem J., 342: 361-368, 1999.  94 Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Riccommistry and Molecular Biology, 30(5): 387-444, 1995.  95 Zhou et al. "A 122 Bp Fragment of the Mouse Prool (11) Collagen Gene of Sufficient to Deper Chondrocyte Expression in Transgenic Mice", J. Cell Science, 108: 3677-3684, 1993.  96 Hormuzki et al. "A Gene-Targeting Approach Identifies A Punction for the First Intro on a Depression of the al. (1) Collagen Gene.", Mol Cell Biol J. 18(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. 84; USA, 94: 14595-14700, 1997.  98 Ye et al. "Targeted Quae Correction: A New Strategy for Molecular Medicine", Molecular Medicine Tajday, P. 241-247, 1998.  100 Yazaki et al. "The Structure had Expression of fine FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochmica et Bjohysica Agá, 1172: 37-42, 1993.  101 Le Fue et al. "Selective Increase in Specific Allermative Spitice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. 84: 1997.  102 Gewitz et al. "Natlocine Acid Therapythes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shatsty Gene Disruption in Migic Models of Development and Disease", Molecular and Cellular Biochemistry, 181/163-179, 1998.  104 Carpetier et al. "Tho Accidence of Differences in Medulation & Ras Expression Wi	<del></del>	90	Toyochima et al. "Human Hangranger: Durification Characteristics Classes and	/_
91 Kussie et al. "Cloning and Functional Expression of A Human Heparanase Ceme" Biochemical and Biophysical Research Communication, 26(1): 183-187, 1999. 92 Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutrocrophin Recoptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999. 93 Ferenae et al. "Biochem J., 342: 361-368, 1999. 94 Ernst et al. "Enzymatic Degradation of Glycosaminophycans", Crit. Rev. in Nicohemistry and Molecular Biology, 30(5): 387-444, 1995. 95 Zhgu et al. "A 182 Bp Fragment of the Mouse Proof (11) Collagen Gene of Sufficient to Direct Chondrocyte Expression in Transgenic Mycs", J. Cell Science, 308: 3677-3684, 2095. 96 Hormuzhi et al. "A Geno-Targeting Approach Identifies A Punction for the First Intron in Papression of the al. (1) Collagen Gene.", Mol Cell Biol J. 18(6): 3368-3375, 1998. Abstract. 97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Rehalatory Blements for Transgene Expression Cassette With Human DNA Rehalatory Blements for Transgene Expression and American Proc. Natl. Acad. 8ci. USA, 9si. 14695-14700, 1997. 98 Ye et al. "Targeted Open Correction: A New Strategy for Molecular Medicine", Molecular Medicine Tolsey, PA31-437, 1998. 99 Lai et al. "Homologous Recombination Based Geno Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract. 100 Yeaki et al. "The Structure And Expression of the FGR Receptor-1 mRNA Isoforms in Rat Tissues". Blochmica et Rjophysica Aca, 1172: 37-42, 1993. 101 Le Fur et al. "Selective Increase b, Specific Alternative Splice Variants of Tyrosinase in Marine Medanomas: A Projected basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5357, 1997. 102 Gewirtz et al. "Walch Leach Acid Therappidus: State of the Art and Future Prospects", Blood, 27(2): 712-736, 1998. 103 Shettyr 'Gene Disruption in Migs. Models of Development and Disease", Molecular and Cellular Biochemistry, 181/163-179, 1994. 104 Cappentier et al. "Tho Accessin		,,		
Biochemical and Biophysical Research Communication, 26(1): 183-187, 1999.  92 Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutrorophin Receptor With Augmented Invasion and Reparamses Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.  93 Freenan et al. "Evidence that Pittelet and Tumour Heparanses Are Similar Enzymes", Biochem 1, 342: 361-368, 1999.  94 Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Ajochemistry and Molecular Biology, 30(5): 387-444, 1995.  95 Zhu et al. "A 182 Bp Fragment of the Mouse Proal (1) Collagen Gene J. Sufficient to Dicert Chondrocyte Expression in Transgenic Mice", J. Cell Science, 08: 3677-3684, 995.  96 Hormuzhi et al. "A Gene-Targeting Approach Identifies A Punction for the First Intro in Expression of the cit (1) Collagen Gene.", Mol Cell Biol J. 8(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Blements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 341: 14695-14700, 1997.  98 Ye et al. "Targend Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Tolny, PA31-437, 1998.  100 Yazaki et al. "The Structure had Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Bjophysica Agá, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific Remains Spice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewitz et al. "The Structure had Depression of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shasty "Gene Disruption in Migs. Models & Development and Disease", Molecular Mechanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Micre", Clinical Canner Receased, 4: 2819-2828, 1998.  105 Shasty "Gene Disruption in M		91	Kussie et al. "Cloning and Functional Expression of A Human Hangrange Gene"	
Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor With Augmented Invision and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.  93 Freeman et al. "Enzymes", Blochem I., 342: 361-368, 1999.  Enter et al. "Enzymes", Blochem I., 342: 361-368, 1999.  94 Enter et al. "Enzymes begandation of Glycostaminoplycares", Crit. Rev. in Riochemistry and Molecular Biology, 30(3): 387-444, 1995.  95 Zhou et al. "A 162 Bp Fragment of the Mouse Proot (11) Collagen Gene I. Sufficient to Deet Chondrocyte Expression in Transgenic Mice", J. Cell Science, 408: 3677-3684, 1995.  96 Hormuzul et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Depression of the et (1) Collagen Gene.", Mol Cell Biol, 18(6): 3368-3375, 1998. Abstrakt.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Régulatory Blements for Transgene Expression in Lung Airways", Proc. Natl. Acad. 3ci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Trageted Ogne Correction: A New Strategy of Molecular Medicine", Molecular Medicine Telay, P.431-437, 1998.  99 Lui et al. "Tongeted Ogne Correction: A New Strategy of Molecular Medicine", Molecular Medicine Telay, P.431-437, 1998.  100 Yazaki et al. "The Structure And Expression of the FGF Receptor-1: mRNA Isoforma in Rat Tissues", Blochimica et Riophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase a Specific Ahrenative Spitoc Variants of Tyrosinase in Murine Melanomas: A Projected Sasis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapethes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Ome Disruption in Mice. Models of Development and Disease", Molecular and Cellular Biochemistry, 187: 163-179, 1994.  104 Carpetine et al. "Nucleic Acid Therapethes: State of the Art and Future Prospects", Blood, 92(2): 712-736, 1998.  105 Shekhar et al. "The Wacanism of Mice Models of		-	Biochemical and Biophysical Research Communication 261(1): 183-187, 1999	
Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells; Int. J. Cancer, 82: 112-120, 1999.  93 Freeman et al. "Evidence That Platelet and Tumour Heparanases Are Similar Enzymes", Biochem 1, 342: 361-368, 1999.  94 Ernst et al. "Enzymatic Degradation of Glycosaminos)y-cans", Crit. Rev. in Riochemistry and Molecular Biology, 30(3): 387-444, 1995.  95 Zhou et al. "A 182 Bp Fragment of the Mouse Proot (11) Collagen Gene J Sufficient to Detect Chondrocyte Expression in Transgenic Mice*, J. Cell Science, 408: 3677-3644, 2955.  96 Hormuziki et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Depression of the al (I) Collagen Gene.", Mol Cell Biol (18(6): 3368-3375, 1998. Abstrate.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sq. U.SA, 94: 1495-14700, 1997.  98 Ye et al. "Targeted Ogae Correction: A New Strategy of Molecular Medicine", Molecular Medicine Telays, P.431-437, 1998.  99 Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Njobhysica Agal, 1172: 37-42, 1993.  101 Le Fuer et al. "Selective Increase is Specifiy Alternative Spiloc Variants of Tyrosinaso in Murine Melanomas: A Projected Plasis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5323-5337, 1997.  102 Gewirtz et al. "Pucleic Acid Therapyfiles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mic. Models of Development and Disease", Molecular Biochemistry, 18/ 163-179, 1999.  104 Carpentier et al. "Pucleic Acid Therapyfiles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  105 Lai et al. "PioNA Vaccination With Melastanic Completements by Alternation of the Planan Factor IX Gene", Journal of Biologicy Chemistry, 270(10): 5276-		92	Walch et al. "Correlation of Overexpression of the Love Affinity n75 Neutrotrophin	
Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.  93 Freeman et al. "Envidence That Platelet and Tumour Heparanases Are Similar Eazymes", Biochem 1, 342: 361-368, 1999.  94 Ernst et al. "Enzymatic Degradation of Glycosaminopycars", Crit. Rev. in Riochemistry and Molecular Biology, 30(3): 387-444, 1995.  95 Zhou et al. "A 182 Bp Fragment of the Mouse Proot (11) Collagen Gene Jr Sufficient to Drect Chondrocyte Expression in Transgenic Mice", J. Cell Science, 108: 3677-3684, 2955.  96 Hormuzgi, et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Depression of the al. (1) Collagen Gene.", Mol Cell Biol J 18(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Requisatory Elements for Transgene Expression for Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Ogne Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P.431-437, 1998.  99 Lal et al. "Thomologous becombination Based Gene Interapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blockhimica et Ripotypsica Aga, 1,172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific/Alternative Spince Variants of Tyrosinase in Murine Melanomas: A Projected/Basif for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapedities: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mig. Models of Development and Disease", Molecular and Cellular Biochemistry, 187, 163-179, 1994.  104 Carpentier et al. "DNA Vascofiation With HuD Sphibits Growth of A Neuroblastoma in Mice", Clinical Cancer (Esseavch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vascofiation of Ufferences in Modulation & Ras Expression With Metastatic Completence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 19945.  108	<b>,</b>		Recentor With Augmented Invasion and Henaramase Production in Human Malignant	
93 Freeman et al. "Evidence That Platelet and Tumour Heparanases Are Similar Enzymes", Biochem J. 342: 361-368, 1999.  94 Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Riochemistry and Molecular Biology, 30(3): 387-444, 1995.  95 Zhou et al. "A 182 Bp Fragment of the Mouse Proot (11) Collagen Gene J Sufficient to Detect Chondrocyte Expression in Transgenic Mice", J. Cell Science, 408: 3677-3644, 2955.  96 Hormuzul et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Depression of the al (I) Collagen Gene.", Mol Cell Biol. [18(6): 3368-3375, 1998. Abstrate.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. 54, USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Ogae Correction: A New Strategy of Molecular Medicine", Molecular Medicine Talays, P4 31-437, 1998.  99 Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Riophysica Agal, 1172: 37-42, 1993.  101 Le Fuer et al. "Selective Increase is Specifie/Alternative Spilor Variants of Tyrosinaso in Murine Melanomas: A Projected Passis for Immunotherapy", Proc. Netl. Acad. Sci. USA, 94: 5323-5337, 1997.  102 Gewirtz et al. "Plucleic Acid Therapyfiles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Micf. Models of Development and Disease", Molecular and Cellular Biochemistry, 18/ 163-179, 1998.  104 Carpentier et al. "Plucked Acid Therapyfiles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  105 Lai et al. "Plucked Acid Therapyfiles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  106 Carpentier et al. "Probacometry, 18/ 163-179, 1994.  107 Shekhar et al. "Role opintron I in Expression of the Human Factor IX Gene", Journal of Biologics C		\		
Enzymes", Biochem J., 342: 361-368, 1999.  Ernst et al. "Enzymatic Degradation of Glycosaminoglycams", Crit. Rev. in Ricchemistry and Molecular Biology, 30(3): 387-444, 1995.  2bgu et al. "A 182 pp Fragment of the Mouse Proat (11) Collagen Gene. J. Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science, 408: 3677-3684, 1995.  96 Hormuzbil et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Bapression of the al (1) Collagen Gene.", Mol Cell Biol J 18(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Dayelopment of An Epithelium-Specific Expression Cassette With Human DNA Requistory Blements for Transgene Expression in Lung Airways", Proc. Natl. Acad. 3cj. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Oane Correction: A New Strategy of Molecular Medicine", Molecular Medicine Today, P.431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geny Iherapy", Exp. Nephrol., 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Bjophysica Apá, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase al. Specifig/Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Netl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewitz et al. "Nucleic Acid Therapethes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry Gene Disruption in Migd. Models at Development and Disease", Molecular and Cellular Biochemistry, 18y. 163-179, 1994.  104 Carpentier et al. "DNA Vaccingio", Critical Reviews in Immunology, 18: 449-484, 1998.  105 Lai et al. "DNA Vaccingio", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurschi et al. "PolNa Vaccingio", Critical Reviews in Immunology, 18: 449-484, 1998.  107 Shekhar et al. "Critical Reviews in Immunology, 18: 449-484, 1998.  108 Lai et al. "Pinka Processing of the Human Factor IX Gene", Journal of Biologics Chemistry, 270(10): 5276-5281, 1995.  109 Linhardt et		93		<del></del>
94 Ernst et al. "Enzymatic Degadation of Glycosaminoglycans", Crit. Rev. in Biochemistry and Molecular Biology, 39(5): 387-444, 1995.  95 Zhqu et al. "A 182 Bp Fragment of the Mouse Proci (11) Collagen Gene I. Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science, 08: 3677-3684, 995.  96 Hormuzhi et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Expression of the all (1) Collagen Gene.", Mol Cell Biol 18(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Dayelopment of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted One Correction: A New Strategy for Molecular Medicine", Molecular Medicine Tedry, P.431-437, 1998.  99 Lai et al. "Homogous Recombination Based Geny Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochmica et Rijophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific/Humative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Sasis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 3532-5337, 1997.  102 Gewitz et al. "Nucleic Acid Therapgedies: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mige! Models of Development and Disease", Molecular and Cellular Biochemistry, 18 / 163-179, 1998.  104 Carpettier et al. "DNA Vascofation With HuD labibits Growth of A Neuroblastoma in Mice", Clinical Cancer (seearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccingd", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron 1 in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1905.  107 Shekhar et al. "Cologosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycoblylogy, 7(2): 277-284, 1997.  108 Durand et al. "Active-Site Motifs				
Special Committee   Spec		94		
25 2 Ju. et al. "A 182 Dp Fragment of the Mouse Proof (11) Collagen Gene of Sufficient to Detect Chondrocyte Expression in Transgenic Mice", J. Cell Science. 08: 3677-3684, 1995.  Hormuzhi et al. "A Gene-Targeting Approach Identifies A Punction for her First latron in Expression of the al (I) Collagen Gene.", Mol Cell Biol 18(6): 3368-3375, 1998. Abstract.  77 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Oene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Todiny, P.431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geny Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Riophysica Agá, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in SpecifigAtlernative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapothes: State of the Art and Future Prospects", Blood, 52(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mig. Models of Development and Disease", Molecular and Cellular Biochemistry, 18 / 163-179, 1998.  104 Carpentier et al. "DNA Vacofination With HuD laphibits Growth of A Neuroblastoma in Mice", Clinical Cancer (seearch, 4: 2819-2824) 1998.  105 Lai et al. "DNA Vacofination With HuD laphibits Growth of A Neuroblastoma in Mice", Clinical Cancer (seearch, 4: 2819-2824) 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, No.5.  107 Shekhar et al. "Cycleation of Differences in Modulation of Ras Expression With Metastasis, 14/2-37, 19945.  108 Durand et al. "Role of Intron I in Expression by Introns: Conversion of An Inhibitory Imput to A Stimulatory Intron by Al			Riochemistry and Molecular Biology, 30(5): 387-444, 1995.	
10 Drect Chondrocyte Expression in Transgenic Mice", J. Cell Science, 108: 3677-3684, 1995.  100 Hormuzki et al. "A Gene-Targeting Approach Identifies A Punction for the First Intron in Expression of the al (f) Collagen Gene.", Mol Cell Biol. 18(6): 3368-3375, 1998. Abstrag.  101 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Robulatory Ellements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  102 Ye et al. "Targeted Oene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Tedny, P.431-437, 1998.  103 Lai et al. "Homologous Recombination Based Geny Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  104 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochtmica et Ripohysica Aya. 1712: 37-42, 1993.  105 Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  105 Gewirtz et al. "Nucleic Acid Therapgelike: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  106 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181 (163-179, 1998.  107 Lai et al. "DNA Vaccination With HuD babibits Growth of A Neuroblastoma in Mice", Clinical Cancer Jesseach, 4: 2819-2829, 1998.  108 Lai et al. "DNA Vaccinof", Critical Reviews in Immunology, 18: 449-484, 1998.  109 Lai et al. "DNA Vaccinof", Critical Reviews in Immunology, 18: 449-484, 1998.  100 Lai et al. "DNA Vaccinof", Critical Reviews in Immunology, 18: 449-484, 1998.  101 Shekhar et al. "Coprelation of Differences in Modulation & Ras Expression With Metastatic Compactence of Mouse Mammary Tumour Subpopulations", Invasion Metastatis, 14, 27-37, 1994/5.  108 Durand et al. "Role offiction for Impurences in Modulation & Ras Expression With Metastatis in Marina House, 1997, 1998.  109 Korb et al. "Simulation of Gene		95		
96 Hormundi, et al. "A Geno-Targeting Approach Identifies A Function for the First Intron in Expression of the al (I) Collagen Gene.", Mol Cell Biol. (18(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Oene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Taday, P.431-437, 1998.  99 Lei et al. "Honologous Recombination Based Geng Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Biophysica Aya., 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase b. Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Nearjofr Immunotherapy", Proc. Netl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapedries: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Miod: Models of Development and Disease", Molecular and Cellular Biochemistry, 187. 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD habits Growth of A Neuroblastoma in Mice", Clinical Cancer (Seaceach, 4: 2819-2828, 1998.  105 Lai et al. "DNA Vaccined", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role offatton in in Expression of the Human Factor IX Gene", Journal of Biologica Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Cogretation of Differences in Modulation & Ras Expression With Metastatic Completence of Mouse Mammary Tumour Subphysholations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolaseb, Invariant Features of Clan Gl-A Glycosyl Hydrolases Deduced From Hydrophobic Sluster Analysis", Glycoblogy, 7(2): 277-284, 1997.  109 Korb et al. "Folysaccharide Lysaes", Applied Biochemistry and Biotechnolog	1		to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 408: 3677-	
Intron in Depression of the al (I) Collagen Gene.", Mol Cell Biol 18(6): 3368-3375, 1998. Abstract.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted One Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P. 431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geno Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Biophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase a Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therappethes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shasty "Gene Disruption in Mige! Models of Development and Disease", Molecular and Cellular Biochemistry, 18): 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD binbits Growth of A Neuroblastoma in Mice", Clinical Cancert Jessearch, 4: 2819-282A, 1998.  105 Lai et al. "DNA Vaccination With HuD binbits Growth of A Neuroblastoma in Mice", Clinical Cancert Jessearch, 4: 2819-282A, 1998.  106 Kurachi et al. "Role of Intron 1 in Expression of the Human Factor IX Gene", Journal of Biologics Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Corfetation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gli-A Glycosyl Hydrolases Deduced From Hydrophobic Nuster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron by Alternation of			3684, 1995.	
1998. Abstract.  97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Que Correction: A New Strategy for Molecular Medicine", Molecular Medicine Taday, P.431-437, 1998.  99 Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochmines et Rijophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase a Specific Alternative Splice Variants of Tyrosinaso in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapedites: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 187 163-179, 1998.  104 Carpentier et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.  105 Lai et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Corfetation of Differences in Modulation of Ras Expression With Metastasis Completence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 147-737, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Suster Analysis", Glycobishogy, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intry to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1999.  110 Linhardt et al. "Proessing of the Human Heparanase Precursor and Evidence that the		96	Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First	
97 Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Redulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted Que Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P. 431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geny Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Riophysica Aca, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specifig/Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Resign for Immunoherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapeaths: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mige", Models of Development and Disease", Molecular and Cellular Biochemistry, 18/ 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD phibits Growth of A Neuroblastoma in Mice", Clinical Cancer Jesearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccinage", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastasis in Carlo Structure of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 19945.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolasek Invariant Features of Clan Gil-A Glycosyl Hydrolases Deduced From Hydrophobic Guister Analysis", Glycobjelogy, 7(2): 277-284, 1997.  109 Korb al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ads Research, 21(25): 5901-5908, 1993.  110 Linhard et al. "Protysaccharide Lysaes", Ap		l l	Intron in Expression of the al (I) Collagen Gene.", Mol Cell Biol 18(6): 3368-3375,	
Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted One Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P. 431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geno Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Niophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific/Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapethes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mici: Models of Development and Disease", Molecular and Cellular Biochemistry, 18/ 163-179, 1998.  104 Carpentier et al. "DNA Vaccing Intelligence of Carpentier et al. "DNA Vaccing Critical Reviews in Immunology, 18: 449-484, 1998.  105 Lai et al. "DNA Vaccing Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurschi et al. "Role of Intro I in Expression of the Human Factor IX Gene", Journal of Biologics Chemistry, 270(10): 5276-5281, 1905.  107 Shekhar et al. "Cycleidion of Differences in Modulation of Ras Expression With Metastasic Completence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Quester Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intro to A Stimulatory Intron by A Intention of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 Linhard et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Che	·			
Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted One Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P. 431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geno Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Niophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific/Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapethes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mici: Models of Development and Disease", Molecular and Cellular Biochemistry, 18/ 163-179, 1998.  104 Carpentier et al. "DNA Vaccing Intelligence of Carpentier et al. "DNA Vaccing Critical Reviews in Immunology, 18: 449-484, 1998.  105 Lai et al. "DNA Vaccing Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurschi et al. "Role of Intro I in Expression of the Human Factor IX Gene", Journal of Biologics Chemistry, 270(10): 5276-5281, 1905.  107 Shekhar et al. "Cycleidion of Differences in Modulation of Ras Expression With Metastasic Completence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Quester Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intro to A Stimulatory Intron by A Intention of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 Linhard et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Che		97	Chow et al. "Development of An Epithelium-Specific Expression Cassette With	
Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.  98 Ye et al. "Targeted One Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P.431-437, 1998.  99 Lai et al. "Homologous Recombination Based Geno Therapy", Exp. Nephrol. 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et aliophysica Agá, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific/Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Netl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Theraposities: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Diaruption in Mice. Models of Development and Disease", Molecular and Cellular Biochemistry, 187: 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccinge", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intro I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 78(10): 5276-5281, 1905.  107 Shekhar et al. "Corletation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subgulations", Invasion Matastasis, 1472-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gif-A Gilycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intro to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Afas Research, 21(25): 5901-5908, 1993.  110 Linhardt et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 1, 29590, 1999.  111 Linhardt et al. "Efficient	1	i	Human DNA Regulatory Elements for Transgene Expression in Lung Airways",	
Molecular Medicine Tolgay, P. 431-437, 1998.  99 Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGR Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Biophysica Acia, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinaso in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapetries: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 189. 163-179, 1998.  104 Carpentier et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.  105 Lai et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.  Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5275-5281, 1995.  107 Shekhar et al. "Coprelation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Scittle-Site Motifs of Lysosomal Acid Hydrolases Invariant Features of Clan Gft-A Glycosyl Hydrolases Deduced From Hydrophobic Nuster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intro to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1999.  110 Linhardt et al. "Proysaccharide Lysass", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  111 Linhardt et al. "Polysaccharide Lysass", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TiBs, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Col.3, § 1, Claims 1-24.  110 Clark			Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.	
Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et aliophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-537, 1997.  102 Gewirtz et al. "Nucleic Acid Therapethes: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mige: Models at Development and Disease", Molecular and Cellular Biochemistry, 18). 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Jessearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccinator, Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Introa I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Corleation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14, 27-37, 1994/5.  108 Durand et al. "Active-Sire Motifs of Lysosomal Acid Hydrolasek Invariant Features of Clan Gil-A Glycosyl Hydrolases Deduced From Hydrophobic Suster Analysis", Glycobjelogy, 7(2): 277-284, 1997.  109 Korb at al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intro to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1999.  110 Linhardt et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  111 Linhardt et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  112 Linhardt et al. "Polysacchari		98		
7(1):11-14, 1999. Abstract.  100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Biophysica Agra, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase b. Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basi for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapeutles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice. Models of Development and Disease", Molecular and Cellular Biochemistry, 18/. 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Sphibits Growth of A Neuroblastoma in Mice", Clinical Cancer (Assearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Introa I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 27(10): 5276-5281, 1995.  107 Shekhar et al. "Corclation of Differences in Modulation of Ras Expression With Metastatic Compétence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gif-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acts Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  110 Linhardt et al. "Polysaccharide Lysaes", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  111 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", 7188, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "			Molecular Medicine Taday, P.431-437, 1998.	
100 Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Blochimica et Niophysica Aga, 1172: 37-42, 1993.  101 Le Fur et al. "Selective Increase is Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therappents: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 18/ 163-179, 1998.  104 Carpentier et al. "IDNA Vaccination With HuD lahibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-282-1998.  105 Lai et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role offintron I in Expression of the Human Factor IX Gene", Journal of Biologica Chemistry, 270(10): 5276-5281, N95.  107 Shekhar et al. "Coffelation of Differences in Modulation of Ras Expression With Metastatic Compétence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/ 27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gif-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb A al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulation of Gene Expression of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 Linhardt et al. "Polysaccharide Lysaes", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  111 Linhardt et al. "Polysaccharide Lysaes", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TiBs, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-	ŀ	99		
in Rat Tissues", Blochimica et Riophysica Aga, 1172: 37-42, 1993.  Le Fur et al. "Selective Increase & Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Rasis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapedites: State of the Art and Future Prespects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mic.: Models of Development and Disease", Molecular and Cellular Biochemistry, 187. 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD babibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccination With HuD babibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  106 Kurachi et al. "Role of Intro I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1905.  107 Shekhar et al. "Cofrelation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14 27-37, 1994/s.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases Invariant Features of Clan Gil-A Glycosyl Hydrolases Deduced From Hydrophobic Ruster Analysis", Glycobjology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  111 Linhardt et al. "Polysaccharide Lysses", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eu				
Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapediles: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice." Models of Development and Disease", Molecular and Cellular Biochemistry, 18 // 163-179, 1998.  104 Carpentier et al. "DNA Vaccineit Mice." Models of Development and Disease", Molecular in Mice.", Clinical Cancer Research, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccineit", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1905.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastasis, 14/27-37, 1994/s.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gif-A Glycosyl Hydrolases Deduced From Hydrophobic Nuster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron by Alternation of the Splice Donor Sequence", Nucleic Acks Research, 21(25): 5901-5908, 1993.  110 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  111 Linhardt et al. "Polysaccharide Lysses", Applied Biochemistry and Biotechnology 12: 125-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		100		-
in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapentics: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Diaruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 18 // 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Jesearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccinas", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpolyulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases Invariant Features of Clan GJ/A Glycosyl Hydrolases Deduced From Hydrophobic Suster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion ox An Inhibitory Intron to A Stimulation of Gene Expression by Introns: Conversion ox An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  111 Linhardt et al. "Polysaccharide Lysses", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.				
USA, 94: 5332-5337, 1997.  102 Gewirtz et al. "Nucleic Acid Therapenings: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 18 // 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Jessearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccinos", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Introa I in Expression of the Human Factor IX Gene", Journal of Biologica Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpolulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrophobic Sluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  111 Linhardt et al. "Polysaccharide Lysses", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		101	Le Fur et al. "Selective Increase D. Specific Alternative Splice Variants of Tyrosinase	
102 Gewirtz et al. "Nucleic Acid Therapetits: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 18/. 163-179, 1998.  104 Carpentier et al. "DNA Vacchaiton With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Jesearch, 4: 2819-282A, 1998.  105 Lai et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurschi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastasis Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases Invariant Features of Clan Gl/1-A Glycosyl Hydrolases Deduced From Hydrophobic Stuster Analysis", Glycoblology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29583, 29590, 1999.  11 Linhardt et al. "Polysaccharide Lysses", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  110 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  111 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.	. ]			
Blood, 92(3): 712-736, 1998.  103 Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181/163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Cortelation of Differences in Modulation of Ras Expression With Metastatic Completence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases. Invariant Features of Clan Gif-A Glycosyl Hydrolases Deduced From Hydrophobic Nuster Analysis", Glycobjology, 7(2): 277-284, 1997.  109 Korb al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulation of Gene Expression of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29583, 29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		100		
103 Shastry "Gene Disruption in Mice." Models of Development and Disease", Molecular and Cellular Biochemistry, 18 / 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice.", Clinical Cancer Kesearch, 4: 2819-2824, 1998.  105 Lal et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Confelation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14 27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gri-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycoblology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29581-29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.	i	102		
and Cellular Biochemistry, 181/ 163-179, 1998.  104 Carpentier et al. "DNA Vaccination With HuD shibits Growth of A Neuroblastoma in Mice", Clinical Cancer Kesearch, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccing", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Completence of Mouse Mammary Tumour Subportulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases. Invariant Features of Clan Gif-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 airbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		102	B1000, 92(3): 712-736, 1998.	
Carpentier et al. "DNA Vaccinaiton With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  Lai et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.  Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biologica Chemistry, 270(10): 5276-5281, 1895.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Completence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases' Invariant Features of Clan Gri-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958/29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Calams 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		103	Shasiry "Gene Disruption in Mice: Models at Development and Disease", Molecular	
in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.  105 Lai et al. "DNA Vaccing", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1895.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gil-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29584, 29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		104		
105 Lai et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.  106 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Corfetance of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Fluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 t. 29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.		104		
Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan Gh-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 \( \) 29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.	<del></del>	105		
Journal of Biological Chemistry, 270(10): 5276-5281, 1995.  107 Shekhar et al. "Cortelation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan Gif-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acts Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", T1BS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and			Kurechi et al "Role of intron Lin Everescion of the Human Factor IV Gene"	
Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Correlations of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases, Invariant Features of Clan GM-A Glycosyl Hydrolases Deduced From Hydrophobic Sluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958/29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	• [	100	Journal of Riological Chemistry 270(10): 5276-5281 1905	
Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14/27-37, 1994/5.  108 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases; Invariant Features of Clan GM-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29581- 29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", T1BS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		107		
Metastasis, 14/27-37, 1994/5.  Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GM-A Glycosyl Hydrolases Deduced From Hydrophobic Gluster Analysis", Glycobiology, 7(2): 277-284, 1997.  Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  It airbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	ľ			
Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Sluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	Į		Metastasis, 14/27-37, 1994/5.	
of Clan GrA Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1993.  110 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		108		
Glycobjology, 7(2): 277-284, 1997.  109 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	ļ		of Clan GA-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis".	
Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Ards Research, 21(25): 5901-5908, 1993.  110 fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29583, 29590, 1999.  111 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	f	- 1	Glycobjology, 7(2): 277-284, 1997.	
Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Adds Research, 21(25): 5901-5908, 1993.  110 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999.  11 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		109	Korb A al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory	
Adds Research, 21(25): 5901-5908, 1993.  110 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958 (29590, 1999).  11 Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	į		Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic	
the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958, 29590, 1999.  Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		1	A dis Research, 21(25): 5901-5908, 1993.	
29590, 1999.  Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		110		
Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.  Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		1	the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958	
12: 135-176, 1986.  112 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  113 Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and				
Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	ľ	11/		
Tibs, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.  Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and				
Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	X	7112		
Eukaryotic Vector", Gene, 108(2): 193-199, 1991.  114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and				
114 Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and		113		
			Eukaryotic Vector", Gene, 108(2): 193-199, 1991.	
Production of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3):		114		
	/ 1	į		\
337-350, 1998.		į	357-350, 1998.	1
· _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ · · _ ·	<u></u>		· ·	

\_----

<u> </u>			
	115	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection	
<del></del>	11.6	Studies <sup>n</sup> , Ann. NY Acad. Sci., 738: 104-115, 1994.	
	116	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene	
		Regulatory Sequences", Biochem. Cell Biol., 80(6): 777-788, 2002.	
	117	Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic	
		Chickens", Nature Biotechnology, 19: 396-399, 2002.	
	118	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated	
		Transport Into the Chicken Egg Yolk", Mol. Immunol., 38(8): 619-625, 2002.	
}	No	Clark et al. "Pharmaceuticals From Transgenic Livestock", TIBTECH, 5: 20-24,	
1	Ι,Κ		
	100	1987.	
1	120	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and	
		Alpha-Lactalbumin cDNA Clones", J. Biol. Chem., 256(1): 526-32, 1981.	
ĺ	121	campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and	
		Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984.	•
	122	Gorodetsky et al. "Isolation and Characterization of the Bos Taurus B-Casein Gene".	·
l j		Gene, 66: 87-96, 1988.	
	123	Alexander et al. "Complete Sequence of the Bovine β-Lactoglobulin DNA", Nucleic	···
		Acids Research, 17(16): 6739-6744, 1989.	•
	124	Benezra et al. "Thrombin Enhances the Degradation of Heparan oulfate in the	
	124	Beneza de als información de Degradation of reparamourate in the	
		Extracellular Matrix by Tumor Cell Heparanase", Exptl. Cell. Res., 201: 208-215,	
		1992.	
ļ i	125	Harlow et al. "Antibodies - A Laboratory Manual", Cold Spring Harbor Press, P.	
		471-510, 1988.	
	126	Murray et al. "The Extracellular Matrix", Harper's Birchemistry, McGraw-Hill	
		Professional, 24th Ed., Chap.57, P.667-685, 1998.	
	127	Selvan et al. "Heparan Sulfate in Immune Responses", Ann. NY Acad. Sci., 797:	
		127-139, 1996.	
	128	Prockop "Marrow Stromal Cells as Stem Cell for Nonhematopoietic Tissues",	
		Science, 276; 71-74, 1997.	
	129	Krivit et al. "Microglia: The Effecto Cell for Reconstitution of the Central Nervous	
		System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal	
		Storage Diseases", Cell Transplant, 4(4) \385-392, 1995. Abstract.	
<u> </u>	130	Polyment of a Blicohomical Characteristics Characteristics of the second Characteristics of the	
	130	Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th	
	121	Internatl, Conf. on Molec. Biol. and Pathology of Matrix, Session IV.	
	131	Lazarus et al. "Ex Vivi Expansion and Subsequent Infusion of Human Bone Marrow-	
		Derived Stromal Pregenitor Fells (Mesenchyman Progenitor Cells): Implications for	
		Therapeutic Use", Bone Marrow Transplantation, 16: 557-564, 1995.	
	132	Pomahac et al. "Tissue Engineering of Skin", Crit. Ray. Oral Biol. Med., 9(3): 333-	
		344, 1998. Abstract.	
	133	Benathan et al. "Living Epidermal and Dermal Substitutes for Treatment of Severely	
		Burned Patients", Nev. Med. Suisse Romande, 118(2): 149 153, 1998. Abstract-Art.	
	1	in French.	
	134	Wang et al. "Pasic Fibroblast Growth Factor Enhances Bone-Oraft Incorporation:	
	'	Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	
<del></del>	135	Duffy et al. "Maximizing Flap Survival in A Prefabrication Model Using Exogenous	
	.,,	and Endagenous hEGE: A New Annuacht Missaure 12(4), 121 120 120	
ľ		and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 170, 179, 1996. Abstract.	
<del></del>	124		
<b> </b>	136	Garner "Epidermal Regulation of Dermal Fibroblast Activity", Plast. Recenstr. Surg.,	
		192(1):135-139, 1998. Abstract.	
	137	Raghunath et al. "Cultured Epithelial Autografts: Diving From Surgery Into Matrix	
	/	Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	
	138	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds",	
		American J. Surg., 170(1): 75-83, 1995. Abstract.	
	1/39	Kawaja et al. "Employment of Fibroblasts for Gene Transfer: Applications for	
ر ل		Grafting Into the Central Nervous System", Genet. Eng. NY, 13: 205-220, 1991.	
	l	Abstract.	1
	140	Maillard et al. "Pre-Treatment With Elastase Improves the Efficiency of	<del></del>
		Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene	
	1	Therapy, 5: 1023-1030, 1998.	1
/	141		
	141	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in	\
		Osteoinductive or Conductive Implants", Acta Orthop. Scand. Suppl., 269: 1-33,	<b>\</b>
		1996. Abstract.	

	142	Wang "Basic Fibroblast Growth Factor Infused at Different Times During Bone Graft Incorporation. Titanium Chamber Study in Rats", Acta Orthop. Scand., 67(3): 229-236, 1996. Abstract.	
	143	Inui et al. "Local Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits".	
	144	Tabata et al. "Bone Regeneration by Basic Fibroblast Growth Factor Complexed With Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1998. Abstract.	
	145	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", Acta Orthop. Scand., 60(4): 473-476, 1989. Abstract.	
	14	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991.  Abstract.	
	147	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Uter Therapy: Findings in A Rat Model", J. Gastroenterol., 31(6): 777-784, 1996. Abstract.	·
	148	Chlebaun et al. "The Development and Enhancement of the Collateral Circulation in An Animal Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(7): 202-207, 1994. Abstract.	·
	149	Aplin "Adhesion Molecules in Implantation", Reviews of Reproduction, 2(2): 84-93, 1997.	
	150	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the Establishement of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116, 1998. Abstract.	
	151	Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum. Reprod. Update, 2(4): 302-321, 1996.	
,	152	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases During Blastocyst Implantation", Contracept Fertil Sex, 22(1): 48-51, 1994. Abstract. Article in French.	
	153	Smith et al. "Expression of Heparen Sulfatt Protoglycan (Perlecan) in the Mouse Blastocyst Is Regulated During Normal and Delayed Implantation", Dev. Biol.,	
	154	184(1): 38-47, 1997. Abstract.  Abrahamsohn et al. "Implantation and Recidualization in Rodents", J. Exp. Zool., 266(6): 603-628, 1993. Abstract.	
	155	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9): 679-684, 1996.	
	156	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176, 1996. Abstract.	
	157	Watson et al. "A Grewth Factor Phenotype Map for Ovine Preimplantation Development", Bjol. Reprod., 50(4): 725-733, 1994. Abstract.	
	158	Carlone et al. "Embryonic Modulation of Basic Fibroblast Crowth Factor in the Rat Uterus", Biology of Reproduction, 49(4): 653-665, 1993.	
	159	Wordinger et al. "The Immunolocalzation of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Stages of Embryo Implantation", Growth Factors, 11(3): 1/5-186, 1994. Abstract.	•
	160	Schulz et al. "Growth Factors in Preimplantation Mammalian Embryds", Oxford Review of Reproduction in Biology, 15: 43-81, 1993. Abstract.	
	161	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J., 330: 1341-1350, 1998.	
	162	Esko et al. "Tumor Formation Dependent on Proeoglycans Biosynthesis", Science, 241(4869): 1092-1096, 1988. Abstract.	
	168	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and Avtivity by Cell Density and Heparan Sufate", J. Biological Chemistry, 274(19): 13534-13540, 1990.	
	164	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", American Journal of Physiology, 275: H23-H30, 1998.	/
	165	Sasisekharan et al. "Heparinase Inhibits Neovascularization", Proc. Natl. Acad.Sci. USA, 91: 1524-1528, 1994.	
	166	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases", Journal of Biological Chemistry, 271(17): 10079-10086,	

<u> </u>	T	1996.	
	167	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular Matrix", Cell Regulation, 1: 833-842, 1990.	
	168	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of Cellular Physiology, 148: 274-280, 1991.	
	169	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain From An Inhibitor to A Potent Activator of FGF-2", Nature Medicine, 4(6): 691-697, 1998.	
	170	Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer, 45: 1088-1095, 1990.	<del></del>
	171	Hoogewerf et al. "CXC Chemokines Connective Tissue Activating Peptide-Illand Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Endymes", J. ajol. Chem., 270(7): 3268-3277, 1995.	
	172	Oldburg et al. "Characterization of A Platelet Endoglycosidase Degrading Heparin- Like Polysaccharides", Biochemistry, 19: 5755-5762, 1980.	
	173	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples From Patients With Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.	
	174	Kang et al. "Projectin-Inducible Enhancer Activity of the First Intron of the Bovine β-Casein Gene", Mol. Cells, 8(3): 259-265, 1998. Abstract.	
	175	Gottschalk et al. "Sumatic Gene Therapy. Present Situation and Future Perspective", Arzneimittelforschung, 48(11): 1111-1120, 1998. Abstract.	
	176	Guriec et al. "CD44 Isoforms With Exon V6 and Mescastasis of Primary N0M0 Breast Carcinomas", Breast Cancer Res. Treat., 44(8):261-268, 1997. Abstract.	
	177	Hida et al. "Antisense E1AA Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloprotoinase Activities" Am. J. Pathol., 50(6): 2125-2132, 1997. Abstract.	
	178	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastash", Nature Medicine, 5(7): 793-802, 1999.	
	179	Faber-Elman et al. "Involvement of Wund-Associated Factors in Rat Brain Astrocyte Migratory Response to Axona Injury: In Vitro Simulation", J. Clin. Invest., 97(1): 162-171, 1996.	
	180	Zheng et al. "Increment of hFIX expression With Endogenous Intron 1 In Vitro", Cell Res., 7(1):21-29, 1997 Abstract.	
	181	Welch et al. "Expression of Libozymes in Gene Cransfer Systems to Modulate Target RNA Levels", Curr. Opin Biotechnol., 9(5): 486-496, 1998. Abstract.	
	182	Gewirtz et al. "Facilitating Oligonucleotide Delivery, Helping Antisense Deliver on Its Promise", Proc. Natl. Acad. Sci. USA, 93: 3161-3 (3, 1996.	
	183	Green et al. "Antise se Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", Journal of American Cell Surgery, 191(1) 93-105, 2000.	
	184	Agrawal "Anylsense Oligonucleotides: Towards Clinical Trials, TIBTech, 14: 376-387, 1996.	
	185	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules", Bioconjugate Chem., 8: 935-940, 1997.	•
	186	Luft 7 Making Sense Out of Antisense Oligodeoxynucleotide Delivery Getting There Is Half the Fun". J. Mol. Med, P.75-76. 1998.	
t	187	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998.	
	188	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides", Molecular and Cellular Biochemistry, 172: 213-225, 199	
	189	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research Communications, 231: 540-545, 1997.	
	190	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense Oligonucleotides", Biochimica et Biophysica Acta, 1520: 105-114, 2001.	
	191	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A Structured RNA Target", Biotechnology and Bioengineering, 65(1): 1-9, 1999.	

	1		
\	192	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression	
\	1	Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research, 61(21):	
		7855-7860, 2001.	
	193	Clancy "Handbook of Microbiology", 1: 239-242, 1974.	
	194	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving	
	1 -	Biotechnology", American Society for Microbiology, Chap.2-3, 1990.	
	195	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes	/
	/ '>3		
		Inducible by Respiratory Mucus Derived From Cystic Fibrosis Patients", Mol.	•
	1	Microbiol., 22(5): 1005-1012, 1996. Abstract.	
	198	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutany	
		Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)*, Clin. Exp.	·
		Immunol., 106(2): 374-399, 1996. Abstract.	
	197	Davies et al. "Regulation of the Alginate Biosynthesis Gene AlgC in Pseudomonas	
		Accuginosa During Biofilm Development in Continuous Culture", Appl. Edviron.	
		Michobiol., 61(3): 860-867, 1995. Abstract.	
	198	Azghani et al. "A Beta-Linked Mannan Inhibits Adherence of Pseudopionas	
		Acruginasa to Human Lung Epithelial Cells", Glycobiology, 5(1): 39-44, 1995.	
	1	Abstract.	
	199	Ofek et al. "Racterial Adhesion to Cells and Tissues", Chapman & Hall, NY, P.114-	
	1 .,,	118, 148-153, 118-423, 420-423, 1994.	
	200		
	200	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of A	
		Bacterial Biofilm', Science, 280: 295-298, 1998.	
	201	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill	
		Biofilms of Mucoid Psyudomonas Aeruginosa", Can. Microbiol., 43(11): 999-	
		1004, 1997. Abstract.	L
	202	Stickler et al. "An Assessment of the Ability of A Silver-Releasing Device to Prevent	
	-	Bacterial Contamination of Ocethral Catheter Drainage Systems", British J. Urology,	
	1	78: 579-588, 1996.	
	203	Potera "Bacteria in Biofilms Exchange Developmental Signals", ASM News, 64(6):	
		321-322.	
	204	Gabriel et al. "In Vitro Adherence of Reudomonas Aeruginosa to Four Intraocular	
		Lenses", J. Catatact Refract. Surg., 24. 129, 1998.	
	205	Pier "Rationale for Development of Immunotherapies That Target Mucoid	
	203	Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt.,	
	ı		
	206	98: 350-360, 1997. Abstract.	
	200	Goldberg et al. "Biologic Aprivities of Antobodies to the Neutral-Polysaccharide	•
4.	j	Component of the Pseudononas Aeruginosa Lipopolysaccharide Are Blocked by O	
	j	Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun., 63(1): 21-	
		26. Abstract.	
	207	Meluleni et al. "Muscid Pseudomonas Aeruginosa Growing in A Biofilm In Vitro	
	l l	Are Killed by Opponic Antibodies to the Mucoid Exopolysaccharide Capsule But Not	
		by Antibodies Produced During Chtonic Lung Infection in Oystic Fibrosis Patients",	
		J. Immun., 156(4): 2029-2038, 1995. Abstract.	L
	208	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella	
	1	Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol, Lett.,	
	1	130(1); 1-57, 1995. Abstract.	
	209	Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa	
	1	Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 154(4): S1 \$5-\$182,	
	1	1996. Abstract.	
	210	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial	
	210		i
		Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Pro Natl.	
	+	Acad. Sci. USA, 94(22): 12088-12093, 1997.	
	21/	Boucher et al. "Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis:	
		Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in	
]	/	A Mouse Model of Respiratory Infection", Infect. Immun., 65(9): 3838-3846, 1997.	<b>N</b>
		Abstract.	
	212	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoidy Pseudomonas	
		Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J.	\
	_l	Bacteriol., 178(2): 511-523, 1996. Abstract.	<b>\</b>
	213	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoid	<del></del>
	1	Pseudomonas Aeruginosa and Inflammation in A Mouse Model of Repeated	<b>\</b>
		Respiratory Challenge", Infection and Immunity, 66(1): 280-288, 1998.	\ <b>\</b>
		1 ampliants, Similaring , interested and millimity, out 17. 200-200, 1770.	

	1.004		
N	214	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to	
		Bronchopulmonary Infection With Pseudomonas Aeruginosa", J. Clin. Invest.,	. /
		100(11): 2810-2815, 1997.	
	215	Mrsny et al. "Addition of A Bacterial Alginate Lyase to Purulent CF Sputum In Vitro	
	i	Can Result in the Disruption of Alginate and Modification of Sputum	
	}	Viscoelasticity", Pul. Pharmacol., 7(6): 357-366, 1994. Abstract.	
	216	Wiils et al. "Short-Term Recombinant Human DNase in Bronchiectasis. Effect on	/
<b>\</b>	7 - 10	Clinical State and In Vitro Sputum Transportability". Abstract.	
	1010		
	217	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediaty.	•
		Pulmonol., 22(6): 402-407, 1996. Abstract.	
	218	Randall et al. "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Spytum:	•
		Implications to Pulminary Targeting Strategies", J. Drug. Therapy, 4(4): 233-243,	•
	ì	N996.	
	219	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the	
		Extracellular Polysaccharide of Mucoid Pseudomonas Aeruginosa", Antimicrob.	
•	ŀ		
<u></u>	1000	Agents, Chemother., 42(4): 974-977, 1998. Abstract.	
	220	Speert et al. "Modulation of Macrophage Function for Defense of the Lung Against	
L		Pseudomonas Aeruginosa", Behring Inst. Mitt., 98: 274-282, 1997 Abstract.	<u> </u>
I	221	Ying et al. Alginate, the Slime Exopolysaccharide of Pseudomenas Aeruginosa,	
		Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-Proteinase	•
		Inhibitor, and Accelerates Inhibition by Secretory Leukoprofease Inhibitor", Am. J.	
		Cell. Moll. Biol., %(2): 283-291, 1996. Abstract.	
	222	Jöhansen et al. "Chronic Pseudomonas Aeruginosa Pneymonia: A New Prophylactic	
	***		
<b> </b>	202	Principle", Behring Inst. Mitt., 90: 269-273, 1997. Abstract.	
	223	Pina et al. "The Role of Nuoroquinolones in the Promotion of Alginate Synthesis and	
1		Antibiotic Resistance in Psyudomonas Aeruginosa, Curr. Microbiol., 35(2): 103-	
		108, 1997. Abstract.	· ·
	224	Spencer "Invasive Streptococci, Eur. J. Clin Microbiol. Infest. Dis., 14(Suppl. 1):	
<u>l</u> .	į.	S26-S32, 1995. Abstract.	
	225	Mengistu et al. "Continuous Cultura Studies on the Synthesis of Capsular	
ł		Polysaccharide by Klebsiella Pneumogiae K1", J. Appl. Bacteriol., 76(5): 424-430,	
<b>1</b>	<b>I</b> .	1994. Abstract.	
<del></del>	226		
1	226	Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated With Rapidly	
	<del> </del>	Fatal Outcome in Taiwan", J. Formos Med. Assoc., 95(5): 364-371, 1996. Abstract.	
1	227	Moses et al. "Relative Contributions of Hyalthonic Capsule and M Protein to	
1		Virulence in A Mucoid Strain of the Group A Sceptococcus", Infect. Immun., 65(1):	
		64-71, 1997. Abstract.	
	228	Scott et al. "Visualization of An Extracellular Mucoid Layer of Treponema Denticola	
		ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species*, Oral	
1		Microbiol. Immunol, 12(2): 121-125, 1997. Abstract.	
<del></del>	229	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression	· · · · · · · · · · · · · · · · · · ·
	***	in Contribution of Contin Authorities Inflant Immun. 66/10/14016-01.1007	
1	1	in Septricemia and Septic Arthritis", Infect. Immun., 65(10), 4216-21, 1997.	
	1	Abstract.	·
l	230	Wessels et al. "Effects on Virulence of Mutations in A Locus Essential for	
ŀ	1	Hyaluronic Acid Capsule Expression in Group A Streptococci", Infect. Immun.,	
	<u> </u>	62(2): 483-441, 1994. Abstract.	
	231	Farnd de et al. "A Direct Spectrophotometric Microassay for Sulfated	
!	1 -	Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248,	
Į.		1982.	
<del></del>	232	Associated to Alginate in	
ļ	232		
1		Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", PENS	
	<b> </b>	Microbiol. Lett., 147(2): 195-202, 1997. Abstract.	
Į.	238	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the	
ļ		Expolysaccharide From Mucoid and Non-Mucoid Pseudomonas Aeruginosa", FEMS	
1	X	Microbiol. Letters, 77(1-3): 35-44, 1992. Abstract.	
	234	Jorba et al. "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned	<del></del>
<i> </i>	1	by Aminosugars", Rev. Esp. Fisiol., 36(2): 155-161, 1980. Abstract.	\
<del></del>	225		<del>\</del>
/	235	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis	\
<b>-</b>	<del> </del>	in Lactococcus Lactis", Appl. Environ. Microbiol., 67(1): 33-41, 2001. Abstract.	
/	236	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intraheptic Biliary	
1/		Epithelial Cells Bearing Defective (Delta-f508) Cystic Fibrosis Transmembrane	1
<b>V</b>	I	Conductance Regulator", Hepatology, 27(1): 7-14, 1998. Abstract.	

	Loos	TV 1 - 1 m 1 / CD 1	
	237	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90)	
	1	Maintained in A Low Concentration of Serum, Biochem. J., 207(3): 369-379.	
		Abstract.	
	238	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered	
•		Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med.,	
	1	62(1): 113-122, 1997. Abstract.	
<del></del>	239		
•	V 239	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts",	
		Pediatr. Research, 9(9): 698-702, 1975.	
	240	Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic Fibrosis	
		and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.	
		Abstract.	
	241	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin.	
	1 24.	Microbiol., 6(5): 591-593, 1987. Abstract.	
	1040		
	242	Alison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basje.	
		Michobiol., 34(1): 3-10, 1994. Abstract.	
	243	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung	
	1	Infection in Patients With Cystic Fibrosis", J. Clin. Microbiol., 26(12): 2505-2509,	
	1	1988. Abstract.	
	244	Macone et al. "Mucoid Escherichia Coli in Cystic Fibrosis", The New England	
	244		•
		Journal of Medicine, 304(24): 1445-1449, 1981. Abstract.	
	245	Tatnell et al. "Characterisation of Alginates From Mucoid Spains of Pseudomonas	
		Aeruginosa*, Biochemical Society Transactions, 24: 404S 1996.	
	246	Tatnell et al. "Chemical Analysis of Alginates From Musoid Strains of Pseudomonas	
		Aeruginosa", Biochemical Society Transactions, 22: 370S, 1994.	
	247	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by Non-Mucoid Pseudomonas	
•	247	laging et al. Colonisation of Cystic Florids Facility by Foot-Visiontal Scientification	
	1	Aeruginosa - Characterisation of the Alginate From Mucoid Variants", Biochemical	
		Society Transactions, 24: 4066, 1996.	
	248	Drigues et al. "Comparative Studies of Lipoporysaccharide and Exopolysaccharide	
		From A Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent	
		Mutants", Journal of Bacteriology, 162(2) 504-509, 1985. Abstract.	
	249	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides",	
	247	Biotech. Adv., 12: 393-448, 1994.	
	1		
	250	Anatolii "Hyaluronic Capsule as One of the Factors of Hemolytic Streptococcus	•
	1	Pathogenicity", Chem. Abstracts 95(17): 339, 1977. Abstr.118714 in Zh. Mikrobiol.	
	-	Epidemiol. Immunobiol., 2: 22-27, 1977.	
	251	Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem.	
	l	& Molecular Biol., 13: 1-32, 1984.	
	252	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V.,	
	2,52		
	<del> </del>	P.1-33, 1984.	
	253	Gospodarowicz et al Permissive Effect of the ExtraCellular Matrix on Cell	
		Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7):4094-4098, 1980.	
	254	Li et al. "Immun chemical Localization of Heparanase in Mause and Human	
	1	Melanomas", Lift. J. Cancer, 45: 1088-1095, 1990.	· .
	255	Graham et al "Comparison of the Heparanase Enzymes From Mause Melanoma	
		Cells, Mouse Microphages, and Human Platelets", Biochem. and Mol. Biol. Int.,	
		39(3): 563-571, 1996.	1
	+	1 45 (5) 7	<u> </u>
	256	Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996.	
	257	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and	]
	1	Medicine", Annu. Rev. Biochem., 50: 657-680, 1981.	<u> </u>
	258	riedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in	
	1 -00	Mouse Mammary Gland Development Suggests A Role in Hormone Action and	r
	1 /		
	<del>                                     </del>	Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996.	
	259	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human	ł
		Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6086, 1990. Abstract.	
		Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease",	X
	<b>1/260</b>		
	260		<b>  \</b>
	1	J. Nat. Cancer Inst., 85: 1725-1732, 1993.	\
-/	260 261	J. Nat. Cancer Inst., 85: 1725-1732, 1993.  Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and	\
	1	J. Nat. Cancer Inst., 85: 1725-1732, 1993.  Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613,	
	1	J. Nat. Cancer Inst., 85: 1725-1732, 1993.  Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613, 1983.	
	1	J. Nat. Cancer Inst., 85: 1725-1732, 1993.  Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613,	
	261	J. Nat. Cancer Inst., 85: 1725-1732, 1993.  Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613, 1983.	

<b>\</b>	263	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-	
		Lymphocytes*, International Journal of Cancer, 47(1): 92-98, 1991.	
	264	Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal	
		Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.	
	265	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on	
	į	STN, US National Library of Medicine (Bethesda MD), 1996.	
	266	Hillier et al. "The WashU-Merck EST Project", No. N30845, Databse GenBank on	
`	X	STN, US National Library of Medicine (Bethesda MD), 1996.	
	267	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-	
	- 1	Interscience, New York: 2.1.1-2.1.2, 1991.	
	268	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic	
	200	Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.	
	269		
	209	Rasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Varo	
		Using Combined Treatment With Nacystelyn and RhDNase", Pediatric Pulmonology,	,
	l	22: 161-166, 1996.	
	270	Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92	
		(Suppl.64): 6A-44S - 6A-52S, 1992.	
	271	Lieberman The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4,	
		1970.	
	272	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Froc., 39(13): 3067-	
		3074, 1980. Abstract.	
	273	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate	
	-//	Transport and Intrace Jular Inorganic Sulfate Content in Cystic Fibrosis Airway	
•	ļ	Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.	
	274	Cheng et al. "Increased Salfaton of Glycoconjugates NY Cultured Nasal Epithelial	
	2/4		· ·
	İ	Cells From Patients With Cystic Fibrosis", J. Clip. Invest., 84(1): 68-72, 1989.	
	<del> </del>	Abstract.	
	275	Boat et al. "Epithelial Cell Dystanction in Cystic Fibrosis: Implications for Airways	
	<u> </u>	Disease", Acta Paediatr. Scand. Sappl., 363, 25-29, 1989.	
	276	Schwatz et al. "CpG Motifs in Bacterial PNA Cause Inflammation in the Lower	
		Respiratory Tract", J. Clin. Invest., 109(1): 68-73, 1997. Abstract.	
	277	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis:	
·	į	Relationship Between Levels of Highly Sulfated Mucin Component and Severity of	
		the Disease", Clinica Chimica Ana, 132: 143-155, 1983.	
	278	Allen "Opportunities for the Use Aerosolized at - Antitrypsin for the Treatment of	
•		Cystic Fibrosis", Chest, 110/256S-260S, 1996.	
<del></del>	279	Schwab et al. "Increased Atherence of Staphylocoucus Aures From Cystic Fibrosis	
		Lungs to Airway Epithehal Cells", Am. Rev. Respir., 148(2): 365-369, 1993.	
		Abstract.	
	280	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomanas Aeruginosa Requires	
	200		
		Facilitated Transport of D-Ghicose by Macrophages", J. Immunol., 154(7): 3420-	
	1001	3428, 1995. Abarract.	
	281	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in	
l		Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice*,	
ļ. <u> </u>	<u> </u>	APMIS, 305(11): 838-842, 1997. Abstract.	
	282	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected	
	<u> </u>	With seudomonas Aeruginosa", Eur. Respir., 10(10): 2312-2318, 199 Abstract.	
	283	Zahm et al. "Early Alterations in Airway Mucociliary Clearance and Inflanation of	
ì	1	the Lamina Propria in CF Mice", Am. J. Physiol., 272(3 Pt 1): C853-C859, 1997.	l
	1	Abstract.	
	284	Thompson et al. "Identification of Chondroitin Sulfate B in Human Lung Mast	
		Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract.	
	295	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-	<del></del>
	7	Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997.	
	y		<b>k</b>
<b></b>	1 204	Abstract.	<del>\                                    </del>
<i> </i>	286	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of	<b>\</b>
/	I	Lipoprotein Lipase to Cultured Bovine Endothelial Cells", J. Clinical Invest., 68(4):	. \
	<u> </u>	995-1002, 1981. Abstract.	
	287	Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in	1
		Feline Myocardial Ischemia-Reperfusion Injury", J. Pharm. Exp. Ther., 283(3): 1032-	<b>\</b>
		1038, 1997. Abstract.	\
	1		· \
<del></del>	<del></del>		<u> </u>

	288	Versenabiles at Blantonbil Classes Inhibitas Dadress Mantashil Champathan	
\	200	Yamaguchi et al. "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattactant	
1		Production After Ischemia-Reperfusion in Rat Liver", Gastroenterology, 112(2): 551-560, 1997. Abstract.	
<del></del>	289	Matgolies et al. "Identification of A Major Heparin-Precitable Protein in Human	
\	207	Series and its Deletionship to Out of Eigenstein Budiety Box 16(2), 191 196 1992	
\		Serum and Its Relationship to Cystic Fibrosis <sup>a</sup> , Pediatr. Res., 16(3): 181-186, 1982.  Abstract.	
$\overline{}$	290		<b>-/</b>
	290	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of	
	λ	Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun.,	
	291	66(3): 994-999, 1998. Abstract.	
	25	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J	
	1	Vet. Med. Sci., 59(8): 727-728, 1997. Abstract.	
	292	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (XSV)	
	<del> </del>	o Host Cells", Arch. Virol., 142(6): 1247-1254, 1997. Abstract.	
	293	Alvarez-Dominguez et al. "Host Cell Heparian Sulfate Proteoglycans Mediate	
	ĺ	Attachment and Entry of Listeria Monocytogenes, and the Listerial Surface Protein	
	1	ActA & Involved in Heparan Sulfate Receptor Recognition", Infection & Immun.,	
	1	65(1): 78-88, 1997. Abstract.	
	294	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by	
	↓	Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539/1997. Abstract.	
	295	Shakibasi et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the	
		Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate	
	ļ	Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.	
	296	Inaba et al. "Effect of Heparinon Infection of Cells by Percine Reproductive and	
		Respiratoy Syndrome Virus", Am. J. Vet. Res., 58(5) 488-491, 1997. Abstract.	
	297	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target	
		Cell Heparan Sulfate", Nafare Medicine, 3(8): 866 871, 1997. Abstract.	
	298	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite	
	1	Protein and Thrombospondin Is Mediated by its Glycosminoglycan-Binding Region	
		and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.	
	299	Robert et al. "Chondroitin-4-Sulphate (Procoglycan), A Receptor for Plasmodium	
	l	Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial	
	<del> </del>	Cells", Res. Immunol., 146(6): 383-393, 1995. Abstract.	
	300	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate	
	İ	Receptors on Host Cells and Peneirin Country-Receptors on the Trypanosomes",	
	1001	Mol. & Biochem. Parasit., 65: 73-83, 1994.	
	301	Berkow "The Merck Manual", Merck Research Laboratories, P.201, 204, 1308, 177-	
		179, 1016-1017, 194-197, 885, 601, 1997.	
	302	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of	
<u> </u>	<del> </del>	Therapies", Pediatr. Pylmonol, 28(4): 248-54, 1999. Abstract.	
	303	Frederiksen et al. "Antibiotic Treatment of Initial Colombation with Pseudomonas	
	·	Aeruginosa Postpones Chronic Infection and Prevents Detectoration of Pulmonary	
	400	Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, May 1997.	
	304	Frederiksen et al. "Changing Epidemiology of Pseudomonas Acruginosa Infection in	
		Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol. 28(3): 159-166,	
	205	1999. Abstract.	
	305	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Ratients With	
	1	Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", New England	
<del></del>	206	Journal of Medicine, 340(1): 23-30, 1999. Abstract.	
	306	Tring et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Pactors to athogenesis of Pneumonia in A Neonatal Mouse Model of Infection", Infection	
	307	Immun., 64(1): 37-43, 1996. Abstract.  Bennett et al. "Effect of Uridine 5'-Triphosphate Plus Amiloride on Mucociliary	
	30/		
	1 /	Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 153(6 Pt.1):	
	200	1796-1801, 1996. Abstract	
	308	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children With	
		Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 156(4 Pt.1): 1197-1204, 1997.	\
	200	Abstract.	<del>\</del>
	309	Naparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading Heparan	\
/	1212	Sulphate Endoglycosidase", Nature, 310(5974): 241-244, 1984. Abstract.	<b>—</b>
	310	Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis: A Review	<b>\</b>
	I	of New and Potential Interventions", Pediatric Pulmonology, 24: 143-146, 1997.	<b>\</b>
	<u> </u>	<u> </u>	L

<u> </u>			
	311	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", Chest, 115: 1120-1126, 1999.	
	312	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast Under Central Surveillance",	
		Science, 289: 1501-1504, 2000.	
<b>\</b>	313	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and	
		Regeneration", Nature Biotechnology, 16: 247-252, 1998.	
\	314	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB Journal, 15: 1661-1663, 2001.	
	315	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASED	
	7	Journal, Published Online, 2001.	·
	316	Finkel "Potential Target Found for Antimetastasis Drugs", Science, 285: 33-34, 1999.	
	317	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of A Good Thing",	
		NG, 13(5): 178-182, 1997.	
	318	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During	
		Endochondral Ossification", Exp. Cell. Res., 229(1): 126-136, 1996. Abstract.	
	319	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as	
		Osseous Cicatrizing Agents <sup>a</sup> , Ann. Endocrinol., 55(2): 121-123, 1994. Abstract.	
İ	320	Blanquaert et al. "Heparan-Like Molecules Induce the Repair of Skull Defects",	
		Bone, 17(6): 199-506, 1995. Abstract.	
	321	Muir et al. "Histomorphometric Analysis of the Effects of Stantiard Heparin on	·
		Trabecular Bone in Vivo", Blood, 88(4): 1314-1320, 1996. Abstract.	
	322	Hoffman et al. "Hungan Bone Morphogenic Protein 2 Contains A Heparin-Binding	
		Site Which Modifies its Biological Activity", Eur. J. Bischem., 237(1): 295-302,	
		1996. Abstract.	
1	323	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-	·
1		Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell.	
		Biol. 143(4): 1113-1128, 1998, [Abstract]	
]	324	Loredo et al. "Regulation of Gifcosaminogly an Metabolism by Bone	-
· .		Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am. J. Vet. Res.,	-
		57(4): 554-559, 1996.	
	325	Kiberstis et al. "Bone Health in the Balance", Science, 289: 1497, 2000.	
	326	Service "Tissuc Engineers Build New Bone", Science, 289: 1498-1500, 2000.	
	327	Stracke et al. "Autotaxin, Tumor Motility Stimulating Exophosphodiesterase", Advan. Enzyme Regul., 37: 135, 44, 1997. Introduction.	
	328	Bost et al. "Antibodies Against A Peptide Sequence Within the HIV Envelope	
	-	Protein Crossreacts With Human Interleukin-2" Nmmunol. Invest., 17: 577-586,	
		1988.	
	329	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use	
		of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J.	
		Histochem. Cytochem. 43: 881-886, 1995.	
	330	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular	
[		Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2):	
		551-557, 1987.	
	331	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Ultranslated	
		Sequence: Suggests Complex Post-Transcriptional Regulation of TM Gene Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.	·
		Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.	
	332	Ross The Pathogenesis of Atheroscerosis: A Perspective for the 1990s, Nature,	
		362/801-809, 1993.	
	333	Prinak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine,	
ļ	1	<b>6</b> (8): 828-829, 1997.	
	334	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sullate	:
		Proteoglycan Proteoglycans*, J. Cell. Biol., 116(5): 1273-1281, 1992.	
	735	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor a ls Formed From	
/	7	the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA,	<b>\</b>
		92: 5037-5041, 1995.	<b>\</b>
	336	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is	\
	1	Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation",	
		Cell, 79: 1015-1024, 1994.	<b>—</b>
	337	Vlodavsky et al. "Endothelial Cell-Derived Basic Fibroblast Growth Factor:	\
	1	Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl.	<b>\</b>
<u>V</u>	L	Acad. Sci. USA, 84: 2292-2296, 1987.	

	338	Vlodavsky et al. "Involvement of the ExtraCellular Matrix, Heparin Sulfate	<del></del>
		Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and	
	339	Metastis", Tumor Angeogenesis, P.125-140, 1997.  Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular	/
	339	Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry, 28: 1737-1743, 1989.	
	340	Nicolson "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion, Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met. Rev., 7: 143-188, 1988.	
	341	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996. Claims: 9, 10.	
	342	Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns	
		Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547)/3-174,	
	742	1395. GenBank Entry AA304653, 1997. Claims: 30. Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share In Vitro	
	343	Invasive Properties of Malignant Cells", J. Cellular Physiology, 136: 425-462, 1988.	
	344	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta,	
		24: 424-430, 2003.	
	345	Dempsey et al. "Heparanase Expression in Invasive Trophoblast and Acute Vascular	
		Damage", Glycobiology, 10(5): 467-475, 2000. Abstract, P.475, Col.1 - P.471, Col.1, P.472, Col.1, § 4. Col.2, § 2.	
	346	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological	
		Human Placenta*, Melecular Human Reproduction, 8(6): 566-573, 2002.	
	347	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During	
	348	Gestation", Reproduction 121: 573-580, 2001.  Edwards et al. "Some Properties and Applications of Monoclonal Antibodies",	
	1 340	Biochem, Journal, 200: 1-10N 981.	
	349	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary	
	250	Hemochromatosis", PNAS, 95(5), 2492-2497, 1998.	
	350	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive BioMedicine Online 2002, 4(2): 170-175, 2002. Abstract.	
	351	Bean et al. "Fertilization In Vitro Increases Non-Disjunction During Early Cleavage	
		Divisions in A Mouse Model Systom", Human Reproduction, 17(9): 2362-2367,	
	352	2002. Abstract.  Brinster et al. "Restoration of Pertility by Gerna Cell Transplantation Requires	
	332	Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003.  Abstract.	
	353	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes From Cryopreserved	
	1	Primordial Mouse Folicles After Sequential In Vivo Transplantation and In Vitro	
	354	Maturation", Biology of Reproduction, 64: 171-178, 2001. Abstract.  Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-	
	334	Micromanipulator for In Vitro Fertilization Using Frozen-Thewed Mouse	
		Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell	ľ
	255	Stage", Biology of Reproduction, 66: 3810385, 2002. Abstract.  Pfaff et al. "Cryobiology of Rat Embryos 1: Determination of Zygore Membrane	
	355	Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies,	
	1	and the Development of Improved Cryopreservation Methods", Biology of	ļ
	<del></del>	Reproduction, 63: 1294-1302, 2000. Abstract.	
	356	Sildaglar et al. "The Mouse as A Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", Human Reproduction, 14(1): 55,59,	ļ
		1999. Abstract.	
	357	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to	
		Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", Biology of	<u> </u>
	358	Reproduction, 62: 178-185, 2000. Abstract.  Prahalada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the	<del></del>
	<b>/</b> 330	Neonatal Mouse Model", Biology of Reproduction, 38: 935-943, 1988. Abstract	
7	359	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters	\ \ \
$\angle$		the Ovary and Oviduct", Biology of Reproduction, 28: 735-744, 1983. Abstract.	<del></del>
7	360	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice : 1-2, Summer 2002.	\
	1	Δ, ΟΨΕΙΠΙΙΟΙ ΔΟ <b>V</b> Δ.	1

-

		200	
X	361	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA",	
	1 1	Proceedings American Association for Cancer Research Annual Meeting, 1992, 33:	
	1 1	57, 1992. Abstract.	/
	362	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical	
		DNA by Oligonucleotides", Angew.Chem. Int. Ed. Engl. 32: 666-690, 1993.	
	363	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992.	/
	303	• • • • • • • • • • • • • • • • • • • •	
<del></del>		Abstract.	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	364	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL	. i
l		Antisense Oligodeoxynucleotides", Science, 253: 562-565, 1991. Abstract.	
	385	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential	
1		Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: Aprin	1
ł		Vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA, 28:	i
	1	<b>\2351-2355</b> , 1991.	
	366	Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRN	
	300	Block the Effects of Interleukin I in Cultured Murine and Human Fibroplasts and in	
			į į
<u></u>		Mice J. Clin. Invest., 88: 1190, 1991. Abstract.	
	367	Agrawal "Antisense Oligonucleotides As Antiviral Agents", Trends Biotechnol.,	
		10(5): 152-158, 1992. Abstract.	
	368	Ngo et al. "The Protein Folding Problem and Tertiary Structure", Ed Birkhauser,	
	1 1	Boston, P.49 \495, 1994.	
	369	Ferber et al. "Paycreatic and Duodenal Homeobox Gene 1 Induces Expression of	
		Insulin Genes in Diver and Ameliorates Streptozotocin-Induced Hyperglycemia",	
1	1 1	Nature Medicine, 6(6): 568-572, 2000.	
	370	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling Is Defined by	
i	3/0	Pericyte Coverage of the Preformed Endothelial Network and Is Regulated by PDGF-	
	۱ ۱	Pencyte Coverage of the Preformed Encouncillat Network and is Regulated by Piodr-	
		B and VEGF*, Development, 125: 1591-1598, 1998.	
	371	Vukicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Protein 1	
		(Bone Morphogenetic Protein V), Proc. Natl. Acad. Sci. USA, 93: 9021-9026, 1996.	
	372	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49:	
1		437-438, 1987.	
	373	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human	
1	"	Parathyroid Hormone-Related Peptige (hPTHrP) of Malignancy on Bone Resorption	
1	l i	and Formation in Organ Culture" Sone, 4: 717-720,1993.	
	374	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of	
1	3/4	Computational Approaches in the Genomic Bra", Trends in Biotechnology, 18: 34-	
1			•
		39, 2000.	
1	375	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome	
		Research, 10: 398-400/2000.	
	376	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends	
	<u> </u>	in Genetics, 14(6): 248-250, 1998.	
	377	Smith et al. "The Challenges of Genome Sequence Annotation or The Devil Is in the	
		Details", Nature Biotechnology, 15: 1222-1223, 1997.	_
	378	Brenner "Errors in Genome Annotation", Trends in Genetics, \$5(4): 132-133, 1999.	
}	379	Bork "Go Funting in Sequence Databases But Watch Out for the Traps", Trends in	
	"	Genetics 12(10): 425-427, 1996.	
<del></del>	380	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino	<b>-</b>
	300	Acid Substitutions", Science, 247: 1306-1310, 1990.	
	100-	Actional State No. A 17002 1000	<del> </del>
	381	???/A Genesq, Accession No. AA17083, 1999.	<u> </u>
	382	Dendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Orafting",	1
		Methods in Enzymology, 8: 83-93, 1995.	
	383	Miao et al. "Cloning, Expression and Purification of Mouse Heparanase", Prolein	
ļ		Expression and Purification, 26: 425-431, 2002.	<u>L</u>
	364	Coligan et al. "Current Protocols in Immunology", Immunology - Laboratory	
1		Manuals, 1991.	l
	385	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene From	
	1 303	Flavobacterium Heparinum", Proc. Natl. Acad. Sci. USA, 90: 3660-3664, 1993.	
<b>—</b>	204	Gordon-Cardo et al. "Expression of Basic Fibroplast Growth Factor in Normal	<del>  \                                   </del>
	386		
	<del> </del>	Human Tissues", Laboratory Investigation, 63: 832-840, 1990.	<del></del>
	387	Harper "Harper's Biochemistry", 24th Ed., P. 660-685.	<b></b>
	388	Boat et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia	<b>\</b>
	1	Cells From Patients With Cystic Fibrosis", Journal of Clinical Invetment, 84(1): 68-	\
X		72, 1989. Abstract.	<b>\</b>

	389	Nossuli et al. "Heparinas III Exerts Endothelial and Cardioprotective Effects in	
		Feline Myocardial Ischemia-Reperfusion Injury", Journal of Pharmaceutical Experimental Therapy, 283(3): 1032-1038, 1997. Abstract.	
	390	Nakajima et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.	
	391	Wands Federal Circular, 1988,	
	392	Fisher CCPA, 1970.	
	993	Carson et al. Mucin and Proteoglucan Functions in Embryo Implantation", BioEssays, 20(7): 577-583, 1998. Abstract, P.580, Col.2, § 2, P.582, Col.1, Fig.1.	
	394	Clonotech Laboratories "RT-PCR Methods and Applications Book 1", Clonotech Laboratories, 1st Ed., P.1-15, 26, 40, 1991.	
_	395	Novagen "PET System Manual", Novagen, 6th Ed., P.11, 1995.	
	396	Eunis et al. "Rapid Cloning of HLA-A,B cDNA by Using the Polymerase Chain Reaction: Frequency and Nature of Errors Produced in Amplification", PMAS USA, 87: 2833-2837, 1990.	
	397	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions as An Extracellular Matrix-Degrading Enzyme or as A T-Cell Adhesion Molecule, Depending on the Local PH", Journal of Experimental Medicine, 81: 1929-1934,	
	398	1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucitytes", Biochem. J., 192: 517-525, 1980.	
	399	Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm. 191: 269-274, 1993.	
	400	Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.	
_	401	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: \$12-538, 1996.	
	402	Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.	
	403	Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.	
	404	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", Bio Techniques, 20: 136-141, 1996.	
	405	Sambrook et al. "Molecular Cloning, A Laboratory Manual", CSH Laboratory Press, 2: 7.37-7.52, 1989.	
	406	Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression", Curr. Opin. Biotech., 6: 527 533, 1995.	
	407	Freshney "Animal Cell Culture", P.48-49.	
	408	Chang et al. "Differential Ability of Heparan Sulfate Protecoglycans to Assemble the Fibroblast Growth Factor Receptor Complex In Situ", KASEB Journal, 14: 137-144, 2000.	
	409	Hillier et al. "The WashU-Merck EST Project", Database EMBL Accession No. N45367, XP 092198420, 1996. Abstract.	
	410	Marra et al. "The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. Al12204, XP 002198426, 1998. Abstract.	
	411	Marra et al. "The WashU-HHMI Mouse Est Project", Database EMBL, Accession No. A2047943, XP002198424, 1996.	
	412	Evan, et al. "Human Chromosome 11 187a8 Cosmid, Complete Sequence", Database EMBL, Accession No. U73640, XP002198427, 1996. Abstract.	
	413	Maniatis et al. "Extraction, Purification and Analysis of mRNA From Eukahyotic Cells", Moleular Cloning Manual, chapt. 6: 188-246, 1982.	
	414	Suggs et al. "Use of Synthetic Nucleotides as Hybridiztion Probes: Isolation of Cloned DNA Sequences for Human β2-Microglobulin", PNAS, 78(11): 6613-6617, 1981. P.13.	
<i>1</i>	415	Alberts et al. "Molecular Biology of the Cell", Arland Publishing, 2nd Ed., P. 195-196, 598, 1989.	
	416	Sigma Catalog, P. 275, 1992. Collagenase Listing.	
	417	Ehle et al. "Immunoaffinity Chromatography of Enzymes", Bioseparation, 1(2): 97-110, 1990.	
/	418	Hidde et al. "Construction and Characterization of A Fusion Protein of Single-Chain Anti-Carcinoma Antibody 323/A3 and Human Beta-Glucuronidase", Cancer Immunology Immunotherapy, 45(5): 266-272, 1998.	

		·	
	419	Takayama et al. "Neutrophil-Dependent Goblet Cell Degranulation: Role of	7
		Membrane-Bound Elastase and Adhesion Molecules", American Journal of	
		Physiology, 275(2/Part 1): L294-L302, 1998.	
<del></del>	100		
	420	Lider et al. "Inhibition of T Lymphocyte Heparanase: Purification, Characterization	
	[	and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.	_ /
	421	Nadav et al. "Activation, Processing and Trafficking of Extracellular Heparanase by	7
		Primary Human Fibroblasts", Journal of Cell Science, 115(10): 2179-2187, 2002.	
	400		/
	<b>A</b> 22	Goldshmidt et al. "Cell Surface Expression and Secretion of Heparanase Markedly	<b>'</b>
		Promote Turnor Angiogenesis and Metastasis", Proc. Natl. Acad. Sci. USA, 99(15):	
		10031-10036, 2002.	
	423	Guo et al. "Protein Tolerance to Random Amino Acid Change", PNAS, 101(25):	
	423		
		9205-9210, 2004.	
	424	Ribrino "RT-PCR Method & Applications", Clonotech Laboratories, 1st Ed. 1: 11,	
ı		13, 23, 41, 26, 1991.	
<b></b>	425	Wight et al. "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9(1): 1-20,	
1	423		
L		1989.	
	426	Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60:	
	ŀ	443-475, <b>N</b> 91.	
	422	Ruoslahti et al. "Proteoglycans as Modulators of Growth Factor Activities", Cell, 64:	
1	427		
		867-869, 1991	
	428	Vlodavsky et al. Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma	
I		Proteins", in: Basic Membranes: Cellular and Molecular Aspects, Academic Press,	
1	1	Orlando, Fla., P. 327343, 1993.	
	4555		
j .	429*	Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the	
}		Immune System: Possible Involvement in Diapedes's and Extra Vasation", Invasion	
		& Metastasis, 12(2): 112-137, 1992. Abstract.	
	430°	Vlodavsky et al. "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species	
	430		
		of Heparin", Invasion & Metashsis, 14(1-6): 290-302, 1994/95.	
-	431	Liotta et al. "Tumor invasion and the Extra Cellular Matrix", Laboratory	
ŀ	1	Investigation, 49(6): 636-647, 1983.	
	430	Vlodavsky et al. "Lymphoma Cell-Modated Degradation of Sulfated Proteoglycans	
1	432		•
į.		in the Subendothelial ExtraCellular Manix: Relationship to Tumor Cell Metastasis",	
ļ	Ì	Cancer Research, 43: 2704-2711, 1/83.	
	433	Vlodavsky et al. "Involvement of Heparanase in Tumor Mctastasis and	
l .	755		
	<del> </del>	Angiogenesis", Isr. J. Med. Sci., 24(9-10): 464-470, 1988.	<u> </u>
	434	Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by	
1		Blocking Tumor-Cell-Derived Heparanases", Int. Cancer, 40: 511-517, 1987.	
	435	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
	133	Activity of Human Tumor Cells Maintained on Extravellular Matrix Versus Plastic",	
	ł		
	1	Cell, 19: 607-616, 1980.	
	436	Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth	
1	1	Factor: A Regulatory Mechanism? <sup>a</sup> , Trends Biochem. Sci., 16: 268-271, 1991.	
<b></b>	437	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of	···
	1 <sup>33</sup>		1
	1	Allograft Survival by Treatment of Animals With Low Doses of Heparin", The	'
	L	Journal of Clinical Investigation, 83: 752-756, 1989.	
	438	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in	I
1	1	Hepayin", FEBS Letters, 117(1): 203-206, 1980.	
<del></del>	420	Sugnalter et al. "Importance of Size, Sulfation and Anticoagulant Activity in the	<del></del>
1	439	Sugnature et al. importance of Size, Suffation and Anticoagulant Activity in the	Ţ.
1		Petentiation of Acidic Fibroblast Growth Factor by Heparin", J. Biol. Chem.,	I
1		<b>2</b> 54(12): 6892-6897, 1989.	<u> </u>
F	440	Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release of	
1	"" /	Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular	]
1		Dask Linconst Clown Lactor Lioni die Assental Eddonielinin and Evracelinia	I
L	$\bot \angle$	Matrix", Biochemistry, 31(7): 2080-2088, 1992. Abstract.	
	<b>4</b> 41	Inoue et al. "Selective N-Desulfation of Heparin With Dimethyl Sulfoxide	] .
	<b>X</b>	Containing Water or Methanol <sup>n</sup> , Carbohydrate Research, 46: 67-95, 1976.	<b>X</b>
<b></b>	442	Nagasawa et al. "Solvolytic Desulfation of Glycosaminoglycuronan Sulfates With	<b>/</b>
	442	Inggosawa et al. Solvolytic Description of Citycosamillogyonionan Scrinces with	<b>\</b>
	1	Dimethyl Sulfoxide Containing Water or Methanol", Carbohydrate Research, 58: 47-	
	İ	55, 1977.	
	443	Matia Bar-New et al. Inhibition of Heparanase-Mediated Degradation of	
i /	''	Extracellular Matrix Heparin Sulfale by Non-Anticoagulant Heparin Species", Blood,	
	1		
1/	1	70(2): 551-557, 1987.	1
V	1		

<del></del>	444	Consideration at all #00 mulation of Consol Padethalial Call Parliferation In Vita	<del>r</del>
\	444	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cell Proliferation In Vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977.	
<del></del>	445	Haimovits-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell-	<b> /</b>
	443	Derived Factors", Blood, 78: 789-796, 1991.	
	446	Vlodavsky et al. "Extracellular Matrix-Resident Growth Factors and Enzymes:	
	1	Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metatastis	
`	<b>\</b> I	Rev., 9: 203-226, 1990.	
	447	Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Anionic	/
	Z,	Compounds", J. Bioactive and Compatible Polymers, 8: 317-337, 1993.	
	448	Benezra et al. " Antiproliferative Activity to Vascular Smooth Muscle Cells and	<del></del>
	110	Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds",	ł
	<b>`</b>	Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
	449	Natz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor	
	777	Binding of A Heparain-Mimicking Polyaromatic Anionic Compound", J. Amer. Soc.	
		Nephrology, P.1688-1697, 1997.	
	450	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding	<del></del>
•	1430	Dimerization, Signaling, and Angiogenic Activity by A Synthetic Heparam-	ŀ
		Mimicking Polyaromatic Compound", J. Clin. Invest., 99(7): 1565-1578, 1997.	ł
	451	Benezra et al A"Reversal of Fibroblast Growth Factor-Mediated Autogrine Cell	
	751	Transformation by Aromatic Anionic Compounds", Cancer Research, 52: 5656-5662,	
		1992.	ļ
	452	Irimura et al. "Chemically Modified Heparins as Inhibitors of Haparan Sulfate	
	732	Specific Endo-β-Gluouronidase (Heparanase) of Metastatic Malanoma Cells",	f
	•	Biochemistry, 25: 5322 5328, 1986.	ł
	453	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated	· ···
•	4.33	Polysaccharides", Int. J. Cancer, 39: 82-88, 1987	ŀ
	454	Omitz et al. "Heparin Is Required for Cell-Free Binding of Basic Fibroblast Growth	
	4.74	Factor to A Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and	•
	İ	Celhular Biology, 12: 240-247, 1992.	
	455	Yayon et al. "Cell Surface, Heparin", ike Molecules Are Required for Binding of	
	1 733	Basic Fibroblast Growth Factor to Its Nigh Affinity Receptor", Cell, 64: 841-848,	
•		1991.	
	456	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate	
	1 .50	Proteoglycans That Promote Binding of Besic Fibroblast Growth Factor to Its	
		Receptor", J. Biol. Chem., 269(1): 114-121, 1994.	
	457	Bartlett et al. " Comparative Analysis of the Ability of Leucocytes, Endothelial Cells,	i
	1	and Platelets to Degrade the Subendonelial Basement Membrane: Evidence for	İ
	- 1	Cytokine Dependence and Detection of A Novel Sulfatase", Immunology and Cell	ì
	i.	Biol., 73: 113-124, 1995.	1
	458	Nakajima et al. " A Solid-Phase Substrate of Heparanase Its Application to Assay of	
	1	Human Melanoma for Heparan Sulfate Degradative Activity", Analytical	}
	1	Biochemistry, 157: 162-171/1986.	
	459	Oosta et al. "Purification and Properties of Human Platalets Hegaritanase", J. Biol.	
		Chem., 257(19): 11249-1255, 1982.	Į.
	460	Sewell et al. "Human Mononuclear Cells Contain An Endoglycosidese Specific for	
		Heparan Sulfate Glycosaminoglycan Demonstrable With the Use of X Specific	l
	1	Solid-Phase Metabolically Radiolabelled Substrate", Biochem J., 264: 177-783, 1989	l
	461	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian	
	i i	Heparanase Activity", Biochemical Journal, 325: 229-237, 1997.	1
	462	Mullings et al/"New Reducing Sugar Assay for the Study of Cellulases", Enzyme	
	i i	Microb. Technol., 6: 491-496, 1984.	
	463	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and A	
	- 1	Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1932.	L
	464	Linhard "Capillary Electrophoresis of Oligosaccharides", Methods in Enzymology,	
	L_	230: 265-280, 1994.	<b></b> .
	465	Base et al. " Analysis of Glycospingolipids by Fluorophore-Assisted Carbohydrate	
		Electrophoresis Using Ceramide Glycanase From Mercenaria Mercenaria",	
	1	Analytical Biochemistry, 222: 270-274, 1994.	\
<del>-</del>	466	Jackson "The Use of Polyacrylamide-Gel Electrophoresis for the High-Resolution of	
		Separation of Reducing Saccharides Labelled With the Fluorophore 8-	\
		Aminonaphtalene-1, 3, 6-Trisulphonic Acid, Biochem J., 270: 705-713, 1990.	<b>\</b>
	i /	· · · · · · · · · · · · · · · · · · ·	Ī

	1 4 6 9 1	Control of the Contro	
$\mathbf{N}$	467	Coquet et al. "Applications of A Post-Column Fluorigenic Reaction in Liquid	
\	1	Chromotagraphy for the Determination of Glucose and Fructose in Biological	
	460-	Matrices <sup>n</sup> , Analytica Chemica Acta, 252: 173-179, 1991.	<del>                                     </del>
	468	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell-	
	i }	Specific Agt 11 Library Using Antibodies Directed Against A Putative Heparanase	
<del></del>	1.0	Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994.	/
•	469	Zsolnai et al. "Directional Immobilization of Heparin Onto Nonporous Surface of	Y
		Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.	
	410	Bellott et al. "Closing the Loop in Combinatorial Chemistry", European	
<u></u>		Pharmaceutical Contractor, 1997.	
1	471	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by	
<u></u>	l	Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.	<del></del>
l	472	Yan et al. "Potentialities of A New Class of Anticlotting and Antihemorrhigic	
		Polyners", J. Macromol. Sci. Chem., 4(3): 693-714, in Chem. Abst. Alv. 1970	
		41845 In: Chem. Abst. AN, 1970 418456.	ļ
1	473	Mes et al "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of	
		Sugars and Sugar Derivatives Reported in Glycoproteins", J. Chromatogr., 43(\$):	
<u> </u>	<u>                                   </u>	480-486, 1989.	<del> </del>
	474	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and	
ŀ		Differentiation of Sugars and Sugar Derivatives in Glycop oteins", J. Chromatrogr.,	
	170	38(1): 120-125, 1988.	<del> </del>
	475	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
		Activity of Human Tumar Cells Maintained on Expecellular Matrix Versus Plastic",	i
	476	Cell, 19: 607-616, 1980.  Burgess et al. "The Heparin-Rinding (Fibroblay) Growth Factor of Proteins", Annu.	<del> </del>
	476		į
	-	Rev. Biochem., 58:.575-606, 1389.	
	477	Campbell et al. "Heparan Sulfate Degrading Enzymes Induce Modulation of Smooth	1
	470	Muscle Phenotype", Experimental Cell Research, 20: 156-167, 1992.  Eisenberg et al. "Lipoprotein Lipase Phances Binding of Lipoproteins to Heparan	
	478	Sulfate on Cell Surface and Extracehula Matrix", J. Clin. Invest., 90: 2013-2021,	1
l		1992.	
	479	Folkman et al. "A Heparin-Binning Angiogenic Protein - Basic Fibroblast Growth	<del> </del>
	7'7	Factor - Is Stored Within Basement Membrane Am. J. Pathology, 130(2): 393-400,	
1		1988.	
<del> </del>	480	Folkman et al. "Angiogonic Factors", Science, 235: 442-447, 1987.	
	481	Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its	<del>                                     </del>
	101	Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules",	1
		Journal of Biological Chemistry, 267(9): 6093-6098, 1992	1
	482	Matzner et al. Degradation of Heparan Sulfate in the Subendothelial Extracellular	<u> </u>
1		Matrix by A Leadily Released Heparanase From Human Neutrophils", Journal of	Į.
		Clinical Investigation, 76(4): 1306-1313, 1985.	
	483	Molline to et al. "Major Co-Localization of the Extracellular-Matrix Degradative	
		Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils",	1
	I _ 1	Bioghem. J., 327: 917-923, 1997.	
	484	Narindrasorasak et al. "High Affinity Interactions Between the Altzheimek's β-	
•	}	Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate	1
		Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991,	<u> </u>
	485	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-	
		Derived Di- and Trisaccharides", Science, 268: 432-436, 1995.	
	486	Rapraeger et al. "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast	J
	1	Growth and Myoblast Differentiation", Science, 252: 1705-1709, 1991.	<u> </u>
	487	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and	
	1	Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells*, J.	
		Biol. Chem., 268(14): 10160-10167, 1993.	
	488	Hudson "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4:395-402, 1998.	
Signature	<u> </u>	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to piace a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

PTO/SB/08A ( 0-96)

Date

Complete if Known

Please type a plus sign (+) inside this box → 
Approved for use through 10/31/99 OMB 0651-0031

Framiner

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI:
Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control manher.

Substitute for form 1449A/PTO

Application Number 10/851,135 INFORMATION DISCLOSURE Filing Date 05/24/2004 First Named Inventor Pecker\_ STATEMENT BY APPLICANT Group Art Unit 1623 (use as many sheets as necessary) **Examiner Name** Shect Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS gelude name of the author (in CAPITAL LETTERS), title of the article (when appropriate, title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-joure num1 er(s), No.1 Initials T2 publisher, city and/or country where published. Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Bazyme is a Heterodimer", J. Biol. Chem., vol. 274, No. 42, pp. 295:17-29590, 15 Oct. 1999. Hulett et al, "Cloring of Mammalian Heparanase, an Important Enzyme in Tum or Invasion and Metastasis", Nature Medicine, 5(7):803-209, 1999 Toyoshima et al, "Human Heparanase: Purification Characterization, Cloning, and Expression", J. of Biolog. Chemistry, vol. 274. 36. 34. pp. 24153-24160, 20 Aug. 1999 Miao et al, "Cloning, Expression, and Purffication of Mouse Heparanase", Protein Expression and Purification, 26:425 471, 2002 Freeman et al, "Human Platelet Heparanase: Purification, Characterization and

Catalytic Activity", Biochem J., 230(3): 134-1350, 1998.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

<sup>1.</sup> Unique citation designation number, 2. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1448A/PTO Application Number 10/785,116 INFORMATION DISCLOSURE Filing Date February 25, 2004 STATEMENT BY APPLICANT First Named Inventor PECKER Iris et al (use as many sheets as necessary) Art Unit 1652 **Examiner Name** Sheet of Attorney Docket Number 27674 U.S. PATENT DOCUMENTS es, Columns, Lines, Where evant Passages or Relevant cument Number ation Date Name of Parentee or Initials MM-DD-YYYY Applicant of Cited Docu Figures Appear Number-Kind Code<sup>2 (The</sup> US-5,362,641 08-8-1994 Fuks et al. 1 2 US-5,399,35 03-21-1995 Leshchiner et al 3 US-5,550,116 Lormeau et al. 08-27-1996 4 US-5,667,501 09-16-1997 Fowler et al. 5 US-5,739,115 04-14-1998 Fugedi et al 6 US-6,177,545 01-13-2001 Pecker et 02-19-2002 7 US-6,348,344 Ayal-Hershkovitz et al. 8 US-4,946,778 08-8-1990 Ladner et al. US-5,997,863 9 07-1-1999 Zimmermann et al. US-6,242,238 05-5-2001 10 Freeman et al. 11 US-5,688,679 11-18-1397 Powell 12 US-6,387,643 05-14-2008 Heinrikson et al. 13 US-6,423,312 07-23-2002 Yacoby-Zeevi US-6,531,129 14 01-1-2003 Pecker et al. US-4,455,296 15 06-19-1984 Hansen et al. Regan et al. 16 US-5,571,506 05-5-1996 17 US-5,917,830 06-29-1999 Chen et al. 18 US-5,859,660 01-12-1999 Perkins et al. 19 US-5,600,366 04-4-1997 Schulman US-6,020,931 01-1-2000 20 Bilbrey et al. 21 US-5,968,822 10-19-1999 Pecker et al. 11-28-2000 22 US-6,153,187 Y coby-Zeevi 23 US-6,664,105 12-76-2003 Pecker et al. 24 US-5,145,679 06-8-1992 Hason 25 US-5,736,137 **07-7-1998** Anderson et al. 26 US-5,194,596 03-16-1993 Tischer et al. 27 US-5,350,836 09-27-1994 Kopchick et 28 US-6,562,950 05-13-2003 Peretz et al. 29 US-6,699,672 02-2-2004 Pecker et al. US-5,580.86 30 03-3-1996 Rosen et al. 31 US-5,474 83 12-12-1995 Kuna et al. US-2002/0102560 32 01-1-2002 Pecker et al. 33 US-6,790,658 09-14-2004 Pecker et al. 34 US,6,798,658 09-28-2004 Takedomi et al. US-5,618,709 35 08-8-1997 Gewirtz et al. US-5,656,595 36 08-12-1997 Schweighoffer et al. 37 US-4,683,195 07-28-1987 Mullis et al. US-5,602,095 02-11-1997 Pastan et al. 39 US-4,859,581 08-22-1989 Nicholson et al. 40 US-4,882,318 11-21-1989 Vlodavsky et al. 41 US-5,129,877 07-14-1992 Gallo et al. 42 US-5,206,223 04-27-1993 Vlodavsky et al 43 US-5,332,812 07-26-1994 Nicolson et al.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	~	halfinda faafaan 44404 MTO		Complete		
	Su	bstitute for form 1448A/PTO		Application Number	10/785	
	INE	ORMATION DISCLOSURE		Filing Date	Februs	ary 25, 2064
				First Named Inventor		ER ipis et al
`	/SIA	TEMENT BY APPLICANT		Group Art Unit	1652	
		(use as many sheets as necessary)		Examiner Name		
Sheet		Of		Attorney Docket Number	27674	
		OTHER PRIOR ART – NON PATENT				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), item (book magazine, journal, serial symposium, catal publisher, city and/or count	og, etc.) dat ry where pu	ne, page(s), volume-issue numb ablished.	CI(8).	T3
	44	Hulett et al. "Cloning of Mammalian Heparan Invasion and Metasassis", Nature Medicine, S	(7): 803-8	309 <b>,</b> 1999.		
	45	Toyoshima et al. "Human Heparanase: Purific Expression", J. of Biolog. Stemistry, 274(34)	: 24/53-	24160, 1999.		
	46	Kussie et al. "Cloning and Functional Express Biochemical and Biophysical Research Comm	unicatio	n 261(1): 183-18 <b>7,</b> 1999.	<b>"</b> ,	
	47	Freeman et al. "Evidence that Platelet ad Tur Enzymes", Biochem J. 342: 361-368, 1999	nour Hep	eranases are Similar		
	48	Dempsey et al. "Heparanase, A Totential Regi- TIBS, 25(8): 349-351, 2000 P.350, Col.1, § 1	lator of 0	CellMatrix Interactions, 1, Claims 1-24.		
	49	Goshen et al. "Purification and Characterization Expression by Cultured Cytotrophoblasts", M. 679-684, 1996.	olecular Ì	Heman Reproduction, 2(		
	50	Freeman et al. "Human Platelet Heparanase: F Catalytic Activity", Biochem. J., 330: 1341-13				
	51	Vloda sky et al. "Mammalian Heparanase: Go in Tumor Progression and Metastasis", Nature 002139970, 1999.			tion	
	52	Uno et al. "Antisense-Mediated Suppression of Inhibits Pleural Dissemination of Human Can 7855-7860, 2001.				
Signature				Considered		

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14 his collection is estimated to take 2 hours to complete foliationing gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form another suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur ther. Complete i Known Substitute for form 1449A/PTO **Application Number** 10/781,758 INFORMATION DISCLOSURE Filing Date January 14, 2003 First Named Inventor ILAN, Neta et al. STATEMENT BY APPLICANT **Group Art Unit** 1652 (use as many sheets as necessary) **Examiner Name** Sheet Or 2 Attorney Docket Number U.S. PATENT DOCUMENTS U.S. Parent Document Pages, columns, lines, Where ind Code Cite Number Date of Publication of Cited Document MM-DD-Relevant Examiners Name of Patentee or Applicant Passages or Relevant Figures Initials No. 1 of Cited Document Appear FOREIGN PATENT DOCUMENTS Foreign Pate Documents Date of Publication of Cited Document MM-DD-Pages, columns, lines, Where Relevant Examiners Cite Name of Patentee or No. Offico3 76 Kind Code<sup>5</sup> Initials Applicant of Cited Document Passages or Relevant Figures Appear **B**ignature Considered

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the rental number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

\*Please type a plus sign (+) inside this box → ☑
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE:

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control in inber Complete f Known Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE Filing Date First Named Inventor STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), side if the Examiner . Cite nem (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issus numb r(s), Initials No. T2 publisher, city and/or country where published. Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis\*, Nature Medicine, 5(7): 793-862, 1999. Qifferential Ability Of Heparan Sulfate Protecogly cans To Assemble The Fibroblast Scowth Factor Receptor Complex In situ", FASEB Journal, 14: 37-144, 2000. Ishai-Michaeli et al. "hyportance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular Matrix". Biochemistry, 31(7): 2080-2088, 1992. Abstract Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules", Journal of Biological Chemistry, 26 (9), 6093-6098, 1992. Hulett et al. "Cloning of Mammalian Acparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine 5(7): 803-809, 1999.

Toyoshirna et al. "Human Heparanase: Purification, Characterization, Cloning, End Expression", J. of Biolog. Chemistry, 274(34): 2153-24160, 1999 **a**miner Date Considered

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

JUN 1 3 2006 B

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Redu re required to respond to a collection of information unless it counsins a valid OMB country number. Complete if Known Substitute for form 1449A/PTO Application Number 10/781,758 INFORMATION DISCLOSURE Filing Date January 14, 2003 STATEMENT BY APPLICANT First Named Inventor ILAN Neta et al Art Unit (use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 18 27525 U.S. PATENT DOCUMENTS gcument Number Name of Patenton or WW-DD-AAAA Applicant of Cited Docum nt Passages or Relovant Figures Appear d Code<sup>7 (In</sup>o Number-L US-6,177,345 01-13-2001 Pecker et al. US-6,348,34 2 02-19-2002 Ayal-Hershkovitz et al US-4,946,778 3 08-8-1990 Ladner et al. US-5,997,863 4 07-7-1999 Zimmermann et 5 US-6,242,238 05-5-2001 Freeman et 6 US-5,688,679 11-18-1997 Powell 7 US-6,387,643 05-14-2002 Heinrikson et al. US-6,423,312 OT-23-2002 Yacoby-Zeevi 01-1-2003 9 US-6,531,129 Perker et al. US-4,455,296 10 06-19 1984 Lansen et al. 11 01-1-1996 US-5,571,506 Regan et al. 12 US-5,917,830 06-29-1999 Chen et al. 13 US-5,859,660 01-12-1999 Perkins et al. 14 US-5,600,366 04-4-1997 Schulman 15 US-6,020,931 01-1-2000 Bilbrey et al. 16 US-5,968,822 10-19-1999 Pecker et al. 17 US-6,153,187 11-28-2000 Yacoby-Zeevi 18 US-6,664,105 12-16-2003 Pecker et al. US-5,145,679 19 08-8-1992 Hinson 20 US-5,736,137 07-7-1998 Anderson et al. 21 US-5,194,596 03-16-1993 Tischer et al. 22 US-5,350,836 09-27-1994 Kopchick et al. 23 US-6,562,950 05 (3-2003 Peretz et al. 24 US-6,699,672 02-2-2004 Pecker et al. 25 US-5,580.862 03-3-1996 Rosen et al. 26 US-5,474,983 12-12-1995 Kuna et al ·27 US-2002/0102560 01-1-2002 Pecker et al 28 US-4,859,581 01-1-1989 Nicholson et al. 29 US-4,882,318 01-1-1989 Vlodavsky et al. 30 US-5,129,87/ 01-1-1992 Gallo et al. 31 US-5,206,223 04-27-1993 Vlodavsky et al **32**· US-5,332,812 07-26-1994 Nicolson et al. US-5,762,641 US-5,399,351 33 08-8-1994 Puks et al. 34 01-1-1995 Leshchiner et al U6-5,550,116 35 01-1-1996 Lormcau et al. 36 US-5,667,501 01-1-1997 Fowler et al 37 US-5,739,115 01-1-1998 Fugedi et al FOREIGN PATENT DOCUMENTS Pages, Cob Initi **Publication Date** Pereigo Patent Docum Name of Patentee or Where Relevant P MM-DD-YYYY Applicant of Cited Document Country Code\* Number\* Kind Code\* (if known) or Relovant Figures Appe PCT WO 99/57244 11-11-1999 Ben-Artzi et al.

	40	PCT WO 99/11798	03-11-1999	Pecker et al.	
	41	PCT WO 88/01280	01-1-1988	Nicolson et al.	
	X	PCT WO 95/04158	09-9-1995	Hoogewerf et al.	
	43	PCT WO 99/21975	06-6-1999	Freeman et al.	
	44	PCRWO 91/19197	12-12-1991	Nicolson et al.	
L	45_	PCT WO 05/04518	02-16-1995	Midha et al.	
	46	PCT WO 03/096645 A2	01-23-2003	Bohlen et al.	
	47	PCT WO 97/11684	04-4-1997	Bennett et al	
	48	PCT WO 91/02977	07-7-1991	Fuks et al.	
	49	PCT WO 97/27327	07-31-1997	Van Ness et al.	
	50	PCT WO OO/52149	08-8-2000	Yacobi-Zeevi	
	51	PCT WO 00/52178	08 8-2008	Pecker et al.	
Examiner Signature				Date Considered	

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawling through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usfo.gov.or/mmPEP 901.04">https://www.usfo.gov.or/mmPEP 901.04</a>. <sup>2</sup> Enter Office that issued the document, by the two letter code (MIPO Standard ST.3). <sup>4</sup> For Japenese patent document, or indication of the year of the reign of the Emperor must precede the sartal number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language This collection of patentiation is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public Which is to file (and by the USPTO to processs) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours a complete, including gethering, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commission in the amount of files of U.S. Patent and Nacdemark Office, Jr.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006, OMB 0651-0031

U.S. Patent and Tradernark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/781,758 Filing Date INFORMATION DISCLOSURE January 14, 200 First Named Inventor ILAN Neta et al STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) Examiner Name Sheet 18 Attorney Docket Number 27525 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS luclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number publisher, city and/or country where published. Initials No. T² Wight et al. "The Role of Proteoglycans in Cell Adhesion, Migration and 52 Pholiferation", Curr. Opin. Cell. Biology, 4: 793-801, 1992. 53 Jackson et al. "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Review, 71(2): 481-536, 1991. Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features 54 of Clan GN-A Glycosyl Hydrolases Deduced from Hydrophobic Gluster Analysis", Glycobiolog (7(2): 277-284, 1997. Korb et al. "Sthuulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Denor Sequence", Nucleic Acids Research 21(25): 5901-5908, 1993. Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Meterodimer", Journal of Biol. Chem., 274, (42): 29587-29590, 1999. 57 Linhardt et al. "Polysaccharde Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986. 58 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", v TIBS, 25(8):349-351, 2000. P. 350, Col. 1/3 1; P.350, Col.3, § 1; Claims: 1-24. Niwa et al. "Efficient Selection for High-Expression Transfectants With a Novel 59 Eukaryotic Vector<sup>n</sup>, Gene, 108(2):198-199, 1991. Clark "The Mammary Gland as a Pioreactor: Expression, Processing, and Production 60 of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3):337-350, 61 Mirault et al. "Transgenic Gutathione Peroxidase Mouse Models for Neuroprotection Studies", Ann NY Acad Sci, 738:104-115, 1994. Lampard et al. " Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene V Regulatory Sequences, Biochem Cell Biol., 80(6):77, 788, 2002. 63 Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002. 64 Morrison et al Sequences in Antibody Molecules Important for Receptor-Mediated Transport Ipto the Chicken Egg Yolk", Mol Immunol., 38(8): 619-625, 2002. 65 Clark et al. "Pharmaceuticals from Transgenic Livestock", TIBTECH, 5: 20-24, 1987. Richards et al. "Construction and Preliminary Characterization of the Rat Casein and 66 Alma-Lactalbumin Cdna Clones", J. Biol. Chem., 256(1): 526-32, 1981 Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rapand Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984. Gorodetsky et al. "Isolation and Characterization of the Bos Taurus β-Casein Ogne", Gene, 66: 87-96, 1988. Alexander et al. "Complete Sequence of the Bovine β-Lactoglobulin cDNA', Nuclei Acids Research, 17(16): 6739-6744, 1989. Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase." Exptl. Cell. Res. (1992) vol. 201:208-215 Harlow et al. "Antibodies" A Laboratory Manual, eds. Harlow et al.: 471-510. 71 Murray et al. "The Extracellular Matrix", found in Harper's Biochemistry, 24th Ed., McGraw-Hill Professional, Chap. 57, pp 667-685, 1998. Selvan et al. "Heparan Sulfate in Immune Responses", An. NY Acad. Sci., 797: 127-

•			
• .1			
		139, 1996.	
	74	Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", Science 276: 71-74, 1997.	v /
<del></del>	75	Krivit et al. "Microglia: The Effector cell for reconstitution of the Central Nervous	
		System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal	<i>i</i> /
		Storage diseases", Cell Transplant, 4(4): 385-392, 1995.(Abstract)	
	76	Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th Int'l.	
	V	conf. On Molec. Biol. And Pathology of Matrix, Session IV.  Lazarus et al. "Ex Vivi Expansion and subsequent Infusion of Human Bone Marrow-	/ <u>/</u>
	~	Derived Stromal Pregenitor Cells (Mesenchymal Progenitor cells): Implications for	
		therapeutic Use", Bone Marrow Transplantation, 16:557-564, 1995.	V
	78	Pomahac et al. "Tissue Engineering of Skin" Crit Rev Oral Biol Med, 9(3):333,344,	
		1998. (abstract)	V
	79	Bonathan et al. "Living epidermal and Dermal Substitutes for Treatment of Severely	,
ļ		burned Patients", Rev Med Suisse Romande, 118(2): 149-153, 1998. (Abstract-art in French)	
	80	Wang et al. "Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation:	
		Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	. J
	81	Duffy et al. Maximizing Flap Survival in a Prefabrication Model Using Exogenous	
		and Endogenous bFGF: A New Approach", Microsurgery, 17(1): 176-179, 1995. Abstract.	<b>V</b>
	82	Abstract.  Garner "Epiderma Regulation of Dermal Fibroblast Activity", Plast. Reconstr. Surg.,	
ļ	<b>V</b>	102(1):135-139, 1998, Abstract.	J
	83	Raghunath et al. "Cultured Epithelial Autografts: Diving from Surgery into Matrix	
	•	Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	V
	84	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds",	V
	85	American J. Surg., 170(1):73-83, 1995. Abstrage Kawaja et al. "Employment of Libroblasts for Gene Transfer: Applications for	•
İ	65	Grafting into the Central Nervous System", Genet Eng (NY), 13: 205-220, 1991.	<b>→</b>
		Abstract.	
	86	Maillard et al. "Pre-Treatment with Elestase Improves the Efficiency of Percutaneous	
1		Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene Therapy, 5: 1023-1030, 1998.	V
	87	Wang "Basic Fibroblast Growth Vactor for Mimulation of Bone Formation in	
	•	Osteoinductive or Conductive Implants", Acta Orthop Scand Suppl, 269: 1-33, 1006	v ·
		(abstract)	•
	88	Wang "Basic Fibroblast Growth Factor Infused at Oifferent Times During Bone	
		Graft Incorporation. Titanium Chamber Study in Rais, Acta Orthop Scand, 67(3): 229-236, 1996. Abstract.	<b>√</b>
	89	Inui et al. "Loca Application of Basic Fibroblast Growth Factor Minipellet Induces	
		the Healing of Segmental Bony Defects in Rabbits".	✓
	90	Tabata et al. "Bone Regeneration by Basic Fibroblast Grown Factor Complexed with	
		Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1998. Abstract.	٧ .
j	91	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", Acta Orthop. Spand., 60(4): 473-476, 1989. Abstract.	V
	92	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic	
		Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-481, 1991.	V
		Abstract.	
	93	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Ocer	١٥
	94	herapy: Findings in a Rat Model", J. Gastroenterol, 31(6): 777-784, 1996. Abstract.  Chleboun et al. "The Development and Enhancement of the Collateral Circulation in	<u> </u>
1	~ /	an Animal Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(3): 202-207, 1394.	J
		Abstract.	•
	95	Aplin "Adhesion Molecules in Implantation", Rev Reprod, 2(2): 84-93, 1997.	٧
X	96	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the	
	1	Establishement of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116,	V
<del>-/- </del>	97	1998. Abstract.  Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum.	<del>\</del>
	·	Reprod. Update, 2(4): 307-321, 1996.	v <b>\</b>
	98	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases	
/		During Blastocyst Implantation", Contracept Fertil Sex, (art in French) 22(1): 48-51,	V <b>\</b>
	i	1994. Abstract.	· •

<b>N</b>	100	Combb and MR	
	99	Smith et al. "Expression of Heparan Sulfate Protoglycan (perlecan) in the Mouse	
	1	Blastocyst is Regulated during Normal and Delayed Implantation <sup>®</sup> , Dev. Biol., 184(1): 38-47, 1997. Abstract.	. /
	100	Abrahamsohn et al. "Implantation and Decidualization in Rodents", J. Exp. Zool.,	<del>                                     </del>
		266(6): 603-628, 1993 Abstract.	
	101	Goshen et al. "Purification and Characterization of Placental Heparanase and Its	/
1	N	Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9):	1
<u> </u>	<u> </u>	679-684, 1996.	X
	102	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse	
	\	Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176	J
	103	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation	
1	1.05	Revelopment", Biol. Reprod., 50(4): 725-733, 1994. Abstract.	lv
	104	Carlone et al. "Embryonic Modulaiton of Basic Fibroblast Growth Factor in the Rat	
		Uterlys", Biol. Reprod. 49(4): 653-665, 1993. Abstract.	1
	105	Wordinger et al. "The Immunolocalization of Basic Fibroblast Growth actor in the	
1	1	Mouse Uterus During the Initial Stages of Embryo Implantation" Growth Factors,	V
<u> </u>	100	11(3): 175\186, 1994. Abstract.	
i	106	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", Oxf. Rev.	1
<b></b>	107	Reprod. Biol., 15:43-81, 1993. Abstract.  Freeman et al. "Fluman Platelet Heparanase: Purification, Characterization and	ļ
1	1	Catalytic Activity Biochem. J., 330: 1341-1350, 1998. Qlaims: P.X: 1-47, 51-58/	V
L		Y,P: 48-50.	ľ
	108	Esko et al. "Tumor Formation Dependent on Procoglycans Biosynthesis", Science,	,
		241(4869): 1092-1096, P\( 88. Abstract.	J
	109	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and	
	Į	Avtivity by Cell Density and Heparan Sufate", Biological Chemistry, 274(19):	J
	110	13534-13540, 1990. Hayward et al. "Cellular Mechaniums of Heparinase III Protection in Rat Traumatic	
l	***	Shock", American Journal of Physiology 275:H23-H30, 1998.	
	111	Sasisekharan et al. "Heparinase Inhibity Neovascularization", Proc. Natl. Acad.Sci.,	
		91:1524-1528, 1994.	V
1	112	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and	
1	l	Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase,	V
	1	Plasmin, and Heparanases", Journal of Biological Chemistry, 271(17):10079-10086, 1996.	•
	113	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and	
		Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular	
		Matrix", Cell Regulation, 1: 833-842, 1990.	ν
	114	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of	~
<del> </del> -	115	Cellular Physiology, 148: 274-280,1991.	
	115	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain	
·		from an Inhibitor to a Potent Activator of FGF-2", Nature Medicine, 4(6):691-697, 1998.	V
	116	Jin et al. "Immunochemical Localization of Henaranase in Mouse and Human	
		Melanoghas", Int. J. Cancer. 45: 1088-1095, 1990.	ν
	117	Hoogswerf et al. "CXC Chemokines Connective Tissue Activating Petride-III and	
	l	Neutrophil Activating Peptide-2 Are Henarin/Henaran Sulfate-Degrading Enzymes"	V
	118	J. Biol. Chem., 270(7):3268-3277, 1995.	
	110	Oldberg et al. "Characterization of a Platelet Endoglycosidase Degrading Henarin- Like Polysaccharides", Biochemistry 19: 5755-5762, 1980.	V
	119	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine	
		Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive	V
		RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.	•
	120	Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Boyine	<u> </u>
/I	121	B-Casein Gene", Mol Cells, 8(3):259-265,1998. Abstract.	V
	121	Gottschalk et al. "Somatic Gene Therapy. Present Situation and Future Perspective",	$\lambda$
	122	Arzneimittelforschung, 48(11):1111-1120, 1998. Abstract.  Guriec et al. "CD44 Isoforms with Exon v6 and Mestastasis of Primary N0M0 Breast	
		Carcinaomas", Breast Cancer Res. Treat., 44(3):261-268, 1997. Abstract.	v <b>\</b>
	123	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by	
		Reducing Matrix Metalloproteinase Activities", Am. J. Pathol., 50(6): 2125-2132,	· \

•				
` <i>•</i>	• .			
••	• •			
•			1997. Abstract.	Γ
• •		125	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain	
· •			Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation, J. Clin. Invest., 97(1):162-171, 1996.	1
•	. /	126	Zheng et al. "Increment of hFIX Expression with Endogenous Intron 1 in vitro", Cell Res, 7(1):21-29, 1997 (abstract)	~/
	1	127	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", Cur.r Opin. Biotechnol., 9(5):486-496, 1998. Abstract.	
·		128	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise", Proc. Natl. Acad. Sci. USA, vol. 93: 3161-3163, April 1996.	V
		129	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the	
	İ		Modulation of Gene Expression in Human Disease", Journal of American Cell Surgery, 191(1): 93-105, 2000.	<b>V</b>
		130	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", Reviews: 276-387.	<del> .                                      </del>
	<del></del>	131	Rajar et al. "Covalent Protein-Oligonucleotide Conjugates for Elfficient Delivery of	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
		132	Antisense Molecules". Bioconjugate Chem., 8, 935-940, 1997.  Luft " Making sense out of Antisense OligodeoxynucleotideDelivery. Getting there is	<b>V</b>
		133	Half the Pun". J. Mol. Med, 75-76. 1998.  Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human	v
		133	Hernatopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hernatopoietic Cell Subset". Blood, 91(3): 852-862, 1998.	V
		134	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides". Molecular and Cellular Biochemistry, 172: 213-225, 1997.	<b>V</b>
		135	Motokumi et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides into the Myocardium Using HVI Liposome Method", Biochemical and Biophysical Research Communications 231: 540 545, 1997.	ν
		136	Jayaraman et al. "RationalSelection and QuantitativeEvaluation of Antisense Oligonucleotides", Biochimica et Biophysica eta 1520: 105-114, 2001.	v
		137	Walton et al. "Prediction of Antisanse Oligonucleotide Binding Affinity to a Structured RNA Target". Biotechnology and Bioengineering, 65(1): 1-9, 1999.	ν
		138	Uno et al. "Antisense-Mediated Supplession of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research 61(21), 7855-7860, 2001.	v
		139	Clancy "Handbook of Microbiology", Vol. 239-242, 1974.	V
		140	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving Biotechnology", Chapters 2-2, 1990. American Society for Microbiology.	V
		141	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes Inducible by Respiratory Mucus Derived from Cystic Fibrosis Patients", Mol. Microbiol. 22(5): 1005/1012, 1996. [Abstract]	٠٧.
•	.·	142	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis Transmemrane Conductance Regulator (CFTR)", Clin Exp. Immunol. 106(2): 374-399 [1996. [Abstract]	V
		143	Davies et al. Regulation of the Alginate Biosynthesis Gene and in Pseudomonas Aeruginosa During Biofilm Development in Continuous Culture, Appl. Environ. Microbiol 61(3): 860-867, 1995. [Abstract]	V
		144	Azghani et al. "A Beta-linked Mannan Inhibits Adherence of Pseudomonas Aeruamosa to Human Lung Epithelial Cells", Glycobiology 5(1): 39-4, 1995. [Abstract]	V
	•	145	Otek et al. "Bacterial Adhesion to Cells and Tissues", Chapman and Hall, New York, 1994, pp. 114-118, 148-153, 418-423, 420-423.	V
		146	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm", Science 280: 295-298, 1998.	ν.
ı		147	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid Pseudomonas Aeruginosa", Can. J. Microbiol. 43(11): 999-1004, 1997. [Abstract]	V
	-	148	Stickler et al. "An Assessment of the Ability of a Silver-Releasing Device to Prevent Bacterial Contamination of Urethral Catheter Drainage Systems", British J. Urology 78: 579-588, 1996.	1
		149	Potera "Bacteria in Biofilms Exchange Developmental Signals", ASM News 64(6): 321-322.	V
		150	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular	ļ
	/		Lenses", J. Catatact Refract. Surg. 24: 124-129, 1998.	V

. •				
			•	
		1161	I Discribed to the Company of the Co	
		151	Pier "Rationale for Development of Immunotherapies that Target Mucoid Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt.	
•			98: 350-360, 1997. [Abstract]	`
		152	Goldberg et al. "Biologic Activities of Antobodies to the Neutral-Polysaccharide	
• •			Component of the Pseudomonas Aeruginosa Lipopolysaccharide are Blocked by O	~
•			Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun. 63(1): 21-26. [Abstract]	ĺ
		153	Meluleni et al. "Mucoid Pseudomonas Aeruginosa Growing in a Biofilm in vitro are	
	1	N	Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule but not by	<i> </i>
	1		Antibodies Produced During Chtonic Lung Infection in Cystic Fibrosis Patients", J.	\ <u>\</u>
	ļ	154	Immun. 155(4): 2029-2038, 1995. [Abstract]	
	1	154	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett.	<b>Y</b>
	1		100(1): 51-57, 1995. [Abstract]	~
		155	Piecet al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa	
			Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 154(4): S175-S182,	v
		156	1996. Abstract]	ļ
		136	Pier et al. Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung. Proc. Natl.	\ \
			Acad. Sci. U.A., 94(22): 12088-12093, 1997.	Į.
		157	Boucher et al. Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis.	
•			Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in a	V:
	1		Mouse Model of Respiratory Infection", Infect. Immun. 65(9): 6838-3846, Sep. 1997. [Abstract]	V
		158	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoidy Pseudomonas	<del>                                     </del>
			Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J.	
	<u></u>		Bacteriol. 178(2): 511-523, 1996. [Abstract]	
•		159	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Palmonary Clearance of Mucoid	
	I		Pseudomonas Aeruginosa and Inflammation in a Mouse Model of Repeated Respiratory Challenge", Infection and Immunity 66(1): 280-288, 1998.	V.
	<b></b>	160	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to	<b></b>
	1		Bronchopulmonary Infection with Pseudopionas Aeruginosa", J. Clin. Invest.	,
			100(11): 2810-2815, 1997.	<u> </u>
		161	Mrsny et al. "Addition of a Bacterial Angillate Lyase to Purulent CF Sputum in vitro	•
	1		can Result in the Disruption of Alginate and Modification of Sputum Viscoelasticity", Pul. Pharmacol. 7(6): 357-306, 1994. [Abstract]	1
	<del></del>	162	Wiils et al. "Short-Term Recombinant Human Doase in Bronchiectasis. Effect on	
	L		Clinical State and in vitro Spaum Transportability. [Abstract]	V
	1	163	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediatr.	<i>\</i>
	<del></del>	164	Pulmonol. 22(6): 402-407, 1996. [Abstract]	<u>'</u>
		104	Randall et al. "Distribution of DNA and Alginate in Purtlent Cystic Fibrosis Sputum: Implications to Pulminary Targeting Strategies", J. Drug. Therapy 4(4): 233-243,	
	l		1996.	ľ
•		165	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminogly osides Through the	
		1	Extracellular polysaccharide of Mucoid Pseudomonas Aeruginose", Antimicrob.	<b>V</b>
	<del></del>	166	Agents. Chemother. 42(4): 974-977, 1998. [Abstract]  Speert et al. "Modulation of Macrophage Function for Defense of the Lung against	<del> </del>
			Pseudomonas Aeruginosa", Behring Inst. Mitt. 98: 274-282, 1997. [Actract]	v
		167	Ying et al. "Alginate, the slime Exopolysaccharide of Pseudomonas Aeraginosa,	
			Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-proteinase	
			mhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", Am. J. Cell. Moll. Biol. 15(2): 283-291, 1996. [Abstract]	~
•		168	Johansen et al. "Chronic Pseudomonas Aeruginosa Pneumonia: A new Prophylactic	
			Principle", Behring Inst. Mitt. 90: 269-273, 1997. [Abstract]	V
•		169	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and	
		/	Antibiotic Resistance in Pseudomonas Aeruginosa", Curr. Microbiol. 35(2): 103-108,	<b>\</b> ^
	<del></del>	170	1997. [Abstract] Spaces "Investor Streetscoop" For J. Clin Minarkial Infact Dia 14 Suppl. 1:	<del>\</del>
		'''	Spencer "Invasive Streptococci", Eur. J. Clin. Microbiol. Infest. Dis., 14 Suppl. 1: S26-S32, 1995. [Abstract]	N
		171	Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular	<del>\</del>
	I /	1	Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol. 76(5): 424-430,	ı <b>\</b>

Hauch et al. "Invasive Streptococci Presumonias Infection Associated with Rapidly Patal Outcome in Taiwaw", J. Formos Med. Assoc. 95(2): 545-71, 1995 (Abstract)				
173   Moses et al. Relative Combourions of Hyshuronic Cupsule and M Protein to Scills	<b>X</b>	172	Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated with Rapidly	
Virulence in a Mucoid Strain of the Group A Streptococcus", Infect. Immum. 65(1): 64-71, 1997. [Abstract] 174 Scott et al. "Visualization of an Extracellular Mucoid Layer of Treponema Denticola ATCC 33405 and Strafece Sugar Lectula Analysis of Some Treponema Species", Oral Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract] 175 Milsson et al. "The Rule of Staphylococcus Polysaccharide Microcapsule Expression in Septricemia and Septic Arthritis", Infect. Immum. 63(10): 4216-21, 1997. [Abstract] 176 Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyadronic clid Capsule Expression in Group A Streptococci", Infect. Immum. 62(2): 436-441, 1904. [Abstract] 177 Faraglale et al. "A Direct Spectrophotometric Microsassy for Sulfated Citycogaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982. 178 Pasquier et al. "Implication of Neutral Polysaccharides Associated of Alginate in Inhibition of Murine Marcrophage Response to Pseudomonas Aspiginoses", FEMS Microbiol. Loke, 147(2): 195-202, Feb. 1997. Abstract. 179 Marry et al. "Independent of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Acruginosa", FEMS Microbiol. Letters, X(1-2): 33-44, Nov. 1992. Abstract. 180 Jorde et al. [Varintion in the P. Aeruginosa Polysaccharide Systatesis Conditioned by Aminosugars"] (authrity stranslation), Rev. Esp. 28iol. 34(2): 15-161, 1980. Abstract. 181 Ramos et al. "Residential plays and the Systatesis Conditioned by Aminosugars" (authrity stranslation), Rev. Esp. 28iol. 34(2): 15-161, 1980. Abstract. 182 Bassar et al. "Tyreputation of Proteoglypsis by Human Lung Efforbalastic (IMR-90) maintained in a Low Concentration of Shum)", Biochem. J. 207(3): 369-379. Abstract. 183 Vogel et al. "Troduction of Proteoglypsis by Human Lung Efforbalastic (IMR-90) maintained in a Low Concentration of Shum)", Biochem. J. 207(3): 369-379. Abstract. 185 Welch et al. "Complex Spécharide Metabollan in Orginic Fibrosis Fibrosis Fibrosis Fibrosis a				
174   Scott et al. "Visualization of an Extracellular Musoid Layer of Treponema Denticola ATCC 34/05 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol. 12(2): 121-125, 1997. [Abstrace]		173	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to	
174   Scott et al. "Visualization of an Extracellular Musoid Layer of Treponema Denticoh ATCG 33405 and Surface Sugar Lection Analysis of Some Treponema Species", Onl Microbiol. Immunol. 12(2): 121-125, 1997. [Abstrace]   175   Nilsson et al. "The Role of Staphylococcur Polysaccharide Microcapsule Expression in Septricennia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997. [Abstrace]   176   Wessels et al. "Effects on Virulence of Mutations in a Locus Escential for Hypdranic clid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 435-441, 194. [Abstrace]   177   Farbatic et al. "A Direct Spectrophotometric Microcassay for Sulfated Glycogaminoglycans in Cardiage Cultures", Connective Tissue Research 9: 247-248, 1982.   178   Pasquier dt al. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeriginosa", FEMS Microbiol. Leq. 147(2): 195-202, Feb. 1997. Abstract.   179   Marty et al. "Indipence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Parduménas Aeruginosa", FEMS Microbiol. Leq. 147(2): 195-202, Feb. 1997. Abstract.   180   John et al. [Pariation in the Parenginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (authly's translation), Rev. Esp. 25iol. 36(2): 155-161, 1980.   Abstract.   181   Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lacis", Appl. Paviron. Microfiol. 67(1): 33-41, 2001. [Abstract]   182   Bhaskar et al. "Dysregulation of Protocyloghydin Production by Intraheptic Billary Brithelial Cells Bearing Defective (dolate, 968) Cystic Fibrosis Transmembrane Conductance Regulator", Hepstology, 27(1): 7-14, Jan. 1998. [Abstract]   183   Vogel et al. "Tronduction of Protocyloghydin by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Sokumi", Biochem J. 207(3): 369-379.   Abstract.   185   Welch et al. "Complex Speciality of Microbiol. 26(2): 145-150.   186   Albusyd al. "Staphyl			Virulence in a Mucoid Strain of the Group A Streptococcus", Infect. Immun. 65(1):	V /
ATCC 33405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract]  15 Milsson et al. "The Role of Suphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997.  [Abstract]  176 Wessle et al. "Effects on Virulence of Mutations in a Locus Essential for Hyadronic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 436-441, 194. [Abstract]  177 Faragale et al. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response Associated & Alginate in Inhibition of Mutrice Macrophage Response Res			64-71, 1997. [Abstract]	
ATCC 33405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract]  15 Milsson et al. "The Role of Suphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997.  [Abstract]  176 Wessle et al. "Effects on Virulence of Mutations in a Locus Essential for Hyadronic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 436-441, 194. [Abstract]  177 Faragale et al. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response to Pseudomonas Associated & Alginate in Inhibition of Mutrice Macrophage Response Associated & Alginate in Inhibition of Mutrice Macrophage Response Res		174	Scott et al. "Visualization of an Extracellular Mucoid Layer of Treponema Denticola	
Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract]  175  Nilson et al. "The Role of Shaphylococcal Polysaccharide Microcapsule Expression in Septricemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997. [Abstract]  176  Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hypafronic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 435-441, 1994. [Abstract]  177  Parkale et al. "A Direct Spectrophotometric Microsassy for Sulfated Chychouminoghycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.  178  Paquier èt al. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition on Murine Macrophage Response to Pseudomonas Apolginosa", FEMS Microbiol. Letters, 19(2): 195-207, Feb. 1997. Abstract.  179  Marty et al. "Inhibence of Nutrient Media on the Chemical Composition of the Expolysaccharide' from Mucoid and non-Mocoid Pseudomfans Aeruginosa", FEMS Microbiol. Letters, 19(1-2): 33-44, Nov. 1992. Abstract.  180  Jorba et al. "Evariation in the P. Arenginosa Polysaccharide Synthesis Conditioned by Aminosugars" (authly's turnslation), Rev. Esp. Esiol. 36(2): 155-161, 1980.  Abstract.  181  Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lettis", Appl. Roviron. Microfiol. 67(1): 33-41, 2001. [Abstract]  182  Bhaskar et al. "Dysregulation of Protocoglyps Production by Intraheptic Billiary Epithelial Cells Bearing Defective (delta-1908) (2): 2015 Fibrosis Transmembrane Conductance Regulator", Hopatology, 27(1): 7-14, Jan. 1998. [Abstract]  183  Vogel et al. "Production of Protocoglypsking by Human Lung Fibroblasts (filkR-90) maintained in a Low Concentration of Synthy", Blochem J. 207(3): 369-379.  Abstract.  184  Hill et al. "Organ-Specific Ovey Sulfation of Ciyicosaminoglycans and Altered Extracellular Matrix in A Mysis Model of Cybic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  187  188  Allison et al. "Polysaccharide Media Beticrial Adhesion to Human Nesse"				
Nilsson et al. "The Role of Suphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997.				
in Septricentia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997. [Abstract]  Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyaphonic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 438-441, 1994. [Abstract]  177 Farhalae et al. "A Direct Spectrophotometric Microassay for Sulfiated Glyckuminoglycens in Cardiage Cultures", Connective Tissue Resemph 9: 247-248, 1982.  178 Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition on Murine Macrophage Response to Pseudomonas Agriginosa", FEMS Microbiol. Letters, 19(2): 195-202, Feb. 1997. Abstract.  179 Marty et al. "Implence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomfans Averginosa", FEMS Microbiol. Letters, 19(1-2): 35-44, Nov. 1992. Abstract.  180 Jorbs et al. "Evariation in the P. Areginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract.  181 Ramos et al. "Relationship between Glycolysis fud Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Paviron. Microphol. 67(1): 33-41, 2001. [Abstract]  182 Blussar et al. "Dyracegulation of Protocopych Production by Intraspelle Billary Epithelial Cells Bearing Defective (delas 103) Cystic Fibrosis Transmembrane Conductance Regulator," Hopatology, 27(1): 7-14, Jan. 1993. [Abstract]  183 Vogel et al. "Production of Protocopych Production by Intraspelle Billary Epithelial Cells Bearing Defective (delas 103) Cystic Fibrosis Thomas and Altered Extracellular Matrix in A Mofes Model of Cyste Fibrosis," Biochem. J. 2073; 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Cyste Fibrosis," Biochem. Mod., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis," Biochem. Mediated Extracellular Matrix in A Mofes Model of Cyste Fibrosis, Fibroblasts", Pediatr, Research, 994 969-702, 1975.  186 Rahmoune et al. "Tabined and Cyste	<b></b>	175		
[Abstract] 176 Wessle et al. "Effects on Virulence of Mutations in a Locus Essential for Hyapfronic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 436-441, IP94. [Abstract] 177 Pardule et al. "A Direct Spectrophotometric Microssasy for Sulfated Chechaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982. 178 Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Asaginesa", FEMS Microbiol. Lab., 147(2): 195-202, Feb. 1997. Abstract. 179 Marry et al. "Inhiperace of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Asaginesa", FEMS Microbiol. Letters, 74(1-3): 35-44, Nov. 1992. Abstract. 180 Jorbs et al. "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars" (authr's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract. 181 Remos et al. "Relationship between Glycolysis fade Exopolysaccharide Biosynthesis in Lactococcus Lectis", Appl. Taviron. Microfiel. 67(1): 33-41, 2001. [Abstract] 182 Blaskar et al. "Dysregulation of Protocoglysh Production by Intraheptic Billary Epithelial Cells Bearing Defoctive (delta-fo8) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology. 27(1): 7-14, Ins. 1998. [Abstract] 183 Vogel et al. "Troduction of Protocoglyshe by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Shum)", Biochem J. 207(3): 369-379. Abstract. 184 Hill et al. "Organ-Specific Over Sulfation of Cylycosaminoglycans and Altered Extracellular Matrix in A Mysse Model of Cybs: Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract. 185 Rehmounce et al. "Chydratria Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Broophitis", Am. J. Resp. Cell & Mol. Biol., 3(4): 315-320, 1991. Abstract. 187 Rehmounce et al. "Cyloradrolina Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Broophitis", Am. J. Resp. Cell & Mol. Biol., 3(4): 315-320	1	X		
176   Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyalfornic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 436-441, 1994. [Abstract]				<b>V</b>
Acid Capsule Expression in Group A Streptococci*, Infect. Immun. 62(2): 436-441, [No.4] (Abstract)  177 Farhalte et al. "A Direct Spectrophotometric Microassay for Sulfated Glycobaminoghycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.  178 Pasquier et al. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aerginosa", FEMS Microbiol. Letters, 74(72): 195-202, Feb. 1997. Abstract.  179 Marty et al. "Inducence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, 74(1-3): 354-44, Nov. 1992. Abstract.  180 Jorba et al. "Potraticola in the P. Aeruginosa Polysaccyfaride Synthesis Conditioned by Aminosugars"] (author's translation), Rev. Esp. Efiol. 36(2): 155-161, 1980.  Abstract.  181 Ramos et al. "Relationship strenslation), Rev. Esp. Efiol. 36(2): 155-161, 1980.  Abstract.  182 Bhaskar et al. "Poysregulation of Proteoglysia Production by Intraheptia Bilary Epithelial Cells Bearing Defective (delta £003) Cystic Fibrosis Transmembrane Conductance Regulator", Hopatology, 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglysia by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Skum)", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Cybcosaminoglycans and Altered Extracellular Matrix in A Mogis Model of Cysic Fibrosis", Biochem. Mol. Med. 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Textin-Mediated Bacterial Adhesion to Human Lung Fibrosis Fibrosissts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rehmoune et al. "Chybridrolin Sulfate in Sputum FromPasients With Cystic Fibrosis and Chronic Bronghist", Am. J. Resp. Cell & Mol. Biol., 5(6): 315-320, 1991. Abstract.  187 Beuth et al. "Latenties and Cystic Fibrosis", The New England Interesting and Chronic Bronghist", Am. J. Resp. Cell & Mol. Biol., 5(6): 315-320, 1991. Abstract.  189 Abstract.  1		126		
1904.   Abstract    177   Farkale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycotaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.   1982.   1982.   1882.   1882.   1883.   1884	1	1/0		
177   Farhdale et al. "A Direct Spectrophotometric Microassay for Sulfated Glyconaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.   178   Pasquier dt al. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeriginosa", FEMS Microbiol. Lott., 147(2): 195-202, Feb. 1997. Abstract.   179   Marty et al. "InSupence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, X(1-3): 354-48, Nov. 1992. Abstract.   180   Jorba et al. ("Variation in the P. Aeruginosa Polysaccyfaride Synthesis Conditioned by Aminosugars") (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980.   181   Ramos et al. "Relationship between Glycolysis fund Expolysaccharide Blosynthesis in Lactococcus Lactia", Appl. Rovinon. Micropiol. 67(1): 33-41, 2001. [Abstract]   182   Bhaskar et al. "Dysregulation of Tyrotoglysis Production by Intraheptic Billary Epithelial Cells Bearing Defective (delts 1993) Cystis Fibrosis Transmembrane Conductance Regulator", Hopatology, 27(1): 7-14, Jen. 1998. [Abstract]   183   Vogel et al. "Production of Protoglyska's by Human Lung Fibroblasts (fMR-90) maintained in a Low Concentration of Schum", Biochem J. 207(3): 369-379. Abstract.   184   Hill et al. "Organ-Specific Over Sulfation of Cylycosaminoglycans and Altered Extracellular Matrix in A Mojes Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.   185   Welch et al. "Complex Scharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.   186   Rehmoune et al. "Cylydrofroitin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronghist", Am. J. Resp. Cell & Mol. Biol., 3(6): 315-320, 1991. Abstract.   187   Bush et al. "Listin-Mediated Bacterial Adhesion to Human Nasue", Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.   188   Alison et al. "Polysaccharide Production in Pseudomonas				
Giyechaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.  178    Pasquier & al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aegiginosa", FEMS Microbiol. Let. 417(2): 195-202, Feb. 1997. Abstract.  179    Marty et al. "Inhuence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, 12(1-3): 35-44, Nov. 1992. Abstract.  180    Jorba et al. "Partiatioba in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars" (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980.  Abstract.  181    Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Raviron. Microbiol. 67(1): 33-41, 2001. [Abstract]  182    Bhaskar et al. "Dysregulation of Protoeglypa Production by Intraheptic Biliary Epithelial Cells Bearing Defective (delta 509) Cystic Fibrosis Transmembrane Conductance Regulator", Hepstologa. 27(1): 7-14, Jan. 1993. [Abstract]  183    Vogel et al. "Production of Protoeglypain by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Soum)", Biochem J. 207(3): 369-379.  Abstract.  184    Hill et al. "Organ-Specific Over Sulfation of Clycocaminoglycans and Altered Extracellular Matrix in A Myfise Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185    Welch et al. "Complex Scharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9):698-702, 1975.  186    Rahmone et al. "Cythordorium Sulfato in Sputum Fronk Patients With Cystic Fibrosis and Chronic Bronolitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.  187    Beach et al. "Induced Escherichia coli in Cystic Fibrosis", The New England Journal of Medicines 304(24): 1445-1449, June 11, 1981. Abstract.  188    Alismon et al. "Polysaccharide Froduction in Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4045, 1	<u></u>			
1982.  178 Paquier & al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeuginosa", FEMS Microbiol. Leg. 147(2): 195-202, Feb. 1997. Abstract.  179 Mary et al. "Inhipence of Nurient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, X(1-3): 35-44, Nov. 1992. Abstract.  180 Jorba et al. "Ivariations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (autiliar's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980.  Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lectis", Appl. Sanviron. Microphol. 67(1): 33-41, 2001. [Abstract] in Lactococcus Lectis", Appl. Sanviron. Microphol. 67(1): 33-41, 2001. [Abstract] Blaskar et al. "Dysregulation of Proteoglysis and Exopolysaccharide Biosynthesis in Lactococcus Lectis", Appl. Sanviron. Microphol. 67(1): 33-41, 2001. [Abstract] Blaskar et al. "Dysregulation of Proteoglysis by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Sauny", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modes Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Raimonne et al. "Chyordoviin Sulfate in Sputum Front Patients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., Si(4): 315-320, 1991. Abstract.  187 Beuth et al. "Cystic-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol. 34(1): 3-10, 1994. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach," J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.  190 Jacobe et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, J		177		
Pesquier & I. "Implication of Neutral Polysaccharides Associated & Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeuginosa", FEMS Microbiol. Let., 147(2): 195-202, Feb. 1997. Abstract.   179	{	ľ	Glycocaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248,	J
Inhibition of Murine Macrophage Response to Pseudomonas Assigniosa", FEMS Microbiol. Lett. 147(2): 195-202, Feb. 1997. Abstract.  179 Marty et al. "Inhibition of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomónas Aeruginosa", FEMS Microbiol. Letters, X(1-3): 35-44, Nov. 1992. Abstract.  180 Jorba et al. ("Variatioha in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (autility's translation), Rev. Esp. Béiol. 36(2): 155-161, 1980.  Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Raviron. Microbiol. 67(1): 33-41, 2001. [Abstract]  182 Bhaskar et al. "Dysregulation of Proteoglysis of Expositions framsmembrane Conductance Regulator", Hepatolog. 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglysis by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Shum)", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mydse Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Scharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.  186 Rahmoune et al. "Cybordroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., 1(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Gettin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  189 Albison et al. "Robinscharide Production in Pseudomonas Cepach", J. Basic. Microbiol. 6(6): 591-593, 1987. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Chemical Analysis of Alginstes from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 4068, 1996.  192 T			1982.	
Microbiol. Leg. 147(2): 195-202, Feb. 1997. Abstract.  179 Marty et al. "Indusence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomónas Aeruginosa", FEMS Microbiol. Letters, 74(1-3): 35-44, Nov. 1992. Abstract.  180 Iorbo et al. ("Variation in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (authar's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract] Esp. Esiol. 2		178	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in	
Microbiol. Leg. 147(2): 195-202, Feb. 1997. Abstract.  179 Marty et al. "Indusence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomónas Aeruginosa", FEMS Microbiol. Letters, 74(1-3): 35-44, Nov. 1992. Abstract.  180 Iorbo et al. ("Variation in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (authar's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract] Esp. Esiol. 2			Inhibition of Murine Macrophage Response to Pseudomonas Aegiginosa", FEMS	i
179 Marty et al. "Influence of Nutrient Media on the Chemical Composition of the Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, X(1-3): 35-44, Nov. 1992. Abstract.  180 Jorba et al. ["Variatiohs in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (autilur's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Anviron. Microbiol. 67(1): 33-41, 2001. [Abstract]  182 Bhaskar et al. "Dysregulation of Proteoglysis Production by Intraheptic Billary Epithelial Cells Bearing Defective delta 508) Cystic Eibrosis Transmembrane Conductance Regulator", Hepatolog. 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglysis by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Shumi", Biochem J. 207(2): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Citycosaminoglycans and Altered Extracellular Matrix in A Moste Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Syncharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Cybordorioni Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.  190 Abstract.  191 Abstract.  191 Abstract.  192 Analysia of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4084, 1996.  193 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 4084, 1996.  194 Drigues et al. "Comparative St				·
Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, X(1-3): 35-44, Nov. 1992. Abstract.  180 Jorba et al. "Variation in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars" (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract]  182 Bhaskar et al. "Dysregulation of Proteoglyon Production by Intraheptic Billiary Bpithelial Cells Bearing Defective (delts-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatologh, 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglyons by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Sound", Biochem J. 207(3): 369-379.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mydise Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Specharide Metabolism in Oystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.  187 Beath et al. "Listin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Folysaccharide Production in Pseudomonas Cepach," J. Basic. Microbiol. 26(1): 3-10, 1994. Abstract.  189 Albus 4 al. "Staphylococcus Aureus Capsular Types and Antibody Regionse to Lung Infection: Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 4048, 1996.  191 Tatnell et al. "Chernical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Socie		179		
Microbiol. Letters, X(1-3): 35-44, Nov. 1992. Abstract  180 Jorba et al. ["Variations in the P. Aeruginosa Polysaccylaride Synthesis Conditioned by Aminosusgars"] (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980. Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Paviron. Microbiol. 67(1): 33-41, 2001. [Abstract]  182 Bhaskar et al. "Dysregulation of Proteoglych Production by Intraheptic Billiary Bpithelial Cells Bearing Defective delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatolog, 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglypas by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Shum)", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modes Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Specharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr, Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.  187 Beath et al. "Lettin-Mediated Bacterial Adhesion to Human Lissue", Eur. J. Clin. Microbiol. 5(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  190 Jagos al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infesion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 2(2): 2305-2509, 1988. Abstract.  191 Tamell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  192 Tamell et al. "Chomical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 4048, 1996.  194 Drigues et al. "Comparative Stud				<b>/</b>
Jorhe et al. ["Variatione in the P. Aeruginosa Polysacofaride Synthesis Conditioned by Aminosugars"] (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980.  Abstract.  181 Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactoococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract]  182 Bhaskar et al. "Dysregulation of Proteoglych Production by Intraheptic Billiary Bpithelial Cells Bearing Defective' (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatolog. 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglycha by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Strum)", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Clycosaminoglycans and Attered Extracellular Matrix in A Mudse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Specharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr, Research, 9(9) 969-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronolitis", Am. J. Resp. Cell & Mol. Biol., \$(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lactin-Mediated Bacterial Adhesion to Human Nisue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infestion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1998. Abstract.  190 Jaccone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tarnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomona Aeruginosa", Biochemical Society Transactions 22: 4304, 1996.  193 Tarnell et al. "Characterisation of Kolsinaso of Nucoid Strains of Pseudomonas Aer				
by Aminosugars"] (author's translation), Rev. Esp. Essiol. 36(2): 155-161, 1980.  Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Paviron. Microbiol. 67(1): 33-41, 2001. [Abstract]  182 Blaskar et al. "Dysregulation of Protocopytes Production by Intraheptic Biliary Brithelial Cells Bearing Defective (delta-£08) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Protocopytes by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Seum)", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modes Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Absfract.  185 Welch et al. "Complex Saccharide Metabolism in Oestic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., \$5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Kissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach," J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Integrion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2205-2509, 1985. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 408S, 1996.  194 Drigues et al.		180		•
Abstract.  181 Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Paviron. Microlifol. 67(1): 33-41, 2001. [Abstract] in Lactococcus Lactis", Appl. Paviron. Microlifol. 67(1): 33-41, 2001. [Abstract] Bhaskar et al. "Dysregulation of Proteoglych Production by Intraheptic Biliary Epithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatologi, 27(1): 7-14, Jan. 1998. [Abstract] Abstract]  183 Vogel et al. "Production of Proteoglychas by Human Lung Fibroblasts (fMR-90) maintained in a Low Concentration of Scum)", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over-Sulfation of Clycosaminoglycans and Altered Extracellular Matrix in A Modes Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Setcharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.  186 Rahmoune et al. "Chendroitin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronolitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol (69): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol (36): 591-593, 1987. Abstract.  189 Albus, et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2x05-2509, 1983. Abstract.  190 Jiacone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Blochem	[	100		.,
181 Rames et al. "Retationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Snviron. Microfiol. 67(1): 33-41, 2001. [Abstract]  182 Blaskar et al. "Dysregulation of Proteoglych Production by Intraheptic Billiary Brithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglypags by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Soum)", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modes Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.  186 Rahmoune et al. "Chydrodrotiin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.  187 Beuth et al. "Lactin-Mediated Bacterial Adhesion to Human Kissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et gl. "Polysaccharide Production in Pseudomonas Cepach," J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Integrion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2205-2509, 1998. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tathell et al. "Characterisation of Aliginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 4048, 1996.  193 Tathell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseud	1			
in Lactococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract]  Bhaskar et al. "Dysregulation of Proteoglych Production by Intraheptic Billiary Epithelial Cells Bearing Defective' (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatolog. 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglyshas by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Shumi", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mose Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Saccharide Metabolism in Oestic Fibrosis Fibroblasts", Pediatr. Research, 9(9)/698-702, 1975.  186 Rahmone et al. "Chyndroinis Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., 1(4): 315-320, 1991. Abstract.  187 Beuth et al. "I ettin-Mediated Bacterial Adhesion to Human Rissue", Bur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol. 4(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infestion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 205-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonal Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  192 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonal Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonal Aeruginosa", Biochemical Society Transactions 22: 4068, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysacc		101		
Bhaskar et al. "Dysregulation of Proteoglych Production by Intraheptic Biliary Bpithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatologh 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglypings by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Seum)", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Clycosaminoglycans and Altered Extracellular Matrix in A Mosse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Saccharide Metabolism in Oestic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronofitis", Am. J. Resp. Cell & Mol. Biol., 1(4): 315-320, 1991. Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Jacone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Chomical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum	1	181		<b>y</b> *
Bpithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteoglyyans by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Soum)", Biochem J. 207(3): 369-379. Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Setcharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach," J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infestion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2305-2509, 1988. Abstract.  190 Maccone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomona. Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Chonical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				
Conductance Regulator", Hepatologh 27(1): 7-14, Jan. 1998. [Abstract]  183 Vogel et al. "Production of Proteogly and by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Setum", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modse Model of Cybic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 8(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus, et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infegion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2205-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  192 Tatnell et al. "Chomical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193 Tatnell et al. "Chomical Society Transactions 22: 3108, 1994.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from A Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		182	Bhaskar et al. "Dysregulation of Proteoglycon Production by Intraheptic Biliary	
183 Vogel et al. "Production of Proteoglysas by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Secum)", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mosse Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 8(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis". The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tamell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  192 Tamell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193 Tamell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		ľ	Epithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane	v *
183 Vogel et al. "Production of Proteoglysas by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Secum)", Biochem J. 207(3): 369-379.  Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mosse Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 8(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis". The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tamell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  192 Tamell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193 Tamell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.			Conductance Regulator", Hepatology 27(1): 7-14, Jan. 1998. [Abstract]	
Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modso Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chyondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 3(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infegion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 7505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tarnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  202 Tarnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193. Tatnell et al. "Colonisation of the Alginate from Mucoid Variants", Blochemical Society Transactions 22: 3108, 1994.  194. Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	•	183	Vogel et al. "Production of Proteoglystas by Human Lung Fibroblasts (IMR-90)	
Abstract.  184 Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Modso Model of Cysic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  185 Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chyondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 3(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infegion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 7505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tarnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  202 Tarnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193. Tatnell et al. "Colonisation of the Alginate from Mucoid Variants", Blochemical Society Transactions 22: 3108, 1994.  194. Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	l		maintained in a Low Concentration of Secum)", Biochem J. 207(3): 369-379.	<b>✓</b>
Extracellular Matrix in A Mode Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  Welch et al. "Complex Secharide Metabollsm in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chyondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infestion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 205-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginates from Mucoid Variants", Blochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				
Extracellular Matrix in A Mode Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.  Welch et al. "Complex Secharide Metabollsm in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chyondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infestion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 205-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginates from Mucoid Variants", Blochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		184	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered	
185   Welch et al. "Complex Secharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.   186   Rahmoune et al. "Chondroitin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., S(4): 315-320, 1991.   Abstract.   187   Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.   188   Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.   189   Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infegtion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 7305-2509, 1988. Abstract.   190   Jiacone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.   191   Tamell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.   192   Tamell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.   193   Tamell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.   194   Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Murants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				<i>J</i>
Welch et al. "Complex Scheharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chyondroitin Sulfate in Sputum FromPatients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 8(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Rissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 205-2509, 1988. Abstract.  190 Alacone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 4048, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 4068, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				
Pediatr. Research, 9(9) 698-702, 1975.  186 Rahmoune et al. "Chondroitin Sulfate in Sputum Front Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		185		
186 Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Kissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2x05-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tamell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chornical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406X, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	1			
and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., \$5(4): 315-320, 1991.  Abstract.  187 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Rasponse to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2305-2509, 1988. Abstract.  190 Hacone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 4048, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 3108, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Blochemical Society Transactions 24: 4068, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		106		
Abstract.  Beuth et al. "Lettin-Mediated Bacterial Adhesion to Human Kissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.  Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2x05-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		100		
Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Kissue", Eur. J. Clin. Microbiol. 6(6): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Rasponse to Lung Infestion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				١
Microbiol. 6(5): 591-593, 1987. Abstract.  188 Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 205-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	<del></del>	107		
Microbiol. 665: 391-393, 1987. Abstract.  Allison et pd. "Polysaccharide Production in Pseudomonas Cepach", J. Basic. Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2x05-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	Į '	18/		v
Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	<b> </b>	100	MICTODIOL O(0): 391-393, 1987. AOSTRACT.	
Microbiol 34(1): 3-10, 1994. Abstract.  189 Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	1	198	Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic.	V
Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2805-2509, 1988. Abstract.  190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.			Microbig 34(1): 3-10, 1994. Abstract.	
190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		189		
190 Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	l i		Infegtion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2305-2509,	~
Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		الــــا		3.
Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.  191 Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  192 Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		190	Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England	
Tamell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  Tamell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tamell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	<b>[</b>		Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.	
Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.  Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonal Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		191		
Tainell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonal Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tainell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				~
Acruginosa", Biochemical Society Transactions 22: 310S, 1994.  193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Acruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		1/2		
193. Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	Į l			V
Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Blochemical Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		103		<b></b>
Society Transactions 24: 406S, 1996.  194 Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		. , , ,	Appropriate Characterisation of the Abricate Same Mariate Variante Disaberran	
Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				X
from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	<b></b>	104		<del></del>
Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.		194		l., <b>\</b>
	/			<b>^                                   </b>
195   Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides",				
	V	195	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides",	

	т	Disash Adv. 13, 202 449 1004	T
<del>\</del>	196	Biotech. Adv. 12: 393-448, 1994.	
	130	Anatolii "Hyaluronic Capsule as one of the Factors of Hemolytic Streptococcus	
		Pathogenicity", Chem. Abstracts 86(17): 339, Abstr. 118714 citing Zh. Mikrobiol.	
<del></del>	107	Epidemiol. Immunobiol. 2: 22-27, 1977.	
	197	Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem.	
·····	100	& Molecular Biol., 13: 1-32, 1984.	
`	198	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V.,	
	<del>- \</del>	Inc., N.Y.: 1-33, 1984.	
•	163	Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell	
	1	Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980.	
	200	Li et al. "Immunochemical Localization of Heparanase in Mouse and Human	•
	1 000	Melanomas", Int. J. Cancer 45: 1088-1095, 1990.	
	201	Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma	
	1	Calls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bigl. Int.,	
	1000	39(3): 563-571, 1996.	
	202	Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996.	
	203	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and	
	1	Medicine Annu. Rev. Biochem., 50: 657-680, 1981.	
	204	Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in	
		Mouse Mammary Gland Development Suggests A Role in Hermone Action and	
	+==-	Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996.	
	205	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human	•
	1200	Breast Epithelial Cel Line, MCF-101", Cancer Res., 50/6075-6086, 1990.	
	206	Miller et al. "Xenograf Model of Progressive Human Proliferative Breast Disease",	
<del></del>	1000	J. Nat. Cancer Inst., 85: 725-1732, 1993.	
	207	Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and	
	1	Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613,	
	200	1983.	
	208	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular	
		Heparanase", Molecular Biology/Blachevistry. Proceedings of the American	
	1200	Association for Cancer Research, 37.495, 1996.	
	209	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-	
	210	Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991.	
	210	Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal	
	211	Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.	
	1 211	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on	
	212	STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10.	
	712	Hillier et al. "The Washy -Merck EST Project", No. V30845, Databse GenBank on STN, US National Library of Medicine (Bethesda Mix), 1996. Claims: 9, 10.	
	213	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-	
	213	Interscience, New York: 2.1.1-2.1.2, 1991.	
······	214	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic	
	214	Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.	
	215	Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro	
• •		Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology,	
	]	22: 161,166, 1996.	
	216	Crystyn "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92	
		(Suppl.64): 6A-44S - 6A-52S, 1992.	
	217	Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4,	
		1970.	
	218	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-	
		3074, 1980. Abstract.	
	218	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate	
	17	Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway	
	<b>y</b>	Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.	
	220	Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial	<del></del>
		Cells From Patients With Cystic Fibrosis", J. Clin. Invest., 84(1): 68-72, 1989.	<b>\</b>
		Abstract.	1
	221	Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways	$\overline{}$
	'	Disease", Acta Paediatr. Scand. Suppl., 363: 25-29, 1989.	1
	222	Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower	
		Respiratory Tract <sup>a</sup> , J. Clin. Invest., 100(1): 68-73, 1997. Abstract.	1
<u> </u>		1 100 1 1 100 1 1 100 1 1 100 1 1 100 1 1 100 1 1 100 1 1 100 1 1 100 1 1 1 100 1	

•	•			
		223	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis:	Γ
• •			Relationship Between Levels of Highly Sulfated Mucin Component and Severity of	1
•			the Disease", Clinica Chimica Acta, 132: 143-155, 1983.	
		224	Allen "Opportunities for the Use Aerosolized al - Antitrypsin for the Treatment of	
• •	<u> </u>	1225	Cystic Fibrosis", Chest, 110: 256S-260S, 1996.	
		225	Schwab et al. "Increased Adherence of Staphylococcus Aures From Cystic Fibrosis	
	`	$\mathbf{V}$	Lungs to Airway Epithelial Cells", Am. Rev. Respir., 148(2): 365-369, 1993.  Abstract.	
		226	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires	/
	ľ	7	Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-	
			3428, 1995. Abstract.	
		227	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in	
		j i	Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice.	ł
			ARMIS, 105(11): 838-842, 1997. Abstract.	]
٠	i	228	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected	
		-	With seudomonas Aeruginosa", Eur. Respir., 10(10): 2312-2318, 1997. Abstract.	
	'	229	Zahm et al. "Early Alterations in Airway Mucociliary Clearance and Inflamation of	
	1		the Lamina Propria in CF mice", Am. J. Physiol. 272(3 Pt 1): C853 C859, 1997. [Abstract]	
		230	Thompson et al. "Identification of Chondroitin Sulfate E in Human Lung Mast	ļ
		120	Cells", J. Immunel., 140(8): 2708-2713, 1988. Abstract.	
4		231	Giuffre et al. "Moracyte Adhesion to Activated Aortic Engothelium: Role of L-	
,			Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997.	
			Abstract.	
		232	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of	
			Lipoprotein Lipase to Cultured Bovine Endothelia/Cells", J. Clinical Invest., 68(4):	
			995-1002, 1981. Abstract.	
		233	Hayward et al. "Heparinase III Exerts Endotherial and Cardioprotective Effects in	
			Feline Myocardial Ischemia-Reportusion Injury", J. Pharm. Exp. Ther., 283(3): 1032-1038, 1997. Abstract.	
		234	Yamaguchi et al. "Neutrophil Elastasa Linibitor Reduces Neutrophil Chemoattactant	
		1	Production After Ischemia-Reperfusion in Rat Liver", Gastroenterology, 112(2): 551-	
		1 1	560, 1997. Abstract.	
		235	Matgolies et al. "Identification of A Major Reparin-Precitable Protein in Human	
			Serum and Its Relationship to Cystic Fibrosis Pediatr. Res., 16(3): 181-186, 1982.	
			Abstract.	
		236	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of	
			Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun.,	
		237	66(3): 994-999, 1998. Abstract.  Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J.	
		]2,	Vet. Med. Sci., 59(8): 727-728, 1997. Abstract.	
	-	238	Krusat et al. "Herarin-Dependent Attachment of Respiratory Syncytial Virus (RSV)	
			to Host Cells" Arch. Virol., 142(6): 1247-1254, 1997. Abstract.	
		239	Alvarez-Doplinguez et al. "Host Cell Heparian Sulfate Proteoglycans Mediate	
	•		Attachmen and Entry of Listeria Monocytogenes, and the Listerial Surface Protein	
			ActA Is involved in Heparan Sulfate Receptor Recognition", Infection & Immun.,	
		1040	65(1);/8-88, 1997. Abstract.	
		240	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by	
		241	Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539, 1997. Abstract.  Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the	·
		1	Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate	
	•		Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.	
l		242	Inaba et al. "Effect of Heparinon Infection of Cells by Porcine Reproductive and	
			Respiratory Syndrome Virus", Am. J. Vet. Res. 58(5): 488-491, 1997. Abstract.	
		243	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target	
		<u> </u>	Cell Heparan Sulfate", Nature Medicine, 3(8): 866-871, 1997. Abstract.	
Į.		244	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite	_
			Protein and Thrombospondin Is Mediated by Its Glycosminoglycan-Binding Region	1
1		1245	and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.	$\angle$
1		245	Robert et al. "Chondroitin-4-Sulphate (Procoglycan), A Receptor for Plasmodium	. `
1	/	i i	Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial	

	1246	Tyr	
	246	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate	
<b>  \</b>	i	Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes",	<b>'</b>
	1	Mol. & Biochem. Parasit., 65: 73-83, 1994.	
	247	Berkow "The Merck Manual". R. Berkow, M.D., Ed-in-Chief, Mcrck Research	
	<u> </u>	Laboratories: 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.	
	248	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part IL. Use of	-
	1	Therapies", Pediatr. Pulmonol. 28(4): 248-54, Oct. 1999. [Abstract]	
,	249	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas	/
	V.	Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary	ſ
ĺ.		Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, May 1997.	l
<del></del>	250	Endering et al. (Character Full of Character Ful	
	250	Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa Infection in	
ĺ	1	Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol. 28(3): 159-166,	
·		Sep. 1999. [Abstract]	
	251	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Patients with	
		Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group, New England	
		Journal of Medicine 340(1): 23-30, Jan. 7, 1999. [Abstract]	
	252	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to	
		Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", Infect. Immun.	
	1	64(1): 37-4, 1996. Abstract.	
	253	Bennett et al. Effect of Uridine 5'-Triphosphate plus Amilorine on Mucociliary	<u> </u>
		Classes in Adult Custic Ethernial A. J. B	
ľ	1	Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 153(6 Pt.1):	
	264	1796-1801, June 1096. [Abstract]	
İ	254	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children with	
Ì	]	Cystic Fibrosis", Am. Respir. Crit. Care Med. 156(4 Pt.1): 1197-1204, 1997.	
		Abstract.	
1	255	Naparstek et al. "Activated T Lymphocytes Produce a Matrix-Degrading Heparan	
<u>.                                    </u>	l	Sulphate Endoglycosidase", Vature, 310(5974)/241-244, 1984. Abstract.	
	256	Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis: A Review	<del></del>
		of New and Potential Interventions", Pediatric Pulmonology 24: 143-146, 1997.	
	257	Rubin "Emerging Therapies for Cyatic Fibrosis Lung Disease", Chest 115: 1120-	
	/	1126, 1999.	
	258		
	236	Ducy et al. "The Osteoblast: A Sophist cated Fibroblast under Central Surveillance",	
	260	Science 289: 1501-1504, 2000.	
•	259	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and	
		Regeneration", Nature Biotechyology 16: 243, 252, 1998.	
	260	Elkin et al. "Heparanase as Mediator of Anglogenesis,: Mode of Action", The	
		FASEB Journal 15: 1661-1663, 2001.	
	261	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB	<del></del>
		Journal, Published online, May 29, 2001.	
	262	Finkel "Potential Target Found for Antimetastasis Druga", Science 285: 33-34, July	
		2, 1999.	
	263	Webster at al "DGED Activation in Chalant Disease The Land	
	203	Webster et al. "PGFR Activation in Skeletal Disorders: Too Much of a Good Thing", TIG 13(5): 178-182, May 1997.	
<del></del>	264	Chimage at 4 (6 md and 2 md at 2 md at 2 md	
1	264	Shimazu et d. "Syndecan-3 and the Control of Chondrocyte Proliferation During	
	-	Endochondral Ossification", Exp. Cell. Res. 229(1): 126-136, 1996, Abstract.	·
	265	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as	
		Ossegus Cicatrizing Agents", Ann. Endocrinol. (Paris) 55(2): 121-123 1994.	
		[Abstract]	
:	266	Blanquaert et al. "Heparan-Like Molecules Induce The Repair Of Skull Defects".	<del></del>
		Bone, 17(6): 499-506, 1995. Abstract.	
•	267	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on	
		Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract]	
		11-65-00 1 BIL. 1770 , Dioce 50(4). 1314-1320, August 13, 1970. [A08IRG]	
	26#		
1	268	Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding	
	268	Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302.	
		Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract]	
	269	Site Which Modifies its Biological Activity, Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-	
		Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)" J. Cell	
		Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)" J. Cell	\ .
		Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Buhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract]	<u></u>
	269	Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract] Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone	<u></u>
	269	Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract] Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures". Am. J. Vet. Res.	<u></u>
	269	Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract] Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone	

	272	Service "Tissue Engineers Build New Bone", Science 289: 1498-1500, 2000.	i
<b>\</b>	273	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase",	
	254	Advan. Enzyme Regul. 37: 135-144, 1997. Introduction.	
	274	Bost et al. "Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2", Immunol. Invest. 17: 577-586, 1988.	
	275	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use	
		of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J. Histochem. Cytochem. 43: 881-886, 1995.	
	276	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular	
		Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.	
	277	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated	
	1	Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene	
		Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.	
	278	Ross "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s", Nature, 362: 301-809, 1993.	
	279	Putnak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine, 3(8): 828-329, 1997.	
	280	Shieh et al. Cell Surface Receptors for Herpes Simplex Virus Age Heparan Sulfate	
	281	Proteoglycan roteoglycans", J. Cell. Biol., 116(5): 1273-1281/1992.  Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor a Is Formed from	
	201	the Extracellular Matrix by the Enzyme Heparanase", Proc Natl. Acad. Sci. USA,	
		92: 5037-5041, 1993	
	282	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is	
		Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation, Cell, 79: 1015-1024, 1994.	
	283	Vlodavsky et al. "Endothelia Cell-Derived Basis Fibroblast Growth Factor:	
		Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl.	
	284	Acad. Sci. USA, 84: 2292-2296, 1987.  Vlodavsky et al. "Involvement of the Extra Cellular Matrix, Heparin Sulfate	<u> </u>
	204	Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and	
	1	Metastis", Tumor Angeogenesis, P.12/40, 1997.	
	285	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular	
		Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry,	
	286	28: 1737-1743, 1989.  Nicolson "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion,	
	100	Invasion and Growth of Matignant Cells at Specific Secondary Sites", Cancer Met. Rev., 7: 143-188, 1988.	
	287	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996. Claims; 9, 10.	
	288	Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns	
		Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174,	
	200	1995. GenBank Entry AA304653, 1997. Claims: 30.	
	289	Yagel et al. "Normal Normetastatic Human Trophoblast Cells Share in vitro Invasive Properties of Malignant Cells", J. Cellular Physiology 136: 455-463, 1988.	
	290	Kizaki eval. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta 24: 424-430, 2003.	
	291	Demosey et al. "Heparanase Expression in Invasive Trophoblasts and Acute Vascular	
		Damage", Glycobiology 10(5): 467-475, 2000. Abstract. P. 470, Col. 1 - P. 471, Col. 1; P. 472, Col. 1, § 4 - Col. 2, § 2. Claims: 1-24.	
	292	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological	
•		Human Placenta*, Molecular Human Reproduction 8(6): 566-573, 2002.	
	297	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During	-
	294	Gestation", Reproduction 121: 573-580, 2001. Claims: 1-50.  Edwards et al. "Some Properties and Applications of Monoclonal Antibodies",	
/		Biochem. Journal 200: 1-10, 1981.	
	295	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary	
<del></del>	296	Hemochromatosis", PNAS 95(5): 2492-2497, 1998.  Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive	<del></del>
	~~~	BioMedicine Online 2002 4(2): 170-175, 2002. Abstract.	\
	297	Bean et al. "Fertilization in vitro Increases Non-Disjunction During Early Cleavage	
/	L	Divisions in a Mouse Model System", Human Reproduction 17(9): 2362-2367, 2002.	

:

\	T	Abstract.	
	298	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003.  Abstract.	
	299	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes from Cryopreserved Primordial Mouse Follicles after Sequential In Vivo Transplantation and In Vitro Maturation*, Biology of Reproduction 64: 171-178, 2001. Abstract.	
	300	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo- Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse	
	301	Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell Stage", Biology of Reproduction 66: 3810385, 2002. Abstract.  Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrade	
		Reproduction 63: 1294-1302, 2000. Abstract.	
	302	Yesilonglar et al. "The Mouse as a Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", Human Reproduction (4(1): 55-59, 1999. Abstract.	
	303	Ejima et al. Vinduction of Apoptosis in Placentas of Pregnant Mice Exposed to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System*, Biology of Reproduction 62, 178-185, 2000. Abstract.	
	304	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Yaginal Adenosis Using the Neonatal Mouse Molel", Biology of Reproduction 38: 935-943, 1988. Abstract.	
	305	Newbold et al. "Exposure to Diethylstilbestrol During/Pregnancy Permanently Alters the Ovary and Oviduct", Biology of Reproduction 26: 735-744, 1983. Abstract.	
	306	777 "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice: 1-2, Summer 2002.	
	307	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA", Proceedings American Association for Canter Research Annual Meeting 1992, 33: 57, 1992. Abstract 343. Claims: X:\-10, 15-18. / Y: 11-14.	
	308	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides", Angew. Gran. Int. Ed. Engl. 32: 666-690, 1993.	
	309	Cohen "Oligonucleotide Therapeutics", Thends in Biotechnology 10: 87-91, 1992.  Abstract.	
	310	Szczylik et al. "Selective Inhibition of Leukenia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleordes", Science 253, 562-565, 1991. Abstract.	
	311	Calabretta et al. "Normal and Leukemic Hematophietic Cell Manifest Differential Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An in vitro Study Relevant to Bone Marrow Purging", Proc. Vatl. Acad. Sci. USA 88: 2351-2355, 1991.	
	312	Burch et al. "Oligodeoxynucleotides Antisense to the Intercukin 1 Receptor mRN Block the Effect of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice", J. Clin. Invest. 88: 1190, 1991. Abstract.	
	313	Agrawal "Artisense Oligonucleotides As Antiviral Agents", Trends Biotechnol., 10(5): 152/158, 1992. Abstract.	
-	314	Ngo et al. "The Protein Folding Problem and Tertiary Structure", K. Merz, Jr. and S.Le Grand, Ed Birkhauser Boston: 491-495, 1994.	
	315	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", Nature Medicine, 6(5): 568-572, 2000.	
	316	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling is Defined by Pricyte Coverage of the Preformed Endothelial Network and is Regulated by Pricyte B and VEGF", Development 125: 1591-1598, 1998.	•
	3/7	Vukicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)", Proc. Natl. Acad, Scie., 93: 9021-9026, 1996.	
	318	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49: 437-438, 1987.	
	319	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormono-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture", Bone, 14: 717-720,1993.	
	320	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotech., 18: 34-39,	

·	Γ"	2000.	
<del></del>	321	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Res., 10	<del> </del> -
1	J2'	: 398-400, 2000.	
<del></del>	322	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends	
\		in Genetics, 14(6): 248-250, 1998.	
	323	Smith et al. "The Challenges of Genome Sequence Annotation or "The Devil is in the	/
		Details***, Nature Biotechn., 15: 1222-1223, 1997.	
	324	Brenner "Errors in Genome Annotation", Trends in Genetics, 15(4): 132-133, 1999.	<b>/</b>
	325	Bork "Go Hunting in Sequence Databases but Watch out for the Traps", Trends in	<b></b>
	12	Genetics, 12(10): 425-427, 1996.	Į
···	326	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino	<del> </del> -
	320	Acid Substitutions", Science, 247: 1306-1310, 1990.	ţ
	327	?? A Genesq, Accession No. AA17083, 1999.	<del> </del>
<del>,</del>	328	Beildig et al. "Humanization of Rodent Monoclonal Antibodies by CDR grafting".	<del> </del>
	1 220	Methods, 8: 83-93, 1995.	Į.
	329 ·	Miao et al. "Cloning, Expression and Purification of Mouse Hearangee", Protein	<del> </del>
	727	Expression and Purification, 26: 425-431, 2002.	1
	330	Coligan et al. "Current Protocols in Immunology", Green Publishing Assoc. 1991.	<del>}</del> -
	331	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene from	<del></del>
	,,,	Flavobacterium Heparinum", Proc. Natl. Acad. Sci., 90: 3668-3664, 1993.	1
	332	Gordon-Cardo et al. "Expression of Basic Fibroplast Growth Factor in Normal	<del></del>
	202	Human Tissues", Laboratory Investigation, 63: 832-840 1990.	l
	333	Harper "Harper's Biochemistry", 24th Ed., P. 660-685	<del></del>
	334	Boat et al. "Increased Salfation of Glycoconjugates NY Cultured Nasal Epithelia	<del> </del>
		Cells From Patients With Cystic Fibrosis", Journal of Clinical Invetment, 84(1): 68-	
_		72, 1989. Abstract.	1
	335	Nossuli et al. "Heparinas III Pyerts Endothelia And Cardioprotective Effects In	<del></del>
	333	Felino Myocardial Ischemia-Reperfusion Injury", Journal of Pharmaceutical	
		Experimental Therapy, 283(3): 1022-1039, 1997. Abstract.	
	336	Nakajima et al. "Immunochemical Decalization of Heparanase in Mouse and Human	<b></b>
		Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.	
	337	Wands Federal Circular, 1988,	
	338	Fisher CCPA, 1970.	
·	339	Carson et al. Mucin And Prote glucan Functions In Embryo Implantation",	
		BioEssays, 20(7): 577-583, Abstract. P. 580, Col. 2, § 2; P. 582, Col. 1, Fig. 1.	ŀ
		Claims: 1-24.	
	340	Clonotech Laboratories "RT-PCR Methods and Applications Book 1", Clonotech	
		Laboratories, 1st Ed., 7.1-15, 26, 40, 1991.	
	341	Novagen "PET System Manual", Novagen, 6th Ed., P. 1, 1995.	
	342	Ennis et al. PNAS/USA, 87: 2833-2837, 1990.	
	343	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An	
		Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule,	
		Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.	
	344	Murphy of al. The Latent Collagenase and Gelatin of Human Polymorphonuclear	
<u> </u>		Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.	. •
	345	More et al. "Human Neutrophil Gelitanase Is A Collagenase Type IN", Biochem. &	
		Bigohys. Res. Comm., 191: 269-274, 1993.	
	346	Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng.	
		13: 167-182, 1991.	
	347	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia	
	/	Coli", Microbiolog. Rev., 60: 512-538, 1996.	
	348	Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.	
	649	Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing	
		Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.	
	350	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged	<b>/</b>
		Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.	
/-	351	Sambrook et al. "Molecular Cloning", CSH Laboratory Press, 1989.	1
7	352	Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression".	-
<b>/</b>		Curr. Opin. Biotech., 6: 527-533, 1995.	\
	353	Freshney "Animal Cell Culture", P.48-49.	-
	355	Wight et al. "Coll Biology of Arterial Proteoglycans", Arteriosclerosis, 9(1): 1-20,	

\		1989.	Τ
	356	Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991.	
$\overline{}$	357	Ruoslahti et al. "Proteoglycans As Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991.	
	358	Viodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Basic Membranes: Cellular and Molecular Aspects, P. 327-343, 1993.	
	359	Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extra Vasation", Invasion	
	360	& Metastasis, 12(2): 112-127, 1992. Abstract; Claims: 1-24.  Vlodavsky et al. "Inhibition of Tumor Metastasis Inhibiting Species of Heparin"	ļ
	361	Invasion & Metastasis, 14(1-6): 290-302, 1994/95.  Liotta et al. "Tumor Invasion and the ExtraCellular Matrix", Laboratory Investigation, 49(6): 636-647, 1983.	
	362	Vlodavsky et al. "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Research, 43: 2704-2711, 1983.	
···	363	Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med. Sci., 24(9-10): 464-470, 1988.	
	364	Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanases", Int. J. Cancer 40: 511-517, 1987.	
	365	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980	
	366	Viodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.	:
	367	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", J. Clin. Invest., 83: 752-756, 1989.	
	368	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", FEBS Letters, 117(1): 203-266, 1980.	
	369	Sudhalter et al. "Importance of Size, Sulfation and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Crowth Factor by Heparin", J. Biol. Chem., 254(12): 6892-6897, 1989.	
	371	Inoue et al. "Selective N-Desy fiation of Hepanin with Dimethyl Sulfoxide containing Water or Methanol", Carbobydrate Research, 46,67-95, 1976.	
	372	Nagasawa et al. "Solvolytic Desulfation of Glycosuminoglycuronan Sulfates with Dimethyl Sulfoxide Containing Water or Methanol:, Carbohydrate Research, 58: 47-55, 1977.	
	373	Matia Bar-New et al Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.	
	374	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cell Proliferation In Vitro by Fibroblant and Epidermal Growth Factors", Exp. Eye Res., 23, 75-89, 1977.	<u> </u>
	375	Haimovity-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell- Derived Factors", Blood, 78: 789-796, 1991.	
	376	Vlodevsky et al. "Extracellular Matrix-Resident Growth Factors and Puzymes: Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metatastis Rev., 9: 203-226, 1990.	
		Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Aniomic Compounds", J. Bioactive and Compatible Polymers, 8:317-337, 1993.	
	378	Benezra et al. "Antiproliferative Activity to Vascular Smooth Muscle Cells and Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds", Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
	379	Katz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor Binding of a Heparain-Mimicking Polyaromatic Anionic Compound", J. Am. Soc. Nephrology, 1688-1697, 1997.	
	380	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding Dimerization, Signaling, and Angiogenic Activity by a Synthetic Heparain-Mimicking Polyaromatic Compound", J. Clin. Invet., 99(7): 1565-1575, 1997.	1
	381	Benezra et al. "Reversal of Fibroblast Growth Factor-mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research, 52:5656-5662,	

		1992.	
	382	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo-β-glucuronidase (Heparanase) of Metastatic melanoma Cells", Biochemistry, 25:5322-5328, 1986.	
	383	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated Polysaccharides", Int. J. Cancer, 39: 82-88, 1987	
	384	Ornitz et al. "Heparin is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to a Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and	
	385	Cellular Biology, 12:240-247, 1992.  Yayon et al. "Cell Surface, Heparin-Like Molecules Are Required For Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64: 841-849, 1991.	
	386	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans that Promote Binding of Basic Fibroblast Growth Factor to its Receptor:, J. Bjo. Chem., 269(1):114-121, 1994.	
	387	Bartlett et al. "Comparative Analysis of the Ability of Leucocytes, Enothelial Cells, and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for Cytokine Dependence and Detection of a Novel Sulfatase", Immurology and Cell Biol., 73: 113-124, 1995.	
	388	Nakajima et al. " A Solid-Phase Substrate of Heparanase: Its Application to Assay of Human Melanoma for Heparan Sulfate Degradative Activity, Analytical Biochemistry, 151: 162-171, 1986.	·
	389	Oosta et al. "Purification and Properties of Human Platalets Heparitinase", J. Biol. Chem.; 257(19): 11232-11255, 1982.	
	390	Sewell et al. "Human Mononuclear Cells Contain an Endoglycosidase Specific for Heparan Sulfate Glycosan inoglycan Demonstrable with the Use of a Specific Solid-Phase Metabolically Radio abelled Substrate", Prochem J., 264: 777-783, 1989	
	391	Freeman et al. "A Rapid Quartitative Assay for the Detection of Mammalian Heparanase Activity", Biochem L, 325: 229/237, 1997.	
	392	Mullings et al. "New Reducing Supar Assay for the Study of Cellulases", Enzyme Microb. Technol., 6:491-496, 1984.	
	393	Taylor et al. "A Colorimetric Method or the Quantitation of Uronic Acids and a Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1992.	
•	394	Linhardt "Capillary Electrophores of Oligosaccharides", Methods in Enzymology, 230:265-280, 1994.	
	395	Basu et al. "Analysis of Gly ospingolipids by Eluorophore-Assisted Carbohydrate Electrophoresis Using Ceramide Glycanase from Mercenaria mercenaria", Analytical Biochemistry, 222:270-2/4, 1994.	
	396	Jackson "The Use of Polyacrylamide-gel Electrophoresis for the High-Resolution of Seperation of Reducing Saccharides Labelled with the Kluorophore 8-aminonaphtalene-1/3,6-trisulphonic Acid", Biochem J., 20: 705-713, 1990.	
	397	Coquet et al. "Applications of a Post-Column Fluorigenic Reaction in Liquid Chromotagraphy for the Determination of Glucose and Fructose in Biological Matrices", Analytica Chemia Acta, 252: 173-179, 1991.	
	398	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell- Specific et 1 Library Using Antibodies Directed Against A Putative Heparanase Amino Terminal Peptide", Int. J. Cancer, 56:286-294, 1994. Claims: 1, 3, 5-7, 15-17.	
	399	Zsolvai et al. "Directional Immobilization of Heparin onto Nonporous Surface of Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.	
	400	Pharmaceutical Contracotr, 1997.	
	401	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.  Yen et al. "Potentialities of a new Class of Anticlotting and Antihemorrhagic	·
	403	Polymers", J. Macromol. Sci., Chem., 4(3), pp. 693-714 in Chem. Abst. AN, 1970 418456  Mes et al. "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of Sugar and Sugar Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Positives Pos	\ <u> </u>
	404	Sugars and Sugar Derivatives Reported in Olycoproteins", J. Chromatogr., 43(\$),pages 480-486, 1969.	
	404	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and Differentiation of Sugars and Sugar Derivatives in Glycoproteins", J. Chromatrogr., 38(1): 120-125, 1968.	

	405	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
		Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic",	
		Cell, 19: 607-616, 1980.	
	406	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor of Proteins", Annu.	
\	1	Rev. Biochem., 58:.575-606, 1989.	. /
	407	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth	
	407		
	400	Muscle Phenotype", Experimental Cell Research, 20: 156-167, 1992.	/
	408	Eisenberg et al. "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan	
		Sulfate on Cell Surface and Extracellular Matrix, J. Clin. Invest., 90: 2013-2021,	
		1992.	
	409	Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth	
	<b>\</b>	Factor - Is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393/400,	
	1	1988.	•
	410	Folkman et al. "Angiogenic Factors", Science, 235: 442-447, 1987.	
	412	Matther et al. "Degradation of Heparan Sulfate in the Subendothelial Expacellular	
	412	Matrix by a Readily Released Heparanase from Human Neutrophils", J. Clin. Invest.	
	į		
	<u>.</u>	76(4): 1306-1313, Oct. 1985.	
	413	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative	
		Enzymes Hegaranase and Gelatinase in Tertiary Granules of Human Neutrophils",	
	L	Biochem. J., 327: 917-923, 1997.	
	414	Narindrasorasak et al. "High Affinity Interactions Between the Altzheimer's β-	
	'	Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate	
		Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991.	•
	415	Omitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-	
	713	Derived Di- and Trisaccharides", Science, 268: 432,436, 1995.	
<del></del>	110	Derived Di- and Trisacchardes, Science, 200, 4329430, 1993.	
	416	Rapraeger et al. "Requirement of Heparan Sulfate," or bFGF-Mediated Fibroblast	
		Growth and Myoblast Differentiation", Science 252: 1705-1709, 1991.	
•	417	Zhong-Sheng et al. "Role of Heoaran Sulfate Proteoglycans in the Binding and	
		Uptake of Apolipoprotein E-Enrithed Remgant Lipoproteins by Cultured Cells", J.	
		Biol. Chem., 268(14): 10160-1016 1993.	
	418	Hudson "Recombinant Antibody Fraggent", Curr. Opin. Biotech., 4:395-402, 1998.	
	419	Schoepe et al. "Neutralization of Hemotytic and Mouse Lethal Activities of C.	
	1	Perfringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by	
	]	Monoclonal Antibodies", Microbiol. Pathogenesis, 23: 1-10, 1997.	
	420	Chiba et al. "Generation of Neutralizing Antibody to the Reserve Transcriptase of	
	420	Human Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious	
		Furnal infinition desired with Type 1 by minuting of white with an infectious	
	12.	Vaccinia Virus Recombinant", J. Immunological Methods, 207:53-60, 1997.	
٠.	421	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and	
		Number:, Genetic Engineering News: 23-49, 1998.	
	422	Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to	
	1	Mature, Mainstream Applications as Clinical Therapeutics, Genetic Engineering	
		News: 4, 35, 1997.	
	423	Danheiser "Rifuxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk	
		Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997.	
	424	Rader et al. "A Phage Display Approach for Rapid Antibody Humanization:	<del></del>
	~~~	Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 35: 8910-8915.	
	1	1998	
	425		<u> </u>
	425	Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the	
	1	Edidermal Growth Factor Receptor: Recovery Antagonistic Activity",	
		Immunotechnology, 3: 71-81, 1997.	
	426	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in	
		Heparain", FEBS Lett., 117: 203-206, 1980	
	47/1	Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-	
	/	167, 1988.	
	428	Ngo et al. "Computational Complexity, Protein Structure Prediction, and the	
		Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure	<b>\</b>
	1		
	400	Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495.	<del>- \</del>
	429	Colman "Effects of amino Acid Sequence Changes on Antibody-antigen	
	L	Interactions", in Research in Immunology, 1994; 145(1): 33-36.	
1.	430	Abaza et al. "Effects of Amino Acid Substitutions Outside an Antigenic Site on	
		Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by	<b>\</b>
<b>/</b>	1	Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of	\

		1475 400 444 1000	
<b></b>		Myoglobin", in Journal of Protein Chemistry, 11(5): 433-444, 1992.	
	431	Lederman et al. "A Single amino Acid Substitution in a common African allele of the	
	1 }	CD4 Molecule Ablates Binding of the Monoclonal antibody, OKT4", Molecular	
	L	Immunology 28: 1171-1181, 1991)	
	432	Li et al. "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from	
		other Biological Activities", PNAS 77: 3211-3214, 1980)	
	433	Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Cell Invasion:	<b>Y</b>
1	NI	Selected Enhancement of Heparanase Activity and Heparanase Degradation of	
1		Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 2856-2863, 1996	ł
		also in: Advances in Enzyme Regulation, 37: 111-134, 1997.	
	434	Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanage", J.	
İ	1	Surg. Res., 67: 98-105, 1997.	
	435	Rechler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined	
· ·		Specificity", Nature 256: 495-497, 1975.	
<del> </del>	438	Kussidet al. "Cloning and Functional Expression of a Human Heparadase Gene",	
1	""	Biochemical and Biophysical Research Communication 261(1): 187-187, 1999.	1
<b> </b>	439	Walch et al "Correlation of Overexpression of the Low-Affinity 775 Neutrotrophin	
1	""	Receptor with Augmented Invasion and Heparanase Production in Human Malignant	
1		Melanoma Celle", Int. J. Cancer 82: 112-120, 1999.	1
<del></del>	440	Freeman et al. "Exidence that Platelet and Turnour Heparanases are Similar	
i	ן יייין	Enzymes", Biochem J. 342: 361-368, 1999.	
	441	Ernst et al. "Enzymath Degradation of Glycosaminoglycans", Crit. Rev. in	<del> </del>
1	***	Biochemistry and Molecular Biology, 30(5): 387-444, 1995.	
<b> </b>	442	Zhou et al. "A 182 bp Fragment of the Mouse proul(11) Collagen Gene is Sufficient	1
	442	to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 108: 3677-	
	1		
	442	3684, 1995.  Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First	<del> </del>
	443	Intron in Expression of the al (I) Callagen Gene.", Mol Cell Biol., 18(6): 3368-	
1		3375,1998. Abstract.	
ļ		Chow et al. "Development of an Epithelium-Specific Expression Cassette with	
1	444	Human DNA Regulatory Elements for Transgene Expression in Lung Airways",	
İ	1	Proc. Natl. Acad. Sci., 94:14696-14700, 1997.	
	146	Ye et al. "Targeted Gene Correction: A New Shategy for Molecular Medicine",	
	445	Molecular Medicine Today: 431-437, 1998.	1
	1446	Lai et al. "Homologous Accombination Based Gene Therapy", Exp. Nephrol,	<del> </del>
	446		1
	447	7(1):11-14, 1999. Abstract.  Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms	<b></b>
	447	in Rat Tissues", Prochimica et Biophysica Acta, 1172: 37-42, 1993.	ŀ
	440	In Kar Hissues", Prochimica et Biophysica Acta, 1172: 37-42, 1993.  Le Fur et al. "Selective Increase in Specific Alternative Splide Variants of Tyrosinase	<del> </del>
	448	in Murine Melanomas: A Projected Basis for Immunotherapy Proc. natl. Acad. Sci.,	i
	1	in Murine Metanomas: A Projected Basis for Immunotherapy Crioc. Ball. Acad. Sci., 94; 5332-5637, 1997.	
	440	Gewirtzet al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects",	<del>                                     </del>
	449	Blood 92(3): 712-736, 1998.	1.
	450	Shartry "Gene Disruption in Mice: Models of Development and Disease", Molecular	<del>                                     </del>
	450		1
	46:	and Cellular Biochemistry, 181: 163-179, 1998.	<del>                                     </del>
.	451	Carpentier et al. "DNA Vaccinaiton with HuD Inhibits Growth of a Neuroblastoma in	1
	1	Mice", Clinical Cancer Research, 4: 2819-2824. 1998.	<del>}</del>
	452/	Lai et al. "DNA Vaccines" Critical Reviews in Immunology 18: 449-484, 1998.	<del> </del>
1	453	Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene",	1
<u> </u>	Y	Journal of Biological Chemistry 270(10): 5276-5281, 1995.	<del>\</del>
/	454	Shekhar et al. "Correlation of Differences in Modulation of ras Expression with	
	l	Metastatic Competence of Mouse Mammary Tumour Subpopulations*, Invasion	
<u></u>	<del> </del>	Metastasis, 14: 27-37, 1994/5.	<del>  \</del>
	L	<u> </u>	<del> </del>
			<del></del>
	<b>—</b>		<del></del>
Signature	نـــــــــــــــــــــــــــــــــــ	Considered	
-			

<sup>&</sup>quot;EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to piece a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

plus sign (+) inside this box  $\rightarrow$  +

## PTO/SB/08A (10-96)

Approved for use through 19/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ter the Paperv	vork Redu	ction Act of 19	995, no pen	sons are	required to respu	Patent od to a collection of uformati	JN GILLESS 14 C	Complete i	Known	_
		Substitute f	nr form 14	49A/PT	0		App	lication Number	10/371,218	_
								ng Date	92/24/2003	
	II.	<b>VFORM</b>	IATI(	I NC	DISCLOS	SURE		Named Inventor	Zcharia	_
	S	TATEN	<b>MENT</b>	BY	APPLIC	CANT		up Art Unit	1652	
•	\ "							miner Name		
		(use a	s many :	sheets	as necessar			orney Docket Number	28/83	
neet		$\overline{}$			Of			miey Docket Islander	1 9 105	_
icci		_			U.S. P	ATENT DOCUME	V15		T	_
		U.S. Parent	Documen	ni i			1		Pages, columns, lines.	
1	1	Wind Code <sup>2</sup>			· l		1 1	Date of Publication of	Where Relevant Passages or Relevant	
caminers	Cite	Number	(Diagov		Name o	f Patentee or Ap licant		Cited Doggment	Figures Appear	
itials	No.1				- ol	Cited Documer t	_	MM-DØ-YYYY	ļ	
		5,362	641		Fuks et al		_	11-08-1994	ļ	
	<del></del>	5,968			Pecker et a	1 up - 1-12 2015	4	10-19-1999	<del> </del>	
	<del></del>	<b>→</b> 6,177			Peaker et a	1 20 <u>4.4</u>		01-23-2001	<del>- </del>	
	<del> </del>	6,348			Aval-Hers	hkovitz et al		02-19-2002	J	_
	<del> </del> :	0,348	,	-						
	├	<del> </del>		$\vdash$						
	<del> </del>	<del> </del>		$\vdash$		<del></del>				
	<b>├</b> ──	<del> </del>		┼─						_
	<del>                                     </del>	<del> </del>		+	<del> </del>	$\overline{\mathbf{x}}$				
	<b>↓</b>	<del> </del>		+-	<del> </del>					
	<b>↓</b>	<b></b>		┼	<del> </del> -	<del></del>				
	1			+-	<del> </del>	<del>/</del>				
	↓			┼	<del>                                     </del>					_
		<b></b>		┼			1			_
		<del></del>		╂—						_
	┷			+-				<b>—</b>		
				┵	FOREL	GN PATENT DOC	MENTS			_
			reign Pat	1000	PUREI	<u> </u>			1	1
	1 -		reign ran			Name of facentee	or	Date of Publication of	Pages, columns, lines, Where Relevant	l
Examiners Initials	Cite No.	Office	Nur	iber*	Kind Code <sup>3</sup>	Applicant of tited Do	cument	Cited Document MM-DD-YYYY	Passages or Relevant	ı
Initials.	1,40.				(if knowa)				Figures Appear	+
		-Wg	99/57	244		Ben-Artzi et al		11-11-1999	<u> </u>	+
	<del></del>	WO	99/57			Pecker et al		11-11-1999	<del>  \</del>	╁
	+-	1 wo	99/11			Pecker et al		03-11-1999		╁
	<del></del>	7 70	77/11	.,,,	<del>                                     </del>	† <del></del>			<del></del>	+
<b>)</b>	_/_					<del>                                     </del>				4
	4-		+		<del>                                     </del>	<del> </del>				4
-			1		<u> </u>			Date		•
Examin	er i							Considered	1	

<sup>\*</sup>EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Tims will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief I normation Officer, Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Doc. nents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwo	ork Reduction	Act of '995, no persons are required to respond to a collection ( i information un	less it contains a	valid OMB control	number.	<del></del>					
		estitute for form 1449A/PTO	L	Complete	, KIROWI						
	300	AGRICULTURA CANTON ACTUAL CANT	Application		10/37						
	INFO	ORMATION DISCLOSURE	Filing Date		02/24/						
	CT A	TEMENT BY APPLICANT	First Name		Zchar	a					
	SIA	TEMBRE DI ALL DICHELL	Group Art		1652						
		(use as many sheets as necessary)	Examiner 1	Vame .							
l Shoot	1	Of 2	Attorney Do	ocket Number	25/183						
Sheet		OTHER PRIOR ART - NON PATENT LITER	ATURE DO	CUMENTS							
Examiner	Cite	In this came of the nutbor (in CAPITAL LETTER i) title of the	article (when ar	propriate), title	f the						
Initials	No.	item (book magazine immal, serial symposium, c stalog, etc.) da	ue, page(s), vol	ume-issuc nymh	er(s),	T <sup>2</sup>					
Hullais		publisher, city and/or country where pr	ablished.	Eura							
Ì	1 1	Vildavsky et al, "Mammalian Heparanase Gene Clon	ing, Express	902 1000	uon						
		in Tumor Progression and Metastasis", Na. ure Medicin	ne, 3(7):793	-807, 1999							
1	.   1	Kussie et al, "Cloning And Functional Expression Of		e varanase Ge	ne,						
	∔	Biochem Diophys Res Commun., 261(1):183-187, 1999	January 5	mmena In Tu	-201	<del></del>					
}	j j	Hulett et al, Cloning Of Mammalian Hep:ranase, An	Important E	ilzyme m ru	.001						
		Invasion And Metastasis", Nat Med., 5(7): 503-09, 199	haminati	on Clonina	and	<u>-</u>					
7	١, ,	Toyoshima et al, Human Heparanase: Purification, Cl	114179C1CT1Z2[[]	or, Croming,	ши						
		Expression", J. Biological Chemistry, 274-34):24153- JFairbanks et al, "Processing Of The Huma 1 Heparange	Dreeness-	And Fuidens							
}		That The Active Enzyme Is A Heterodime ", J Bio Cl	ham 274(A'	71.20587-205	20	!					
İ			иет., 2 г <del>ч</del> (ч	c j. 27301-273	70,						
		1939.  Dempsey et al, "Heparanase, Potential Regulator of	Call Matrix	Interactions"							
1			CEIS-WIALIA	inciacuons	•						
		TISS, 25(8):349-351, 2000 Niwa et al, "Efficient Selection For High: expression"	Tennefectant	c With A Nor	·el						
1 .	1	Eukaryotic Vector", Gene, 108(2):193/19/, 1991	r ransiectarii	2 W 101 W 140	-01	}					
		Clark, AJ, "The Mammary Gland as a Bicreactor: Exp	america Pro	cessing and							
i		Production of Recombinant Proteins", J. Nammary G	Jand Biol A	nd Moonlasia							
	1	3(3):337-350, 1998	inia moi. 7	na treopiasia	•						
		Mirault et al, "Transgenic Glatathione Per oxidase Mo	nse Modela	for Neugary	ection						
<b>,</b>		Studies", Ann NY Acad Sci. 738:104-115. 1994	dec Modele	ior ivedopror		1					
		Studies , Ann IVI Acua Seg 758.104-115. 1554	ed By Chick	en I vsozvin	Gene	<del></del>					
	Ì	Lampard et al, "Secretion Of Foreign Proteins Mediated By Chicken Lysozyme Gene Regulatory Sequences", Biochem Cell Bic I., 80(6):77, 788, 2002									
ļ		Warmen et al "Expression of Expression in the	Fig White	of Transpeni	<u>c</u>						
1	į.	Harvey et al, "Expression of Exogenous Frotein in the Eag White of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002									
<b> </b>		- Morrison et al. Sequences In Antibody Molecules Important For Receptor-Mediated									
1	1	Transport Into The Chicken Egg Yolk", Nol Immunol., 38(8):619-625, 2002									
		Clark et al. "Pharmaceuticals from Trans; enic Livestock", TIBTECH, 5:20-24, 1987									
<del></del>		Richards et al, "Construction And Prelim nary Charac	cterization O	f The Rat Ca	sein						
1	1	And Alpha-Lactalbumin Cdna Clones", J Biol Chem.	. 256(1):526	-32, 1981							
		Campbell et al, "Comparison Of The Whey Acidic Pr	rotein Genes	Of The Ra:	\nd						
1	]	Mouse". Nucleic Acids Res. 1984 Nov 26.12(22):868	5-8697.	1		1					
<b></b>		Gorodetsky et al, "Isolation and Characte ization of the	he Bos Taur	us B-Casein	ene".						
1		Gene, 66:87-96, 1988		•	1	i					
<del></del>		Alexander et al, "Complete Sequence of the Bovine B	3-Lactoglobi	lin cDNA'.	<b>Vucleic</b>	7					
1		Acids Research, 17(16):6739-6744, 1989				<b></b>					
	/										
		<u> </u>	<del></del>	Data		<del></del>					
Ekaminer			ł	Date	l	1					
Signature	)		i	Considered							

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time vill vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Info mation Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: ...ssistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformar be with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number, 2. Applicant is to place a check mark here if En pish language Translation is attached.

PTO/SB/08A (10-96)

Please type o plus sign ( $\tau$ ) inside this box  $\rightarrow$ Approved for use through 10/31/99 OMB 0651-0031

Approved for use turning 10/31/79 ONIS 00/11/00 ONIS DEPARTMENT Of CONMERCE

Patent and Trademark Office: U.S. DEPARTMENT Of CONMERCE

Light the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of internation unless it contains a valid OMB control number.

Campulete if Known

ter the Paperwe	nris Reducti	on Act of 19	93. no perso	ID DE I	equired to respin	to to a consection of a touristant		Complete		نے
		Substitute :	for form 14	49A/P1	Ю		App	lication Number	10/456,573	
		:CODA	a a TYA	<b>331</b> 1	DISCLO	CURE		ng Date	06/09/2003	
							Firs	t Named Inventor	Iris PECKER	
•	S	TATE	MENT	BY	APPLI	CANI		up Art Unit	1646	
		luse a	is manv .	sheet	s as nece <b>s</b> sa	ערַע)	Exa	miner Name		
		<u> </u>			Of	12	Atte	mey Docket Number	2867?	
heet	11	<del>/</del>			1'91	PATENT DOLUMENT	Š		/	
		U.S. Pagen	t Docume	nt I			T			
Examiners Initials	Cite No. 1	Number	Kind Co	nde.		of Patentee or Applicant of Cited Docume it	1	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Wh Relevant Passages or Relevant Figu Appear	
	<del>                                     </del>	6,177	545		Pecker et	al		01-23-2001		
	<del>                                     </del>	5,968	822		Pecker et			10-19-1999		
	<del>  </del>	6,664			Pecker et			12-16-2003	ļ	
		6,242			Freeman e		<u> </u>	06-05-2001.		_
		0,2.12	,, <u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>							
	<del>                                     </del>	<u> </u>								
	<del>                                     </del>	l		<del>                                     </del>			$\perp$			
	<del>                                     </del>			$\vdash$						
	+					X				_
	<del>                                     </del>									<u> </u>
	<del>                                     </del>								<del></del>	
	1			T						
	$\top$						_			_
		1					$\lambda$			
	1						_ _	<b></b>		_
					FORE	GN PATENT DOCUM	ENTS		<del></del>	_
	T	Fo	reign Pate	ni Onc	uments			Date of Publication of	Pages, columns, lines.	ı
Examiners Initials	Cite No.	Office	Number		Kind Code <sup>3</sup> (if known)	Name of Patentee or Applicant of litted Docum	ent	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	ľ
	1	WO	03/006	645		IMCLONE: YSTEMS		01-23-2003		Ļ
<del>)</del>	+-		!							누
	1	1							<del>                                     </del>	<u>:</u>
		1	1						<del></del>	十
	/								<del>                                     </del>	十
	1	1						<del></del>	<del> </del>	4
Examine	· .							Date Considered		_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicar t.

Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO stion designation number. See attached Kinds of U.S. Patent Document. Enter Office that issued the occument, by the involution code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must proceed the senial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible of Applicant is to place a check mark here if English language Translation in attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time vill vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: A isistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box 
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Vising the Program's Reduction Act of 1995, no persons are required to respond to

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of i formation unless it contains a valid OMB control curriber. Complete if Known 10/456,573 Substitute for form 1449A/PTO Application Number 06/09/2003 Filing Date INFORMATION DISCLOSURE Iris PECKE First Named Inventor STATEMENT BY APPLICANT 1646 Group Art Unit Examiner Name (use as many sheets as necessary) 2567 Attorney Docket Number Sheet OTHER PRIOR ART – NON PATI NT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTER .), title of the article (when appropriate), title the Cite Examiner item (book, magazine, journal, serial symposium, c stalog, etc.) date, pagets), volume-issue nun T² No. publisher, city and/or o untry where published. Initials Modavsky et al, "Inhibition of tumor meta tasis by heparanase inhibiting species of in", Invasion Metastasis. 1994-95;14 1-6):290-302 (abstract) Parish et al, "Evidence that sulphated poly accharides inhibit tumour metastasis by blocking umour-cell-derived heparanases'. Int J Cancer. 1987 Oct 15:40(4):511-8. Lider et al, Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals vith low doses of hyparins', J Clin Invest. 1989 Mar;83(3): \$\sqrt{52-6.} Gewirtz et al, "Nucleic acid therapeutics: state of the art and future prospects", 3lood. 1998 Aug 1:92(3):712-36. Hida et al, "Antisense ENAF transfection r strains gral cancer invasion by reducing matrix metalloproteinase astivities", Am J Pathol 1997 Jun;150(6):2125-32 (abstract) Thuong et al, "Sequence-specific recognit of and modification of double-helical DNA by oligonucleotides", Angew Chen Int. Ed. Engl., 32:666-690, 1993 Cohen, JS, "Oligonucleotide therapetrics', Trends Biotechnol., 10(3):87-91, 19992 (abstract) Szczylik et al, "Selective inhibition of leu emia cell proliferation by BCR-ABL antisense oligodeoxymucleotides, Science . 1891 Aug 2:253(5019):562-5. (abstract) Calabretta et al, "Normal and leukemic he natopoietic cells manifest differential sensitivity to inhibitory effects of c-myb a itisense eligodeoxynucleotides: an in vitro study relevant to bone plarrow purging", 1'roc Natl Acad Sci U.S.A. 1991 Mar 15;38(6):2351-5. Burch et al, "Oligonucleotides antisense t) the interleuking receptor mRN block the effects of interletkin 1 in cultured murine and hum fibroblats and in mice". J Clin Invest.. 88(4):1190-1196, 1991 (abstract "Antisense oligonucleotides: s antiviral agents", Trends Biotechnol, Agrawal S. 10(5):152-158, 19992, (abstract) Uno al. "Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cincer cells". Cuncer Res. 2001 61(21):7855-60. Date Kaminer Considered Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance : ith MPEP 609. Draw line through citation if not :n conformance and not considered. Include copy of this form with next communication to applicant

<sup>.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if En; ish language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief information Officer, Patent and Trademark Office. Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: . ssistant Commissioner for Patents, Washington, DC 20231.

Signature

Considered

11:

Approved for use through 10/31/99 OMB 0651-0031

Pagent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Ur der the Paperwork Reduction Act of 1935, no persons are required to respond to a collection of information unless it contains a valid OAIB control a unber Complete if Known Substitute for form 1449A/PTO 10/645,659 **Application Number INFORMATION DISCLOSURE** Filing Date 08/22/2003 STATEMENT BY APPLICANT First Named Inventor YACOBYZEEVI Ciroup Art Unit 1635 (use as many sheets as necessary) Examiner Name Sheet Or Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) file of the un (book, magazine, journal, serial symposium, catal.q. etc.) date, page(s), volume-issae numt er(s). Initials No. T! publisher, city and/or country where published. Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", J. Biol. Chem., vol. 274, 36, 42, pp. 2951.7-29590, 15 Oct 1999. Hulett et al. "Cloring of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastacis", Nature Medicine, 5(7):803-889, 1909 Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, vol. 274. 34. pp. 24153-24160, 20 Au<sub>3</sub>. 1999. Miao et al, "Cloning, Expression and Purification of Mouse Heparanase", Protein Expression and Purification, 26:423-434, 2002 Freeman et al. "Human Platelet Heparanase: Parification. Characterization and Catalytic Activity", Biochem J., 350(3): 1341-1350, 1998. Mininer Date

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

E inden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

<sup>10</sup> NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC::0231.



1 TO/SB/08a (08-03)

Approved for use throu th 07/31/2006. OMB 0651-0021
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE

Under the P	perwork:	Reduction Act of 1995, Inc. A.TRI	Le required	o respond to a co	allection of information (					
		Substitute for form 1449A/	PTO		Complete if Kn. wn					
<b>\</b> .					Application N	umber		22,502		
	INFO	RMATION DISC	LOSU	RE	Filing Date			ust 22, 2003		
	STAT	<b>TEMENT BY APP</b>	LICA	NT	First Named In	ventor		CC BY-ZEEVI Orove et al		
	\				Art Unit		164	4		
		ise as many sheets as nec	exzary)		Examiner Nan	ne	1			
Sheet	1	<b>Y</b>	of	111	Attorney Dock	et Number	268	72		
			U.S	PATENT	DOCUMENTS					
L'xantiner Initials*	Cite No.	Occument Number		ation Date JD-YYYY		Patentee or Cited Document		Pages, Columns, Lines, Where Delevant Passages or Relevant Figures Appear		
	<del>                                     </del>	Number-Rind Code <sup>2 to Long</sup>	00 0 10	10.4	Colo			K		
	2	US-5,362,541 US-5,399,35	08-8-19			iner et al	_/			
	+						/	<u> </u>		
	3	US-5,550,116 US-5,667,501	01-1-19			au ct al.		<del> </del>		
	5	US-5,739,115	01-1-19			er et al				
	6		01-1-19			di et al		<del></del>		
	7	US-6,177,545 US-6,348,344	02-19-2			er et al. Novitz et al		<del></del>		
	8	US-4,946,778	08-8-19			r et al.		<del></del>		
	9	US-5.997,863	07-7-19			er et ar. nann et al.		<del></del>		
	10	US-6.242,238	05-5-20			nann et al. an et al				
	10 US-6,242,238 11 US-5,688,679 12 US-6,387,643 13 US-6,423,312		11-18-1			well				
			05-14-2			son et al.		<u> </u>		
			07-23-2			y-Zeevi				
	14	US-6,531,129	01-1-20			er et al.				
	15	US-4,455,296	06-19-1		Part	n et al.				
	16	US-5,571,506	01-1-19			n et al.				
<del></del>	17	US-5,917,830	06-29-1			et al.				
<del></del>	18	US-5.859,660	01-12-1			is et al.				
	19	US-5,600,366	04-4-19			ılman				
	20	US-6.020.931	01-1/20			y et al.		<del>_</del>		
	21	US-5.968.822	10-19-1			et al.				
	22	US-6,153,187	11-28-2			y-Zevi				
	23	US-6.664.105	12-16-2			r et a				
	24	US-5.145,679	08-8-19			ison				
	25	US-5.736.137	07-7-19			on et al.				
	26	US-5.194,596	03-16-1			er et al.				
	27	US-5,350,826	09-27-1			ck et al.	1			
	28	US-6.562,950	05-13-2			z et al.		<del></del>		
	29	US-6.699.672	02-2-20			r et al.		<b>\</b>		
	30	US-8.580.862	03-3-19			n et al.				
	31	US-5.474.983	12-12-1			et al.				
	32	US-2002/0102560	01-1-20			r et al.				
	33	US-4.859.581	01-1-19			on et al.				
<del></del>	134	US-4,882.318	01-1-19			sky et al.				
	35	US-5,129,877	01-1-19			et al.				
	36	US-5,206,223	()4-27-1			sky et al				
	37	US-5.332.812	07-26-1			on et al.				

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if r of in conformance and not considered, include copy of copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. "Enter Office that issued the document, by the two-letter code ( VIPO Standard ST.3). "For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the pate it document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. "Applicant is to place a check r lark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pt blic which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tal a 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office; U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

U.S.Patent and Trademark Office; U.S. DI PARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid OME control number.

$\mathbf{\Lambda}$		Su	bstitute for form 1449A/PTO		Complete if Kn non						
			·		Application Number 10/72:,502						
			ATION DISCLOSURE		Filing Date August 22, 2003						
	<b>STA</b>	TEM	ENT BY APPLICANT	•		amed Inven	tor		BY-ZEE	VI Oron et	al
1		(			Art Un	<del></del>	·	1644			
		use as r	nany sheets as necessary)			ier Name					
Sheet		<u> </u>	of	•	Attorne	y Docket N	lumber	26872			
F	Cae	$\overline{}$	FOREIG	<u>y paten</u>	YT DOC	UMENTS					
Examiner Initials*	No.		Foreign Patent Documents		tion Date	Name	of Patentee	Ler		anns, Lives,	1
	1	Countr	Cook Number Kind Code (#known)	IG-WW	<b>)-YYYY</b>	Applicant	of Cited Doc	ument		vant Passages Figures Appear	•
	38		WO 90/57244	11-11-	999	Ben-Artz	et al.				十
	39	PCT	WO 99/37153	11-11-	999	Pecker et		/			+-
	40	PCT	WO 99/11308	03-11-1	999	Pecker et					+
	41	PCT	WO 88/01280	01-1-19	988	Nicolson		<del></del>			+
	42	PCT	WO 95/04158	09-9-19	95	Hoogewe	rf.ct al.				+-
	43	РСТ	WO 99/21975	06-6-19	999	Freeman				·	十
	44	PCT	WO 91/19197	12-12-1	1991	Nicolson					T
	45	PCT	WO 95/04518	02-16-1	995	Midfla et	al.				$\top$
	46		WO 03/006645 A2	01-23-2	2003	Bohlen et	al.				T
	47		WO 97/11684	04-4-19		Bennett e	t al.				i
	48		WO 91/02977	97-7-19		Fuks et al	•				i .
	49		WO 97/27327	0731-1		Van Ness	et al.				Г
	50		WO OO/52149	08-8-80		Yacobi-Z	eevi				Т
	51	PCT	WO 00/52178	08-8-20	100	Pecker et	al.				
	<u>і</u> ,	نـــــــــــــــــــــــــــــــــــــ	T			L					
- <u>-</u>			OTHER PRIOR ART	- XON P	ATENT	LITERATI	JRE DO	CUMEN	TS		
Examine	er	Cite No.1	Include name of the author (in CA	rial samusi	FIT:RS), (N	e of the article	e (when app	ropriate),	title of the	١.	~
initials		.NO.	item (book, magazine, journal, er	her, city and	Vor country	whose publish	red.	ine-155ue 1	unucus).	T <sup>2</sup>	
		52	"Mouse Models for Reprodu	ctive Bio	logy Res	earch wu	w.jax.or	g/jaxmi₄	e: 1-2,		
			Summer 2002.							Ī	
	ĺ	53	Abaza et al. "Effects of Amir	10 Acid S	ubstitutio	ons Outside	an Antig	enic Site	on		
			Protein Binding to Monoclon	al Antibo	dies of P	redetermine	ed Specif	icity Ob	ained by		
			Peptide Impunization: Demo	onstration	with Reg	ion 94-100	(Amiger	nic Site .	·) of		
<u> </u>		54	Myoglobia", in Journal of Pr	otein Che	mistry, I	1(5): 433-4	44, 1998			<u> </u>	
		54	Adams et al. "Initial Assesme	ent of Hur	nan Gene	e Diversity	and Expr	ession F	atterns		
	- 1		Based Upon 83 Million Nucl 1995. GenBank Entry AA304	COUGES 01	CDNA S	sequence",	Nature, 3	11(054)	): 3-1/4,	İ	
		55	Agrawal "Antisense Oligonu	clastides	on Amtivi	ml Ananta"	Tuonala	Distant			
	- 1	. J	10(5): 152-158, 1992. Abstra	ricoliues : ri	as Wilfial	iai Agents	. i renus	piotect	ngi.,	}	
		56	Agrawal "Antisense Oligonus		Towards	Clinical T	riale" Da	uioven :	76 200	├	
		81	Albus et al. "Staphylococcus	Aureus C	angular '	Cunce and A	ntibody	Pasmoni	2101111	<del> </del>	
	<b>,</b>		Infection in Patients with Cys	tic Fibros	sis". J. Cl	lin. Microbi	ni 26/12	1. 2505-	2500 Eurig		
			1988. Abstract.		, , ,		v 20(12	<i>j.</i> 2303-	2307,		
		58	Allison et al. "Polysaccharide	Producti	on in Pse	udomonas	Cenacia"	J. Basi	·.	<b>\</b>	
			Microbiol 34(1): 3-10, 1994.	Abstract.				,	••		
Examine							Date			•	<u></u>
Signatur	re						Conside	red	1	•	1

\*EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uselo.gog/">www.uselo.gog/</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (it in PO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pu silc which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak i 2 hours to complete, including gathering, preparing, and submitting the complete that application form to the USPTO. Time will vary depending upon the individual car. e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO MIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use throw In 07/31/2006, OMB 0651-033 U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERC 2

Under the Paperwi	NK NEGOCIRIO	Act of 1995, no persons are required to respond to a colle	ctuo of information unless			i
	Sut	stitute for form 1449A/PTO	- <del> </del>	Complete if I		
\		mich bicci coupe	Application Num		7: 2,502	
		ATION DISCLOSURE	Filing Date		gı st 22, 2003	
\ST/	ATEM:	ENT BY APPLICANT	First Named Inve			VI Oroge et al
		•	Art Unit	164	4	
	(use as n	nany sheets as necessary)	Examiner Name			
Sheet	N_	of 11	Attorney Docket	Number 268	7:	/
	538	Anatolii "Hyaluronic Capsule as one of	the Factors of Her	nolytic Streptoco	o cus	
		Pathogenicity", Chem. Abstracts 86(17	): 339. Abstr. 1187	14 citing Zh. Mi	k obiot.	
	10	Epidemiol. Immunobiol. 2: 22-27, 1977	7.	·		<u> </u>
	60	Armstrong et al. "Lower Airway Inflam	rmation in Infants a	and Young Child	ich with	
	1	Cytic Fibrosis". Am. J. Respir. Crit. C	are Med. 156(4 Pt.	1): 1197-1204,	<b>597</b> .	1
	61	Abstract.				<u> </u>
	01	Bean civil. "Fertilization in vitro Increa	ses Non-Disjunction	on During Early	C eavage	İ
	1	Divisions in a Mouse Model System", I Abstract.	tuman Keproducti	on 17(9 <b>):</b> 2362-2	267, 2002.	
	62	Bendayan "Possibilities of False Immu	nom to show i as I.D.	- 1	<del></del>	<del> </del> -
1	02	of Monoclonal Authorities: The Examp	locytochemical Ke lo of the Anti Brois	suus Generated I	D'ine Use	
	l	Histochem. Cytochem. 43: 881-886, 19	65 (1) (1) (2) (1) (1) (1) (1)	Builli Antibody	, ).	
	63	Bendig et al. "Human ration of Rodent	Manaclanal April	adias by CDP C	- ni	<del></del> -
	"	Methods, 8: 83-93, 1993	William Titti	odies by CDR O	ritting,	
	64	Benezra et al. "Thrombin Inhances the	Degradation of He	nama Sulfate in		<del> </del>
1	'	Extracellular Matrix by Tumor Cell He	paranase." Exptl C	ell Res (1992)	uni	1
		201:208-215		, .		}
	.65	Benjamin et al. "A Plasticity Window f	or Blood Vessel Re	modelling is De	f ned by	<del> </del>
ŀ	1	Pericyte Coverage of the Preformed En	othelial Network	and is Regulated	liv PDGF-	
		B and VEGF", Development 125: 157)	<b>€1598, 1998</b> .	•	-	ł
	66	Bennett et al. "Effect of Uridine 5" Trip	hosphate plus Ami	loride on Mucoc	i iary	1
·		Clearance in Adult Cystic Fibrosis". Ar	n. J. Respir. Crit. C	arc Med. 153(6	F.: I):	
		1796-1801, June 1996. [Abstract]				<u> </u>
	67	Berkow "The Mcrck Manual". R. Berko	ow, M.D. Ed-in-Cl	nief, Merck Rese	rch .	
	1.60	Laboratorics: 201, 204, 308, 177-179,	1016-1017, 194-19	97, 885, 601 , 19	97.	
	68	Beuth et al. "Lectin-Mediated Bacterial	Adhesion to Numa	ın Tissue". Eur	J Clin.	
	69	Microbiol. 6(5): 597-593. 1987. Abstra	ct.		<del></del>	<u> </u>
1	99	Bhaskar et al. "Desregulation of Proteo Epithelial Cells Bearing Defective (delt	glycan Production	by Intraheptic B	il ary	ļ
j		Conductance Regulator", Hepatology 2	a-1308) Cystic Fibi	osts Fransmeme	n me	İ
	70	Blanquacy et al. "CMDBS. Functional	Applous of Sulfate	Vo. [A DSTract]	<del></del>	<del> </del> -
	"	Osseous Cicatrizing Agents". Ann. End	Androgs of Surfact	7) 121-103 100	o as	
<b>!</b>		[Abstract]	ocimoi. (1 ans) 55(	2). 121-13. 19:		į
	71	Blanquaert et al. "Heparan-Like Molecu	iles Induce The Re	nair Of Skull No	f ·cts"	<del></del>
	1	Sonc. 17(6): 499-506, 1995. Abstract.	ares modele rice inc	pun Orokun n	1.013.	
	72	Bork "Go Hunting in Sequence Databas	ses but Watch out fo	or the Traps". Tr	rends in	
		Genetics. 12(10): 425-427, 1996.		po <b>, .</b> .		
	77	Bork "Powers and Pitfalls in Sequence.	Analysis: The 70%	Hurdle", Genon	n: Res. 10	
		: 398-400, 2000.	_	•		
7	74	Bost et al. "Antibodies Against a Peptid	le Sequence within	the HIV Envelo	Protein	
		Crossreacts with Human Interleukin-2",	Immunol. Invest.	17: 577-586, 198	31.	
	75	Bowie et al. "Deciphering the Message	in Protein Sequenc	es: Tolerance to	/.mino	
<del></del>	<b></b> _	Acid Substitutions", Science, 247: 1306	-1310, 1990.		· <del>-</del> <del></del>	
Examiner			•	Date		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's enique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usato.gov">www.usato.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (\(\textit{iPO}\) Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pates t document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check it ark here if English language

Transmission is attached.

by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to prace a check if ark here if chighest tanguage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak is 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

I TO/SB/08a (08-03)

Approved for use throu ph 07/31/2006, OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DI PARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if K. wwn Substitute for form 1449A/PTO **Application Number** 10/7: 2,502 INFORMATION DISCLOSURE Filing Date Aug. st 22, 2003 First Named Inventor YAC DBY-ZEEVI Orog et al STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 2687 : Brenner "Errors in Genome Annotation". Trends in Genetics. 15(4): 132-133, 1999 77 Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2013 78 Burth et al. "Oligodeoxynucleotides Antisense to the Interleukin I Recepto mRN Block the Effects of Interleukin I in Cultured Murine and Human Fibry blas s and in Micen. J. Clin. Invest. 88: 1190, 1991. Abstract. Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Diffe ential 79 Sensitivity to ohibitory Effects of C-myc Antisense Oligodeoxynucleotide: An in vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA 88: 2351-2355, 1991. Carpentier et al. "DNA Vaccinaiton with HuD Inhibits Frowth of a Neurob astoma in Mice". Clinical Cancer Research, 4: 2819-2824, 1999.

Carson et al. Mucin And Proteoglucan Functions of Embryo Implantation". 80 81 BioEssays, 20(7): 577-583. Abstract. Chow et al. "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airw 195", 82 Proc. Natl. Acad. Sci., 94:14695-14700 / 997.

Cohen "Oligonucleotide Therapeutics". Trends in Biotechnology 10: 87-91. 1992. 83 Abstract. 84 Coligan et al. "Current Protocols in Immunology". Green Publishing Assoc. 1991 Colman "Effects of amino Acid Sequence Changes on Antibody-antigen 85 Interactions", in Research in Immunology, 1994; \45(1): 33-36. 86 De Vouge et al. "Immung selection of GRP94/Endoptasmin From A KNRK Cell-Specific Agt I Library Using Antibodies Directed Against A Putative Hepa anase Amino-Terminal Pestide", Int. J. Cancer, 56:286-294, 1994. 87 Dempscy et al. "Heparanase Expression in Invasive Trophodasts and Acute Vascular Damage", Glypobiology 10(5): 467-475, 2000, Abstract. Dempsey et al. "Heparanase. A Potential Regulator of CellMatri Interactio is". TIBS, 25(8):349-351, 2000. Doerks et al. "Protein Annotation: Detective Work for Function Prediction" Trends in Genetics, 14(6): 248-250, 1998. Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysac haride 90 om a Virulent Strain of Pseudomonas Solanacearum and From Three Avir Bent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract. Ducy et al. "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance Science 289: 1501-1504, 2000. Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant "eatures of Clan GH-A Glycosyl Hydrolases Deduced from Hydrophobic Cluster Analysis", Glycobiology 7(2): 277-284, 1997. 93 Edwards et al, "Some Properties and Applications of Monoclonal Antibodie;", Biochem. Journal 200: 1-10, 1981. Caminer

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if n x in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.ussto.gov">www.ussto.gov</a> or MPEP 901.04. Inter Office that issued the document, by the two-letter code (\*/IPO Standard ST.3).
For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the pater t document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check in ark here if English tanguage

Considered

Signature

Traiscapion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the putilic which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Approved for use thros at 07/31/2006, OMB 0651-0031 U.S.Pateni and Trademark Office; U.S. DI PARTMENT OF COMMERCIE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMF country animber. Substitute for form 1449A/PTO Complete if K town Application Number 10/7: 2,502 INFORMATION DISCLOSURE Filing Date Augi st 22, 2003 TATEMENT BY APPLICANT First Named Inventor YAC OBY-ZEEVI Oron et al Art Unit use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposer to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System". Bit logy Reproduction 62: 178-185, 2000. Abstract. 95 Exin et al. "Heparanase as Mediator of Angiogenesis.: Mode of Action", Ty FASEB Journal 15: 1661-1663, 2001. 96 Ennis et al. PNAS USA, 87: 2833-2837, 1990. 97 Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. R.v. in Biochemistry and Molecular Biology, 30(5): 387-444, 1995. 98 Faber-Elman & al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Siny lation", J. Clin. Invest., 97(1):162-171, 1996. 99 Fairbanks et al. "Processing of the Human Heparanase Precursor and Evide ice that the Active Enzyme is a Uctorodimer", Journal of Biol. Chem. 274.(42): 29537-100 Farndale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 101 Ferber et al. "Pancreatic and Duode al Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorate Streptozotocin-Induced Hyperglyce nia", Nature Medicine, 6(5): 568-572, 2009. 102 Finkel "Potential Target Found for Antimetastasis Drugs", Science 285: 33-34, July 2, 1999. 103 Fisher CCPA, 1970. 104 Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynuclcotides\*. Molecular and Cellular Biothemistry, 172: 213-225, 1997. Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar 105 Enzymes", Biochemy J. 342: 361-368, 1999. 106 Freeman et al. "Haman Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J., 330: 1341-1350, 1998. 107 Gewirtz et al Facilitating Oligonucleotide Delivery: Helping Antisense De iver on its Promise. Proc. Natl. Acad. Sci. USA, vol. 93: 3161-3163. April 1996. 108 Gewirtzet al. "Nucleic Acid Therapeutics: State of the Art and Future Prost ects". Blood 92(3): 712-736, 1998. 109 Goder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal Cellular Physiology, 148: 274-280,1991. 110 Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990. Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction 2(9): 679-684, 1996. Green et al. "Antisense Oligonucleotides: An Evolving Technology for the 112 Modulation of Gene Expression in Human Disease", Journal of American C :11 Surgery. 191(1): 93-105, 2000. Examiner Date Signature Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n & in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's inique citation designation number optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (VIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater I document. Nicht of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check in six here if English language

Transazion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the put tic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to talv 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cat is. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS.

"PO/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office: U.S. D PARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to resound to a colle-

Linder the Paperw	mrk Reduction	a Act of 1995, no persons are required to respond to a colle	ction of information unless			t.
	Su	bstitute for form 1449A/PTO	<del>                                     </del>	Complete if I		
\		ATION DICCLOSUPE	Application Numb		!2.502	
		ATION DISCLOSURE	Filing Date		st 22. 200	
<b>\</b> ŞT	ATEM	ENT BY APPLICANT	First Named Inver			VI Oron et al
			Art Unit	1644	4	
	(use as	many sheets as necessary)	Examiner Name			
Sheet	N .	of 11	Attorney Docket N	Number 268	12	
l	IN	Haimov-Kochman et al. "Localization of	of Hepranase in Nor	mal and Pathole	gical	
		Human Placenta". Molecular Human R	eproduction 8(6): 50	66-573, 2002.		1
	114	Harlow et al. "Antibodies" A Laborator	y Manual, eds. Harl	low et al.: 471-5		
ł	115	Natch et al. "Alginate Lyase Promotes I	Diffusion of Amino	glycosides Thro	gh the	
		Extracellular polysaccharide of Mucoid	Pseudomonas Aeri	iginosa". Anti-n	iemb.	
		Agents. Chemother. 42(4): 974-977, 19	98. [Abstract]			
	116	Hayward et al. "Cellular Mechanisms o	f Heparinase III Pro	tection in Rat T	aumatic	
		Shock". Agerican Journal of Physiolog	y 275:H23-H30, 19	98.		
	117	Hida et al. "Antisense ETAF Transfection	on Restrains Oral C	ancer Invasion t	. /	
	1	Reducing Matrix Metalloproteinase Act	livities". Am. J. Patl	hgl., 50(6): 2125	5·2132,	1
		1997. Abstract.		7		1
	118	Hill et al. "Organ-Specific Over-Sulfation	on of Glycosamino	lycans and Alto	ed	Ī
	1	Extracellular Matrix in A Mouse Model	of Cystic Fibrosis"	. Biochem. Mol	. Med.,	
		62(1): 113-122, 1997. Abstract.			•	
	119	Hillier et al. "The WashU-Merck EST F	roject" GenBank E.	ntry N32056, 19	)6.	
	120	Hillier et al. "The WashU-Merck EST P	miccy No N3082	4 Database Gor	Bank on	
· · · · · · · · · · · · · · · · · · ·		STN. US National Library of Medicine	(Bernesda MD), 19	96.		
	121	Hillier et al. "The WashU-Merck EST P	polect", No. N3084	5. Databse Gent	ank on	
···		STN, US National Library of Medicing	(Bethesda MD), 19	96.		i
•	122	Hoffman et al. "Human Bone Morpkoge	nic Protein 2 Conta	ins a Henarin-P	nding	
	1	Site Which Modifies its Biological Acti	vil ". Eur. J. Bioch	em. 237(1): 295	- 302,	
		[ 1996. [Abstract]	_			·
	123	Hoogewerf et al. "CXC Chemokines Co	nnective Tissue Ac	tivating Peptide	· III and	
	1	Neutrophil Activating Peptide-2 Are Ho	parin/Heparan Sull	ate-Degrading E	izymes".	}
		J. Biol. Chem., 270(7):2268-3277, 1995		_		•
	124	Hormuzdi et al. "A Gene-Targeting Ap	proach Identifies A	Function for the	First	<del></del>
	i	Intron in Expression of the at (1) Collag	en Gene.". Mol 💸	ll Biol., 18(6): 3	. 68-	
		3375,1998. Abstract.	`	<b>\</b>		
	125	Hulett et al. "Floning of Mammalian He	paranase, an Impor	tan Enzyme in	uncor	
	<u> </u>	Invasion and Metastasis". Nature Medic	ine: 5(7): 803-809.	1999.		
	126	Imai et al. "Osteoblast Recruitment and	<b>Bone Formation En</b>	hanced by Cell	Aatrix-	
		Associated Heparin-Binding Growth-As	sociated Molecule	(HB-GAM)", J.	Zell.	
·	ļ	Biol 143(4): 1113-1128, 1998. [Abstrac	<u>:1]</u>			·
	127	Ishai-Michaeli et al. "Heparanase Activi	ty Expressed by Pla	telets. Neutroph	ls. and	
	1 4	Lymphoma Cells Releases Active Fibro	blast Growth Facto	r From Extracel	dlar -	
<del></del>		Matrix". Cell Regulation, 1: 833-842, 19	990	···		
	129	Jayaraman et al. "RationalSelection and	QuantitativeEvalua	tion of Antisens	·: \	
		Oligonucleotides", Biochimica et Bioph	ysica Acta 1520: 10	5-114, 2001.		
	129	Jin et al. "Immunochemical Localization	of Heparanase in N	Mouse and Hum	n	
	1.0-	Melanomas", Int. J. Cancer. 45: 1088-10	95, 1990.			
	130	Jin et al. "Molecular Cloning and Expres	ssion of Human Her	paranase cDNA'	<b>'</b> .	
	1	Proceedings American Association for C	Cancer Research An	nual Meeting 19	92, 33:	
	<b>-</b>	57, 1992. Abstract		-		
Caminer				Date		
Signature				Considered		
EAAMINEK: INKIA	u reierence	considered, whether or not citation is in conformance	with MDCD COO Dear lies	- All		

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n st in conformance and not considered, include copy of copy of this form with next communication to applicant. <sup>3</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (t I/PO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check n ark have if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the putilic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cate. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office., U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO \* HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

and the second second second second second second second second second second second second second second second

Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Tradenark Office: U.S. D. PARTMENT OF COMMERCE and of information unless it continues a valid OMI Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

k				TO THE REAL PROPERTY OF THE ACT OF	it Countries a value Of	<u> </u>	TOT HEIDER	<u> </u>	
1	<b>\</b>	Sut	ostitute for form 1449A/PTO		Complete if				
i	\		ATTION DIGGS COLLEGE	Application Numb		<u> 72:2.</u>			
			ATION DISCLOSURE	Filing Date			22, 2003		
ı	STA	ATEM	ENT BY APPLICANT	First Named Inver			<u>3Y-ZEE'</u>	VI Orga	et al
ł				Art Unit	16	44			
		(use as i	nany sheets as necessary)	Examiner Name	l				
1	Sheet	7	of 11	Attorney Docket N	lumber 26	872	$\overline{}$		
Ì		151	Jorba et al. ["Variations in the P. Acrug	inosa Polysaccharid	le Synthesis C	or dit	ioned	T	
			by Aminosugars"] (author's translation)	. Rev. Esp. Fisiol. 3	6(2): 155-161	, 198	0/		
Ì			Abstract.					1	
Į		132	Xato et al. "Physiological Degradation	Converts the Soluble	e Syndecan-1	Elo	Jomain		
l			from an Inhibitor to a Potent Activator	of FGF-2". Nature A	Aedicine, 4(6)	.6 II-	697,	1	
I			1998						
l		133 Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Pizzo-							
l		Micromanipulator for In Vitro Fertilization Using Frozen-Thawer Mouse							
I		Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell							
l	<del></del>	Stage", Biology of Reproduction 66: 3810385, 2002, Abstragt.							
ŀ		134	Kiberstis et al. "Bunc Health in the Bala	ince", Science 289	1497, 2000.				
I		133	Kizaki et al. "Cloning and Localization	of Heparanase in Be	ovine Placenta	". Pla	acenta	ļ	
ŀ		136	24: 424-430. 2003.						
l		130	Kizaki et al. "Expression of Heparanase Gestation", Reproduction 131: 573-580.	nikna in Bovine i	Placenta Durin	g	1		
ł		137	Kuehler et al. "Continuous Curures of I	Supplied Calls Same	A .:	<del></del>			
Ì		137	Specificity", Nature 256: 495-491, 1975	rusco/Cells Secretin	ig Antibody of	r ed	letined	٠.	
ŀ		138	Konstan et al. "Current Understanding of		Dan constitution				
İ	•	,,,,	Fibrosis", Pediatric Pulmonology, 24	7 ule inilainmatory 37-142 1007	Process in Cy	5t C	i	1	
ł		139	Konstan et al. "Putterns of Medical Prac	Noo in Cursia Eibea	sies Down II I I I			<b></b>	
İ		'''	Therapies". Pediatr. Pulmonol. 28(4): 24	IR- A Oct 1000 LA	SIS: Part II. US	e n	,	ł	
ł		140	Korb et al. "Stimulation of Gere Expres	sion by Introns: Co	nversion of an	T. 5:1	hitom	<del></del>	<del></del>
Į			Intron to a Stimulatory Intron by Altera	tion of the Splice De	nnor Seguence	" Ni	cloic	ĺ	•
Ì			Acids Research 21(25): 5/01-5908, 199	3.	onor ocquence		icicic		
ľ	1	141	Kosir et al. "Early Huyan Breast Carcin	noma Cells Produce	Extra Cellular				
Į			Heparanase". Molecy far Biology/Bioche	mistry. Proceed age	of the Americ	ca ı		ĺ	
Ĺ			Association for Cancer Research, 37: 49	<b>95. 1996.</b>				ĺ	
ſ		142	Kosir et al. "Human Prostate Carcinoma	Cells Produce Extr	a ellular Hepa	iri na	se". J.		
L			Surg. Res., 67: 98-105, 1997.					ĺ	
Ļ		143	Kosir et al Abstract 3378. Cancer Res.,	37: 495, 1996.					
l		144	Kroneny ett et al. "Oligodeoxyribonucle	otide Uptake in Prir	nary Human				
l			Hemptopoietic Cells Is Enhanced by Ca	tionic Lipids and De	epends on the			ŀ	
Ļ			Hematopoietic Cell Subset", Blood, 91(	<u>3): 852-862, 1998, </u>					
l		145	Kurachi et al. "Role of Intron I in Expre	ssion of the Human	Factor IX Ger	16			_
ŀ		111	Journal of Biological Chemistry 270(10	): 5276-5281, 1995.					· · ·
l		146	Kussie et al. "Cloning and Functional Ex	xpression of a Huma	in Heparanase	Cen	e",		
ŀ		147	Biochemical and Biophysical Research	Communication 261	(1): 183-187,	1: <u>99</u>			
ŀ		148	Lai et al. "DNA Vaccines" Critical Revi	ews in Immunology	18: 449-484,	1:98			
l		140	Lai et al. "Homologous Recombination 7(1):11-14, 1999, Abstract,	Based Gene Therapy	y", Exp. Neph	ro,	1		
ŀ		149	Laskov et al. "Production of Heparanase	hu Namal and Ma					
I		177	Lymphocytes". International Journal of	coy Normai and Nec	opiastic Murin	c · B	- 1	•	
l	Examiner	<b></b>	Symphocytes . International Journal of	Carice 4/(1): 92-98	Date		┸		<del>\</del>
١	Signature				Considered		1		1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number 'coptional'). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="mailto:mww.usain.gov">mww.usain.gov</a> or MPEP 90.1.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (f //PO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check in six here if English tanguage

by the appropriate symbots as indicated on the document under VVIPO Standard S1. 16 if possible. Application is to precise disched.

Trianslation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the purific which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 1.2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. D. PARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it commits a valid (JMI) control number.

(maer the raperwink	Reduction /	let of 1995, no persons are required to respond to a colle	ction of information entess if co	DESERVA VERIO (7/	VII COMITOR	industri.
<b>√</b>	Subs	titute for form 1449A/PTO		Complete if		
			Application Number		7 2.50	
INFO	DRMA	TION DISCLOSURE	Filing Date		g 151 22	, 2003
STA	TEME	ENT BY APPLICANT	First Named Invento			-ZEEVI Oron et al
/2	1 13.111		Art Unit	164	<u>+</u>	
	use as m	any sheets as necessary)	Examiner Name			
Sheet	8	of II	Attorney Docket Nu			
	150	Le Fur et al. "Selective Increase in Spec	cific Alternative Splic	e Variants o	f Fyrosi	inase
		in Murine Melanomas: A Projected Bas 94: 5332-5337, 1997.				
	151	Lederman et al. "A Single amino Acid	Substitution in a comm	non African	a Jele o	of the
	i	CQ4 Molecule Ablates Binding of the i	Monoclonal antibody.	OKT4", Mg	cular	!
1 1		Immunology 28: 1171-1181. 1991)				<u> </u>
	152	Li et al "Immunochemical Localization	s of Heparanase in Mo	ouse and Hu	ווג וח	<b>]</b>
		Melanomes", Int. J. Cancer 45: 1088-10	095, 1990.			
	153 -	Li et al. "B Endorphin Omission Analo		nnymoreacti	v ty fro	m
		other Biological Activities", PNAS 77:	3211-3214. 1980)			
	154	Lider et al. "Suppression of Experimen	tal Autoimmune Disc	ases and Pro	k ngatio	on of
		Allograft Survival by Treatment of Ani	mals With Low Dose:	s of Heparin	". J. Cli	n.
		Invest., 83: 752-756, 1989.		1.01		
1	155	Linhardt et al. "Polysactharide Lyases" 12: 135-176, 1986.	Applied Burchemist	ry and Biote	c inoiog	gy
	156	Liu et al. "Live Offspring by In Vitro F	ertilization of Oocyte	s from Cryo	ni escrve	ed
1	130	Primordial Mouse Follicles after Seque	ntial In Vivo Transpla	antation and	la Vitro	
1 1		Maturation". Biology of Reproduction	64: 71-178, 2001. Al	bstract.		
	157	Loredo et al. "Regulation of Glycosum	ipoglycan Metabolism	by Bone		
		Morphogenetic Protein-2 in Equinc C	tilage Explant Cultur	es". Am. J. \	V∙t. Res	s.
		57(4): 554-559, 1996,	1			!
	158	Luft " Making sense out of Antisense (		Delivery: Ge	tting th	ere is
		Half the Fun". J. Mol. Med. 75/16. 199	8.			
	159	Macone et al. "Mucoid Escherichia col	i in Cysth Fibrosis".	The New En	g and	
		Journal of Medicine 304(24): 1445-144	19, June 11, 1981. Ab:	stract.		
	160	Marchetti et al. "Neuro rophin Stimula	tion of Human Meland	oma Celi Inv	/a sion:	:
		Selected Enhancement of Heparanase	Activity and Heptrana	ise Degradat	kn of	•
1		Specific Heparan Sulfate Subpopulation			19 , ز 8	<del>9</del> 6.
		also in: Advances in Enzyme Regulation	n, 37: 111-134, 1997			<del></del>
	161	Marty et al. "Influence of Nutrient Med	na on the Chemical C	omposition	o the	:MS
		Expolysace aride from Mucoid and no		im varinging	۱. i E	CIVIS
	163	Microbiol. Letters. 77(1-3): 35-44. No. Massague "The TGF-BETA Family of	Crowth and Different	liation Facto	m" Cel	11 49.
1	162	Massague "The TGF-BETA Family of   437-738, 1987.	VIIVACII ORG DIRECCIII	LIALIUM FA	CEI	", ¬'.
ļ	163	Menezo et al. "Mouse and Bovine Moo	lels for Human IVE"	Reproductiv	<del>\</del>	
	103	BioMedicine Online 2002 4(2): 170-17	IS 2002 Abstract	Reproductiv	•	•
	164	Miao et al. "Cloning, Expression and	Purification of Mouse	Hearanase*	l'roten	
	'••'/	Expression and Purification, 26: 425-4	31, 2002.		,	
ļ	185	Mollinedo et al. "Major Co-Localization	on of the Extracellular	-Matrix Deg	r dative	e
		Enzymes Heparanase and Gelatinase in	Tertiary Granules of	Human Net	it ophil:	s", 🔪
	<b>(</b>	Biochem J., 327: 917-923, 1997.	•			
	166	Motokuni et al. "In Vivo Transfer Effi				
		Myocardium Using HVJ-Liposome M	ethod", Biochemical a	ınd Biophysi	c il Res	earch
		Communications 231: 540-545, 1997.				
Examiner				Date	. [	<b>\</b>
Signature				Considered		and and and

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through chation - not in conformance and not considered, include copy of only from with next communication to applicant. Applicant's unique citation designation number (optional), See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pit tent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a chec: mark here if English language Translation is are attached.

Triansiation is attached
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to also 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Off car, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS T 3 THIS ADDRESS.

Approved for use through 07/31/2006, OMB 0651-0031 U.S.Patent and Trademark Office; U.S. D PARTMENT OF COMMERCE

Cinci inc i dani	Incometes	a recent 1493, the persons are required to required to a confer	chan of information unless	Er e entaturo B	id OM 1 cor	introl number.
	Su	ibstitute for form 1449A/PTO	L		te if I not	wn
<b>\</b> \		_	Application Numb	per	10/722,	
		ATION DISCLOSURE	Filing Date		Aug 1st	22, 2003
T.	ATEM	IENT BY APPLICANT	First Named Inver	ntor		BY-ZEEVI Orop et a!
<b>\</b>			Art Unit		164-	
	use us	many sheets as necessary)	Examiner Name			
Sheet		of 11	Attorney Docket N	Number	268. 2	
	16	Muir et al. "Histomorphometric Analysi	is of the Effects of ?	Standard He	lepari 1 O	n
·		Trabecular Bone in vivo", Blood 88(4):	: 1314-1320, August	t 15, 1996.	(Abs rac	cil /
	168	Mullings et al. "New Reducing Sugar A Microb. Technol., 6:491-496, 1984.	•			
	169	Nakajima et al. "Heparanases and Tumo 167, 1388.				i
	170	Naparstel et al. "Activated T Lymphocy Sulphate Enloglycosidase", Nature, 310	0(5974): 241-244-1	ORA Ansir	act	
	171	Newbold et al "Exposure to Diethylstill	bestrol During Preg	nanev Pern	naner fly	Alters
	172	the Ovary and Oviduct". Biology of Rep	production 28: 735-	7,44, 1983.	Abst act	t.
	1/2	Ofek et al. "Bactern Adhesion to Cells 1994, pp. 114-118, 148-153, 418-423, 4	120-423.			1
	173	Oldberg et al. "Characterization of a Plan	stelet Endoglycosida	ase Degrad	ing F en:	arin-
		Like Polysaccharides", Biochemistry 19	9: 5755-57 <b>62</b> , 1980.		• ,	
i	174	Parish et al. "Evidence That Sulphated P	Polysacolarides Inh	ibit Tumor	Met: sta	sis by
	<del>                                     </del>	Blocking Tumor-Cell-Derived Neparana	ases" Int. J. Cancer	r. 40: 511-5	17 1387	7
	175	Pasquier et al. "Implication of Neoval Pa	olysaccharides Ass	ociated to /	Algin ite	in
		Inhibition of Murine Macrophage Respu	ise to Pseudomona	is Aerugino	osa", El	MS
	176	Microbiol, Lett. 147(2): 195-202, Feb A Pfaff et al. "Cryobiology of Rat Emoryo:	997. Abstract.	C'America I		
	1,75	Permeability Coefficients for Water and	S Determination	of Zygore n	∕lemi ran	10
	İ	and the Development of Improved Cryo	oracorustion Metho	neir Acuva	ition and	rgies.
- <del></del>		and the Development of Improved Cryon Reproduction 63: 1294-1302, 2000. Abs	stract.	us . Divio	gy or	
	177	Pilbeam et al. "Comparison of the Effect	ts of Various Lengt	hs of Synth	etic Hun	man
İ		Parathyroid Hormone-Kelated Pentide (h	hPTHrP) of Malign:	ancy on Bo	ne R :so	rntion
: 	<u> </u>	and Formation in Organ Culture", Bone,	. 14: 717-720.19 <b>v</b> 3.			i
	178	Prahalada et al. "Diethylstilbestrol-Induc	ced Cervical and	winal Ader	nosis Usi	ing the
		Neonatal Mouse Model", Biology of Rer	production 38: 935-	-943. 1988.	. Abs: mc	, I
	179	Prockop "Marrow Stromal Cells as Stem Science 276: 71-74, 1997.	Cells for Nonhema	atopajetic T	ſissu•s",	,
	180	Rahmorne et al. "Chrondroitin Sulfate in	- Coutum From Pat	ionte Will		'!L!
	1	and chronic Bronchitis". Am. J. Resp. C	'ell & Mol. Biol. 56	197- 312-35 19112 A 114-	CASH : L	IDFOSIS
	·	Abstract.	.eli ce mich. mich., si	147. 315-32	157.	
	181	Kajur et al. "Covalent Protein-Oligonucle	entide Conjugates f	or Elfficier	n Deliv	ery of
		Antisense Molecules". Bioconjugate Che	em., 8, 935-940, 195	97.	•	
	182	Ramos et al. "Relationship Between Glyc	colysis and Exopoly	vsaccharide	Bio yn	thesis
		in Lactococcus Lactis", Appl. Environ. N	Microbiol. 67(1): 33	3-41, 2001.	[Abs rac	cti
	182	Reddi "Role of Morphogenetic Proteins i	in Skeletal Tissue E	ingineering	and	<u> </u>
	<u> </u>	Regeneration", Nature Biotechnology 16	5: 247-252, 1998,		_	N
	184	Richardson et al. "Regulation of Basic Fi	ibroblast Growth Fa	actor Bindi	t na gn	
		Avtivity by Cell Density and Heparan Su	ufate", J. Biological	Chemistry	, 274 [19	):   \ \
	╙	13534-13540, 1990,				
Ekaminer				Date		
Signature	<u> </u>			Considere	<b>:</b> d	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n xt in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optionat). See Kinds Codes of USPTO Patent Documents at <a href="https://www.ustrio.gog">www.ustrio.gog</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (in APO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. With a discussion of the propriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a checkin ark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pu silc which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak > 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office. U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO \* HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use throu th 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE to a finformation unless it contains a valid OMB control number.

	Sui	bsitus for form 1449A/PTO	Complete if K. town				
\		A THOSE DECOMES TO	Application Numb				
•		ATION DISCLOSURE	Filing Date		st 22, 2003		
16.	TATEM	ENT BY APPLICANT	First Named Inven		OBY-ZEEVI Orop et al		
•	<b>\</b> .		Art Unit	1644			
	<del></del>	many sheets as necessary)	Examiner Name				
Sheet	16	of 11	Attorney Docket N	umber 2687			
	183	Sasisekharan et al. "Heparinase Inhibit	s Neovascularization	", Proc. Natl. Ac	ad.Sci.		
	1.01	91:1524-1528, 1994.	· ·				
	186	Selvan et al. "Heparan Sulfate in Immu 130, 1996.					
	187	Service "Tissue Engineers Build New I	Bone". Science 289:	1498-1500. 200			
	188	Shastr "Gene Disruption in Mice: Mo and Cellular Biochemistry, 181: 163-1	79. 1998.				
	189	Shekhar et at "Correlation of Difference	ces in Modulation of	ras Expression	vith		
		Metastatic Competence of Mouse Man Metastasis, 14: 23-37, 1994/5.	•				
	190	Shimazu et al. "Syndecan-3 and the Co Endochondral Ossification", Exp. Cell.	ntrol of Chondrocyce	Proliferation D.	uring		
	191	Skolnick et al. "From Goges to Protein	Structure and functi	on: Novel Appl	rations of		
		Computational Approaches in the Gene 2000.	omic Era". Prends in	Biotech., 18: 34	39.		
	192	Smith et al. "The Challenges of Genom	e Seguence Annotati	on or "The Dov	l is in the		
	1 '/-	Details***. Nature Biotechn., 15: 122-1		on or the Dev	i is in the		
<del></del>	193	Sutherland "Structure-Function Relation	natios in Microbial	Exonolysacchari	les"		
	1	Biotech, Adv. 12: 393-448, 1994.	<b>X</b>				
	194	Szczylik et al. "Selective Inhibition of Antisense Oligodcoxynucleotides". Sci	Lenkemia Cell Prolif	eration by BCR	ABL		
	195	Tang et al. "Contribution of Specific P	scudomonas Acrugin	osa Virulence F	ctors to		
	1	Pathogenesis of Pneumonia in a Neona	tal Mouse Model of	Infection". Infec	. Immun		
		64(1): 37-43, 1996. Abstract.	\				
	196	Tatnell et al. "Characte isation of Algir	nates from Muchid St	rains of Pseudo	nonas		
		Aeruginosa", Biochomical Society Trai	nsactions 24: 4045, 1	996.			
	197	Tatnell et al. "Che nical Analysis of Al	ginates from Mucoid	Strains of Pseu	lomonas		
		Aeruginosa", Biochemical Society Tran					
	198	Tatnell et al. Colonisation of Cystic F	ibrosis Patients by no	n-Micoid Pseud	omonas		
		Aeruginos: - Characterisation of the A	lginate from Mucoid	Variante", Bioc	iemical		
		Society Transactions 24: 406S, 1996.					
	199	Thuorg et al. "Sequence-Specific Reco	gnition and Modifica	ntion of Double-	Helical		
		DNA by Oligonucleotides", Angew.Ch	em. Int. Ed. Engl. 32	: 666-690, 1993			
	200	Poyoshima et al. "Human Heparanase:	Purification, Charact	erization, Cloni	lg and		
		Expression", J. of Biolog. Chemistry, 2	74(34): 24153-2416	0, 1999.			
	201	Uno et al. "Antiscnse-Mediated Suppre	ssion of Human Hep	aranase Genc E::	pression		
		Inhibits Pleural Dissemination of Huma	an Cancer Cells", Ca	ncer Research 6	(21),		
	202	7855-7860, 2001.	Manada Indibida		-W. Jan.		
		Vlodavsky et al. "Inhibition of Tumor I Metast., 14(1-6): 290-302, 1994/95.					
	203	Vlodavsky et al. "Mammalian Heparan in Tumor Progression and Metastasis",	ase: Gene Cloning, E Nature Medicine, 5(	Expression and Fi 7): 793-802, 1999	unction 9.		
yaminer				Date			
ignature	- I -			Considered	`		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicants unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (\*VIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pate it document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. \* Applicant is to place a check in ark here if English language

by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check in ark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pulkic which is to file (and by the USPTO to process) an application. Confidentiatity is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 3.2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cails. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO "HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031

IJ.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE on of information unless it contains a valid OML control number.

Inder the Papers	ark Reduction	Act of 1995, no persons are required to resp	and to a colle	aren of information unless it contains a v	and OAL	control number.	<del></del>
		stitute for form 1449A/PTO		Comp	nere y	.movn	
<b>\</b>				Application Number		2.502	
IN	<b>FORM</b>	TION DISCLOSURE		Filing Date		ist 22, 2003	10
		ENT BY APPLICANT		First Named Inventor		OBY-ZEEV	1 Orogret at
4.	AI DIVII	EIVI DI ATI EICH		Art Unit	164-		
`	use us n	nany sheets us necessary)		Examiner Name	1		
Sheet		of 1		Attorney Docket Number	2687		
,,,cct	204	Vogel et al. "Production of Pr	oteoglyca	ns by Human Lung Fibrobla	sts (IM	3-90)	
	20.	maintained in a Low Concent	ration of S	Scrum)", Biochem J. 207(3):	369-3	9.	
	1 `	Abstract					
	205	Vikicevic et al. "Induction of	Nephrro	enic Mesenchyme by Osteo	genic F	otein I	
	-03	(Rona Morphovenetic Protein	7)". Proc	., Natl. Acad, Scie., 93: 9021	-9025,	1996.	
	206	Walch et al. "Correlation of C	)verexpre	ssion of the Low-Affinity p7	5 Xeut	otrophin [	
	200	Receptor with Augmented In	vasion and	Henaranase Production in	luman	Malignant	
		Melanoma Calls". Int. J. Cand	er 82: 1	12-120, 1999.			
	207	Walton et al. "Prediction of A	ntisense	Digonucleotide Binding Aff	inity to	а	
	70'	Structured RNA "broct", Bio	technolog	v and Bioengineering, 65(1)	: 1-9. 1	)99.	
	208	Wany "Basic Fibrobast Grov	vih Factor	for Stimulation of Bone For	rmation	in	
	200	Osteoinductive or Conductive	Implant	". Acta Orthop Scand Suppl	. 269: 1	-33, 1006	
	ı	(abermer)					
	209	Webster et al. "FGFR Activa	ion in Sk	eletal Disorders: Too Much o	of a Go	nd Thing",	
	207	TIG 13/51: 178-182 May 19	9 <b>7</b>				
	210	Welch et al. "Complex Sacch	aride Mei	moolism in Cystic Fibrosis F	ibrobla	ils".	
	1 210	Pediate Research 9(9): 698-	702. 1935				
	211	Weller "Implications of Early	Inflamat	and Infection in Cystic F	ibrosis	A Review	
	""	of New and Potential Interve	ntions"	ediatric Pulmonology 24: 14	3-146.	1997.	
	212	Wessels et al. "Effects on Vin	rulenue of	Mutations in a Locus Essen	tial for	Hyaluronic	
	215	Acid Capsule Expression in C	Group A S	Streptococci", Infect. Immun.	. 62(2)	433-441,	
		1994 [Abstract]		•			
	213	Whitelock et al. "The Devret	ation of I	luman Endothelial Cell-Deri	ived Pe	lecan and	
		Release of Round Basic Libr	oblast Gre	owth Factor by Stromelysin.	Collag	:nase,	
	ŀ	Plasmin, and Heparapases".	Journal of	Biological Chemistry, 271(1	17):100	79-10086.	
	ı	1006					
	214	Yagel et al. "Normal Nonme	tastatic H	uman Trophoblast Cells Cha	re in vi	ro Invasive	
	1	Properties of Malignant Cell	s". J. Cell	ular Physiology 136: 455- <b>46</b>	2, 1988	•	
	215	Vazaki et al "The Structure	and Expre	sion of the FGF Receptor-	WR.N.	1 Isoforms	1
•		in Rat Timues" Biochimica	et Biophy	sica Acta, 1172: 37-42, 1993	3.		ļ
	216	Ye et al. "Targeted Gene Co	rrection: A	A New Strategy for Molecula	ar Með	ine".	ļ
		Molecular Medicine Today:	431-437.	1998.			· 
	217	Vesildaglar et al. "The Mous	c as a Mo	ndel to Study Adhesion Form	nation F	gniyollc	•
	1 -	Endoscopic Surgery: A Preli	iminary R	eport", Human Reproduction	14(1)	: 55-59,	1
		1000 Abstract					
	218	Zhou et al. "A 182 bp Fragm	ent of the	Mouse proul(11) Collagen	Gene i	. Sufficient	<b>\</b>
		to Direct Chondrocyte Expre	ession in '	Fransgenic Mice", J. Cell Sci	ience l	บช: 3677-	
	X	3684, 1995,					<del>  \                                   </del>
	219	Zhou et al. "HFE Gene Know	ckout Pro	duces Mouse Model of Here	ditary		
		Hemochromatosis", PNAS 9	5(5): 249	2-2497, 1998.			<del>                                     </del>
Bignature					Conside	red	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Trans ation is attached.

\*This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including ushring, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Or foer, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS. THIS ADDRESS.

SEND TO: Commissioner for Patenta, P.O. Box 1450, Alexandria, VA 22313-1450.

## PTO/SB/08A (10-96)

Approved for use through 10/31/99 OME 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE.
Ifornation unless it contains a valid Oh1B control number.

oder the Papers	vari. Redu	ction Act of	1995. no per	zouz sı	e required to	espond to a collection of information u	nless is contains a valid OMB contr	ol number.	<del>-</del> -
inter and it do	-						Complete	11 1010111	<i>j.</i>
			for form 14				Application Number	10/341,582	
	IN.	FORM	MATIC	ON	DISCL	OSURE	Filing Date	01/14/2003	
. \						ICANT	First Named Inventor	llan et al	
	<b>(</b> )	IAIL	ALC:IA I	DI	AFFL	ICANI	Group Art Unit	1652	
		(use d	s many s	sheei	s as neces	sary)	Examiner Name		_
Sheet		<u> </u>			OL	4	Attorney Docket Number	25449	
JHOCK		$\overline{}$			Ū.S	PATENT DOCUMENTS	S		<u>.</u>
Examiners Initials	Cite No	U.S. Pare	Cind Co	یو	Nam	e of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, line: Where Relevant Passages or Relevan Figures Appear	
		5,997	.863	1	Zimmen	nann et al	12-07-1999	<u> </u>	
		5,362			Fuks et	ıl	11-08-1994		<b>.</b>
		6,242			Freeman		06-05-2001		
		5,968			Pecker		10-19-1999		
		5,688			Powell		11-18-1997		
		6.387			Heinrik	on et al	05-14-2002		
		7,507	,,,,,,,						
							•		
					<del> </del>				
				<u> </u>	<b></b>				
				┝	<del>                                     </del>				_~~
					<del>                                     </del>				
				-	<del>                                     </del>				
	ļ				<del>                                     </del>		4		
	<b>!</b>			<del>                                     </del>	<del>                                     </del>				
	<u> </u>	<u> </u>		<del> </del> -					
	<u> </u>	<u> </u>		<u> </u>	FOR	IGN PATENT DOCUME	INTS	<del></del>	
	<del>,</del>	F	eign Patent	<u> </u>		IGN PATENT DOCUME	311.10		Ϊ
Examiners Initials	Cite No. 1	Orfice <sup>3</sup>	Number	K	ind Code <sup>2</sup> if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	
	<del> </del>	wo	95/041	58		Hoogwerf et al	02-09-1995		
	<del>├</del>	<del>  "U</del>	77041	٣	L.,	***************************************			
	<del> </del>		<del>                                     </del>						L
	+	/	<del>                                     </del>	+					
		1	1						I
	-	<del> </del>	<del> </del>	-+-					Ţ
	X	<del> </del>	╂				<del></del>		J
	┸~.	<u> </u>				L	Date		7
Examiner Signature							Considered	1	

\*EXAMINER: Initial it reference considered, whether or not clistion is in conformance with MPEP 609. Draw line through clistion if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

		Patent	Approved for use throng and Trademark Office: U.S. DEPA	rtment o	COMMERC
der the Paperwo	rk Recuerion A	et of 1993, no persons are required to respond to a collection of informatic	Complete	if Known	
		situte for form 1449A/PTO	Application Number	10/341.5	582
\				01/14/20	
	LNFO	RMATION DISCLOSURE	Filing Date		
	CTAT	EMENT BY APPLICANT	First Named Inventor	Ilan et a	<u>'</u>
			Group Art Unit	1652	<i></i>
•	(4	ise as many sheets as necessary)	Examiner Name		<u></u>
heet	T2.	Of 4	Attorney Docket Number	25449	
		OTHER PRIOR ART - NON PATENT LIT	ERATURE DOCUMENTS		
xaminer	Cite	Include name of the author (in CAPITAL LETTERS), title of	the article (when appropriate), title	ofthe	•
nitials	No.	ican (book magazine journal serial symposium, catalog, CIC	.) date, page(s), volume-issue num)	fer(5),	T,
iluais	! 140.	publisher, city and/or country who	ere published.	ationity	
		Richardson et al, "Regulation of Basic Fibroblast C	frowin factor Binding and A	cuvity	
	1 . !	by Cell Density and Heparan Sulfate", J. Biologica	i Chemistry,	ì	
	1	274(19) \ 3534-13540			
	T	Hayward e al, "Cellular Mechanisms of Heparinas	e III Protection in Rat Traur	natic	
	1 ' 1	Shock" American Journal of Physiology 275:H23	-H30, 1998. 🖊		
	<del> </del>	Sasisekharan et al, "Heparinase Inhibits Neovascul	arization", Froc. Natl. Acad.	USA,	
		91-1524-1528 1944			
	+	Whitelock et al. "The Degradation of Human Endo	thelial Cell-derived Perlecan	n and	
		Release of Bound Basic Fibroblast Growth Factor	by Stromelysin, Collagenase	<u>.</u>	
	- [	Plasmin, and Heparanase, J. Biological Chemistr	771(17)-10079-10086, 19	96	
		Vlodavsky et al, "Expression of Heparanase by P	Calete and Circulating Cells	of the	
		Immune System: Possible Involvement in Diap do	ric and Extravasation" Inv	rsion	
	•	Immune System: Possible involvement in Diapeter	SIS and Extravasation , inve		
	<u> </u>	Metastasis, 12:112-127, 1992	11 Disales Newsonkile	and	
		Ishai-Michaeli et al, 'Heparanase Activity express	sed by Platelets, Neutrophilis	, and	
	1 ;	Lymphoma Cells Releases Active Fibrolliast Grov	vth Factor from Extracellular		
	1	Matrix", Cell Regulation, 1:833-842. 1990			
		Godder et al, "Heparanase Activity in Cultured Er	idothelial Cells", J. Cellular	1	•
	•	Physiology 148-274-280, 1991		L	
		Kato et al "Physiological Degradation Converts t	he Soluble Syndecan-1 Ector	domain	
	i i	frim an Inhibitor to a Potent Activator of FGF-2",	Nature Medicine, 4(6):691-	697,	
	1 .	1008			
		Ernst et al, "Enzymatic Degradation of Glycosam	inog cans", Critical Rev. in		
	- 1	Biochemistry and Mol. Biology, 30(5):387-444. 1	995		
		Linhardt et al, "Polysaccharide Lyases", Applied	Riochemistry and Riotechno	logy.	
	1	Linnardt et al. Priysaccharide Lyases , Apptied I	The Distriction	٠.	
		12:135-176, 1986  Kosir et al, "Auman Prostrate Carcinoma Cells Pr	nduce Extrace bular Henama	188e" /	
	1	Kosir et al. Fluman Prostrate Carcinoma Cells Pi	Oduce Extracertial Tepara		
·		Surgical Bes., 67:98-105, 1997			
	1	Jin et al immunochemical Localization of Hepari	mase in Mouse and Mount	1	
	<u> </u>	Meladomas", Int. J. Cancer, 45:1088-1095, 1990	7	a shoe	
	1	Fairbanks et al, "Processing of the Human Hepar	mase Precursor and Evidence	E MIRI	
	1	Active Enzyme is a Heterodimer". J. Biol. Ch	iem., 274(42):29587-29590)	1222 ·	·
		Hoosewerf et al. "CXC Chemokines Connective	Tissue Activating Peptide-1	Trang	
		Neutrophil Activating Peptide-2 are Heparain/He	paran Sulfate-degrading		
		Enzymnes" J. Biol. Chem., 270(7):3268-3277, 1	995		
		Ngo et al "Computational Complexity, Protein S	tructure Prediction, and the		L .
	X	Levinthal Paradox", Chap. 14 from "The Protein	Folding Problem and Tertic	עזע	
		Structure Prediction", Merz and LeGrand, Eds.,	Birkäuser, Boston, 1994		
	<del></del>	Oldberg et al, "Characterization of a Platelet End	oglycosidase Degrading		
/.	, ,	Villagia Lila Polymorhandes Rinchemietra 10	)·<755_5767 1980 <i>;</i>		
		Heparin-Like Polysaccharides", Biochemistry, 19	Transl Date '-la	190. 10 16	60-3664
Examiner	70	hose on of fepamena can	A VIA Considered	44-143	
Signature		nce considered, whether or not channel in conformance with N	TO THE TAX TO A TO A TO A TO A TO A TO A TO A		

<sup>1.</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner

PTO/SB/08A (10-96)

Considered

and the second s

Approved for use through 10/31-99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/341,582 01/14/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Ilan et al STATEMENT BY APPLICANT Group Art Unit 1652 Examiner Name (use as many sheets as necessary) Attorney Docker Number Of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Cite Examiner T2 item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue num No. Initials publisher, city and/or country where published. Ressie et al, "Cloning and Functional Expression of a Human Heparanase Gene", Biochem. And Biophysical Res. Comm., 261:183-187, 1999 Walch et al, Correlation of Overexpression of the Low-Affinity p75 Deurotrophin Receptor with Augmented Invasion and Heparanase Production in Juman Malignant Melanoma Sells", Int. J. Cuncer, 82:112-120, 1999 Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", Int. J. Cuncer, 79(6):560-564, 1998 (abstract only) Zhou et al, "A 182 by Fragment of the Mouse proo1(1) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mige", J. Cell Science, 108:3677-3684, 1995 Hormuzdi et al, "A Gene-Targeting Approach Lientifies a Function for the First Intron in Expression of the Alpha 1(I) Collagen Gene", Mol. Cell Biol., 18(6):3368-3375, 1998 (abstract Only) Kang et al, "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine Beta-Casein Gene", Mol Cells, 8(3):23-265, 1998 (abstract only) Chow et al, "Development of an Epithelibon-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Nat. Axad. Sci. USA, 94: 4695-14700, 1997 Gottschalk et al, "Somatic Gene Therapy. Present Situation and Future Perspective", Arzneimittelforschung, 48/(1):1111-1120, 1998 (Austract only) Ye et al, "Targeted Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, Oct. 1998, pp 431-437 Lai et al, "Homologous Recombination Based Gene Theraw", Exp Nephrol, 7(1):11-14, 1999 (abstract only) Yazaki et al, "The structure and Expression of the FGF Receptor 1 mRNA Isoforms , Biochemica et Biophysica Acta, 1172:37-42, 1993 Le Fur et al, "Selective Increase in Specific Alternative Splice Variables of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA/94:5332-5337, 1997 Gyriec et al, "CD44 Isoforms with Exon v6 and Metastasis of Primary NOMQ Breast arcinaomas", Breast Cancer Res Treat, 44(3):261-268, 1997 (abstract only) Gewirtz et al, "Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, 92(3):712-736, 1998 Hida et al, "Antisense El AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", Am J Pathol, 50(6):2125-2132, 1997 Shastry, BS, "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181:163-179, 1998 Date

Signature (Considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1.</sup> Unique citation designation number, 7. Applicant is to place a check mark here If English language Translation is attached.

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Rudiction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/341,582 Filing Date 01/14/2003 INFORMATION DISCLOSURE First Named Inventor Ilan et al STATEMENT BY APPLICANT Group Art Unit 1652 Examiner Name (use as many sheets as necessary) Attorney Docket Number l Ot 4 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite T² item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), No.1 Initials publisher, city and/or country where published. Camentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mica", Clinical Cancer Research, 4:2819-2824, 1998 Lai, et al, "DNA Vaccines", Critical Reviews in Immunology, 18:449-484, 1998 Marchettet al, "Neutrotrophin Stimulation of Human Melanoma Well Invasion: Selected Engancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cuncer Research, 6:2856-2863, 1996 DeVouge et al. Vmmunoselection of GRP94/Endoplasmin from a KNRK Cell-Specific Agt Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", Int. J. Cancer, 96:286-294, 1994 Marchetti et al, "Neutropophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Supopulations", Advances in Enzyme Regulation, 37:111-134, 1997 Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degrative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem., 327:917-923, 1997 Freeman et al, "Evidence that Platels," and Tumour Heparanases are Similar Enzymes", Biochem. J., 342:361-268, 199 Hulett et al, "Cloning of Mammalian Heparahase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(N:803-809, 1999 Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7):793802, 1999 Toyoshima et al, "Human Heparanase", J. Biol. Chem. 274(34):24153-24160, 1999 Korb et al, "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Danor Sequence", Nucleic Acids Research 21(25):5901-5908, 1993 Faber-Elmap et al, "Involvement of Wound-associated Factors of Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Che. Invest., 97(1):162-171, 1996 Durand et al, "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Olan GH-A Glycosyl Hidrolases Deduced from Hydrophobic Cluster Analysis', Gycobiology, 7(2):277-284, 1997 Shekhar et al, "Correlation of Differences in Modulation of ras Expression with Metastatic Competence of Mouse Mammary Tumor Subpopulations". Invasion Metastasis, 14:27-37, 1994-5 Kurachi et al, "Role of Intron I in Expression of the Human Factor IX Gene", J. Biological Chemistry, 270(10):5276-5281, 1995 Zheng et al, "Increment of hFIX Expression with Endogenous Intron 1 in vitro", Cell Res, 7(1):21-9, 1997 (Abstract) Welch et al., "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", Curr Opin Biotechnol, 9(5):486-496, 1998 (Abstract) Date Examiner Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Linkove citation designation number. 

Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box  $\rightarrow \boxtimes$ 

PTU/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Pat int and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder	the Paperv	rork Reductio	n Act of I	995, 200 1	ersons are re	quiréd to respum	to a collection of intorin	Complete	if Known	<u></u>
		Substitute	for form	1449A/P	то			Application Number	10/163,993	
		TEO DA	# A 701	i A Ni	DISCI	OSURE		Filing Date	June 7, 2002	
							ì	First Named Inventor	Yacobi-Zegvi	
	S	TATE	MEN	T BY	( APPL	<b>LICANT</b>		Group Art Unit	1652	
		lusen	ות כמו זו	, shoot	s as neces	ttarv)		Examiner Name		
		(nae u		377661	of		6	Attorney Docket Number	02/23884	
Sheet		<del>/</del>				DATENT	DOCUMENTS			
<del></del>		U.S. Paten	Docum	ent	0	. FAI DIVI	DOCOMENTS			
Examiners Initials	Cite No. <sup>1</sup>	Number	Kind (		Nam	ne of Patente of Cited Do	or Applicant cument	Date of Publication of Cited Document MM-DO-YYYY	Pages, columns, lines Where Relevant Passages or Relevant Figures Appear	
	AA	5,688,	679		Powell			LZ-18-1997		
									<del> </del>	
				1					<u> </u>	
									<b></b>	
				1						
					[				<del></del>	
				Ţ					<u> </u>	
							<b>X</b>		<del>- </del>	
					<u> </u>				<u> </u>	
					<u> </u>	/_				
	<u> </u>			—					<del> </del>	
	<u> </u>			↓_	ļ	/			<del> </del>	
								<del></del>		
	<u> </u>			-				<del>\                                    </del>	<del></del>	
	<u> </u>	<u> </u>			FOR	CICN DAT	ENT DOCUMEN	TE	J	
		Form	ign Pater	n Dian	FOR	LIGN PAI	ENT DOCUME	113		$\Gamma$
Examiners Initials	Cite No.	Office)	ign Palei	/	Kind Code <sup>5</sup> (if known)		te of Patentee or t of Cited Document	Date of Publicatics of Cited Document MM-DO-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	7"
	AB	PCZ	99/2	1975		Australia	1 Nat'l University	05-06-1999		
<b></b>	+					T			<b>X</b>	<u> </u>
	1	/								上
		1								
<b></b>		<del>1</del>								1—
		1								<u> </u>
Examine	rI						-: <del>-</del>	Date		\
Signature	.						·	Considered	l	_

\*EXAMINER. Initial if reference considered, whether or not citation is in confirmance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Fatent and Trademark Office. 'Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST 18 if possible, Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031

Paten and Trademark Office U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number 10/163 Application Number Substitute for form 1449A/PTO June 7, Filing Date INFORMATION DISCLOSURE Yacobi-Zeevi First Named Inventor STATEMENT BY APPLICANT 165 Group Art Unit Examiner Name (use as many sheets as necessary) 02/23884 Attorney Docket Number of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETI ERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volum .L<sub>3</sub> Cite Examiner publisher, city and or country where published. Initials No. "The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories. (D) 1997, pg 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 6 /Konstan e. al, "Patterns of Medical Practice in Cystic Fibrosis: Part III. Use of ΛE Therapies". Rediatr Pulmonol, 1999, O:t; 28(4):248-54 (Abstract) Frederiksen et ... "Antibiotic Traetmen. of Initial Cologization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevent Deterioration of Pulmonary AF Function in Cystic Abrosis", Pediutr P Imonol, 1997 May; 23(5):330-335 (Abstract) Frederiksen et al, "Changing Epidemio ogy of Preudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974- '995)" Pediatr Pulmonol, 1999 Sep. АG 28(3):159-166 (Abstract) Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhales Tobramycin Study Group", N. Eng. J. Med., AH 1999 Jan 7; 340(1):23-30 (Abstract) Maizner et al, "Degradation of Hepana" Sulfate in the Subendothelial Extracellular Matrix by a Readiliy Released leparanase from Human Neutropjils. Possible Role in Αl J. Clin. Invest., 1985 Oct; 76(4):1306-1313 Invasion Through Basement Membranes (Abstract) Bennett et al, "Effect of Uridine 5'-Tr:phosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", Am J Respir Crit Care Med, 1996 Jun; 153(6 Pt ŲJ) 1):1796-7801 (Abstract) Vlodavsky et al. Expression Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", Invasion AK Metastusis 1992; 12(2):112-127 (Abstract) Naparstel et al, "Activated T Lymphocytes Produce a Matrix Degrading Heparan Sulphare Endoglycosidase". Nature, 1984 July 19-25; 310(59%):241-244 (Abstract) AL, Armstrong et al, "Lower Airway? Inframation in Infants and Young Children with Slic Fibrosis'. Am J Respir Crit Cure Med, 1997 Oct; 156(4Pt 1) 197-1204 AM' Tang et al, "Contribution of Specific Pseudomonas Aeruginosa Virulende Factors to Abstract) AN Puthogenesis of Pneumonia in a Neo tatal Mouse Medel of Infection", Infe 1996 Jan: 64(1):37-43 (Abstract) Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24 ΆŌ McGraw-Hill Professional 1998, Chap. 57, pp 667-679 Selvan et al. "Heparan Sulfate in Immune Responses". Annals New York Academy AP Sciences, 797:127-139, 1996

Date aminer Considered ignature

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031
emark Cities: I.S. DEPARTMENT Of COMMERCE

		teduction Act of 1995, no		Pater t an	d Indemark Collection of infor	nation unless it contain	s a valid OM	B control number.
Under th				rea to respond 1 7 a v		Comp	plete if Kn	own
	Subs	titute for form 1449A/P	то		[	Application Num	ber	10/163,993
\	DIEC	RMATION	DISCLO	SURE	(	Filing Date		June 7, 2002
					. {	First Named Inve	entor	Yacobi Zeevi
1	STA	rement by	APPLIC	JAN		Group Art Unit		1652
	(	use as many sheet	s as necessa	(עי		Examiner Name	_1	
	·		of			Attorney Docket	Number	02/23884
heet	<del>\</del> 3							
	_	OTUED DE	OP APT -	NON PATENT	LITERATI	JRE DOCUME	NTS	
	-							
xaminer	Cite No.						DC-1550C	T <sup>2</sup>
nitia.s								
	AQ;	/ Weller, Peter H. Fibrusis: A Revi	, "Implication	ns of Early IIII	anauou and terventions"	Infection in Lys	onology.	1
		Fibrasis: A Revi	ew of New a	na Potentiai in	(C) VCIIIIOIIS			
		24:143 146, 199 Konstan, Micha	1 11 11 11 Com	and Lindors and	ding of the l	nflamatory Proc	ess in	
	AR	1	n De Jimania L	Interpolation in	/4'11/-142.	1720		
		CVStic Fibrosis	"Emerging	Therapies for	Cystic Fibr	s Lung Disea	se".	
	A\$ .							
	1-	2.0	Charact N	uriont Media (	on the Chem	ical Compositio	n oi	1
	AT	Evenelycacchar	ride Rom Mı	ICOID AND PION	-Mucala L2d	STOOTH VELABRIO	sa".	1
•	/							
	. AU	1	41	of Neutral Pal	vercenance	S ASSOCIATED TO A	Alginat	1
	7 70	I Inhihisian of M	urine Macro	nhage Kesixon	IC IO PSEULO	mona recasion	osa",	<b>.</b>
		EELIC Microbi	A Lott 1997	PRODUCTION AND A PROPERTY OF THE PROPERTY OF T	とり、レタン・チリエ し	Austracij		<del></del>
	AV	D-1	Comparative	Striblies of Lit	nanoivsacch	aride and .		ŀ
		Cbysoopho	-ide From a '	Virule Stratt	a ot Pseudon	NODAS SOIMIRICEA	uni and	
	از	for Three Avir	ulent Mutant	s", J Factoriol	, 1985 May;	162(2):504-509	,	1
		(Abstract)		/	on Dolumen	haride Synthesis	<del></del>	<del>                                     </del>
	AW	Jorba et al, "Va	ariations in the	P. Aerugina	onell Pau F	haride Synthesis Sp Fisiol, 1980 J	un:	1
	ł	Conditioned by	y Aminosuse	rs (author 3 u a	ain), Nev L	sp 7 13101, 1700 v	,	
	_1	36(2):155-161	(Abstract)	Pauvaen Cilvo	osis and Ex	polysaccharide		
	J AX	Ramos et al,	Relationship	e I actis <sup>n</sup> inn	l Environ M	licrobiol, 2001 J	an;	1
	-	1 27/13/22 41 //	hadenet)		1			
	AY	1 501	Samman lati	on of Prou ogl	ycan Produc	non by Intraher	patic	1
	^1	C-idealial Call	e Beering De	efective (dulta-	-toub) Cystk	CLIBACOSIS LISTES	fite ino mi	e ]
	Y	Candinataria	Deculator" /	ienatalogy, 19	198 Jan: 2701	); /- JALAUSHBC	IJ	
	AZ	1 1/2 1 2 1 115	andustion (	f Protecols can	is Hv Humai	n fring Lagradia	313	
		(IMR 90) Ma	intained In A	Low Concent	ration Of Se	rum". Bioohem	J 1782	ļ
		D-41, 207(3)	·360-370 (A	hetract)				
	BA	Hill et al, "Or	gan-Specific	Over-Sulfitio	n Of Glycos	aminoglycans	Cochen	, 1
	, l	Altered Extra	cellular Matr	nx in A Mouse	: INICIOSI OI (	Cystic Fibrosis".		
		Mol Med., 19	9/ Oct;62(1)	:113-22. (/\bst	holism In Co	stic Fibrosis Fil	broblasts'	<del>,                                    </del>
	BP	Welch et al, "	Complex Sa	ccharide iv: etai	betenet)	, 31.10 1 1010313 1 11		
		Pediatr Res.	19/3 Sep:9(9	):698-702. (Al	Sputum Fron	n Patients With	Cystic	V
	BC	Kanmoune et	ai, "Cnondro "hmnic Dece	chitis", Am J R	Sespir Cell N	iol Biol. 1991		
<b>l</b> .	<b>/</b> i -	Oct;5(4):315-	ARONIC BROW 20 (Abstract	enns , am a n				
	7	Oct3(4):313-	20. ( MDSU 46)	• 7				
L								
Examiner							ate	
Signature	.					Co	onsidered	
Disharate								

PTO/SB/08A (10-96)

Vn	der the Paper	work Reduction Act of 1995, no Substitute for form 1449A/PI	persons are required to reco	a ent und Trademark	Office U.S DEPARTME	NOT ONB 0651-0031
		Substitute for form 1449A/P1		to a concention of inite	AMERICAN STREETS IS CONTRACTOR IN	and OMB control outsides
	ľNi			i	Application Number	if Known
	TIA.	FORMATION I	DISCLOSURE		Filing Date	10/163,993 June 7, 2062
	SI	ATEMENT BY	APPLICANT	• 1	First Named Inventor	Yacoby Zeevi
· [	\			•	Group Art Unit	1652
Sheet	<del></del>	(use as many sheets	as necessary)	i	Examiner Name	1032
Lancer		L	of	5	Attorney Docker Numb	- 100000
	<del></del>	OTHER STATE				er 02/23884
Examiner	Cite	OTHER PRIOR	ART - NON PATE	IT LITERATUR	RE DOCUMENTS	<u> </u>
Initials	No.	the item (buok, magaz	ior (in CAPITAL LETTE	R3), title of the article	(when appropriate), file of	<del>,,  </del>
		num.	bordel mubilish to	orante caranos, etc.) Oil	IC. Dage(s), volumeriesus	T <sup>2</sup>
1	BD	Beuth et al, "Lectin-	Mediated Bacterial	A dissains Where par	olished.	
	100 ×	Clin Microbiol, 1987	7 Oct;6(5):591-3. (A	bstract)	ian Hissue, Eur J	
i	BE	L WILLSON OF STATE AUTOCONOMI	accharida Deceluation	n Pseudomonas	Contain In.	<del></del>
	BF	Microbiol, 1994: 340	(1):3-10 (Abstract)	·	Cepacia , J Basic	
1		Albus et al. "Starthol	OCOCCUE Ausens O-	sular Types And	Antibody Recons	<del></del>
ŀ	"	To Lung Infection In Dec; 26(12):2505-9	Patients With Cysti	c Fibrosis", Jeli	n Microbiol 1000	·
	BG .	Dec; 26(12):2505-9.	(Abstract)			
j i 📯		Macone et al, "Muco 1981 Jun 11:304(24)	id Escherichia Coli	r Cystic Fibrosis	". N Engl J Med	<del></del>
	ВН	1981 Jun 11:304(24):	1445-9 (Abstract)			
2 =		Golberg et al, "An Im Synthesized by Chop	proved Method For	Determining Pro	teoglycans	<del></del>
	"	Synthesized by Chon 24:265-275, 1990	drocytes in Wilture"	Jonnective Ties	UP Rosporch	1
	BI					}
	1	Farnsdale et al, "A Di Glycosaminoglycans 9:247-248, 1982	in Cartilage Cultura	e ne Microassay	for Sulfated	
		9:247-248, 1982	m carthage suithe	Connective Tis	ssue Research,	1
	BJ /	Sutherland, Ian W., "S	Structure-Function B			
		LUMPACIONE CLAIL LIMINACI	Principles of Alaina			
	- 1	Pseudomonas Aerugi Tatnell et al. "Cheric	osa", Biochem Soci	Trans 244040	trains of	
	-	Pseudomonas Arugin Tatnell et al. X olonis	nosa", Biochem. Soc	Trans 22.310	LOGA A	
j						<u> </u>
į					from Musoid	
	BN .	Variants, Biochem. So	oc. Trans., 24:406S.	1996	· · · · · ·	].
		·· Dury et al "The ()	Cleoblast: A Combina		inder Central	<del></del>
						i i
ı						<del></del>
	<b>27</b> -		M 2 Viriliaant Cimin			
	BP	rom Three Avirulent Macone et al. "Mucoid	Frehericki C. Li	logv, May, 1985,	pp 504-509	i l
b	<b>/</b>	Medicine 304(24)-144	AS 1440	Cystic Fibrosis".	New England .I	
	BQ ; VC	fek et al, "Bacterial A	dhesion to Calle and	Tions 7 Ct		
	/1P	ub. 1994, pp 114-118.	. 148-153 418-419	JISSUE", Chapma	an & Hall, N.Y.,	
				74443		

Examiner Signature:

Date Considered

Signature

Approved for use through 10/31/99 OMB 0651-0031

Considered

Patent and Inidemark Office: U.S. DEPARTMENT OF COMMERCE

Under the \*approprix Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB current number. Complete if Known Substitute for form 1449A/PTO 10/163,993 **Application Number** June 7, 3002 Filing Date INFORMATION DISCLOSURE Yacoby-Zeevi First Named Inventor STATEMENT BY APPLICANT Group Art Unit Examiner Name (use as many sheets as necessary) C2/23884 Attorney Docket Number Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LE ITERS), title of the article (when Cite Examiner propriates, title of the item (book, magazine, jo 1mal, serial symposium, comlog, etc.) T² page(s), volume-issue number(s), publisher city and/or country whee published.

Hari, "Role of Morphogenetic "roteins in Skeleta Tissue Initials No. BR Engineering and Regeneration", Nature Liotechnology, Jol. 16, March 1998, pp. 2-7-252 L.A. Dempsey et al., "Heparanase, A Poter tial Regulator of Cell-Matrix BS Interactions", Trends in Biochem Sci, 25:349-351, 2000 Elkin et al., "Heparanase as Mediator of Angi genesis,: mode of action", (BT) The FASEB Journal, \$: 1661-1663, 2001 Elkin et al., "Heparanase as Mediator of Angiogenesis,: mode of action", BU The FASEB Journal, Published online May 29, 2001 E. Finkel, "Portential Target Found for Antimetastasis Drugs", Science, BV July 2, 1999, pp. 33 - 34 1. Vlodavsky, et al., "Mammalian Heparunase: Gene Cloning, Expression and Function in Tumor Progression and Tetastasis". Nature Medicine,  $\overline{B}W$ 1 Vol. 5, No. 7, July 1999, pp. 793 - 802 Webster et al., FGFR Activation in Skeletal Disorders: too much of a BX, good thing, TIG May 1997, Vol. 13, No. 5, pp. 78 - 182 Prockop, D.J. Marow Stromal Cells as Stem Cells for BY Nonhemato oietic Tissues", Science, Vol. 276, 4 April 1997, pp. 71 -- 74 Shmazu, et al., "Syndecan-3 and the control of chondroc te proliferation BZ during endochondral ossification", Exp. Cell. Res. 1996 Nov. 25:229:1, pp. 126-136 (Abstract) Blanquaert et al., "CMDBS, functional analogs of sulfate heparanes, .CA used as osseous cicatrizing agents", Ann. Endocrinol (Paris) 1994 36:2 pp. 121 - 123 Abstract) F. Blanquaert et al., "Heparan-like molecules induce the repair of skull CB; defects", Bone 1995, December 17:6 pp. 499 - 506 (Abstract) Muir et al, "Histomorphometric Analys's of the Effects of Standard Heparin on Trabecular Bone in vivo", Llood, August 15. 1996:88(4):1314 - 1320 (Abstract) Date aminer

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE nt: Reduction Act of 1995

Inter the Paper	work Keduci	ion Act of 19	95, no persuus are requir	ed to respond to a collection o	f information unless it contains a valid OM	B control number.			
		C. darlin da	for form 1449A/PTO		Complete if Known				
		SUUSHURE	101 1011 1449AP1O		Application Number	10/163.993			
	INFO	<b>DRMA</b>	TION DISCI	LOSURE	Filing Date	June 7, 2002			
•			NT BY APP		First Named Inventor	Yacoby-Zcevi			
	Α		MI DI ALI	DICANI	Group Art Unit	1662			
	<b>\</b>	use as m	any sheets as nece	essary)	Examiner Name				
Sheet	6		of	6	Attorney Ducket Number	02/23884			

	OTNER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
No.1	Include mane of the author (in CAPITAL LETTER 5), (title of the article (what appropriate), title of the tiem (book, magazine, journal, serial s/mposium, catalog, etc.) date, page(s) volume-issue number(s), publisher, city aud/or country when published.	· T²
<del>B</del> .)	Hoffman et al, Numan Bone Morphogenic Protein 2 Contains a Heparin-Binding Ste Which Modifies its Biological Activity", Eur. J. Biochem., 237(1):295-202, 1996 (Abstract)	
ĊĒ,	Matrix-Associated Heparin-Plinding Grown-Associated Molecule (HB-GAM)", J Cell Biol, 143(4):1113/128, 1998 (Abstract)	
\	Loredo et al. "Regulation of Glycospinino glycan Metabolism by Bone Morphogenetic Protein-2 in Equipe Cartilinge Explant Cultures". Am J Vet Res, 57(4):554-559, 1996	
9	Kiberstis et al, "Bone Health in the Balance", Science, 289:1497, 2000	
(CH)	Service, R.F., 'Tissue Engineers Build New Bone', Science, 289:1498-1500, 2000	
	Date	<del></del>
	Considered	
	(P) (F) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C	Cite No.¹  Include mane of the author (in CAPITAL LETTER's), title of the arricle (whit appropriate), title of the term (book, magazine, journal, serial s/mposium, catalog, styl date, page(s) volume-issue number(s), publisher, city and/or country when published.  CD  Hoffman et al, "Numan Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem., 237(1):295-102, 1996 (Abstract)  CE  Imai et al, "Osteoblast Requitment and Bone formation Enhanced by Cell Matrix-Associated Heparin-Binding Growin-Associated Molecule (HB-GAM)", J Cell Biol., 143(4):1113/128, 1998 (Abstract)  CF  Loredo et al. "Regulation of Glycosmino glycan Metabolism by Bone Morphogenetic Protein-2 in Equite Cartilage Explant Cultures". Am J Vel Res, 57(4):554-559, 1996  CG  Kiberstis et al, "Bone Health in the Balanch", Science, 289:1497, 2000  CH)  Service, R.F., "Tissue Engineers Build New Bone", Science, 289:1498-1500, 2000  Date

"EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burder Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the ir dividual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, CC 20231.

DO NCT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1.</sup> Unique citation designation number. 3. Applicant is to place a check mark here if English language Translation is attached



PTO/SB/08A (10-96)
Approved for use through 10/21/99 OMB 0651-0031
Pate 11 and Trademark Officer U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/137.351 Application Number May 3, 2002 Filing Date INFORMATION DISCLOSURE Ayal-Hershkavitz et al First Named Inventor STATEMENT BY APPLICANT 1652 Group Art Unit **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 02/25665 Sheet U.S. PATENT DOCUMENTS U.S. Patern Document Pages, columns, lines. Where Relevant Date of Prolication of Cites Document Name of Patentee or Applicant ul Code Exam iners Cite Number Passages or Relevant Figures Appear of Cited Document Initials MM-DD-YYYY 08-07-1990 Ladner et al 4,946,778 AA FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines, Where Relevant Date of Publica Name of Patentee or Examiners Cite Cited Ducnmer Kind Code Applican of Cited Document Office<sup>3</sup> Passages or Relevant Init-als MM-DD-YYYY Figures Appear Date xaminer Considered Signature

\*EXAMINER\* Initial if reference considered, whether or not citation is in confor nance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) <sup>4</sup> For Japanese patent documents, the indication of the year of the Emperor must precade the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patents. Washington, DC 20231.

File Copy

Please type a plus sign (+) inside this box → 🗵

## PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE

Under the Pape	rwork Red	ection Act of 19	995, no persons	ere required to	respond to a collection of inform	nation unless	i: contains a valid OMB cont	e if Known		
Substitute for form 1449A/PTO						<u> </u>	Application Number	09/988,113		
	-	JEOD M		DICCI	OCUDE		iling Date	March 1, 1999		
				DISCLOSURE			First Named Inventor	Pecker et al		
	S	TATEM	IENT B	Y APPI	<b>LICANT</b>	<u> </u>	Group Art Unit	1652		
(use us many sheets as necessary)							Examiner Name	Haison, Richard		
		(1255 125	marie mee	of 3			Attorney Docket Number 01/22781			
heet		<del>\</del>			S. PATENT DOCUMI			, UNIZZIOI		
xaminers nitials	Cite No '	U.S. Parent Number	Document (and Corle* (il-troows)		ne of Patentee or Applican		Date of Publication of Cited Aucument MM-DD-YYYY	Pages, columns, lices. Where Relevant Passages or Relevant Figures Appea:		
	1	5,968,8	322	Pecker	et al		10-19-1999			
	1	5,362,6		Fuks et			11-08-1994			
		6,387,6			son et al		05-14-2002			
		5,688,6		Power			11-18-1997			
	<del>                                     </del>	6,242,2		Freema			06-05-2001			
	<del>                                     </del>	0,272,2	<u> </u>	+						
			•	1						
	1									
				<b></b> _			<del></del>			
					<u></u>	$\overline{}$				
			<u>_</u>			<u> </u>	<del>\</del>	<del></del>		
	—	<u> </u>								
		<u> </u>		FOR	EIGN PATENT DOC	IMENT	re	<del></del>		
		Eomi	n Patent Doci	FUR	EIGN PATENT DUC	OWEN				
Examiners Initials	Cite No.	Office)	Number	Kind Code <sup>5</sup> (if known)	Name of Fatentee Applicant of Cited Doc		Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines. Where Relevant Passages or Relevant Figures Appear		
	1	WO	95/04158		Hoogwerf et a		02-09-1995			
							<del></del>			
							<u> </u>	<del>                                     </del>		
			···	<u> </u>	ļ			<del>                                     </del>		
	1			<u> </u>	L		I Data	<del>                                     </del>		
Examine	. 1						Date Considered	`		
Signature	ŧ						Computered			

<sup>\*</sup>EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statument: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer. Patent and Trademark Office, Washington, DC 20231 OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents. Washington, DC 20231

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner

Signature

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651 0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/988,113 March 1, 1999 Filing Date INFORMATION DISCLOSURE First Named Inventor Pecker et al STATEMENT BY APPLICANT 1652 Group Art Unit Hutson, Richard G. Examiner Name (use as many sheets as necessary) 01/22 Attorney Docket Number of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of t Cite item (book, magazine, journal, scrial symposium, catalog, etc.) date, page(s), volume-issue muniby(s). Examiner T2 No. Initials publisher, city and/or country where published Elegst et al, "Enzymatic Degradation of Glycosaminoglycans", Critical Rev. Biochemistry and Mol. Biology, 30(5):38"-444, 1995 Linhardt et al, "Polysaccharide Lyases", Applied Biochemistry and Biogennology, 12:135-186, 1986 Human Prostrate Carcinoma Cells Produce Extracellular Heparanase", J. Kosir et al. Surgical Res., 67:98-105, 1997 Mollinedo et al, Major Co-Localization of the Extracellular-Matrix Degrative Enzymes Heparanine and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem., 327:917-923, 1997 DeVouge et al, "Immuniselection of GR?94/Endoplasmin from a KNRK Cell-Specific Agt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", Int. J. Cancer, 56:286-294, 1994 Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparamese Activity and Heparamase Degradation of Specific Heparan Sulfate Subpopulations" Cancer Research, 56:2856-2863, 1996 Marchetti et al, 'Neutrotrophin Stimula on of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Arrivity and Heparanase Degradation of Specific Heparan Sulfate Subpopulation;", Advances in Enzyme Regulation, 37:111-134, 1997 Jin et al, Immunochemical Logalization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45:1088-1095, 1990 Fairbanks et al, "Processing of the Human Heparanasa Precursor and Evidence that the Active Enzyme is a Heterodimer", J. Biol. Chem., 2 4(42):29587-29590, 1999 Toyoshima et al, "Haman Heparanase", J. Biol. Chem., 27 (34):24153-24160, 1999 Hoogewerf et al, CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparain/Heparan Sulfate-Aggrading Enzymnes", Biol. Chem., 270(7):3268-3277, 1995 Freeman e al, "Evidence that Platelet and Turnour Heparanases are Similar Enzyme, Biochem. J., 342:361-368, 1999 Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Jumor Progression and Metastasis", Nature Medicine, 5(7):793802, 199 Hulett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Turpor Invasion and Metastasis". Nature Medicine, 5(7):803-809, 1999 Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from "Tie Protein Folding Problem and Tertiary Structure Prediction", Merz and LeGrand, Eds., Birkäuser, Boston, 1994 Oldberg et al, Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", Biochemistry, 19:5755-5762, 1980 Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene",

\*EXAMINER: tritial if reterence considered, whether or not clation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Date

Considered

Biochem. And Biophysical Res. Comm., 261:183-187, 1999

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete tris form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE
Information unless it contains a valid OMB control number.

. d she December	at Dadweign A	et of 1995, no persons are required to respond to a collection of information un	less it contains a valid OMB o	ete if Known	
MET THE PROPERTY OF				09/988	113
		titute for form: 1449A'PTO	Application Number	March	1 1999
	INFO	RMATION DISCLOSURE	Filing Date First Named Inventor		
	CTAT	TEMENT BY APPLICANT		1652	<del></del>
			0.00p.00.00		Richard G.
\	(1	use as many sheets as necessary)	Examiner Name		
haat	13	of 3	Attorney Docket Num	ber 01/227	81
heet	+	OTHER PRIOR ART - NON PATENT LITER	ATURE DOCUMEN	iiis o iba	
xaminer	Cite	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial symposium, catalog, etc.) da			T²
nitials	No.				
	+	of the LOW	-Affinity 0/3 Neuro	rophin	
		person with Augmented Invasion and risparanase P	roduction in Human	Malignant	
		L			
	<del></del>	the second constitute Defecti	on of Malignancy in	Unne	
	1	I complete them Patients with Urothelial Cancer by CD4	14/0-10/C 1-4/10 C	mpennve	
		1	ici oniv <i>u</i>		
		The second of the Mouse prod.()	11) Collabell Gelle 13	Survicient	
	1	to Direct Chondrowte Expression in Transgenic Mice	e , de Cent Science,		
		108:3677-3684, 1993	es a Function for the	First	
	· ·	Horrauzdi et al, "A Gene-Targeting Approach Identification in Expression of the Alpha 1(1) Collagen Gene	" Mol. Cell Biol		
	1				
		18(6):3368-3375, 1998 (abstract Only)  Kang et al, "Prolactin-Inducible Enhance" Agrivity of	the First Intron of th	e Bovine	
	1	-	103u act Cm)		
		I OL I Wile release of the Pine in the little successive	EVALORIAN ALCOHOLIS	with	İ
	1	Human DNA Regulatory Elements for Transgene Ex	pression in Lung Air	ways",	<b>\</b>
	ŀ	1 = 55 4 3 C 2 C C 4 04 1460K 14800 1997			
		Company of all "Somatic Gene Therapy, Present Sil	mation and Future Pe	rspective",	ì
		1 4	SUBLICILLY/		<del>                                     </del>
		Ve et al "Tarreted Gene Correction: A New Strateg.	y for Molecular Medi	icine",	1
Ì	İ	lact to Marketine Todali Oct 1998 rp 431-43%	_		<del> </del>
		Lai et al, "Homologous Recombination Based Gene	herapy", Exp Nepni	roz,	.1
	l	7(1):11-14, 1999 ( abstract only)	CE Placetor I mRN	A Isoforms	
		Yazaki et al, "The structure and Expression of the F	0.27_42 1003	100101	1
		in Rat Tissue", Biochemica et Biophysica Acta, 1172  Le Fur et al., Selective Increase in Specific Alternat		f Tyrosinase	
		in Murine Melanomas: A Projected Bas's for Immur	otherapy". Koc. Na	ıl. Acad. Sci.	1
	· [				
		Gurier et al. "CD44 Isoforms with Exon v6 and Mc	astasis of Primar N	OMO Breast	į
	1	- 4 9 0 C Doe Twor 44(1)'/Die	·200.1771		
		Gewirtz et al, "Nucleic Acid Therapeutics: State of	the Art and Future Pr	rospects",	1
	ţ	<b>√</b> n  nn/23.712 726 1008			<del></del>
		CLAST Topologican Dectroins	Oral Cancer Invasio	n by	, 1
		Hida et al, "Antisense ETAF Transfection Resulting Reducing Matrix Metalloproteinase Activities", Am	J Pathol, 50(6):212:	3-2132, 13	
					4
		Shartey BS "Gene Disruption in Mice Models of	Development and Di	ocase,	
					0
		Camentics et al "DNA Vaccination with HuD Inhi	DIE CLOWING B LACE		
		1 . a. v. Ci I Compan Dorograph A-7:: [Us/X/4, 1]	770		1
		Lai, et al, "DNA Vaccines", Critical Reviews in Im	Date	<u>- '                                   </u>	
Examine			Consi	dered	L
Signature	c	and election in in conformance with MP	P 609. Draw line through	citation if not i	n conformance a

Signature

'EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

'Unique citation designation number. 'A Applicant is to place a check mark here if English language Translation is attached.

'Unique citation designation number. 'A Applicant is to place a check mark here if English language Translation is attached.

'Unique citation designation number. 'A Applicant is to place a check mark here if English language Translation is attached.

'Unique citation designation number. 'A Applicant is to place a check mark here if English language Translation is attached.

'Unique citation for its form is estimated to take 2.0 hours to complete. Tim is will vary depending upon the needs of the individual case. Any comments on the Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Tim is will vary depending upon the needs of the individual case. Any comments on the Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Tim is will vary depending upon the needs of the individual case. Any comments on the Burden Hour Statement. This form is stimulated to take 2.0 hours to complete. Tim is will vary depending upon the needs of the individual case. Any comments on the Burden Hour Statement. This form is stimulated to take 2.0 hours to complete. Tim is will vary depending upon the needs of the individual case. Any comments on the Burden Hour Statement. This form is stimulated to take 2.0 hours to complete this form should be sent to the Chief I down the

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Juder the Paper	work Redu		-		respond to a coll	ection of	aformation unl	<u>ess it c</u>	complete	f Known	_
		Substitute	for form 1449.4	<i>I</i> PTO				Apr	lication Number	09/978,297	/
	TIN.	JEAD I	MATION	ושפרו	OSURE		ì		ng Date	10/17/2001	
							1		t Named Inventor	Yacobi-Zeevi	_
•	S	TATE	MENT E	Y APP	LICANT				up Art Unit	1633	
		(use d	as many she	ets as nece	ssary)				uniner Name	1033	
Sheet	$\Box$	<u> </u>		Of		4		Att	orney Docket Number	9//22716	
				U.	S. PATENT	DOC	<b>IMENTS</b>				
E:caminers Initials	Cite No. 1	U.S. Pare	t Document (ind Code <sup>2</sup> (if move)	Nar	ne of Patentee of Cited Do	or App	licant	Γ	Oute of Publication of Cited Dogment MM-DB-YYYY	Pages, columns, line Where Relevant Passages or Relevan Figures Appear	
	AA	5,688	,679	Powell					11/18-1997		
	<u> </u>			N	_						
<u> </u>									<u> </u>		
								1			
		····		<del></del>			<b>/</b>			<u> </u>	
				1		A			<del></del>	1	
	t							┰		<del></del>	
							<u> </u>		<del></del>	<del></del>	
	1						$\overline{}$	1		<u> </u>	
	<del> </del>			+			-/		<del></del>		_
	<del>                                     </del>		<del></del>		<i></i>			$\leftarrow$		<del></del>	
	<del> </del>	<del> </del>			<del></del>			$\wedge$	<del></del>	<del> </del>	
	<del>                                     </del>	<del> </del> -		<del></del>				<del>  </del>	<del>/</del>	<u> </u>	_
		<u> </u>		FOR	EIGN PATI	NTD	OCUMEN	TE	<del></del>		
	$\tau$	Fore	ign Parent Dot		I	SIVI D	OCUME	<del>'13</del>			Γ.
Examiners Initials	Cite No.	O-Tice <sup>3</sup>	:Sydber*	Kind Code <sup>3</sup> (if known)		e of Pate of Cite	ntee or Document	- 10	Date of Publication of Cited Document MM-DO-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	,
	AB	PCT	99/21975		Australian	Natil	Jaiversity	$\perp$	05-06-1999		
								$\Box$			
											Ţ
Examine									Date Considered	•	1
Signature	; I								Considered	i .	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw-line through citation if nct in conformance and not considered, to this form with next communication to applicant

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent at d Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique ditation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3 <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the paten; document. <sup>5</sup> Kind of document by the appropriate symbols as inclicated on the document under WIPO Standard ST. 16 if pos: ible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

BE

Examiner

**Signature** 

Substitute for form 1449A/PTO

28(3):159-166 (Abstract)

1999 Jan 7; 340(1):23-30 (Abstract)

### PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Tredemark Office: U.S. DEPARTMENT Of COMMERCE

Complete if Known

Application Number 09/978.297 Filing Date INFORMATION DISCLOSURE 10/17/2001 First Named Inventor Yacobi-Zee STATEMENT BY APPLICANT Group Art Unit 1633 Examiner Name (use as many sheets as necessary) Attorney Docket Number 01/22716 Of 1 4 Sheet OTHER PRIOR ART - NON PATEN" LITERATURE DOCUMENTS Examiner Cite T2 Initials No.1 BA The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories, 1991, pp 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601. BB Konstag et al, "Patterns of Medical Practice in Cystic Fibrosis: Part IV. Use of Therapiest, Pediatr Pulmonol, 1999, Oct; 28:4):248-54 (Abstract) BC Frederiksen et al, "Antibiotic Tractment of In tial Colonization with Pseudomonas

Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", Pediatr Pulmon vl. 1997 May: 13(5):330-335 (Abstract) Frederiksen et al, "Changing Epidemiology of Pseudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974-1995)" Pediatr Pulmonol, 1999 Sep;

Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", N. Eng. J. Med.,

Urder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of in cumulion unless it contains a valid OMB control number.

 BF	Matzner et al, "Degradation of Heparan Synfit te in the Subendothelial Extracellular
	Matrix by a Readiliy Released Heparause from Human Neutropjils. Possible Role in
	Invasion Through Basement Membrades, J. Clin. Invest., 1985 Oct;
 <u> </u>	76(4):1306-1313 (Abstract)
 BG	Bennett et al, "Effect of Uridine,"-Triphosphate plus Amiloride on Mucociliary
. ·	Clearance in Adult Cystic Fibrosis", Am J Respir Crit Care Med, 1996 Jun; 153(6 Pt
ŀ	1):1796-7801 (Abstract)
BH	Vlodavsky et al, "Expression Heparanase by Platelets and Circulating Cells of the
1	Immune System: Possible Involvement in Dispedesis and Extravasation", Invasion
}	Metastasis, 1992; 12(2):112-127 (Abstract)
Bi	Naparstek et al, "Activated T Lymphocytes I roduce a Matrix Degrading Heparan
1	Sulphate Endoglycosidase", Nature, 1984 July 19-25; 310(5974):241-244 (Abstract)
 BJ	Armstrong of al, "Lower Airway? Inflamation in Infants and Young Children with
1	Cystic Fibrosis', Am J Respir Crit Care Mea 1997 Oct; 156(4Pt 1): 197-1204
1	(Abstract)
BK	Tang et al, "Contribution of Specific Pseudo nonas Aeruginosa Virulence Factors to
ì	Pamogenesis of Pneumonia in a Neonatal Mouse Model of Infection", Infect Immun,
·	1996 Jan; 64(1):37-43 (Abstract)
BL /	Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24th Ed
	McGraw-Hill Professional 1998, Chap. 57, p 667-679
DM	Selvan et al, "Heparan Sulfate in Immune Responses", Annals New York Academy of
	Sciences, 797:127-139, 1996
BN	Weller, Peter H., "Implications of Early Influmation and Infection in Cystic Fibrosis:
ŀ	A Review of New and Potential Interventions", Pediatric Pulmonology, 24:143-146,
Ŧ	1997

EXAMINER: tritial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will viry depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assis and Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3 <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor rest procedule the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

#### PTO/SB/08A (10)-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of a formation onless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/978,297 Filing Date 10/17/2001 INFORMATION DISCLOSURE First Named Inventor Yacobi Zeevi STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) **Examiner Name** Attorney Docket Number | 01/22716 Sheet 3 Golden et al, "An Improved Method For De ermining Proteoglycans Synthesized by DA Chondrocges in Culture", Connective Tissue Research, 24:265-276, 1990 Farnsdale et a. "A Direct Spectrophotometri: Microassay for Sulfated DB Glycosaminoglycans in Cartilage Cultures", Connective Desue Research, 9:247-248. 1982 Sutherland, Ian W., "Structure-Function Relationships in Microbial Exopolysaccharides", Biotech (dv., 12:393-148, 1994 DC Tatnell et al, "Characterisation of Nginates from Mucoid Strains of Pseudomonas DD Aeruginosa", Biochem. Soc. Trans. 24045, 1996 Tatnell et al, "Chemical Analysis of Alginaus from Mucoid Strains of Pseudomonas DE Aeruginosa", Biochem. Soc Trans., 22:3105, 1994

Tatnell et al, "Colonisation of Cysytic Fibro is Patients by Non-Mucoid DF Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochem. Soc. Trans., 24:406S, 1996 Drigues et al Comparative Studies of Lipo solysaccharide and Exopolysaccharide DG from a Virulaent Strain of Pseudomonas Soi anacearum and from Ruce Avirulent Mutants", J Bacteriology, May, 1985, pp 50 1-509 Macone et al, "Mucoid Escherichia Coli in Cystic Fibrosis", New England Medicine, 304(24):14445-1449 Ofek et al, "Bacterial Adhesion to Cells and Tissue", Chapman & Hall, N.Y., Pub. 1994, pp 114-118, 148-153, 418-418, 420-423 ומ Date Examiner Considered Signature

urden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will hary depending upon the needs of the Individual case. Any comments on the amount pured to complete this form should be sent to the Chief Information Officer, Patent an-I Tredemark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, in this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if Englis in language Translation is attached.

### PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Vinder the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of aformation unless it centains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/978,297 Filing Date INFORMATION DISCLOSURE 10/17/2001 First Named Inventor Yacobi-Zee STATEMENT BY APPLICANT Group Art Unit 1633 (use as many sheets as necessary) **Examiner Name** Attorney Docket Number Sheet Of 01/2/2716 CA Konstan, Michael W., "Current Understanding of the Inflamatory Process in Cyrlic Fibrosis", Pediatric Pulmonology, 24:137-142, 1997 CB Rabin, Bruce K., "Emerging Therapies for Cystic Fibrosis Lung Disease". 115:1120-1126, 1999 CD Pasquier et al, "Implication of Neutral Polys occharides Associated to Alginat Inhibition of Murine Macrophage Response o Pseudomonas Aeruginosa", FEMS Microbiol Log., 1997 Feb 15; 147(2):195-20. (Abstract) Marty et al, "InQuence of Nutrient Media on the Chemical Composition of Exopolysaccharide from Mucoid and Non-Wucoid Pseudony Aeruginosa", FEMS Microbiol Lett, 1992 Nov 1; 77(1-3):35-44 (Abstract) Drigues et al, "Comparative Studies of Liponolysaccharide and Exopolysaccharide From a Virulent Strain of Seudomonas Sols naceanyin and for Three Avirulent Mutants", J Bacteriol, 1985 May; 162(2):50 1-509 (Abstract) Jorba et al, "Variations in the Aeruginosa Polysaccharide Synthesis Conditioned CG by Aminosugars (author's trans!), Rev Esp Fisiol, 1980 Jun; 36(2):155-161 (Abstract) Ramos et al, "Relationship Between Glycos's and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl Environ Microbiol, 2001 Jan; 67(1):33-41 (Abstract) CH CI Bhaskar et al, "Dysregulation of Protoglycun Production by Intrahepatic Epithelial. Cells Bearing Defective (delta-f50) Cystic Tibrosis Transmembrane Conductance Regulator", Hepatology, 1998 Jan; 27(1):7- 4(Abstract) CI Vogel et al, "Production Of Proteoglycans E y Framan Lung Fibroblasts (IMR-90) Maintained In A Low Concentration Of Ser im", Biochem J 1982 Dec 1; 207(3):369-379. (Abstragt) Hill et al, "Organ-Spenfic Over-Sulfation C f Glycosamhooglycans And Altered CK Extracellular Matrix in A Mouse Model Of Lystic Fibrosix, Biochem Mol Med. 1997 Oct;62(1): 1/3-22. (Abstract) CL Welch et al, "Complex Saccharide Metaboli:m In Cystic Fibrosis Fibroblasts" Pediatr Res 1975 Sep;9(9):698-702. (Abstr ict) Rahmoupe et al, "Chondroitin Sulfate In Sp sturn From Patients With Cystic Fibrosis CM And Chronic Bronchitis", Am J Respir Cell Wol Biol. 1991 Oct;5(4):3 15-20. Bouth et al, "Lectin-Mediated Bacterial Adl esion To Human Tissue", Eur J CN Microbiol, 1987 Oct;6(5):591-3. (Abstract)  $\overline{co}$ Allison et al, "Polysaccharide Production in Pseudomonas Cepacia", J Basic Microbiol, 1994; 34(1):3-10 (Abstract) Albus et al, "Staphylococcus Aureus Capsu ar Types And Antibody Response To Lung Infection In Patients With Cystic Fibr sis". J Clin Mizobiol. 1988 Dec; 26(12):2505-9. (Abstract) CO Macone et al, "Mucoid Escherichia Coli In Systic Fibrosis", N Engl J Med. 1981 Jun 11;304(24):1445-9. (Abstract) Examiner Date Signature | Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, in this form with next communication to applicant. This form with next communication to applicant. Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

Unique citation designation number. "See attached Kinds of U.S. Patent Documents, "Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3 For Japanese patent documents, the indication of the year of the reign of the Emperor nust precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will lary depending upon the needs of the Individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (\*) inside this box → 🗷

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031

PRATE TRAINE Patent and Trademark Office: U.S. DEPARTMENT O COMMERCE Under the Paperwork Reduction Act of 1995, no persons are re ed to a collection of information unless it contains a valid OMB control number.

		Substit	ute for form 144	9A/PTO	<u> </u>			Known	
					<u> </u>	Application Number		19/978,	
	11	<b>NFOR</b>	MATIO	N DISCLOSURE	L-	Filing Date	L	<u>)ctobe</u>	17, 2001
	S'	TATE	EMENT I	BY APPLICANT	<u></u>	First Named Inventor		racoby	-Zegvi
i	\				L-	Group Art Unit		.652	
		(use	as many she	eets as necessary)		Examiner Name			G. Hutson
Sheet	11			of	1	Attorney Docket Numb	er (	7/227	6
				·····				<u> </u>	
	<b></b>			U.S. PATENT	DOCUMENTS			,	
Examiners Initials	Cite No.	Numbe	Kirk Cude (if kades)			Date of Publication City Document MI-DD-YYYY		Descar M	, enhimms, lipes here Relevant iges or Relevant purts Apprec
RU	AA	5,9	68,822	Pecker et al		10-19-1999			
						<u>/</u>	$\mathbf{R}$	ECE	
	L	L				<u> </u>			-IVEU
<u> </u>	<u> </u>	<u> </u>				<del> </del>		-	
		ļ <u> </u>		<del>\</del>		<del> </del>		Y O	<del></del>
				<del></del>		750		<b> </b>	
							H <del>CL</del>	NTER	1600/2000
<b></b>	<u> </u>	L				ļ		<u></u>	. 474000
	<u> </u>	ļ	<b></b>					ļ	
	<u> </u>					ļ		<u> </u>	
L	<u> </u>	l				<u> </u>		•——	
<u></u>	_		OTHE	R PRIOR ART - NON	ATENT LITER	ATURE DOCUME	NTS		
Examiner Initials		ite o.'	item (book, m	of the author (in CAPITAL LE gazine, journal, serial sympos publisher, city an	ium, cataing, etc.) da Wor country where p	ite, pageis), volume-issue	), une numb	ir(r).	Τ²
RV	- ^	•		Expression of Heparanas production and Fertility,	c mRNA in Bov	ine Placenta During	Gest	ition,	
	1	<u> </u>					\	i	
					<del></del>				
ļ					<del></del>			<del></del>	
ļ	X								
				1					
			A	1611 1					
Examiner			III.	1/4/01/		Date	T	114	11/03
Signature			[1]	rul ly		Considered			

Burrien Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Wirshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, CC 20231.

nce considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not 🖰 considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-tener code (WIPO Standard ST.3), <sup>5</sup> For Japanese natent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	_												
Form I	РΤΟ	-1449	(Modified)			Atty. Docket 910/16	No.		Applicati 09/260				
\		1	TION DISCLOSUI IN AN APPLICATI ERAL SHEETS IF	ЮИ	'	Applicant: Maty AYA	AL-HERSHK(	DVITZ	t al	₹			
				\$6 <u>?</u> .		Filing Date: March 2, I	.999		Group A 1652	rt Unit:			
<u>.</u>		7		ji/S.	PA7	TENT DOCL	IMENTS						
		KAMINE		DATE			NAME		CLASS	SUB- CLASS	FILING DATE		
AA													
	DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION												
						./		YES	NO				
АВ													
			OTHER	ART (ncludi	ng A	uthor, Title,	Date, Partinent	Pages,	litc.)				
AC	W	Me	Burgess et al, "Tl		nding	g (Fibrob'est)	Growth Facto	r Famil <sub>y</sub>	of Protei	ns", <i>Aunu</i>	Rev		
AD			/Campbell et al, "I Phenotype". Expe	Heparan Sulfa erimental Cell	Res	egrading Euclarch, 20:150	ymes Induce N 5-167, 1992	10dulati	n of Smo	oth Musc	le		
AE			Gordon-Cardo et Laboratory Inves	al, "Expressio tigation, 63:83	n of 2-84	Basic Fibrot 10, 1990	olast Growth Fa	ctor in 1	ormal H	ıman Tiss	ues",		
AF		•	Eisenberg et al, " Surface and Extra	Lipoprotein Li acellular Matri	pase x"	Enhances B . Clin. Inves	inding of Lipor ., 90:2013-202	proteins 1, 1992	o Hepara	n Sulfate	on Cell		
AG			Folkman et al, "A Within Basement	Membrane,	ing Am	Angiogenic J. Path., 130	Protein-Basic F (2):393-400, 19	ibroblas 988	Growth	Factor-Is	Stored		
AH			Folkman et al, "A	Angiogepic Fac	tors	, Science, 2	35:442-447, 19	87					
Al			Gitay-Goren et al on Cell Surface-A	, "The Binding Associated Hep	g of ' parin	Vascular Enc -Like Molec	iothelial Growt ules", J. Bhal. (	h Factor Them., 2	to its Red 7(8):609	ceptors is 3-6098, 1	Dependent 992		
AJ			/Ishai-Michaeli e Grwuth Factor ire 2088, 1992	al, "Important om the Vascul	e of ar Er	Size and Sundothelium a	lfation of Hepa nd Extracellula	rin in Ro Matrix	ease of I	Basic Fibro	oblast :2080-		
AK			Jackson et al, "Gi Phsiological Proc	lycosaminogly cesses", Physic	cans logi	: Molecular cal Rev, 71(2	Properties, Prop 2):481-539, 199	tein Inte	actions, a	nd Role i	n		
AL	П	,	Kjørlen et al, "Pre	oteoglycans: S	truct	ures and Inte	ractions", Ann	u Rev Bi	echem, 60	):443-475	, 1991		
AM	AM Liotta et al, "Tumor Invasion and the Extracellular Matrix", Laboratory Investigation, 49(6):636-64										):636-647,		
AN		<b>/</b> .	Matzner et al, "D Readily Released	egradation of Heparanase f	Hepa rom	aran Sulfate Human Neu	in the Subendor rophils", J. Cli	thelial E n Invest	tracellula , 76:1306-	ar Matrix	by a		
AO													
EXAN	NIV	ER	IM	R_		DAT	E CONSIDER	ED	1/20/00		1		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to a pplicant.

	-	_			She	et 2 of 2					
Form	PTO	<b>D-1</b>	449 (Modifie	d)		Atty. Docket N 910/16	σ.	1	Applicati 09/260,		/
l ·	1		IN AN A	DISCLOSURE APPLICATION THE ETY (F: NE	N F	Applicant: Maty AYAL	-HERSHKOV	ITZ e	. al		1
				N##	3	Filing Date: March 2, 199	<del></del>		Group A 1652	rt Unit	
				<b>₽</b>	W.S. PA	TENT DOCUM	IENTS			/	
		AX. TIV	MINER AL	DOCUMENT NUMBER	DATI	E	NAME	'	LASS	SUB- CLASS	FILING DATE
BA											
			4		FOREIGN	PATENT DOC	UMENTS	丁			<del></del>
	T		DOCUM		DATE	COUNTRY	CLASS	SUB	CLASS	TRANS	LATION
	$oldsymbol{\perp}$									YES	NO
BB	$\perp$		<u> </u>								_
				OTHER AR	T (Including	Author, Title, Da	te, Pertinent Pag	ges, E	c.)		
BCC	en	٤	Narindrase and the Ba 12883, 199	sement Memb	High Affinity in grane Form of I	teractions between Sulfate	een the Alzeime Proteoglycan",	r's β- J Biol	Amyloid	Precursor, 266(20):	Proteins 12878-
BD	П	7	Nakajima	et al, "Hepara	nases and Tum	or Mctastasis", J	l Cellular Bioch	em, 3:	i:157-167	7, 1988	-
BE	П	į			ng and FGF Re , 268:432-436,		n by Synthetic I	Нераг	ın-Derive	ed Di- and	 
BF		Ì	Rapraeger Differentia	et al, "Require ation", Science	ement of Herai 2, 252:1709-170	ran Sulfate for b	GF-Mediated I	Fibrot	last Grov	vth and M	yoblast
BG			Extracellu	lar Matrix: Re	lationship to Tu	umor Cell Metas	of Sulfated Protasis", Concer R	les., 4	3: 2704-2	2711, 1983	3
вн			Vlodavsky 24:464-47		ernent of Hepa	ranase in Tumor	Metastasis and	Angi	genesis"	, Israel J.	Med Sci,
BI			Zhong-She E-Enriched	ing et al, "Role d Remnant Lip	e of Heparan S coproteins by C	ulfate Proteogly Cultured Cells",	cans in the Bind Biolog Chem,	ng ar 268(4	d Uptake :10160-1	of Apoli 0167, 199	ooprotein 3
BJ			Vlodavsky <i>Molecular</i>	et al, "Extrace and Cellular	ellular Matrix-l Aspects of Base	Bound Growth F Ement Membrane	actors, Enzyme s, Academic Pr	s, and ess, Ir	Plasma I c: 1993,	Proteins", pp 327-34	12
ВК	76	2	Wight, 17	, "Cell Biolog	y of Arterial Pr	roteoglycans", A	rteriosclerosis,	9:1-2(	, 1989		
BL	Γ										
ВМ											
BN	Γ									$\overline{}$	
во											
EXA	NIN	ER		Lueg	2	DATE	CONSIDERED		20/00		
EKAM If not i	ilNi n cc	ER:	Initial if refe	erence considered.	ed, whether or no	ot citation is in co	nformance with Next communication	1PEP (	09; Draw	line through	gh citation

X	•				٠		316	201 I UI			•		• •	
				odified)	•	1		Atty. Docket 910/26	No.		Application 09/487	tion No. ,716	/	
-	1		IN.	AN APPIAC AL SHEETS	\$Ħ( IF N	ECESSARY		Applicant: Maty AYA	AL-HERSHKO	VITZ	et al		/	
<b></b>		_	_			MODE OF		Filing Date: January 19	, 2000		Group A	ut Unit:		
<u></u>			_	NO.	\$ 1E	U.S	. PA	TENT DOCU	MENTS	_				
	Ľ	EXAMIN INITIA		DOCUMEN NUMBER	Т	DATE			NAME		CLASS	SUB- CLASS	FILING DATE	
AA	L													
<u> </u>	н	<u> </u>	_	$\overline{}$	_	FOREI	GN I	PATENT DO	OCUMENTS				<u> </u>	
			1	DOCUMENT NUMBER		DATE		COUNTRY	CLASS	SUB-C	CLASS	TRANS	LATION	
AR	AB YES NO													
<b></b>	I		<u> </u>	OTUE		PT (C-)				<u> </u>				
) <del>_</del>	A		Τ,						Date, Pertinent					
AC	1	100g	10	ochem, 38:3	/ <del>)-</del> (	06, 1989	$\Delta$		Grawth Factor					
AD			C: Pi	ampbell et al nenotype", E	"H cper	eparan Sulfa imental Cell	te-Di Rese	grading Ext.	ymes Induce M -167, 1992	odulatio	on of Smo	oth Musc	le	
AE		*	G	ordon-Cardo aboratory Im	et a esti	l, "Expression gation, 63:83	n of	Basic Fibrob	last Growth Fac	tor in N	lormal H	ıman Tiss	ues",	
AF		+	<b>L</b> Ei	senberg et al	. "L	ipoprotein Li	pase	Enhances Bi	nding of Lipop 90:2013-2021	roteins t	о Нерага	n Sulfate	on Cell	
AG			<b>↓</b> Fo	lkman et al.	"A	Heparin-Bina	line	Angiogenic P	rotein-Basic Fi 2):393-400, 198	broblog	Growth	Factor-Is	Stored	
AH		1-1							2):393-400, 198 5:442-417, 198				. *	
Al	Γ	1 1	L/Gi	tay-Goren et	al,	The Binding	z of V	Vascular Enci	othelial Growth	Factor	to its Rec	eptors is I	Dependent	
<u> </u>	╢	1 0	<u> </u>	CON SUITAGE		secialed Hep	MILIN.	-Like Molecu	les", J. Biol. C	tem., 26	7(8):609	3-6098, 19	992	
AJ		1	7-	nai-Michaeli woth Factor 88, 1992	er/a iror	i, "Importance n the Vascula	e of ar En	Size and Suli dothelium an	fation of Hepari d Extracellular	inin Rei Matrix'	lease of B ", <i>Bioche</i> s	asic Fibro nistry, 31:	blast 2080-	
AK		li,	Jac Ph	ckson of al, " siological Pr	Gly oce	cosaminogly sses", Physio	cans:	Molecular P cal Rev, 71(2)	roperties, Prote :481-539, 1991	in Inter	ections, a	nd Role in	l .	
AL	Ц								actions", Annu		chem, 60	:443-475,	1991	
AM		7		otta et al. "Ti					r Matrix", <i>Lab</i> e					
AN			Re	atzner et al, " adily Release	Deg	gradation of I Icparanase fr	lepa om I	ran Sulfate in Tuman Neutr	the Subendoth ophils", J. Clin	elial Ex Invest.	tracellula 76:1306-	r Marix b	ry a	
AO	7	me	<b>V</b> IA	ollinedo et al paranase and	. "M	lajor Co-Loc	aliza	tion of the Ex	tracellular-Ma f Human Neutr	rix Dec	radative	Engumes	17 923,	
EXAN	πN	TDD				<b>~</b>					-1-1	<u>·</u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

APP. Docket No. 910/26 09/487,716  INFORMATION DISCUSSURE CITESTON IN A APPLICATION IN AN APPLICATION OF THE					She	et 2 of :	2							
Maty AYAL-HERSHKOVITZ et al  (USASEVERAL SHEETS IF NECESSARY)    Filing Date:   January 19, 2000   Group Art Unit	Norm PTO-1449 (Modified)  MAY 2 5 2000 2 Atty. Docket No. 910/26  Atty. Docket No. 09/487,716													
SAMINER   DOCUMENT   DATE   NAME   CLASS   SUB-CLASS   DATE			IN AN A	PPLICATION	hr. a.	, ,,	-HERSHKOVI	TZ et al		/				
EXAMINER NUMBER  DATE  NAME  CLASS  SUB-CLASS  FILING DATE  COUNTRY  CLASS  SUB-CLASS  TRANSLATION  PES  NO  BB  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  For Elign Patent (Including Author, Title, Date, Pertinent Pages, Etc.)  Sub-CLASS  TRANSLATION  PES  NO  BCC  Variandrasorasak et al, "High Affinity interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Reparan Sulfate Proteoglycan", J Biolog Chem, 266(20):12878-12883, 1991  BD  Valkajima et al, "FGF Binding and FGF Reseptor Advisation by Synthetic Heparan-Derived Di- and Prisaccharides", Science, 268:432-436, 1995  BF  Rapprager et al, "Requirement of Affaparan Sulfate for DEGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991  BG  Vodavsky et al, "Lymphony Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983  BH  Vodavsky et al, "Involvement of Heparanse in Tumor Metastasis and Angiogenesis", Israel J. Med Sci., 24:464-470, 1988  BI  Vodavsky et al, "Cole of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein Ps-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 28(4):10160-10167, 1993  BJ  Vodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inh. 1993, pp 327-342  BK  Voldavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inh. 1993, pp 327-342  BK  Voldavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inh. 1993, pp 327-342  BK  Voldavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Pres	•	\					2000	Group A	rt Unit					
FOREIGN PATENT DOCUMENTS  DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO  BB  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  BCC Marindrasorasak et al, "High Affinity interactions between the Alzeimer's p-Amyloid Precursor Proteins and the Basement Membrane Form of Huparan Suffiate Proteoglycan", J Biolog Chem., 266(20):12878-12883, 1991  BD Makajima et al, "Heparanases and Tumor Menstasis", J Cellular Biochem., 36:157-167, 1988  BE Omitiz et al, "FGF Binding and FGF Reseptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", Science, 268:432-436, 1995  BF Rapraeger et al, "Requirement of Aleparan Sulfate for DEGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991  BG Vlodasky et al, "Lymphom Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellelar Matrix: Relationship to Tumor Cell Metastasis", Concer Res., 43: 2704-2711, 1983  BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci. 22:464-470, 1988  BI Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci. 24:464-470, 1988  BI Vlodavsky et al, "Extracellular Matrix: Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Vlodavsky et al, "Extracellular Matrix: Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Vlodavsky et al, "Extracellular Matrix: Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Vlodavsky et al, "Extracellular Matrix: Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Vlodavsky et al, "Extracellular Matrix: Bound Growth Factors, Enzymes, and Plasma Proteins			1	· .	U.S. PA	TENT DOCU	MENTS	<del></del>						
FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER  DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO  Sub-CLASS TRANSLATION YES NO  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Sub-CLASS TRANSLATION YES NO  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Sub-CLASS TRANSLATION YES NO  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Sub-CLASS TRANSLATION YES NO  No  Sub-CLASS TRANSLATION YES NO  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Sub-CLASS TRANSLATION YES NO  No  Sub-CLASS TRANSLATION YES NO  No  Sub-CLASS TRANSLATION YES NO					DATI	E	NAME	CLASS						
DOCUMENT NUMBER  DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO  BR  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Normal Pages, Etc.)	BA							1						
NUMBER  OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  BCC  Marindrasorasak et al, "High Affinity interactions between the Alzeimer's \$\text{A-MINER}\$. Amyloid Precursor Proteins and the Basement Membrane Form of High Proteoglycan", \$J Biolog Chem., 266(20):12878-12883, 1991  BD  Wakajima et al, "Heparanases and Tumor Menstasis", \$J Cellular Biochem, 36:157-167, 1988  BE  Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", \$Science, 268:432-434, 1995  BF  Rapraeger et al, "Requirement of fleparan Sulfate for FGF-Mediated Fibroblast Growth and Myoblast Differentiation", \$Science, 252:1/05-1709, 1991  BG  Vlodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix. Relationship to Tumor Cell Metastasis", *Jancer Res., 43: 2704-2711, 1983  BH  Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", *Israel J. Med Sci., 24:464-470, 1988  BI  Lhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein PEmriched Rymnant Lipoproteins by Cultured Cells", *J Biolog Chem., 28(4):10160-10167, 1993  BJ  Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", *Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK  Wight, TN, "Cell Biology of Arterial Proteoglycans", *Arteriosclerosis, 9:1-20, 1989  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609; Draw line through citable EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609; Draw line through citable examined.				/	FOREIGN	PATENT DO	CUMENTS	/	•	<del></del>				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  BCC Varindrasorasak et al, "High Affinity Interactions between the Alzeimer's \$\textit{B}\$-Amyloid Precursor Proteins and the Basement Membrane Form of Hiparan Sulfate Proteoglycan", \$J\textit{Biolog Chem.}\$, 266(20):12878-12883, 1991  BD Valakajima et al, "Heparanases and Tumor Mehastasis", \$J\textit{Cellular Biochem.}\$, 36:157-167, 1988  BE Praitz et al, "FGF Binding and FGF Reseptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", \$Science, 268:432-436, 1995  BF Sulfatarager et al, "Requirement of Heparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", \$Science, 252://05-1709, 1991  BG Vlodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", *Suncer Res., 43: 2704-2711, 1983  BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci., 24:464-470, 1988  BI Vlodavsky et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein B-Britched Refmant Lipoproteins by Cultured Cells", J Biolog Chem., 28(4):10160-10167, 1993  BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", *Arteriosclerosis, 9:1-20, 1989  BL BM DATE CONSIDERED APD DIESTAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation is in conformance with MPEP 609, Draw line through citation is the conformance with MPEP 609, Draw line through citation is the conformance with MPEP 609, Draw line through citation is the conformance with MPEP 609, Draw line through citation is the conformance with MPEP 609, Draw line through citation is the conformance with MPEP 609, Draw line through citation is the conformance with M							T	SUB-CLASS	TRAN	SLATION				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  BCC Varindrasorasak et al, "High Affinity Interactions between the Alzeimer's \$\textit{\textit{Aminer}}\texts and the Basement Membrane Form of Hugaran Sulfate Proteoglycan", \$J\text{ Biolog Chem. 266(20):12878-12883, 1991}  BD Valcajima et al, "Heparanases and Tumor Menastasis", \$J\text{ Cellular Biochem. 36:157-167, 1988}  BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", \$Science, 268:432-436, 1995  BF Rapraeger et al, "Requirement of Reparan Sulfate for BGF-Mediated Fibroblast Growth and Myoblast Differentiation", \$Science, 252:1/105-1709, 1991  BG Vlodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", *Cancer Res., 43: 2704-2711, 1983  BI Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", *Israel J. Med Sci., 24:464-470, 1988  BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein B-Enriched Rymnant Lipoproteins by Cultured Cells", *J\text{ Biolog Chem. 288(4):10160-10167, 1993}  BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", *Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Vight, TN, "Cell Biology of Arterial Proteoglycans", *Arteriosclerosis, 9:1-20, 1989  BL SM BN DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE CONSIDERED DATE ON DATE OF DATE OF DATE OF DATE OF														
BCC Marindrasorasak et al, "High Affinity Interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Huparan Suffate Proteoglycan", J Biolog Chem, 266(20):12878-12883, 1991  BD Makajima et al, "Heparanases and Tumor Menstasis", J Cellular Biochem, 36:157-167, 1988  BE Omitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", Science, 268:432-436, 1995  BF Rapraeger et al, "Requirement of Aleparan Sulfate for BFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252://05-1709, 1991  BG Modasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Vancer Res., 43: 2704-2711, 1983  BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci., 24:464-470, 1988  BI Vlodavsky et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein Te-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993  BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Might, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM BN DATE CONSIDERED DATE C	88													
BCC Marindrasorasak et al, "High Affinity Interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Phoaran Shifate Proteoglycan", J Biolog Chem, 266(20):12878-12883, 1991  BD Makajima et al, "Heparanases and Tumor Menstasis", J Cellular Biochem, 36:157-167, 1988  BE Omitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", Science, 268:432-436, 1995  BF Rapraeger et al, "Requirement of Aleparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252://05-1709, 1991  BG Modasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Vancer Res., 43: 2704-2711, 1983  BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci., 24:464-470, 1988  BI Dong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein Te-Emriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993  BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM BN DATE CONSIDERED A 20   D			<u> </u>	OTHER AR	T (Including	Author, Title, I	Date, Pertinent Pa	ges, Etc.)						
BE Ornitz et al, "FGF Binding and FGF Reseptor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", Science, 268:432-436, 1995  BF Rapraeger et al, "Requirement of Heparan Sulfate for BFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252://05-1709, 1991  BG Wlodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983  BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci, 24:464-470, 1988  BI Chong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remmant Lipoproteins by Cultured Cells", J Biolog Chem, 288(4):10160-10167, 1993  BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM  BN  DATE CONSIDERED Lip 90  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation.		MO	and the B	asement Meml	High Affinity brane Form of	nteractions bet Huparan Sulfa	ween the Alzeime te Proteoglycan",	er's β-Amyloic J Biolog Chem	i Precurso n, 266(20)	r Proteins :12878-				
Repraeger et al, "Requirement of Reparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991  BG Wodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983  BH Wlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci., 24:464-470, 1988  BI Whong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993  BJ Wlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM  BN DATE CONSIDERED   EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation.	BD	14	Vakajima	et al, "Hepara	nases and Tun	nor Metastasis"	, J Cellular Biocl	iem, 36:157-10	67, 1988					
Differentiation", Science, 252://05-1709, 1991  BG Wodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Sancer Res., 43: 2704-2711, 1983  BH Wlodavsky et al, "Involvement of Heparanase in Tumor Metastasia and Angiogenesis", Israel J. Med Sci. 24:464-470, 1988  Bi Chong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein B-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 288(4):10160-10167, 1993  BJ Wlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM  BN DATE CONSIDERED 1990  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation.	BE <sub>.</sub>	1	Prnitz et Prisaccha	al, "FGF Bind rides", Science	ing and FGF R 2, 268:432-434	eceptor Activa , 1995	tion by Synthetic	Heparan-Deri	ved Di- ar	nd				
BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci. 24:464-470, 1988  Bi Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993  BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM  BN  BN  BN  BN  BN  BN  BN  BN  BN	BF	4	Rapraege Different	r et al, "Requir iation", Science	rement of Alepa e, 252:1/05-17	aran Sulfate for 709, 1991	bFGF-Mediated	Fibroblast Gr	owth and l	Myoblast				
BI Chong-Sheng et al., "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993  BJ Clodavsky et al., "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM  BN  BN  DATE CONSIDERED 1990  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation.	BG		Extracelli	ular Matrix: Re	intionship to	Tumor Cell Me	tastasis", Cancer	Res., 43: 2704	<b>-2711, 19</b>	83				
BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342  BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  BL BM  BN  EXAMINER DATE CONSIDERED 1999  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	ВН				vernent of Hep	aranase in Tun	nor Metastash and	l Angiogenesi	s", <i>Israel</i> .	J. Med Sci,				
BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1980  BL BM  BN  EXAMINER DATE CONSIDERED 1990  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation.	BI	1	Zhong-Sl E-Enrich	heng et al, "Ro ed Remnant Li	le of Heparan poproteins by	Sulfate Proteog Cultured Cells	glycans in the Bin ", J Biolog Chem,	ding and Upta 268(4):10160	ke of Apo -10167, 1	lipoprotein 993				
BL  BM  BN  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	BJ	The state of the s	Vlodavsk Molecuj	cy et al, "Extra ir and Ceilular	cellular Matrix Aspects of Ba	c-Bound Growt sement Membr	h Factors, Enzym anes, Academic I	es, and Plasmo ress, Inc. 1993	a Proteins 3, pp 327-	". 342				
BM  BN  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	ВК	MO	Vight, T	N, "Cell Biolo	gy of Arterial	Proteoglycans'	, Arteriosclerosis	, 9:1-20, 1989						
EXAMINER DATE CONSIDERED 1000 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	BL			· · · · · · · · · · · · · · · · · · ·		•								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	ВМ			_				•						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	BN													
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	96													
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	EXA	MINER		insi	R_	DAT	E CONSIDEREI	× 4/29/0	7					
				eference conside	ered, whether or			MPEP 609; Dr	aw line thr	ough citation				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation

Not in conformation and not considered. Include copy of this form with next communication to applicant.

/::	1449	(Mc	odified)				Atty. Docke	t No.		Apr ic 09/ 26	ation No. 0.037	/
	<b>\</b>	IN A	AN APPLICA	TIC	E CITATION ON ECESSARY)	,	Applicant: Oron YA(	COBY-ZEEVI	et al			
<u> </u>	$\overline{}$		<u> </u>				Filing Date: March 2, 1	999		Gro ip	Art Unit:	
		7			U.S.	PAT	TENT DOCU	MENTS				
	EXAMINI INITIAL		DOCUMEN' NUMBER	T	DATE			NAME		CLA: S	SUB- CLASS	FILING DATE
ВА											1	
L					FOREIC	ON P	ATENT D	CUMENTS		/	_l	<u> </u>
		C	OCUMENT NUMBER		DATE	C	OUNTRY	CLASS	SVB-	CLASS	TRANS	SLATION
		_		_	\				1		YES	NO
BB			<del></del>									
-	<del>,</del>	Γ_						Date, Pertinent				
BC	╂	Po	mahac et al,	"Ti	ssue Engineer	ring	of Skin", Cri	t Rey Oral Biol	Med, 9	(3): 3: 3	344, 1998	(abstract)
BD		Be Pa	mathan et al, tients", Rev I	"Li Ved	ving Epiderm Suisse Roma	nde,	nd Dermal St 118(2): 149	stitutes for Tr 153, 1998 (Ab	reatmen stract- a	t of Seve	rely Burne nch)	:d
BE	<b>'</b>	W De	ang et al, Bas pendence in	sic I Rat	Fibroblast Gros", J. Orthop	wth Res,	Nactorn Enh 14(2)/316-2	ances Bone-Gr	aft Inco	rporal to	n: Dose and	d Time
BF	/	Ότ	iffy et al, "M	axi	mizing Flap S	urvi	val n Prefa	brication Mode 176-179, 1996 (	l Heina	Exogen	ous and En	idogenous
E.G		Ga		pide	ermai Regulat			problast Activit			str Surg, 10	02(1):
БH		Ra Su	ghunath et al rg Int, 12(7):	, Cı 478	ultured Epithe 3-483, 1997 (2	lial A	Autografts: I act)	Diving from Sur	gery in	to Ma riz	Biology"	, Pediatr
ВІ		My 83,	yers et al, "Ti , 1995 (abstra	rans act)	plantation of	Kera	tinocytes in	the Treatment of	of Woul	nds", "Im	J Surg, 17	0(1): 75-
55		Ka Ce	waja et al, "F	imp	noyment of Firstern", Genet	ibrot Eng	plasts for Ger	ne Transfer: Ap 05-220, 1991 (a	alicatio	ns for G	rafting into	the
EK		Ma	illard et al, P	re-	Treatment wit	h El	astase Impro	ves the Efficient Therapy, 5	cv or	ercutane	ous Adeno	virus-
EL		Wa	ing, 75, "Bas	ic F	ibrblast Grow	⁄th F	actor for Stir	nulation of Bor 269: 1-33, 1006	e Form	a Chite		tive or
ВМ		W	ing, JS, "Bas	ic F	ibrblast Grow	th F	actor Infused	at Different Ti	mes Di	uring Bo	e Graft	(abetmet)
BN		Inu	i et al, "Loca	l A		Basic	Fibrblast G	rowth Factor M				
во											/	
EXA	IINER						DATE	CONSIDEREI				<del>\</del>
EYAM It not in	INER: Init	ial if tion	reference con and not consid	side lerec	red, whether or	not of the	citation is in c	onformance with	MDED	609; [ rav	v line throu	gh citation
									-5 10 4	prical A.		
-						1991	3of4	٠,٠				

Form PTO-1449 (Modified)

Atty. Docket No.

Appli :ation No.

U9/2 3U,U3 / DRMATION DISCLOSURE CITATION **Applicant** IN AN APPLICATION Oron YACOBY-ZEEVI et al (DSF. SEVERAL SHEETS IF NECESSARY) Filing Date: Grou > Art Unit: March 2, 1999 1643 U.S. PATENT DOCUMENTS **EXAMINER DOCUMENT** DATE NAME SUB-CLAS: **FILING** INITIAL NUMBER CLASS DATE CA FOREIGN PATENT DOCUMENTS **DOCUMENT** DATE COUNTRY **CLASS** SUB CLASS TRANSLATION NUMBER YES NO CB OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) CD Tabata et al, "Bone Regeneration by Basic Fibroblast Growth Factor Complexed with Biodegradable Hydrogels", Biomaterials, 19(72): 807-815, 1998 (abstract) CE Aspenberg et al, "Stimulates Bone Formation. Bone Induction Studied in Rats', Acta Orthop Scand, 60(4): 473-476, 1989 (abstract) CF Aspenberg et al, "Dose-Dependent Stimulation of Bone Induction by Basic Fil rolast Growth Factor in Rats", Acta Orthop Scand, 62(5): 481-4 , 1991 (abstract) CG Matoba et al, "Evaluation Of Omental Implantation for Perforated Gastric Ulc: r Therapy: Findings in a Rat Model", J Gastroenterol, 31(6) 777-784, 1096 (abstract) CH Chleboun et al, "The Developmen and Enhancement of the Collateral Circulation in an Animal Model of Lower Limb Ischaemi, Aust NZ Surg, 64(): 202-207, 1994 (abstract) Aplin, JD, "Adhesion Molegales in Implantation", Rev Regrod, 2(2): 84-93, 1597 CI CJ Lessey et al, "Paracrine Agnaling in the Endometrium: Integhins and the Estab ishment of Uterine Receptivity", J Reprod/mmunol, 39(1-2): 105-116, 1998 (abstract) Burrows et al, "Trophoblast Migration During Human Placental Implantation" Hum Reprod Update, CK 2(4): 307-321, 1966 CL Bischof et al. The Regulation of Endometrial and Trophoblastic Metallaprote nases During Blastocyst Impantation', Contracept Fertil Sex, (art in French) 22(1): 48-31, 1:194 (abstract) CM Smith et al, "Expression of Heparan Sulfate Protoglycan (perlecan) in the Mouse Blastocyst is Regulated During Normal and Delayed Implantation", Dev Biol, 184(1): 38-47, 1997 (abstract) CN Abrahamsohn et al, "Implantation and Decidualization in Rodents", J Exp Zoo', 268(6): 603-628, 1993 (abstract) CO Goshen et al, "Purification and Characterization of Placental Heparanase and i s Expression by Cultured Cytotrophoblasts", Mol. Hum. Repro., 2(9): 679-684, 1996 CP **EXAMINER DATE CONSIDERED** 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; I raw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

449 (Modified) Atty. Docket No. Appli :ation No. 09/2 50,037 CORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION Oron YACOBY-ZEEVI et al (USESEVERAL SHEETS IF NECESSARY) Filing Date: Grou a Art Unit: March 2, 1999 1643 U.S. PATENT DOCUMENTS **EXAMINER** DOCUMENT DATE NAME CLAS! SUB-FILING INITIAL UMBER **CLASS** DATE DA FOREIGN PATENT DOCUMENTS **DOCUMENT** DATE COUNTRY CLASS SUE-CLASS **TRANSLATION** NUMBER YES NO DB OTHER ART (Including Author, Title, Date, Perginent Pages, Etc.) Yoshida, S., "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", Nippon Sanka Fujinka Gaickai Zasshi, 48(3): 170-176, 1996 (abstract) Watson et al, "A Growth Factor Phonotype Map for OvinePreimplantation Development", Biol DE Reprod, 50(4): 725-733, 1994 (abstratt) Carlone et al, "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat Uterus", Biol DF Reprod, 49(4): 653-665, 1993 (abstract) DG Wordinger et al, "The Immunolocalization of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Statges of Embryo Implantation", Growth Factors, 11(3): 17:-186, 1994 (abstract) DH Schultz et al, "Growth Factors in Freimplantation Manimalian Embryos", Oxf l ev Reprod Biol, 15: 43-81, 1993 (abstract) Di Freeman et al, "Human Platelet Heparanase: Purification characterization and Catalytic Activity", Biochem J., 330: 1341-1360, 1998 Esko et al, "Tumor Formation Dependent on Proeoglycans Blasynthesis", Science, 241(4869): 1092-D.J 1096, 1988 (abstract ĎΚ DI. DM DN DO DP DQ DR DS **EXAMINER** DATE CONSIDERED XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

						Snee	1 01 3					
	_	3	.·lodifie	ed)			Atty. Docket N 910/12	lo.		Applicat 09/186		
	•	NI /	AN A	DISCLOSURE APPLICATION SHEETS IF NEC	V	N	APPLICANT Tuvia PER	ETZ ct al			· .	/
•			\		- · ,		Filing Date			Group A	Art Unit	
			7		U.S. F	PAT	ENT DOCUM	MENTS	<del></del>			
		AMINE TIAL	R	OCUMENT NUMBER	DATE		N/	AME	C	CLASS	SUB- CLASS	FILING DATE
AA												
					FOREIGI	N P	ATENT DOC	UMENTS				
*********		-		UMENT IBER	DATE		COUNTRY	CLASS	SUB-C	CI ASS	TRANS	SLATION
	_}				$\Delta$				<u></u>		YES	110
AB												
			0	THER ART (	ncluding	<b>A</b> ut	hor, Title, Da	ite. Pertinent	t Pages	s. Etc.	)	•
AC				al, "The Role o	f Proteogly مرکب			on, Migration	and Prol	iicratio	n", <i>Curr</i> .	Opin. Cell
AD		Jac	kson	et al, "Glycosan s", <i>Physiol. Rev</i>	ninoglycans	: Mc	olecular Proper		teraction	ns and F	Role in Ph	siolcgical
AE		' W	ght et	al, "Cedll Biolo	gy Of Arte	rial l	Proteoglycans"	, Arteriosclero	sis,9:1-2	C, 1989	<del></del>	E2 4 3)
AF		Kj	ellen c	t al, "Proteogly	cans: Struct	gur	s and Interact	ons", Annu. Re	v. Bioch	e.n., 60	: 443-475	
AG		Ru	oslaht	i et al, "Proteog	lycans as M	odu	lators of Grow	th Ractor Activ	ities", C	e'l, 64:	867-869,	1991 2-47
АН		`\ Ba	semen	ky et al, "Extrac et Membranes: ( ando, Fla., 327-	Cellu <b>ig</b> t and	rix-E I Mo	Bound Growsth lecular Aspects	Factors, Enzyr s (eds. Rohrbac	mes and th and T	I lasma ir ıpl), A	n Proteins' Ac ademik	' In دد Press,
Al	,			cy et al, "Expres								
AJ				ky et al, "Ignibit & Metaylasis, I				eparanase Inhit	biting Sp	ecies o	f Heparin	", Zoy}:
AK		Na	kajim	a ct ay, "Heparai	nase and Tu	mor	Metastasis", J	. Cell Biochem	., 36: 15	167,	1988	20437
AL		Lie	otta et	al, "Tumor Inva	sion and th	e Ex	tracellular Ma	trikx", <i>Lab. Inv</i>	rest., 49:	639 64	19, 1983	4£74
АМ		· VI Su	odayel berido	cy et al, "Lymph thelial Extracell	noma Cell N ular Matrik	Medi x", (	ated Degradati Cancer Res., 43	on of Sulfated 3: 2704-2711, I	Proteogl 983	ycans i	the	20437
AN		46	odavsl 4-470,	ky et al, "Involv 1988	ement of H	ераг	anase in Tumo	r Metastasis an	d Angio	g :nesis	", Is. X M	ed., 24:2-
EXAN	MIN	ER					DATE	CONSIDER	ED			
6 <b>98</b> ; I	Dra	ıw lin	e thro	if reference or cough citation in the cough citation in the coupling is a second coupling to the coupling in the coupling is a second coupling to the coupling in the coupling is a second coupling to the coupling is a second coupling to the coupling is a second coupling in the coupling in the coupling is a second coupling in the coupling is a second coupling in the coupling is a second coupling in the coupling is a second coupling in the coupling in the coupling is a second coupling in the couplin	f not in co	d, w	hether or no rmation and	t citation is in not consider	n confo red. Inc	rnand Slude d	ce with Nopy of the	MPER his form

.

ø.

Sheet \_\_2\_ of prm FTO-1449 (Modified) Ally, Docket No. At plication No. 910/12 05/186,200 INFORMATION DISCLOSURE CITATION **APPLICANT** Tuvia PERETZ et al IN AN APPLICATION (UST SEVERAL SHEETS IF NECESSARY) Filing Date Group Art Unit **U.S. PATENT DOCUMENTS EXAMINER DOCUMENT** DATE NAME CLA: iS SUB-FILING INITIAL NUMBER DATE CLASS BA FOREIGN PATENT DOCUMENTS **DOCUMENT** DATE COUNTRY **CLASS** SUB-CL/ SS **TRANSLATION** NUMBER YES NO OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastasis b / Blocking Tumor Cell-BC Derived Heparanase", Int. J. Cancer, 10: 511-517, 1987 20437 BD Vlodavsky et al, "Morphological Appearance, Growy" Behavior and Migratory Activity of Human 2043 Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 980 Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth I actor: A Regulatory & 64 1 BE Mechanism?". Trends Biochem. Sci, 16: 268-27 1991 BF Campbell et al, "Heparain Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle 2004 37 Phenotype", Exp. Cell Res., 200: 156-16, 1992 BG Lider et al, "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival **.∴3**} by Treatment of Animals with Heparinoid Inhibitors of T hymphocyte Heparanare", J. Clin. Invest., 83: 752-756, 1989 ВН Thunberg et al, The Molecular Size of the Antithrombin-Bindin Sequence in He parain", FEBS Lett., 117: 203-206, 1980 81 Goldberg et al, "An Improved Method for Determining Proteoglycan synthesized by Chondrocytes in Culture", Connective Jissue Res., 24: 265-275, 1990 BJ Hudson, PJ, "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4: 395-402, 1998 BK Schoepe et al, "Neutralization of Hemolytic and Mouse Lethal Activities of Cape: fringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by Monoclonal Antibodies", Microbiol. Pathogenesis, 23: 1-10, 1997 BL Chiba et al, "Generation of Neutralizing Antibody to the Reverse Transcriptase of Homan Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious Vaccinia Virus Recombinant". J. Immunological Methods, 207: 53-60, 1997 ВМ ong, JF, "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number Engineering News, July, 1998, pp 23, 49 EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 60%: Draw line through citation if not in conformation and not considered. Include copy of this form ith next communication to applicant.

Form	PTO	1449 (Modifie	ed)		Ally. D	ocket N	0.			ition No.	
1	<b>SOB</b>	MATION D	Neci Oeria	E CITATION	910/1			<del></del>	0 1/18	5,200	
- ""	1	IN AN A	APPLICATION SHEETS IF NE	N	V APPLIC Tuvia		TZ et al				
					Filing C	Date			G: oup /	Art Unit	
				U.S. PA	ATENT DO	OCUM	ENTS		<u> </u>		
		AMINER TIAL	DOCUMENT NUMBER	Γ DA <sup>-</sup>	re		IAME		CLASS	SUB- CLASS	FILING DATE
CA				·							<del>                                     </del>
СВ	_							1	<i></i>		<b> </b>
CD								1			
CE		·			·						
CF	<u> </u>	- <u></u>									
CG	<u> </u>										
СН	ļ										
CI							<del></del>				
<u>~~</u>					<u> </u>						
				FOREIGN			MENTS				
		DOCUMI		DATE	COUNT	RY	CLASS	SUB-	CLASS	TRANS	LATION
										YES	NO
СН	<u> </u>					X	<u></u>				
	·	OTI	HER ART (	Including Au	ithor, Title	e, Date	Pertinent	Page	s, Eitc.)		
CI	`	Sherman-C Mainstrean	Gold, R., "Mor n Application:	nocional Antib s as Clinical T	odies: The herapeutics	Evoluti ", <i>Gene</i>	on from '80 etic Engineer	s Magic	bu lets	to Mature	op 4, 35
င္ပ	\	Danheiser,	SL, "Rituxin	Leads Line Of neering News,	Hopeful M	lab The	ranies ve F				
СК	``	Rader et al.	A Phage Dis	play Approach atl. Acad. Sci.	for Rapid	Antiboo	dy Humaniza	tion: D	esigned (	Combinate	orial V
CL	1	Mateo etal.	"Hymanizatio	on of a Mouse	Monoclona	al Antib	ody that Blo	cks the	Epi lerm	al Growth	Factor
СМ				3	11, 11,111,10		logy, 3. 71-6	1, 1997	<del>\</del> -	•	
CN								<del></del>	-+		
СО						<u> </u>	······································	·		$ar{}$	
CP				<del></del>						$\overline{}$	
EXAM	IINE	R			DA	TE CO	ONSIDERE	D		_	· ·
603. I	Jraw	line throng	reference co gh citation if tion to appli	onsidered, v not in confo	vhether o	r not:c	itation is in	confo	rmaince lud 3 co	with MF	S form

f not in conformation and not considered. Include copy of this form with next communication to applic in

Sheet 2 of 3 Application No. Atty. Docket No. PTO-1449 (Modified) 09/14 ).888 910/10 Applicant: FORMATION DISCLOSURE CITATION Oron YACOBY-ZEEVI IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY) Group Art Unit: Filing Date: 1633 August 27, 1998 U.S. PATENT DOCUMENTS **CLASS** FILING SUB-DATE NAME **EXAMINER** DOCUMENT DATE **CLASS** NUMBER INITIAL BA FOREIGN PATENT LXXCUMENTS TRANSLATION BUB-CLASS CLASS COUNTRY DATE DOCUMENT NUMBER NO YES 7 19/94 JP 06197760 OTHER ART (Including Author, Title, Date, Perlinent Pages, Etc.) Pier, G.B., "Rationale for Development of Immunotherapies that Target Mucoid I seudomonas BD Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst Mitt, 98:350-360, 997 (Abstract) Goldberg et al, "Biologic Activities of Antobodies to the Neutral-Polysaccharide Component of the BE Pseudomonas Aeruginosa lipopolysaccharide are Mocked by O Side Chains and Mucoid Exopolysaccharide (Alginate) ", Infect Immign, 66(1):21-26 (Abstract) Meluleni et al, "Mucoid Pseudomonas Aeruginasa Growing in a Biofilm in vitro are Killed by Opsonic BF Antibodies to the Mucoid Exopolysaccharige Capcule but not by Antibodocs Produced During Chtonic Lung Infection in Cystic Fibrosis Patients, J. Immer, 155(4):2029-2038, 1995 (1.bstract) Philippon et al, "Virulence Factors (agrobactin and mucoid phenotype) in Klebsic Ila Pneumoniae and BG Escherichia coli Blood Culture Isolales", FEMS Microbial Lett, 130(1): 51-57, 1 195 (Abstract) Pier et al, "How Mutant CFTR May Contribute to Pseudomanas Aeruginosa Infection in Cystic BH Fibrosis", Am J Respir Crit Cafe Med, 154(4): \$175-\$182, 1996 (Abstract) Pier et al, "Cystic Fibrosis Fransmembrane Conductance Regulator is an Epithel al Cell Receptor for Вi Clearance of Pseudomonos Aeruginosa from the Lung", Proc Natl Acad Sci USA 94(22): 12088-93, 1997 (Abstract) Boucher et al, "Mucold Pseudomonas Aeruginosa in Cystic Fibrosis: Characteri; ation of Muc Mutations Bl in Clinical Isolates and Analysis of Clearance in a Mouse Model of Respiratory infection", (Abstract) no West. Immum. 1997 Sel., 6561.3988-3546. further information given. Boucher et al Two Distinct Loci Affecting Conversion to Mucoidy Pseudomo as Aeruginosa in Cystic BK. Fibrosis Engode Homologs of the Serine Protease HtrA", J. Bacteriol, 178(2):51 523, 1996 )Abstract) Microbial Pathogenesis in Cystic Fibrosis: Pulmonary Clearance of Mucold Pseudomonas BL Aerugifosa and Inflamation in a Mouse Model of Repeated Respiratory Challenge", Mection and Immyhity, 66(1): 280-288, 1998 Van Heeckeren et al, "Excessive Inflamatory Response of Cystic Fibrosis Mice to Broncho ulmonary BM nfectionn with Pseudomonas Aeruginosa", J. Clin Invest, 100(11): 2810-2815, 1997

EXAMINER DATE CONSIDERED

BN

ENAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605: Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 3

Com F	PTO-1449 (Modified)	Alty. Docket No.	T	
		910/10		lication No. 140,888
A	NFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)	Applicant: Oron YACOBY-ZEEVI		140,000
		Filing Date: August 27, 1998	Grc 16:	up Art Unit:
L	OTHER ART (Including A	Author, Title, Date, Pertinent Pages, I		3
CA	Mrsny et al, "Addition of a Bacterial Al Disruption of Alginate and Modification (Abstract)	lainata I		tro can Result in the
СВ	Wiils et al, "Short-Term Recombinant H vitro Sputum Transportability", (Abstra	ory no turiner mitormation.	/	
СС	Cai et al, "Comparison of Sputum Proce 402-407, 1996 (Abstract)	essing Techniques in Cystic Fibrosis'		
CD	Randall et al, "Distribution of DNA and Pulmonary Targeting Strategies". J Drug	8 1 nerup). 4(4): 233-243/1996		
<b>S</b> E	Hatch et al, "Alginate Lyase Aromotes D polysaccharide of Mucoid <i>Pseudomonas</i> 1998 (Abstract)	Diffusion of Aminogly cosides Through Arruginosa", Antimicrob Agents Ci	hemc	ther, 42(4): 974-977,
CF	Speert et al, "Modulation of Macrophage Aeruginosa", Behring Inst Mitt, 98: 272	202. 1991 (Arostract)		
CG	Ying et al, "Alginate, the slime Exopolys Leukocyte Elastase, Retards Inhibition by Secretory Leukoprotease Inhibitor", Am.	saucharide of <i>Pseudomonas Aerugin</i> y Alphy 1-proteinase Inhibitor, and J J Cel Moll Biol, 15(2): 283-291, 19	Acce 96 ()	lerates Inhibition by
СН	Johansen et al, Chronic Pseudomonas Ae. Inst Mitt, 90: 269-273, 1997 (Abstract)	er ginosa Pneumonia. A New Proph	ylact	.c Principle", Behring
CI	Pina et al, "The Role of Fluoroquinolones Resistance in Pseudomonas Aerugijosa",	, Curr Microbio (, 35(2): 103-108, 1	997	Abstract)
CJ	Spencer, RC, "Invasive Streptorocci", Eu (Abstract)	ur J Clin Microbiol Infest Dis, 14 Su	ippl '	:S26-S32, 1995
- K	Mengistu et al, "Continuous Culture Stud Pneumoniae KI", J Appl Bacteriol, 76(5):	ADSTRact		
CL	Hsuch et al, "Invasive Streptococci Pneum Taiwan", J Formos Med Assoc, 95(5):364	moniae Infection Associated with Rad-371, 1996 (Abstract)		
СМ	Moses et al, "Relative Contributions of H Strain of the Group A Streptococcus", Info	yaluronic Capsule and M Protein of fect Immun, 65(1):64-71, 1997 (Abs	kact:	
CN	Scott et al. Assualization of an Extracellul Surface Sygar Lectin Analysis of Some To 1997 (Abstract)	los Mussid I	<del>_</del>	
со	Nilsson et al. " The Role of Staphylococca Seglic Arthritis". Infect Immun, 65(10): 42	al Polysaccharide Microcapsule Exp 216-21, 1997 (Abstract)	oress:	on in Septricemia and
СР	Vessels et al. "Effects on Virulence of Mi Expression in Group A Streptococci", Infe	utations in a Logue E	alurc bstra	nic Acid Capsule
/				
EXAMIN		DATE CONSIDERED		
XAMINI Tool in co	ER: Initial if reference considered, whether or not conformation and not considered. Include copy of this	itation is in conformance with MPEP 60 is form with next communication to app	09: D	raw line through citation

EXAMINER: unital if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation in conformation and not considered. Include copy of this form with next communication to applicant.

Konn	PTC	<b>-14</b> 4	9 (Modifie	d)			<del></del>	TA	ty. Docket N	la				
\					•			9	19. Docker N	······································		Applicati 09/113,		_ /
ŀ	1		ATION D IN AN A EVERAL S	CLIPPINC	SOLLY	4			oplicant: anna BEN	ARTZI et al				
		_					٠		ing Date: ly 10, 199	8		Group A 1652/		
ļ			7				U.S. PA	TEN	T DOCUM	IEN IS			7	
ļ <u>.</u>		(AM ITIA	INER L	DOCU	MENT		DAT	E		NAME		CLASS	SUB- CLASS	FILING DATE
BA	L			$oldsymbol{\perp}$										
	FOREIGN PATENT DOCUMENTS  DOCUMENT DATE COUNTRY CLASS TRANSLATION													
			NUMBER			D	ATE	C	DUNTRY	CLASS	SUB	-CLASS	TRANS	LATION
ВВ	十			<del></del>		1			<del>. –</del> _				YES	NO
	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
ВС	04	][,	/lodavsky	et al. "	Extrac	ellula	Sequest	tratio	n and Rele	of Fibroble			- Δ Da-	·lotor:
	/A	7.	Accuants!	12 , 176	nas bi	ocnen	n. Sci.,	0: 26	8-271, 199	<u> </u>				
BD	Ц	VC F	Campell et Exp. Cell R	al, "He Res., 200	parin : D: 156-	Sulfat	e-Degrad 1992	l ghi	Enzymes In	duce Modulati	on of S	Smooth M	scle Phe	notype",
BE		L b	ider et al, y Treatme	"Supprent of A	ession nimals	of Ex	perimen Low Do	tal A	u pimmune Heparin",	Diseases and J. Clin Invest.,	Prolon 83: 75	gation of 2-756, 19	Allografi 39	Survival
BF		.   1	hunberg e 17(1): 203	et al, "T	he Mo	lecula	r Size of	he A	Antithramb	in-Binding Sec	luence	in Hepari	ı", FEBS	Letters,
BG		S	udhalter e ibroplast (	t al, "Ir Growth	nporta Factor	nce of r by H	Size, Su egarin",	lfatio J. Bio	on and Ante	000agulant Act 254(12): 6892-	ivity ir 6897,	the Poter	tiation of	Acidic
ВН		/L	hai-Mich	aeli et a	l. "Im	portan	ce of Siz	e and	Sulfation	of Heparin in I	Paleon	of Donie	Fibroplas	t Growth 1992
BI		1/1		"Select	tive M	Desul	fation of	Hen	arin with D	imethyl Sulfox				
<b>3</b> 4		N	agasawa ( ontaining	et al, "S Water	olvoly	tic De	sulfation, Carbo	of C	ilycosamin ate Researc	oglycuronan Soh, 58: 47-55, 1	ulfules 977	With Din	ethyl Sul	foxide
ВК		M	fatia Bar-l	New et.	al, "Inl	hibitio	n of Her	oaran	ase-Mediat	ed Degradation, 70(2): 551-55	of Ex	oncellular	Matrix E	Ieparin
BL		\ p	ospodarov	wicz et	al, "Sti	imulat	ion of C	ome		ial Cell Prolife			Fibrobla	st and
BM Humovits-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell-Derived Pactors", Blood, 18: 789-796, 1991.														
BN (	X	V	lodavsky umor Met	et al, "E atastis a	xtrace and An	llular	Matrix-I	Resid <i>ance</i>	ent Growth	Factors and E	nzyme 203-22	s: Possibl 6. 1990	: Involve	ment in
EXA	IINE		. 20	(	? (	r :	les	<del>- ; ·</del>		ONSIDERED	30		99	
KAM	INE	t: In		rence co	nsidere	d, whe	ther or no	t cital	tion is in cor	formance with l				h citation

Jom !	PTO-14	49 (Modified	<b>i</b> )				Atty. Docket No. 910/8					Application No. 09/113,1 58		
-	\	AATION D IN AN A EVERAL S	PPLICA	NOTTA	ŀ		Applicant Hanna BEN ARTZI et al							
								Filing Date: Group Art Jnit: July 10, 1998 1652 / 6						
		1			τ	J.S. PA	TENT DOCUMENTS							
	EXA!	AINER AL	DOCUI NUMB			DATE		. NAME			CLASS	SUB- CLASS	FILING DATE	
CA														
			Z		FOR	EIGN	PAT	ENT DOC	UMENTS					
		DOCUMENT DATE NUMBER				re	C	DUNTRY	CLASS	3	B-CLASS	TRANS	LATION	
	<del> </del>	<u> </u>		$\rightarrow$	<del></del>					4_		YES	NO	
СВ	<u> </u>	1			1		•					L	·	
CC	اد، ۱۱	D						<del></del>	ite, Perninent I					
CC		Regan et a Bioactive	i, "Mim and Con	icry of <i>ipatibl</i>	t Biolog le Polyn	ical Mineral 8:	317	molecules b -337, 1993	y Polyaromat	ic Ar	nionic Comp	c ınds", J		
CD														
ĊĒ	Katz et al, "Antiproliferative Activity to Glorecrular Mesangial Cells and Receptor Bir Jing of a JHeparain-Mimicking Polyaromatic Anionic Compound", J. Amer. Soc. Nephrology, 1638-1697, 1997								1997					
CF		Miao et al.	,"Modu c Activi	lation ty by a	of Fibro	oblast C	ir 🗸	th Factor-2	Receptor Bin	dino	Dimerizatio	Signal	ing and	
CG		Benezra et Aromatic	al, "Re Anionic	versal Comp	of Fibro	byast C Cance	irow r Re	th Factor-n search, 52:	nediated Auto 5656-5662, 19	crine 992.	Cell Transfe	o: mation l	y	
СН		/ Irimura et glucuronid	al, "Che lase (He	micall parana	y Modi	fied He Aetasta	pari tic n	ns as Inhibi nelanoma C	tors of Hepari	an Su	Ifate Specifi , 25: 5322-5	ic Endo-β 528, 1986		
CI			al, "An	alysi	of the l				letastasis by					
CI		Ornitz et a Receptor a	i, "Hepa nd for N	rin is l	Require	d for C Whole	cll-I	ree Binding ls", <i>Molecu</i>	g of Basic Fib lar and Cellu	robi	st Growth F	a:tor to a	Soluble 992	
СК	Receptor and for Mitogenesis in Whole Cells", Molecular and Cellular Biology, 12: 240-247, 1992  Yayon et al, "Cell Surface, Heparin-like Molecules are Required for Binding of Basic l'ibroblast Growth Factor to its High Affinity Receptor", Cell, 64: 841-848, 1991.													
CL.														
СМ (		Degrade th	ie Suben	idothel	lial Bas	ement l	Mem	brane: Evid	Leucocytes, E lence for Cyto 3-124, 1995.	ndoth	nelial Cells, a	and Platel	ets to ection of	
CN														
EXAM	INER	Alex		LII.	le/				ONSIDERED	3		99		
Engli	INER:	Initial if refe	rence co	nsidere	d, wheth	her or m	ot cit	ation is in co	nformance will	MPI	EP 609; Draw	line throu	gh citation	

com P	TO-14	49 (Modified	<b>i</b> )		Atty. Docket No. Applicatio : No. 09/113,1 58						
, ¬		IN AN A	ISCLOSURE CITA PPLICATION HEETS IF NECESSA			plicant: nna BEN ARTZI et al			/		
•					Filii Jul	ut Unit					
				U.S. PAT	ΓEN	T DOCUMENTS					
	EXAI INITI	MINER AL	DOCUMENT NUMBER	DATE		NAME CLASS SUB- CLAS					
DA											
OTHER ART (Including Author, Title, Date, Pertinent Pages, E.c.)											
Nakajima et al, "A Solid-Phase Substarte of Heparanase: Its Application to Assay of Fuman Melanoma for Heparan Sulfate Regradative Activity", Analytical Biochemistry, 157: 162-171, 1936.											
DC	1	Oosta et a		Properties	of	Human Platalet Heparitana	se", J. Biol. C	he m.", 257	(19):		
DD											
DE		Freeman et al, "A Rapid Quantitative Assay for the Delection of Mammalian Heparan ise Activity", Biochem J., 325: 229-237, 1997.									
DF	1	Mullings et al, "New Reducing Sugar Assay for the Study of Cellulases", Enzyme Mic ob. Technol., 6:491-496, 1984.									
DG	•	Taylor et al, "A colorimetric Method for the Quantitation of Uronic Acids and a Specific Assay for Galacturonic Acid", Analytical Biochemistry, 20, 190-196, 1992.									
DH	N	Linhardt,	R.J., lary Electroph	oresis of	Sligo	osacchari les", Methods in	Enzmology, 23	265-280	, 1994.		
DI	1					by Fluorophere-Assisted C cenaria", Analytical Bioch					
DJ		Reducing	P., "The Use of Poly Saccharides Laboration 270: 705-713, 19	ed with th	ic-go e Flu	el Electrophoresis for the Europhore 8-aminonaphtha	High-Resolution lene-1,3,6-tris	on of Separa culphonic A	ation of .cid",		
DK	1					n Fluorigenic Reaction in Biological Matrices", Anal					
DL	DeVouge et al. "Immunoselection of GRP94/Endoplasmin From a KNRK Cell-Specific Agt11 Library Using Antobodies Directed Against a Putative Heparanase Amino-Terminal Reptide". Int. J. Cancer, 56: 286-294, 1994										
DM	IT	Zsolna et al, "Directional Immobilization of Heparin onto the Nonporous Surface of Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.									
DN		Bellott et Aug., 199		op in Con	nbina	atorial Chemistry", Europe	ean Pharmace	utical Cont	ractor,		
DO	W		et al, "An Improve Live Tissue Resear			Determining Proteoglycan 25, 1990.	s Synthesized	b) Chonds	ocytes# in		
EXA	MINE		on P. W	ely		DATE CONSIDERED	30 500	4.9	$\overline{\mathcal{I}}$		
						tation is in conformance with form with next communicat			ugh citation		

(

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

If not in conformation and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IN VECESSARY)  Alife 0 7 1939 5  Filling Date: March 25, 1998  Group Art Unit: 1652									
(USE SEVERAL SHEETS OF WECESSARY)  All 0 7 1999 C)  Filing Date:  Group Art Unit:									
Filing Date:  Group Art Unit:  March 25, 1998  Group Art Unit:  1652	•								
	1								
U.S. PATENT DOCUMENTS	$\dashv$								
EXAMINER DUCUMENT DATE NAME CLASS SUB- FILING CLASS DATE	7								
CA	$\neg$								
FOREIGN PATENT DOCUMENTS	1								
DOCUMENT NUMBER COUNTRY CLASS SUB-CLASS TRANSLATION									
CB YES NO									
OTHER ART (Allutina Auto Tri	_  ·								
CC Thompson et al, "Identification of Chondroitin Sulfate E in Human Lung Mast Cells", J. Imminol.,	_								
(Figure 1)									
CD Giuffre et al, "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", J Cell Biol, 136(4): 945-956 1997 (Abstarct)	Giuffre et al, "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", J Cell Biol, 136(4): 945-956 (1997 (Abstarct))								
CE OP Shimada et al "Involvement of Call Such IV	Shimada et al "Involvement of Coll Such Tr								
CF CF CF CF CF CF CF CF CF CF CF CF CF C	Chondroitin Sulfate in Spurper Grown Residence with Control of the								
CG Reperfusion Injury", J. Phaym Exp Ther. 283(3): 1032-1038, 1997 (Abstarct)									
CH Q Yamaguchi et al "Neutrophil Blooms Labibin D	<b>.</b>								
CI QQ Mateolies et al. "Identification of a Major Harrist D. "1122): 551-560, 1997 (Abstract)									
CJ QQ Leong et al. "Diffrent Classes of Protecthours Continue as the A.	∦ *								
Cultured Endiothelial and Brain Cells", Infect Immun, 66(3): 994-999 (Abstract)	<b>-</b>								
CK Rasagoe et al, "Effect of Heparin on Infedtion of Cells by Equine Arterità Virus", J Vet Med Sci, 59(8):	_								
CL Krusat et al, "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells", Arch Virol, 142(6) 1247-1254, 1997 (Abstract)	_								
Alvarez-Dominguez et al, "Host Cell Heparian Sulfate Proteoglycans Mediate Attachment and Entry of  Listeria Monocytogenes, and the Listerial Surface Protein Assa." I work to be a supplied to the control of the contr	Alvarez-Dominguez et al. "Host Cell Henerian Sulfate Destant La Vi								
CN (P) Haswara et al, "Inhibitory Effect of Heparin on Red Blood Cell Invasion by Theileria Secrenti Merozoites", Int J Parasitol, 27(5): 535-539 (Abstract) 1997									
co   1467	٢								
СР									
MINER Rebecca Porty DATE CONSIDERED 7-21-99									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation not in conformation and not considered. Include copy of this form with next communication to applicant									

(

,	\	-1449 (Modified)				Atty. Docket N 910/4	No.		Applicat 09/046				
	INFO	RMATION DIS	CLOSURI PLICATIO ETS IF M	E CITA: ON ECESSA	TION 4RY)	Applicant Oron Yacoby ZEEVI							
	<b>E</b> )	AUG 0 7 1990 C				Filing Date: March 25, 1	998		Group Art Unit. 1652				
	18	The second second		_	U.S. PA	TENT DOCUM	MENTS						
	Į EX	AMINER V D	OCUMEN UMBER	T	DATE		NAME	C	CLASS SUB-		FILIN		
DA	<u>.                                    </u>		_								1		
	· 			FO	REIGN I	PATENT DOC	UMENTS			,			
		DOCUMEN' NUMBER	r /	DA	ATE	COUNTRY	CLASS	SUB-	CLASS	TRAN	SLATIO		
DB	+-		<del></del>	1						YES	, "NO		
								<u>.                                    </u>					
DC	Т						ite, Partinent Pa				9,0		
<i></i>	RP	Shakibaci et al Lipoprotein Re 1699-1711, 19	eceptor-ka	elated P	on of the rotein (L	Malaria Circun RP) and Hepay	nsporozoite Prote an Sulfate Prote	tein wit	th the Louis", JE	w Densi xp Med;	ty 184(5):		
			~~ (2 50-34)			•							
DD	RP	Inaba et al, "E	ffect of He	eparino	n Infectio 8-491, 19	on of Cells by P 97 (Abstract)	orcine Reprodu	ctive a	nd Resp	iratory S	yndrome		
DE	RP RP	Inaba et al, "E Virus", Am J I	ffect of He et Res, 58	eparinos 3(5):488 us Infec	tivity De	37 (Appuract)	Porcine Reprodu						
	KP	Inaba et al, "E Virus", Am J I Chen et al, "De Nature Medicia Gantt et al. "Co	ffect of He let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med	eparinos 3(5):488 us Infec 366-871 on to a iated by	tivity De , 1997 Motif Sa	penus on Enve		to Tai	rget Cell	Heparan	Sulfate		
DE	R	Inaba et al, "E. Virus", Am J I. Chen et al, "De Nature Medicia: Gantt et al, "Ca Thrombospond Chem, 272(31) Robert et al, "C	ffect of He let Res, 58 engue Vim ne, 3(8): 8 ell Adhesi lin is Med : 19205-1: cyte Adhe	eparino: 3(5):488 us Infect 366-871 on to a liated by 9213, 1	ctivity De , 1997 Motif SA y its Glyc 997 (Abs	penas on Enve ared by the Macosminoglycan- stract)	lope Protein Bir	orozoite	e Protein	Heparan	Sulfate		
DE DF	RP RP RP	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	and VTCG",	J Biol		
DE DF	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Linding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	and VTCG",	J Biol		
DE DF DG	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	and VTCG",	J Biol		
DE DF DG DH	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	and VTCG",	J Biol		
DE DF DG DH DI DI	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	and VTCG",	J Biol		
DE DF DG DH DI DJ DK	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	Heparan and VTCG", Falciparu ol, 146(6	J Biol		
DE DF DG DH Di DJ DK DL	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	Heparan and VTCG", Falciparu ol, 146(6	J Biol		
DE DF DG DH DI DJ DK DL DM	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicia Gantt et al, "Co Thrombospond Chem, 272(31) Robert et al, "C Infected Erthro 93, 1995. (Abs Herrera et al, "	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	Heparan and VTCG", Falciparu ol, 146(6	J Biol		
DE DF DG DH DI DJ DK DL DM CN	R R R	Inaba et al, "E. Virus", Am J J Chen et al, "De Nature Medicial Gantt et al, "Control Chem, 272(31)  Robert et al, "Confected Erthro 93, 1995. (Abs. Herrera et al. "Control Chem, 272 (31)	ffect of Ho let Res, 58 engue Vinne, 3(8): 8 ell Adhesi lin is Med : 19205-1: Chondroiti cyte Adhe tract)	eparino: 8(5):488 us Infect 166-871 on to a 111-16 by 19213, 1 111-4-Sul 111-16 prency of	Motif Sh. y its Glyc 997 (Abs	ared by the Macosminoglycan- stract) Procoglycassasa Microvascular	lope Protein Bir laria Circumspo Ainding Region n), a receptor fo Endothelial Cell	prozoite a and no pr Plasr ls", Res	e Protein ot by CS nodium	Heparan and VTCG", Falciparu ol, 146(6	J Biol		

Form P	TO-1449 (M	odified)		Atty. Dock 910/1	et No.	Application 08/922,1		2				
•	IN	ON DISCLOSU AN APPLICAT RAL SHEETS IF	ION	Applicant: Iris PECI	(ER et al	à l						
				Grave A	SVE	o ILSO	160					
			1998									
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME CLASS SOR FILI							
AA	Re 1	5,362.641	Nov 94	Fuks et al		435	205					
AB		MD 5.571.506	Nov 96	Regan et al		424	78.17		4			
AC							L	l	4			
	<u> </u>		FOREI	GN PATENT	DOCUMENTS	<del>,</del>			_			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANS	LATION				
		WOMBEN.					YES	МО				
AD	ReM	D <sub>VO 9504518</sub>	Jul 94	PCT					]			
AE												
	<u>.                                    </u>	ОТНЕ	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
AF		Goshen et al. " Cultured Cyto	Goshen et al, "Purification and Characterization of Placental Heparanase and it: Expression by Cultured Cytotrophoblats", Molecular Huiman Reproduction, 2(9): 679-684, 1996									
AG	RPM	Bar-Ner et al. Sulphate by N	"Inhibition of H on-anticoagular	leparanase-Mediated Degradatin of Extracellular Matrix Heparan at Heparin Species", Blood, 70(2): 551-557, 1987								
AH	RPME	Complex Post	"Ataxia-Telang -Transcriptiona	giectasia: Struc I Regulation o	icctasia: Structural Diversity of Untranslated Secuences Suggests Regulation of ATM Gene Expression", Nucleic , cids Rescarch, 25(9)							
Al	RP"	Haimovitz-Fr Blood, 78: 78		activation of P	latelet Heparitanase	by Tumor Cell	Derived F	actors",				
LA P					al Endothelial Cell ., 25: 75-89, 1977							
AK	RP	and Epidemal Growth Factors, Exp. Eye Res., 25: 75-89, 1977  Ernst et al, "Enzymsatic degradation of Glycosaminoglycans", Crit. Rev. In Biochem. & Molec.  Biology, 30(5): 387-444, 1995										
AL	R	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apoliprotein E-enriched Remnant Lipoproteins by Cultured Cells", J. Biol. Clem., 268(14): 10160-10167, 1993										
Añ	A RP		Ross, "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s", ilature, 362: 801-809,									
A	n RP	MD <sub>829. 1997</sub>			eptor for Dengue V				_			
A	° RA	Luborutory I	Investigation, 6	3(6): 832-840,	Fibroblast Growth   1990	Factor in Norma	Human T	lissues",				
D D	AMINER	INER Refres 1 (3/2006										
EX if i	AMINER:	Initial if reference	considered, whet onsidered (ncluda	her or not citati copy of this fo	on is in conformance rm with next commu	with MPEP 609; nication to applic	Draw line t	hrough citat	ion			

F	Form PTO-1449 (Modified)							y. Docket No. 0/1			Applica 08/922		·
			IN AN A	ISCLOSURE O PPLICATION FIEETS IF MEC				plicant: s PECKER e	et al			FE	EC
								Filing Date: Grou September 2, 1997 /6				7/1	5.19°4
r			<del></del>			U.S. PA	TENT DOCUMENTS						780
		EXAM	IINER AL	DOCUMENT NUMBER		DATE		NAME			CLASS	SUB- CLASS	FILING DATE
Γ	ВА		<u> </u>									<u> </u>	
T	FOREIGN PATENT DOCUMENTS												
		DOCUMENT DATE NUMBER					С	OUNTRY	CLASS	SU	B-CLASS	TRAN	SLATION
												YES	NO
T	ВВ												
				OTHER AR	T (Ir	ncluding	Auth	nor, Title, Da	ate, Pertinent P	ages,	Etc.)		
I	BC MD Narindrasorasak et al, "High Affinity Interactions between the Alzheimer's β-Amy oid Precursor												
١		RP		roteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", J. 1 iol. Chem., 266(20): 2878-12883, 1991									
	BD	Chen et al, "Dengue Virus Infectivity Depends opn Envelope Proteion Bin to Target Cell Heparan Sulfate". Nature Medicine, 3(8): 866-871, 1997											
	8E	2	Shieh et a Proteogly	Shieh et al, "Cell Surface Receptors for Herpes Simplex Virus are Heparan Sulfate Proteoglycan Proteoglycans", J. Cell Biol., 116(5): 1273-1281, 1992									
	BF	RP P	Eisenber Surfaces	Eisenberg et al, "Liposprotein Lipase Enhances Binding of Lipoproteins to Hepara 1 Sulfate on Cell Surfaces and Extracellular Matrix", J. Clin. Invest., 90: 2013-2021, 1992									
I	BG	RP	Differen	er et al, "Requi					bFGF-Mediate	d Fib	roblast (	rowth and	Myoblast
	ВН	c.	Lider et Matrix b	al, "A Disacch by the Enzyme	aride Hepa	that Inhii	bits '	Tumor Necr	osis Factor & is . Sci. USA, 92:	For:	ned fron 5041, 1!	the Extrac	ellular
	BI	RAT	Lider et by Treat	al, "Suppression	on of	Experime	ental	Autoimmur	ne Diseases and	Pro	ongation	of Allogra	ft Survival
	BJ	P									ependent on		
	ВК	es	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin Derived Di- and Trisaccharides", Science, 268: 432-436, 1995										
	BL	RM	Spivak-Kroizman et al, "Heparin-Induced Oligomerization of FGF Molecules is F.esponsible for FGF Receptor Dimerization, Activation, and Cell Proliferation", Cell, 79: 1015-1024, 994										
	ВМ	C	Yayon et al. "Cell Surface. Heparin-Like Molecules are required for Binding of Basic Fibroblast Growtle Factor to its High Affinity Receptor", Cell, 64: 841-848, 1991								last Growth		
	BN			_/Nonion-		. ساسطة							
	EXAMINER Reserve Town DATE CONSIDERED 7-21-1811/03/2006												
	EXA if no	MINE!	R Initial if	reference consider	lered, ed. Inc	whether o	r not	citation is in his form with	conformance wi	th MI ation	PEP 609; to applice	Oraw line th nt.	rough citation

F	Form PTO-1449 (Modified)							y. Docket No 0/1			Applicate 08/922,	78ECA	
			IN AN A	ISCLOSURE ( PPLICATION HEETS IF NEC				plicant: s PECKER e	et al	<b>.</b>	GROUP 1998		
							Filing Date: September 2, 1997				Group / A Unit / 18904		
						U.S. PA	ATENT DOCUMENTS					-/-	
		EXAM	-	DOCUMENT NUMBER		DATE	NAME				CLASS	SUB- CLASS	FILING DATE
L	CA												
					FC	DREIGN	PAT	TENT DOCL	JMENTS				
ſ			DOCUMENT DATE NUMBER				С	OUNTRY	CLASS	SUB	-CLASS	TRANS	LATION
		<u> </u>										YES	NO
Ġ	СВ				L								
				OTHER AR	T (lı	cluding	Autl	or, Title, Da	ste, Pertinent P	ages, l	Etc.)		
CC Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasn a Proteins", B													
l		RP	Membranes: Cellular and Molecular Aspects (eds. Rothrbach & Timpl) pp 327-343, Academic Press, Orlasndo, Fla., 1993										
	CD	R	Vlodavsky et al, "Extracellular Sequestration and release of Fibroblast Growth Fac or: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991										
	CE	RE	Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells releases Active Fibroblast Growth Factor from ExtraCellular Matrix", Cell Regularion, 1: 833-842, 1990										
	CF	NEW PROPERTY.	Growth F	Ishai-Michaeli et al, "Importance of Size and Sulfatiuon of Heparin in Release of Easic Fibrobiast Growth Factor from the Vascular Endothelium and ExtraCellular Matrix", <i>Biochen istry</i> , 31(7): 2080-2088, 1992									
	CG	et P							in - Basic Fibro (2): 393-400, 1		Growth :	actor - is S	Stored <sub>:</sub>
	СН	P							oblast Growth . Acud. Sci. US				position
	CI	RA	Folkman	et al, "Angiog	enic	Factors",	Scie	ence, 235: 44	12-447, 1987				
	CJ	eq.	Burgess et al, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins", Annu. Rev.  Biochem., 58:575-606, 1989							ev.			
	СК	e#	Vlodavsky et al, "Involvement of the ExtraCellular Matrix, Heparin Sulfate Protec glycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: <i>Tumor Angeogene:is</i> , Eds. Lewis et al, Oxford Univ. Press, pp 125-140, 1997										
	CL	ea											
	СМ		Bashkin et al, "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellu ar Matrix and is							ind is			
	CN			/Marianne	∌i¤	rino/							
	EXA	MINER	Re	seua.	No.			DATE	CONSIDERED	7	7-21-	9811	03/2006
	EXA if not	MINER	Initial if	reference considere	ered.	whether or	not of the	citation is in his form with	conformance wi	th MPE	P 609: 14	raw line thr	

EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, Include copy of this form with next communication to applic int.

INFORMATION DISCLOSURE CENTRAL  APPLICATION  IN AN APPLICATION  IN AN APPLICATION  APPLICATION  APPLICATION  AND  IN AN APPLICATION  AND  IN AN APPLICATION  IN AN APPLICATION  AND  IN AN APPLICATION  IN AN APPLICATION  IN AN APPLICATION  IN AN APPLICATION  IN AN APPLICATION  AND  IN AN APPLICATION  AND  IN AN APPLICATION  AND  IN AN APPLICATION  AND  IN AN APPLICATION  AND  IN AND  IN AN APPLICATION  IN AND  IN AN APPLICATION  AND  IN AN APPLICATION  IN AND  IN AND  IN AND  IN AN APPLICATION  IN AND  IN A	·			3	Hear I OI		Application	on No.					
INFORMATION DISCLOSURE (TABLE)  (USE SEVERAL SHEETS IF SECESSAR)    May 1, 1998   GROUPEL BOO     CLASS   SUB-CLASS   SUB-CLASS   SUB-CLASS   SUB-CLASS   SUB-CLASS   DATE     May 1, 1998   GROUPEL BOO     May 1, 1998	om Piro	-1449 (Mo	dified)			; No.	09/071,	739					
EXAMINER   DOCUMENT   DATE   NAME   CLASS   CLASS   PRINCE		TNI A	AN APPLICAL	VECESSARY)	Applicant: Iris PEC:	ER et al	JUL	JUL 1 5 1998					
FOREIGN PATENT  DOCUMENT NUMBER  DOCUMENT DATE COUNTRY  CLASS SUB-CLASS TRANSLATION  PRIMBER  DOCUMENT DATE COUNTRY  CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT NUMBER  OTHER ART (Including Author, Ti-lc, Date, Pertinent Pages, Etc.)  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT DATE COUNTRY  CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT CLASS SUB-CLASS  TRANSLATION  VES NO  AC DOCUMENT	(03	L JL / Eld		( Mr 1 4 188	Filing Date: May 1, 19	98	GHG /	24	9				
FOREIGN PATENT DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DATE  COUNTRY  CLASS  SUB-CLASS  TRANSLATION VES  NO  AC  DOCUMENT NUMBER  DOTHER ART (Including Author, Ti-le, Date, Pertinent Pages, Etc.)  AC  DOCUMENT NUMBER  DOTHER ART (Including Author, Ti-le, Date, Pertinent Pages, Etc.)  AC  DOCUMENT NUMBER  DOTHER ART (Including Author, Ti-le, Date, Pertinent Pages, Etc.)  AC  DOCUMENT NUMBER  DOTHER ART (Including Author, Ti-le, Date, Pertinent Pages, Etc.)  AC  DOCUMENT NUMBER  AC  Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology, 1992, 4:793-801  AD  DISTRICT Physiological Processes", Physiological Reviews, 71(2)-481-539, 1991  AE  Wight, T.N., "CellBiology of Arterial Proteoglycans", Anturiosclerosis, 9:1-20, 1989  AF  DOCUMENT AF  Rusolahti et al, "Proteoglycans as Modulate rs of Growth Factor Activities", Cell, 64:867-869, 1991  AB  Class  Rusolahti et al, "Proteoglycans as Modulate rs of Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollecular Aspects (eds. Rochrach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI  DOCUMENT AC Ellisology, 1991  AC Policiars AC Ellisology, 1992  AC Policiars AC Ellisology, 1992  AC Policiars AC Ellisology, 1992  AC Policiars AC Ellisology, 1993  AC Policiars AC Ellisology, 1993  AC Policiars AC Ellisology, 1993  AC Policiars AC Ellisology, 1993  AC Policiars AC Ellisology, 1993  AC Policiars AC Ellisology, 1993  AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Ellisology, 1994  AC Policiars AC Ellisology, 1994  AC Ellisology, 1994  AC Ellisology, 1994  AC Ellisology, 1994  AC Ellisology,	<u></u>			TRADES	ATENT DOC	UMENTS			FILING				
AC DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO  AC Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology, 1992, 4:793-801  AD Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology, 1992, 4:793-801  AE Wight, T.N., "CellBiology of Arterial Proteoglycans," Arteriosclerosis, 9:1-20, 1989  AE Wight, T.N., "CellBiology of Arterial Proteoglycans," Arteriosclerosis, 9:1-20, 1989  AF MAD Ruoslahti et al, "Proteoglycans as Modulaters of Growth Factor Activities", Cell, 64:367-369, 1991  AG Ruoslahti et al, "Proteoglycans as Modulaters of Growth Factor Activities", Cell, 64:367-369, 1991  AH Wight, T.N., "CellBiology of Arterial Proteoglycans," Arteriosclerosis, 9:1-20, 1989  AF Wiodavsky et al, "Proteoglycans as Modulaters of Growth Factor Activities", Cell, 64:367-369, 1991  AF Wiodavsky et al, "Extracellular Matrix-Bou und Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollex ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI Wiodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ Wiodavsky et al, "Inhibition of Tumor, Met statasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1993  AK Wiodavsky et al, "Tumor Invasion and the Extra cellular Matrix", Lab. Invest., 49: 636-643, 1983  AN Wiodavsky et al, "Tumor Invasion and the Extra cellular Matrix", Lab. Invest., 49: 636-643, 1983  AN Wiodavsky et al, "Morphological Appear. nee, Growth behavior and Migratory Activity of Human Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Widdavsky et al, "Morphological Appear. nee, Growth behavior and Migratory Activity of Human Matrix vs. Plastic", Cell, 19: 607-616, 1980	E			DATE		NAME	CLASS						
OCCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION  YES NO  OTHER ART (Including Author, Ti.lc, Date, Pertinent Pages, Etc.)  AC Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology. 1992, 4:793-801  AD Dalesson et al, "Glycosaminoglcans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Reviews, 71(2):481-539, 1991  AE Wight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  AF May Kjellen et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991  AG Ruoslahti et al, "Proteoglycans as Modulater so of Growth Factor Activities", Cell, 64:867-869, 1991  AH WOOdavsky et al, "Extracellular Matrix-Bou and Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollet ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI WOO Vlodavsky et al, "Expression of Heparanas : by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ Woodavsky et al, "Inhibition of Tumor Met astasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302/1995  AK WOO Nakajima et al, "Heparanase and Tumor N. etastasis", J. Cell. Biochem., 36: 157-167, 1988  AL WOO Nakajima et al, "Tymphoma Cell Mediate i Degradation of Sulfaued Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Metastasis by Blocking Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  Vlodavsky et al, "Morphological Appear. nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  DATE CONSIDERED 7/42/911/02/2006	AA							<u> </u>					
AC MD Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology, 1992, 4:793-801  AD Jackson et al, "Glycosaminogleans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Reviews, 71(2):481-539, 1991  AE Wight, T.N., "CellBiology of Arterial Prote oglycans", Arteriosclerosis, 9:1-20, 1989  AF MD Kjellen et al, "Proteoglycans as Modulat rs of Growth Factor Activities", Cell, 64:867-869, 1991  AG Ruoslahti et al, "Proteoglycans as Modulat rs of Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollec ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI DO Vlodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 14: 290-302, 1993  AJ Vlodavsky et al, "Inhibition of Tumor Met statsis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14: 290-302, 1993  AK VJodavsky et al, "Tymphona Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subenduchial Extracellular Matrix: Rela ionship to Tumor Metastasis", Cancer Res., 43: 270-2711, 1983  AN Vlodavsky et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  Vlodavsky et al, "Morphological Appear, nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER DATE OF The Membranes of Tumor Metastasis by Booking Tumor Matrix vs. Plastic", Cell, 19: 607-616, 1980							SUB-CLASS	TRANS	SLATION				
AC Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology, 1992, 4:793-801  AD Wight et al, "Glycosaminoglcans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Reviews, 71(2):481-539, 1991  AE Wight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  AE Wight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  AF Wight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  AF Wiodavsky et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991  AG Ruoslahti et al, "Proteoglycans as Modulaters of Growth Factors, Enzymes and Plasma Protein", in Bustment Membranes: Cellular and Mollecular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI Wiodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ Wiodavsky et al, "Inhibition of Tumor Met stasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14: 290-302, 1993  AK Wiodavsky et al, "Heparanase and Tumor Metastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Wiodavsky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfaued Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis by Blocking Tumor Cell Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AN Wiodavsky et al, "Morphological Appear. nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER War Jane DiBrino/ DATE CONSIDERD 7/12/9911/02/2006				DATE	COUNTRY	CEACO		YES	NO				
AC Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology, 1992, 4:793-801  AD Wight et al, "Glycosaminoglcans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Reviews, 71(2):481-539, 1991  AE Wight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  AF Wight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989  AF Woodavsky et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991  AG Ruoslahti et al, "Proteoglycans as Modulaters of Growth Factors, Enzymes and Plasma Protein", in Bussement Membranes: Cellular and Mollecular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI Woodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ Woodavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14: 290-302, 1993  AK Woodavsky et al, "Heparanase and Tumor Metastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Woodavsky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Woodavsky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Metastasis by Blocking Tumor Cell Metastasis", Cancer Res., 43: 170-2711, 1983  AN Woodavsky et al, "Morphological Appear: nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Woodavsky et al, "Morphological Appear: nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980													
Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current Opinion in Cell Biology. 1992, 4:793-801  AD Ja:kson et al, "Glycosaminoglcans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Reviews, 71(2):481-539, 1991  AE Wight, T.N., "CellBiology of Arterial Prote glycans", Arteriosclerosis, 9:1-20, 1989  AF Jap. Wight, T.N., "CellBiology of Arterial Prote glycans", Arteriosclerosis, 9:1-20, 1989  Kjellen et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991  AG Ruoslahit et al, "Proteoglycans as Modulaters of Growth Factor Activities", Cell. 64:867-869, 1991  AI Wiodavsky et al, "Extracellular Marix-Bou id Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollecular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  Vlodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ Wiodavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14: 290-302, 1993  AK Wiodavsky et al, "Heparanase and Tumor Metastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Wiodavsky et al, "Heparanase and Tumor Metastasis", J. Cell. Biochem., 36: 157-167, 1983  AN Wiodavsky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Wiodavsky et al, "Morphological Appear: nee, Growth Echavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Widdaysky et al, "Morphological Appear: nee, Growth Echavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980	AB		OTUE	R ART (Includ	ling Author, Ti:l	c, Date, Pertiner	nt Pages, Etc.)						
AD Alackson et al, "Glycosaminogleans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Reviews, 71(2):481-539, 1991  AE Wo Wight, T.N., "CellBiology of Arterial Prote glycans", Arteriosclerosis, 9:1-20, 1989  AF Wo Wight, T.N., "CellBiology of Arterial Prote glycans", Arteriosclerosis, 9:1-20, 1989  Kjellen et al, "Proteoglycans as Modulaters of Growth Factor Activities", Cell, 64:867-869, 1991  AG Ruoslahti et al, "Extracellular Matrix-Bou and Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollet ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  Al Wo Vlodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AN Vlodavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14: 290-302, 1993  AK Wo Vlodavsky et al, "Heparanase and Tumor Metastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Wo Vlodavsky et al, "Tumor Invasion and the Extra cellular Matrix", Lab. Invest., 49: 636 664, 1983  AN Wo Vlodavsky et al, "Expression of Heparanase Inhibition of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270 2711, 1983  AN Woodavsky et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AD Vlodavsky et al, "Morphological Appear: nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Water Janne DiBrino/ DATE CONSIDERED 7/12/9911/02/2006		MD T	UIDE.	he Pole of Prot	eoglycans in Ce	ll Adhesion, mig	gration and Prolif	eration", C	Current				
Physiological Processes", Physiological Networks, Arteriosclerosis, 9:1-20, 1989  Wight, T.N., "CellBiology of Arterial Prote-pglycans", Arteriosclerosis, 9:1-20, 1989  Kjellen et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991  Ruoslahti et al, "Proteoglycans as Modulate and Growth Factor Activities", Cell, 64:867-869, 1991  Vlodavsky et al, "Extracellular Matrix-Bou and Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollet ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  Vlodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  Vlodavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1993  AK W Nakajima et al, "Heparanase and Tumor Iv. etastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Liotta et al, "Tumor Invasion and the Extracellular Matrix", Lab. Invest., 49: 636-664, 1983  Vlodavsky et al, "Lymphoma Cell Mediate 3 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN WD Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cells Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AD Vlodavsky et al, "Morphological Appear: nec, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Warrianne DiBrino/ DATE CONSIDERED '7/12/9711/02/2006	AC	M)	Opinion in Cel	0 to to the Call Riology 1992, 4.773-001									
Kjellen et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443471, 1971  AG Ruoslahti et al, "Proteoglycans as Modulate is of Growth Factor Activities", Cell, 64:867-869, 1991  AH WOOdavsky et al, "Extracellular Matrix-Bou id Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollet ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI WOOdavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes is and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ WOOdavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1993  AK WOO Nakajima et al, "Heparanase and Tumor Metastasis", J. Cell. Biochem., 36: 157-167, 1988  AL WOO Nakajima et al, "Lymphoma Cell Mediate i Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN WOO Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AO WOOdavsky et al, "Morphological Appear: nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER WAS Allength Proteoglycans with MPEP 609, Draw line through citation in applications with MPEP 609, Draw line through citation in applications with MPEP 609, Draw line through citations in applications in the proteoglycans with MPEP 609, Draw line through citations in applications with MPEP 609, Draw line through citations in applications with MPEP 609, Draw line through citations in the proteoglycans with MPEP 609, Draw line through citations in applications in the proteoglycans with MPEP 609, Draw line through citations in applications in the proteoglycans with MPEP 609, Draw line through citations in the proteogly	AD	OM	Physiological	Physiological Processes", Physiological Reviews, 7.(2)									
Ruoslahti et al, "Proteoglycans as Modulaters of Growth Factor Activities", Cell, 64.04/00/1997  AH WOOdavsky et al, "Extracellular Matrix-Bou in Growth Factors, Enzymes and Plasma Protein", in Basement Membranes: Cellular and Mollet ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  AI WOO Vlodavsky et al, "Expression of Heparanas; by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ WOO Vlodavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1993  AK WOO Nakajima et al, "Heparanase and Tumor Iv. etastasis", J. Cell. Biochem., 36: 157-167, 1988  AL WOO Vlodavsky et al, "Tumor Invasion and the Extracellular Matrix", Lab. Invest., 49: 636-643, 1983  AN WOO Vlodavsky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN WOO Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-513, 1987  AO WOO Vlodavsky et al, "Morphological Appear. nce, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Warrianne DiBrino/ DATE CONSIDERED 7/12/9911/02/2006	AE	PRO	Wight, T.N., "	CellBiology of	Arterial Protes	Sycans , Arterio	nu Rev Biochen	n., 60: 443	-475, 1991				
Vlodavsky et al, "Extracellular Matrix-Bou id Growth Factors, Enzymes and Fashers Basement Membranes: Cellular and Mollet ular Aspects (eds.Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.  Vlodavsky et al. "Expression of Heparanas; by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  Vlodavsky et al, "Inhibition of Tumor Met istasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1993  AK Vlodavsky et al, "Inhibition of Tumor Met istasis", J. Cell. Biochem., 36: 157-167, 1988  AL Liotta et al, "Tumor Invasion and the Extra incellular Matrix", Lab. Invest., 49: 636-642, 1983  AN Vlodavsky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Vlodavsky et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AO Vlodavsky et al, "Morphological Appears nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  AP Marianne DiBrino/ DATE CONSIDERED 7/12/9911/02/2006	AF	May ()	Kjellen et al, '	Proteoglycans:	Structures and	interactions , A	tor Activities". C	ell, 64:867	-869, 1991				
Al Woodavsky et al, "Expression of Heparanas: by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes's and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ Woodavsky et al, "Inhibition of Tumor Met stasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1993  AK Woodavsky et al, "Heparanase and Tumor Iv etastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Woodavsky et al, "Heparanase and Tumor Iv etastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Woodavsky et al, "Tumor Invasion and the Extra cellular Matrix", Lab. Invest., 49: 636 (20), 1983  AN Woodavsky et al, "Lymphoma Cell Mediate i Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Woodavsky et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AO Woodavsky et al, "Morphological Appear: nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  AP Woodavsky et al, "Morphological Appear: nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  DATE CONSIDERED 7/12/9911/02/2006	AG	Mac											
Vlodavsky et al, "Expression of Heparanas; by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedes s and Extra yasation", Invasion & Metastasis, 12: 112-127, 1992  AJ MD Vlodavsky et al, "Inhibition of Tumor Met stats by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 7995  AK Nakajima et al, "Heparanase and Tumor N. etastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Liotta et al, "Tumor Invasion and the Extracellular Matrix", Lab. Invest., 49: 636-663, 1983  AN Vlodasky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AO Vlodavsky et al, "Morphological Appear: nce, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Matrianne DiBrino/  DATE CONSIDERED 7-12-19 911/02/2006	АН	MPUD)	Basement Me	mbranes: Cellu Iando Fla	ilar ana monet i	nar rispecto (tal							
AJ Woodavsky et al, "Inhibition of Tumor Met astasis by Heparanase Inhibiting Species of Heparin", invasion & Metastasis, 14: 290-302, 1995  AK Nakajima et al, "Heparanase and Tumor Netastasis", J. Cell. Biochem., 36: 157-167, 1988  AL Liotta et al, "Tumor Invasion and the Extracellular Matrix", Lab. Invest., 49: 636-643, 1983  AN Vlodasky et al, "Lymphoma Cell Mediate I Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-513, 1987  AO Vlodavsky et al, "Morphological Appear nee, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Marijanne DiBrino/ DATE CONSIDERED 7/12/9911/02/2006	Al	KO.	Vłodavsky et System: Poss	al, "Expression ible Involveme	nt in Diapeties s			· <del></del>					
Nakajima et al, "Heparanase and Tumor N. etastasis", J. Cell. Biochem., 36: 157-107, 1988  AL Liotta et al, "Tumor Invasion and the Extr cellular Matrix", Lab. Invest., 49: 636-641, 1983  Liotta et al, "Lymphoma Cell Mediate I Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rela ionship to Tumor Cell Metastasis", Cancer Res., 43: 270 2711, 1983  AN Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AO Vlodavsky et al, "Morphological Appearance, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER DiBrino/ DATE CONSIDERED 7/12/9911/02/2006	AJ	MD	Vlodavsky e	Antaetaete 14: .	<b>とサローコロム、エフノン</b>								
Liotta et al, "Tumor Invasion and the Extr cellular Matrix", Lab. Invest., 49: 630-642, 1963  AM Vlodasky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 270-2711, 1983  AN Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  AO Vlodavsky et al, "Morphological Appearance, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Marianne DiBrino/ DATE CONSIDERED 7/12/911/02/2006	AK	PPIN			and Thomas &	tastasis", J. Cell	l. Biochem., 36: 1	57-167, 19	1003				
Vlodasky et al, "Lymphoma Cell Mediate 1 Degradation of Sulfated Total of Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 270. 2711, 1983  AN Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  Vlodavsky et al, "Morphological Appearance, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  EXAMINER Marianne DiBrino/ DATE CONSIDERED 7/10/9911/02/2006		<b>-</b>  ×	Lines et al "Tumor Invasion and the Extracellular Matrix", Lab. Invest., 49: 630-643, 1763										
cell-Derived Heparanase, Int. 3. Cancer, 40.  AO Vlodavsky et al, "Morphological Appear: nce, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980  AP DATE CONSIDERED 7/12/9911/02/2006  EXAMINER DiBrino/ DATE CONSIDERED 7/12/9911/02/2006	AM	M	Vlodasky et al. "Lymphoma Cell Mediate I Degradation of Sulfated Flotcopy" Cancer Res., 43: 2704- Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-										
Tumor Cells Maintained on Extracentum  AP    AP	AN	NEC											
EXAMINER Marjanne DiBrino/ DATE CONSIDERED 7/12/911/02/2006	/ AO	N. N.	Vlodavsky Tumor Cell	et al, "Morphol s Maintained o	ogical Appearar n Extracellular I	nce, Growth behi Matrix vs. Plastic	avior and Migrato c", Cell, 19: 607-	616, 1980					
EXAMINER DISTINO DATE CONSIDERED TO DATE the in its in conformance with MPEP 609; Draw line through citat	AF	>							1/02/2006				
is in conformance with MPEP 609; Draw line through	EX	I I I I I I I I I I I I I I I I I I I											
	EX	AMI: ER:	Initial if reference	e considered, wh	nether or not cita is	on is in conformate m with next com	nce with MPEP 60! munication to anni	r, Utaw IIII icani	- un G.				

AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

**ು**।೮೮1

		Shee	t 3 o	13					
Form F (O-1449 (Modified)			Atty. Doc 910/5	et No	).	1 '	plicatio		<u>~()</u>
INFORMATION DISCL IN AN APPL (USE SEVERAL SHEET	ICATION /C		1 3 (	EN A	ARTZI et al	Gr		JL 1 5 1 ROUP	11
	\ \ \	Mr .	May 1,				5	4/4	
LEGISTENT DOCUMENTS									
	CUMENT	DATE			NAME	CLA	ss	SUB- CLASS	FILING DATE
CA							]		
	FC	OREIGN	PATENT	DOC	UMENTS				
DOCUMENT NUMBER	C	DATE	COUNT	' <b>२</b> Y	CLASS	SUB-CL	ASS	TRANS	LATION
								YES	NO
Н									
O	THER ART (I	ncluding	Author, Ti	:le, D	ate, Pertinent Pa	ges, Etc.	)		
CM MD De Vouge et a Using Antibod 286-294, 1994	lies Directed A	ection of gainst a l	GRP94/Er Putative H	dopla	smin From a KN nase Amino-Terr	VRK Cell	l-Spec ptide",	ific λgtll,	Library incer, 56:
Graham et al, Microphages,	Graham et al, "Comparison of the Heparanase E 1zymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996								
CO Kosir et al, "H	Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-								
CP Kosir et al, Al	ostract 3378, C	ancer Re	s., 37: 495	1996	·				
CO MD Ernst et al, "E 30(5): 387-44	inzymatic Degr 4 1995	adation o	f Glycosa	ninog	lycans", Crit. Re	ev. In Bio	ochem.	. And Mol	Biol.,
MD Gospodarowic Epidermal Gr	cz et al. "Stimu owth Fictors",	lation of Exp. Eye	Corneal E Res., 25:	1doth 25-89	elial Cell Prolife , 1977	ration in	vitro	by Fibrob	last and
Haimovitz-Fr 78: 789-796,		Activatio	n of Platal	et Hep	paritinase by Tur	nor Cell-	-Deriv	red Factor	s", <i>Blood</i> ,
Yelton et al,			: a Power	ul Ne	w Tool in Biolog	gy and M	ledicir	ne", Annu.	Rev.
Friedman et a Gland Develo Biol., 177: 34	opment Sugges	Expressio ts a Role	n of Home in Hormo	obox ie Act	Genes Msx-1 an ion and Epitheli	d Msx-2 al-Strom	in Mo al Inte	ouse Mam eractions"	mary , Devel.
Soule et al, "Cell Line, Mo	Isolation and C CF-10 <sup>ln</sup> , <i>Canc</i>	haracteri: er Res., 5	zation of a 0: 6075-6	Spon 186, 1	taneously Immo	rtalized l	Humai	n Breast E	pithelial
Miller et al. " 85: 1725-132	'Xenograft Mo 2, 1993	del of Pro	gressive I	lumar	Proliferative B	reast Dis	ease",	, J. Nat. C	ancer Inst.,
Nakajima et : Mouse B16 r	al, Heparan Su nelanoma Subl	lfate Degi ines", Sci	radation: I ience, 220	elatio	on to Turnor Inva 613, 1983	asion and	Meta	tastic Pro	perties of
CR /M	Marianne Di	Brino/				<del></del>			<del>/ለን /</del> ንለለደ
EXAMINER (MX)	vaine	Dia	m	DATE	CONSIDERED	71	13)	99	/02/2006

# This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents will not correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox